{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "collapsed": true
   },
   "source": [
    "# CIViC Design Studio\n",
    "\n",
    "#### Purpose \n",
    "Create SECOND Generation Output File For CIViC DesignStudio\n",
    "\n",
    "#### Use\n",
    "CIViC_DesignStudio will pull existing variants from the CIViC Knowledgebase, iterate through all variants, and create an output that can be used to create IDT probes\n",
    "\n",
    "#### Inputs\n",
    "1) variants of interest = from the CIViC Probe DesignStudio Interface, any variants that are selected will be evaluated for probe design.\n",
    "\n",
    "#### Outputs\n",
    "1) CIViC_DesignStudio_coordinates.tsv = for each variant selected, we will provide the chromosome, start, stop, gene, variant and pipeline\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 148,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "false"
      ]
     },
     "execution_count": 148,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#!/usr/bin/env ruby\n",
    "\n",
    "require \"rubygems\"\n",
    "require \"json\"\n",
    "require \"net/http\"\n",
    "require \"uri\"\n",
    "require 'yaml'\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Evaluate DNA-based Variants"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 149,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{\"id\"=>306, \"entrez_name\"=>\"ERBB2\", \"entrez_id\"=>2064, \"name\"=>\"AMPLIFICATION\", \"description\"=>\"Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.\", \"gene_id\"=>20, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>123, \"name\"=>\"transcript_amplification\", \"display_name\"=>\"Transcript Amplification\", \"so_id\"=>\"SO:0001889\", \"description\"=>\"A feature amplification of a region containing a transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001889\"}], \"civic_actionability_score\"=>822.5, \"coordinates\"=>{\"chromosome\"=>\"17\", \"start\"=>37856333, \"stop\"=>37884915, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000269571.5\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/20/summary/variants/306/summary#variant\", \"evidence_items\"=>[{\"id\"=>1011, \"name\"=>\"EID1011\", \"description\"=>\"This Phase II trial (LUX-Breast 3 - NCT01441596) compared afatinib, afatinib plus vinorelbine, or investigator's choice of treatment.  121 patients with HER2 overexpressing breast cancer with CNS recurrence or regression who had previously progressed on trastuzumab or lapatinib were assigned to 3 arms, with endpoint in the intention-to-treat population being patient benefit at 12 weeks defined as absence of CNS or extra CNS progression, no tumor related worsening of neurological symptoms and no increase in corticosteroid dose. Benefit was seen in 30% of 40 patients assigned to afatinib alone, 34.2% of 38 assigned to afatinib plus vinorelbine, and 41.9% of 43 assigned to investigator's treatment choice.  Differences were not statistically significant, and afatanib patients experienced more adverse effects.  While Afatanib did show response in HER2 breast cancer patients, it was not better than investigator's treatment choice and the investigators state that no further development of afatinib for HER2 breast cancer will be planned.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>699, \"name\"=>\"Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.\", \"citation\"=>\"CortÃ©s et al., 2015, Lancet Oncol.\", \"pubmed_id\"=>\"26596672\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26596672\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>12}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1013, \"name\"=>\"EID1013\", \"description\"=>\"Trastuzumab resistance is thought to consist of multiple compensatory mechanisms involving ErbB family members such as increased signaling through ErbB family heterodimers.  The irreversible TKI afatinib blocks EGFR, HER2, ErbB3 and ErbB4.  Thus afatinib was studied in this Phase I trial of trastuzumab-progressed HER2 positive metastatic BC (MBC) in combination with continued trastuzumab treatment, where trastuzumab is still the perferred treatment for trastuzumab-progressed MBC.  Objective response and disease control rates were 11% and 39%.  The authors conclude that the clinical activity observed in this trial warrants further work with afatinib and trastuzumab combination therapy.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>701, \"name\"=>\"Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.\", \"citation\"=>\"Ring et al., 2015, Clin. Cancer Res.\", \"pubmed_id\"=>\"25370464\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25370464\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>6, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1159, \"name\"=>\"EID1159\", \"description\"=>\"The Phase III trial, TH3RESA (NCT01419197), was performed in patients with advanced HER2 breast cancer that was heavily pretreated.  Patients were required to have prior exposure to trastuzumab and lapatinib as well as a taxane.  This patient population has not seen many studies, responds poorly to late-line treatment with trastuzumab, and in this study was treated with trastuzumab emtansine (T-DM1, n=404) vs. physician's choice (usually trastuzumab plus chemotherapy, n=198).  Results showed progression free survival was 6.2 months in T-DM1 treatment vs. 3.3 months under physician's choice, along with lower incidence of grade 3 or worse events with T-DM1.  The authors conclude that their findings in this heavily pretreated population, along with findings in the EMILIA trial, indicate promise for antibody-drug conjugates.  The NCI-MATCH trial with further study T-DM1 in the context of HER2 amplification.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>798, \"name\"=>\"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.\", \"citation\"=>\"Krop et al., 2014, Lancet Oncol.\", \"pubmed_id\"=>\"24793816\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24793816\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>6}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1133, \"name\"=>\"EID1133\", \"description\"=>\"In this Phase III trial, trastuzumab-based treatment was assessed in women with locally advanced or metastatic HER2 positive breast cancer who had progressed on trastuzumab.  Patients had 12 weeks or greater previous trastuzumab treatment with time since end of last cycle less than 6 weeks.  Primary endpoint was time to progression.  78 patients were assigned to each group, with median time to progression of 5.6 months in capecitabine group and 8.2 months in trastuzumab plus capecitabine group.  The results are in contrast to the principle of change of treatment on disease progression, and authors suggest that chemotherapy-sensitizing mechanisms of trastuzumab remain intact in HER2 breast cancer cells with trastuzumab progression.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>32, \"name\"=>\"Capecitabine\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>784, \"name\"=>\"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.\", \"citation\"=>\"von Minckwitz et al., 2009, J. Clin. Oncol.\", \"pubmed_id\"=>\"19289619\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19289619\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>4, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1012, \"name\"=>\"EID1012\", \"description\"=>\"LUX-Breast 1 is a phase 3 trial (NCT01125566) which enrolled 508 patients with metastatic HER2 positive BC who had progressed after adjuvant or first-line trastuzumab. It was thought that the wider range of ErbB family blocking and irreversible properties of afatinib could be beneficial in trastuzumab resistant cancer cells, since ErbB family members are thought to play a role in trastuzumab resistance. Primary endpoint was intention-to-treat group PFS. 339 patients were assigned to afatanib + vinorelbine and 169  to trastuzumab + vinorelbine.  Recruitment was stopped prematurely when it was deemed unlikely that the increased PFS would be seen in the afatinib group. Median PFS was 5.5 months in the afatinib group and 5.6 months in the trastuzumab group.  Afatanib plus vinorelbine was less well tolerated than trastuzumab plus vinorelbine, and the authors conclude that trastuzumab remains the best choice for treatment of trastuzumab-progressed HER2 positive metastatic BC.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>700, \"name\"=>\"Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.\", \"citation\"=>\"Harbeck et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"26822398\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26822398\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1113, \"name\"=>\"EID1113\", \"description\"=>\"In this two arm, Phase III study (NCT00878709) of the efficacy of a 12 month course of the TKI neratinib after trastuzumab-based adjuvant therapy of early stage HER2-positive breast cancer was assessed using invasive disease-free survival as primary endpoint.  HER2 positivity was assessed via FISH.  At 2 year follow-up, 70 vs. 109 disease-free survival events had occurred and disease-free survival rates were 93.9% vs. 91.6% (significant) in neratinib vs. placebo groups respectively.  Distant disease-free survival and time to distant recurrence were similar in both groups.  These results are an interesting contrast to results of long-term adjuvant therapy with trastuzumab (HERA) which did not show significant benefit.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>52, \"name\"=>\"Neratinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>768, \"name\"=>\"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.\", \"citation\"=>\"Chan et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"26874901\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26874901\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1160, \"name\"=>\"EID1160\", \"description\"=>\"The EMILIA study (NCT00829166) was a Phase II trial to assess the efficacy of trastuzumab emtansine (T-DM1, n=495) in comparison to lapatinib plus capecitabine (n=496), in treatment of advanced HER2 positive breast cancer.  Patients were required to have progressed on or after treatments involving trastuzumab and a taxane, and no prior exposure to lapatinib or T-DM1.   Primary endpoints included independently assessed progression free survival (PFS) and safety. PFS was 9.6 months in T-DM1 group vs. 6.4 months in lapatinib plus capecitabine.  Rates of adverse events of grade 3 or higher were greater with lapatinib plus capecitabine.  These results, together with other trials such as TH3RESA indicate promise for T-DM1 therapy in HER2 amplification, and this will be further studied in an arm of the NCI-MATCH trial.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>799, \"name\"=>\"Trastuzumab emtansine for HER2-positive advanced breast cancer.\", \"citation\"=>\"Verma et al., 2012, N. Engl. J. Med.\", \"pubmed_id\"=>\"23020162\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23020162\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>11, \"day\"=>8}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1007, \"name\"=>\"EID1007\", \"description\"=>\"In light of results showing increased PFS using mAB plus TKI in heavily pretreated patients, the efficacy of trastuzumab plus lapatinib in a neoadjuvant setting with untreated stage II or IIIA HER2 positive breast cancer was assessed.  In this randomized 3 arm phase II study (CHER-LOB), patients received (A) chemotherapy plus trastuzumab, (B) chemotherapy plus lapatinib, or (C) chemotherapy plus trastuzumab and lapatinib, with pathologic complete response (pCR) as endpoint.  From 121 patients, pCR rates were 25% in arm A, 26.3% in arm B, and 46.7% in arm C.  The authors conclude these results support the superiority of dual-HER2 inhibition in the neoadjuvant context of HER2 positive BC.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>696, \"name\"=>\"Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.\", \"citation\"=>\"Guarneri et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22493419\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22493419\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1008, \"name\"=>\"EID1008\", \"description\"=>\"This Phase III trial compared the activity of lapatinib vs. trastuzumab vs. sequential trastuzumab followed by lapatinib vs. lapatinib plus trastuzumab in an adjuvant treatment setting.  8381 women were randomized to one of four treatment arms. Patients had HER2 positive non-metastatic operable BC. The primary endpoint was disease free survival.  First results report that after median 4.5 year follow up, a non significant 16% improvement in DFS was seen in trastuzumab + lapatinib vs. trastuzumab alone.  The results are interpreted as showing no added benefit for labatinib addition to trastuzumab in the adjuvant treatment context.  This trial is ongoing but not recruiting patients (NCT00490139).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>697, \"name\"=>\"Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.\", \"citation\"=>\"Zardavas et al., 2015, Breast\", \"pubmed_id\"=>\"26255196\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26255196\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>11}, \"journal\"=>\"Breast\", \"full_journal_title\"=>\"Breast (Edinburgh, Scotland)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>529, \"name\"=>\"EID529\", \"description\"=>\"A randomized clinical trial of 186 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved overall survival, response rate, response duration, time to progression, and time to treatment failure for patients who received trastuzumab in addition to chemotherapy (docetaxel) compared to chemotherapy alone.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>329, \"name\"=>\"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.\", \"citation\"=>\"Marty et al., 2005, J. Clin. Oncol.\", \"pubmed_id\"=>\"15911866\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15911866\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>528, \"name\"=>\"EID528\", \"description\"=>\"A randomized clinical trial of 469 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved time to disease progression, objective response rate, and duration of response for patients who received trastuzumab in addition to chemotherapy compared to chemotherapy alone.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>328, \"name\"=>\"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.\", \"citation\"=>\"Slamon et al., 2001, N. Engl. J. Med.\", \"pubmed_id\"=>\"11248153\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11248153\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2001, \"month\"=>3, \"day\"=>15}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5985, \"name\"=>\"EID5985\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of nine patients (22%) with HER2 amplified/overexpressing pancreatic cancer had a PR with trastuzumab/pertuzumab combination. Another patient had SD > 120days.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5986, \"name\"=>\"EID5986\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. None of the 7 patients with HER2 amplified/overexpressing uterus cancer responded to pertuzumab/trastuzumab.\", \"disease\"=>{\"id\"=>825, \"name\"=>\"Uterine Cancer\", \"display_name\"=>\"Uterine Cancer\", \"doid\"=>\"363\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:363\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1993, \"name\"=>\"EID1993\", \"description\"=>\"We identified 142 patients with metastatic colorectal cancer whose tumors harbored both wild-type exons 2, 3, and 4 in KRAS and NRAS, and wild-type exon 15 in BRAF. All patients received cetuximab after oxaliplatin, irinotecan, and fluoropyrimidine failure. HER2 status was determined using immunohistochemistry and silver in situ hybridization and correlated with cetuximab efficacy. Of 142 RAS and BRAF wild-type tumors, we observed 7 cases (4.9%) of HER2 amplification by SISH. After a median follow-up of 13.2 months (range, 1.4-78.1 months), median progression-free survival (PFS) was significantly different according to HER2 status: 3.1 months in patients with HER2 amplification compared with 5.6 months in those with non-amplified HER2 (HR = 2.73; 95% CI = 1.18-6.31; P = 0.019). Overall survival (OS) was not significantly different between groups, although there was a tendency towards shorter OS in patients with HER2-amplified tumors (HR = 0.31; 95% CI = 0.61-2.82; 10.1 vs. 13.5 months; P = 0.488).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1399, \"name\"=>\"HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.\", \"citation\"=>\"Jeong et al., 2017, Clin Colorectal Cancer\", \"pubmed_id\"=>\"28223103\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28223103\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>1, \"day\"=>25}, \"journal\"=>\"Clin Colorectal Cancer\", \"full_journal_title\"=>\"Clinical colorectal cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5981, \"name\"=>\"EID5981\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. \\nThirty of 114 patients (26%; 95% CI, 19% to 35%) with HER2 amplification/overexpression had objective responses to treatment with trastuzumab plus pertuzumab (two CR, 28 PR). \\nPatients with HER2-amplified/overexpressing metastatic colorectal cancer composed the largest tumor-pathway cohort. In this group of 37 patients with refractory disease (median, four previous lines of therapy), treatment with trastuzumab plus pertuzumab produced PRs in 14 patients (38%; 95% CI, 23% to 55%; Fig 2A). An additional four patients had SD > 120 days. The median DOR was 11 months (range, < 1 to 16+ months; 95% CI, 2.8 months to not estimable).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5983, \"name\"=>\"EID5983\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of seven patients (29%; 95% CI, 4% to 71%) with biliary cancer and HER2 amplification/overexpression had PR, and three had SD > 120 days\", \"disease\"=>{\"id\"=>1065, \"name\"=>\"Biliary Tract Cancer\", \"display_name\"=>\"Biliary Tract Cancer\", \"doid\"=>\"4607\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4607\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5982, \"name\"=>\"EID5982\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Three of nine patients (33%; 95% CI, 8% to 70%) with advanced bladder cancer and HER2 amplification/overexpression had responses (one CR ongoing at 15 months; two PR lasting 1 and 6 months), and two patients had SD > 120 days.\", \"disease\"=>{\"id\"=>18, \"name\"=>\"Bladder Carcinoma\", \"display_name\"=>\"Bladder Carcinoma\", \"doid\"=>\"4007\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4007\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5984, \"name\"=>\"EID5984\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Four of five patients with HER2 amplified/overexpressing salivary gland carcinoma (80%; 95% CI, 28% to > 99%) had responses (all PR).\", \"disease\"=>{\"id\"=>66, \"name\"=>\"Salivary Gland Carcinoma\", \"display_name\"=>\"Salivary Gland Carcinoma\", \"doid\"=>\"0050904\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050904\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1437, \"name\"=>\"EID1437\", \"description\"=>\"In a randomized phase 3 trial, HER2 positive metastatic breast cancer patients given first-line treatment of pertuzumab plus trastuzumb plus docetaxel experienced improved progression free survival (18.5 vs 12.4 months,  P<0.001) and increased objective response rate (80.2% vs 69.3%, P=0.001) than the control group given placebo plus trastuzumab plus docetaxel.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>971, \"name\"=>\"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.\", \"citation\"=>\"Baselga et al., 2012, N. Engl. J. Med.\", \"pubmed_id\"=>\"22149875\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22149875\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>1, \"day\"=>12}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1132, \"name\"=>\"EID1132\", \"description\"=>\"This Phase III trial took patients with locally advanced or metastatic HER2 (ERBB2) positive breast cancer that had progressed on prior trastuzumab treatment.  Patients were given capecitabine (n=161) or lapatinib plus capecitabine (n=163). The primary endpoint of the study was time to progression. Median time to progression was 4.4 months in the capecitabine group and 8.4 months in capecitabine plus lapatinib group (hazard ratio was 0.49 ; 95% confidence interval, 0.34 to 0.71; P<0.001).  The results indicated that lapatinib may be useful in addressing the problem of trastuzumab progression in HER2 breast cancer.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>32, \"name\"=>\"Capecitabine\", \"pubchem_id\"=>nil}, {\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>783, \"name\"=>\"Lapatinib plus capecitabine for HER2-positive advanced breast cancer.\", \"citation\"=>\"Geyer et al., 2006, N. Engl. J. Med.\", \"pubmed_id\"=>\"17192538\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17192538\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>12, \"day\"=>28}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1381, \"name\"=>\"EID1381\", \"description\"=>\"Pharmacologic (A66; p110alpha specific inhibitor) or genetic (cre-mediated knockout) ablation of the p110alpha PI3K isoform reduced tumor growth and tumor formation, respectively, in athymic mice transplanted with cells transduced by MMTV-NeuT (mammary specific overexpression of HER2 that effectively induces tumors). A66 treatment of cells from MMTV-NeuT mouse tumors resulted in decreased lipid kinase activity and phospho Akt levels.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>337, \"name\"=>\"A66\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>937, \"name\"=>\"The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.\", \"citation\"=>\"Utermark et al., 2012, Genes Dev.\", \"pubmed_id\"=>\"22802530\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22802530\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3404385\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>7, \"day\"=>15}, \"journal\"=>\"Genes Dev.\", \"full_journal_title\"=>\"Genes & development\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>961, \"name\"=>\"EID961\", \"description\"=>\"A phase II study involving adult female patients, >=18 years, with stage IIIB or IV HER2-positive (by IHC and/or in situ fluorescence) metastatic breast cancer. All patients were previously treated with trastuzumab and a median of three chemotherapy lines. 41 patients received 50 mg afatinib once-daily until disease progression and the primary endpoint was objective response rate. 4 patients (10% of 41 treated; 11% of evaluable patients) had partial response and 15 patients (37% of 41) had stable disease as best response. Thus a total of 19 (46% of 41) achieved clinical benefit. Median progression-free survival was 15.1 weeks.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>663, \"name\"=>\"A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.\", \"citation\"=>\"Lin et al., 2012, Breast Cancer Res. Treat.\", \"pubmed_id\"=>\"22418700\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22418700\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3387495\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>6}, \"journal\"=>\"Breast Cancer Res. Treat.\", \"full_journal_title\"=>\"Breast cancer research and treatment\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>887, \"name\"=>\"EID887\", \"description\"=>\"In this phase 2 trial, treatment-naive, ERBB2-positive (by IHC) breast cancer patients with stage IIIA, B, C or inflammatory disease were randomized 1:1:1 to afatinib (n = 10), lapatinib (n = 8), or trastuzumab (n = 11). The primary end point was objective response rate. Objective response was seen in 8 afatinib-, 6 lapatinib-, and 4 trastuzumab-treated patients. Afatinib demonstrated clinical activity that compared favorably to trastuzumab and lapatinib for neoadjuvant treatment of HER2-positive breast cancer.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>597, \"name\"=>\"A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.\", \"citation\"=>\"Rimawi et al., 2015, Clin. Breast Cancer\", \"pubmed_id\"=>\"25537159\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25537159\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>4}, \"journal\"=>\"Clin. Breast Cancer\", \"full_journal_title\"=>\"Clinical breast cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1499, \"name\"=>\"EID1499\", \"description\"=>\"ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive (overexpression or amplification) advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer.\", \"disease\"=>{\"id\"=>147, \"name\"=>\"Gastric Adenocarcinoma\", \"display_name\"=>\"Gastric Adenocarcinoma\", \"doid\"=>\"3717\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3717\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>708, \"name\"=>\"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.\", \"citation\"=>\"Bang et al., 2010, Lancet\", \"pubmed_id\"=>\"20728210\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20728210\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>8, \"day\"=>28}, \"journal\"=>\"Lancet\", \"full_journal_title\"=>\"Lancet (London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1050, \"name\"=>\"EID1050\", \"description\"=>\"Efficacy of trastuzumab in HER2 overexpressing NSCLC remains unclear.  In this study using a panel of NSCLC HER2 overexpressing cell lines, antiproliferative effects of trastuzumab emtansine (T-DM1) were observed in a HER2-expression dependant manner, with strongest effects in Calu-3 (high expressing) and no effects in Calu-6 (low expressing).  Trastuzumab did not show notable effects on cell growth in any tested cells.  HER2 positivity in NSCLC is fairly common at 2-20%.  A clinical trial (NCT02289833) is currently underway to asses TDM-1 in HER2 overexpressing lung cancer.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>730, \"name\"=>\"Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.\", \"citation\"=>\"Cretella et al., 2014, Mol. Cancer\", \"pubmed_id\"=>\"24898067\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24898067\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4058446\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Mol. Cancer\", \"full_journal_title\"=>\"Molecular cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1097, \"name\"=>\"EID1097\", \"description\"=>\"HER2 expression in uterine serous papillary carcinoma (USPC) is thought to be associated with poor prognosis and may act as a targetable driver mutation in this cancer.  HER2 overexpression in USPC is more common in African American women.  This report covered 2 African American patients, the first of which presented high-grade endometrial adenocarcinoma with IHC3+ HER2-positivity as well as positivity by FISH.  Prior treatment involved surgery and chemotherapy.  Treatment with pacitaxel/carboplatin with trastuzumab showed clear clinical improvement assessed by CT scan and drop in CA-125 levels from 988 to 7.9 U/mL.  The second patient had USPC, and was treated with surgery and radiation.  Trastuzumab monotheraby was then administered.  After 7 months of treatment, the patient showed no sign of disease progression and CA-125 had dropped from 144 to 41 U/mL.  The investigators conclude there is promise in trastuzumab-based therapies in advanced endometrial cancers, including USPC.\", \"disease\"=>{\"id\"=>185, \"name\"=>\"Uterine Corpus Serous Adenocarcinoma\", \"display_name\"=>\"Uterine Corpus Serous Adenocarcinoma\", \"doid\"=>\"5750\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5750\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>756, \"name\"=>\"Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.\", \"citation\"=>\"Santin et al., 2008, Int J Gynaecol Obstet\", \"pubmed_id\"=>\"18555254\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18555254\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>8}, \"journal\"=>\"Int J Gynaecol Obstet\", \"full_journal_title\"=>\"International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1044, \"name\"=>\"EID1044\", \"description\"=>\"This report details 2 case studies in relapsed HER2 positive SCLC.  In the first case, a 50 pack-year patient showed intense non-mutant HER2 expression by IHC without DNA amplification, and had undergone multiple prior lines of treatment.  With induction of trastuzumab and irinotecan treatment, tumor regression was observed with progression free survival of 4.5 months.  Case 2 involved a 68 year old never-smoker with relapsed SCLC.  Tumor showed HER2 positive SCLC cells with no amplification or mutation.  Third line trastuzumab plus irinotecan brought about some symptom improvement and PFS of 3.5 months.  While the efficacy of trastuzumab against NSCLC with elevated levels of wild-type HER2 expression remains unclear, the authors conclude that trastuzumab based therapy is a promising strategy for chemo-resistant SCLC.\", \"disease\"=>{\"id\"=>174, \"name\"=>\"Lung Small Cell Carcinoma\", \"display_name\"=>\"Lung Small Cell Carcinoma\", \"doid\"=>\"5409\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5409\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>101, \"name\"=>\"Irinotecan\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>727, \"name\"=>\"Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.\", \"citation\"=>\"Kinehara et al., 2015, Lung Cancer\", \"pubmed_id\"=>\"25601188\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25601188\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>3}, \"journal\"=>\"Lung Cancer\", \"full_journal_title\"=>\"Lung cancer (Amsterdam, Netherlands)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1686, \"name\"=>\"EID1686\", \"description\"=>\"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.\\nAmong 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective patient cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1138, \"name\"=>\"A molecularly annotated platform of patient-derived xenografts (\\\"xenopatients\\\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.\", \"citation\"=>\"Bertotti et al., 2011, Cancer Discov\", \"pubmed_id\"=>\"22586653\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22586653\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1687, \"name\"=>\"EID1687\", \"description\"=>\"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed resistance whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1138, \"name\"=>\"A molecularly annotated platform of patient-derived xenografts (\\\"xenopatients\\\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.\", \"citation\"=>\"Bertotti et al., 2011, Cancer Discov\", \"pubmed_id\"=>\"22586653\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22586653\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1688, \"name\"=>\"EID1688\", \"description\"=>\"HER2 amplification (FISH) was assessed in 170 KRAS wt mCRC patients treated with cetuximab or panitumumab.\\nHER2 copy number status was significantly correlated with respoinse rate, PFS and OS. Patients with amplification in all neoplastic cells (4%) had worse outcome compared to patients without amplification (35%, intermediate outcome) or amplification in minor clones (61%, highest survival probability)\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1139, \"name\"=>\"HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.\", \"citation\"=>\"Martin et al., 2013, Br. J. Cancer\", \"pubmed_id\"=>\"23348520\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23348520\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3593567\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>2, \"day\"=>19}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1689, \"name\"=>\"EID1689\", \"description\"=>\"Phase 2 study in 27 patients with HER2 positive (IHC, FISH), KRAS wt metastatic colorectal cancer refractory to standard of care received trastuzumab and lapatinib.\\nAfter a median follow-up of 94 weeks, eight (30%, 95% CI 14-50) of 27 patients had achieved an objective response, with one patient (4%, 95% CI -3 to 11) achieving a complete response, and seven (26%, 95% CI 9-43) achieving partial responses; 12 (44%, 95% CI 25-63) patients had stable disease.\\nA total of 914 patients with KRAS wt were screened for this study, 48 patients (5%) were identified to have HER2-positive tumors.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1140, \"name\"=>\"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.\", \"citation\"=>\"Sartore-Bianchi et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"27108243\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27108243\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1764, \"name\"=>\"EID1764\", \"description\"=>\"In the single arm Phase II study (TDM4258g) breast cancer patients who had progressed on previous anti-HER2 therapy were given transtuzumab emtansine (T-DM1), a HER2 monoclonal antibody and antimicrotubule drug conjugate. 95 trial participants with archival primary tumor were reassessed for HER2 status (positivity defined by FISH or IHC 3+), and 74 patients were confirmed for HER2 positivity and 21 were normal. Overall response rate was 33.8% (95% CI, 23.2% to 44.9%) in patients with confirmed HER2-positive tumors and 4.8% (95% CI, 1.0% to 21.8%) in HER2 normal patients. Median PFS was 8.2 months (95% CI, 4.4 months to not estimable) in patients with confirmed HER2-positive tumors and 2.6 months (95% CI, 1.4 to 3.9 months) in HER2 normal patients.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1229, \"name\"=>\"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.\", \"citation\"=>\"Burris et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21172893\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21172893\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1448, \"name\"=>\"EID1448\", \"description\"=>\"In 5 trastuzumab resistant HER2 overexpressing breast cancer cell lines, combination of the pan-PI3K inhibitor XL147 and trastuzumab treatment induced cell death to similar or greater levels than XL147 alone. In three trastuzumab resistant cell lines tested, colony formation in matrigel was markedly inhibited by combination treatment. Apoptotic markers were apparent with combination treatment. In athymic mice, trastuzumab resistant cell line HR6 was used in tumor xenografts and tumors were allowed to form. Mice subsequently treated with trastuzumab or XL147 showed continued tumor growth without marked difference from control, while combination treatment essentially halted tumor growth rate.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>349, \"name\"=>\"XL147 (Pilaralisib)\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>977, \"name\"=>\"Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.\", \"citation\"=>\"Chakrabarty et al., 2013, Cancer Res.\", \"pubmed_id\"=>\"23204226\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23204226\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3563941\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1042, \"name\"=>\"EID1042\", \"description\"=>\"In this phase II trial a small group of patients with IHC2+ or IHC3+ HER2 NSCLC, in which primary platinum-based therapy had failed, were given either docetaxel or trastuzumab after which both groups were given docetaxel and trastuzumab together.  there was one partial response in the docetaxel group and none in the trastuzumab group.  The authors report that due to the limited clinical activity of trastuzumab-based therapy in this cohort, as well as similar results in other trastuzumab studies, that targets other than HER2 in NSCLC should be considered for future study.  This 2004 study remains cited in 2016 literature in discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC, but mutant HER2 in NSCLC has been further studied and a picture of different HER2 mutations being potentially responsive to specific targeted therapies is emerging.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>725, \"name\"=>\"Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.\", \"citation\"=>\"Lara et al., 2004, Clin Lung Cancer\", \"pubmed_id\"=>\"14967075\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/14967075\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>1}, \"journal\"=>\"Clin Lung Cancer\", \"full_journal_title\"=>\"Clinical lung cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1380, \"name\"=>\"EID1380\", \"description\"=>\"The HER2/Neu mammary tumor mouse model MMTV-NeuT was employed to demonstrate dependence of HER2 tumor formation on PIK3 p110alpha isoform. MMTV-NeuT mice were crossed with floxed p110alpha mice. Diassacociated tumors cells from these mice were treated with Cre adenovirus to delete p110alpha, or GFP adenovirus, and cells were transplanted into athymic mice. GFP treated cells formed new tumors, while p110alpha deletion blocked tumor formation indicating tumor dependence on PI3KA. Next, MMTV-NeuT tumors were dissociated and treated with pan-PI3K inhibitor GDC-0941. Reduced lipid kinase activity and reduced phospho-Akt levels were seen in these cells. Administration of 125 mg/kg GDC-0941 to athymic mice with transplantation of tumor cells caused marked reduction of tumor cell volume in comparison to control treatment.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>141, \"name\"=>\"Pictilisib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>937, \"name\"=>\"The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.\", \"citation\"=>\"Utermark et al., 2012, Genes Dev.\", \"pubmed_id\"=>\"22802530\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22802530\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3404385\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>7, \"day\"=>15}, \"journal\"=>\"Genes Dev.\", \"full_journal_title\"=>\"Genes & development\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1439, \"name\"=>\"EID1439\", \"description\"=>\"In a randomized open label phase 3 study (NCT00553358), women with HER2 positive primary breast cancer treated with lapatinib plus trasuzumab had higher rates of pathological complete responses than seen in control groups receiving either IV trastuzumab or oral lapatinib alone (combination treatment pCR rate of 51% vs 29.5% and 24.7% for trastuzumab and lapatinib alone, respectively).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>972, \"name\"=>\"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.\", \"citation\"=>\"Baselga et al., 2012, Lancet\", \"pubmed_id\"=>\"22257673\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22257673\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>2, \"day\"=>18}, \"journal\"=>\"Lancet\", \"full_journal_title\"=>\"Lancet (London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1382, \"name\"=>\"EID1382\", \"description\"=>\"Treatment of cells obtained from MMTV-NeuT mouse mammary tumors with the p110beta selective inhibitor TGX-221 showed significant but minimal reductions in lipid kinase activity and negligible reductions in phospho Akt levels. In simmilar cells subjected to p110alpha isoform knockout, TGX-221 treatment fully blocked Akt activation, indicating that TGX-221 was fully inhibiting the p110beta isoform. Athymic mice recieved MMTV-NeuT tumor cell transplants and were treated with TGX-221, which resulted in significant but minimal reduction in tumor growth compared to controls.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>338, \"name\"=>\"Tgx 221\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>937, \"name\"=>\"The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.\", \"citation\"=>\"Utermark et al., 2012, Genes Dev.\", \"pubmed_id\"=>\"22802530\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22802530\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3404385\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>7, \"day\"=>15}, \"journal\"=>\"Genes Dev.\", \"full_journal_title\"=>\"Genes & development\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1693, \"name\"=>\"EID1693\", \"description\"=>\"A 71-year old male with metastatic extramammary Pagetâs disease of the scrotum overexpressing Her2/neu was treated with trastuzumab, achieving a complete response. At 12 months, he maintains stable disease.\", \"disease\"=>{\"id\"=>779, \"name\"=>\"Scrotum Paget's Disease\", \"display_name\"=>\"Scrotum Paget's Disease\", \"doid\"=>\"3444\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3444\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1142, \"name\"=>\"Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.\", \"citation\"=>\"Barth et al., 2015, Case Rep Oncol Med\", \"pubmed_id\"=>\"25692060\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25692060\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4322830\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"Case Rep Oncol Med\", \"full_journal_title\"=>\"Case reports in oncological medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1393, \"name\"=>\"EID1393\", \"description\"=>\"155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 2 of 24 patients tested were found to have HER2 amplification (but no baseline samples available for analysis). One patient of which had a metastasis sample which was reported to have only HER2 amplification whereas another autopsy specimen from the same patient was HER2 negative but EGFR T790M positive.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}, {\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>943, \"name\"=>\"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.\", \"citation\"=>\"Yu et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23470965\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23470965\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3630270\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1891, \"name\"=>\"EID1891\", \"description\"=>\"Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. 4 patients with HER2 amplified NSCLC were enrolled in the trial, no one among them had a response.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>44, \"name\"=>\"Dacomitinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>729, \"name\"=>\"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.\", \"citation\"=>\"Kris et al., 2015, Ann. Oncol.\", \"pubmed_id\"=>\"25899785\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25899785\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>7}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1432, \"name\"=>\"EID1432\", \"description\"=>\"In a randomized phase II study, first line treatment of HER2-positive metastatic breast cancer with trastuzumab emtansine (T-DM1) resulted in improved progression free survival and fewer serious adverse effects when compared to treatment with combination trastuzumab plus docetaxel (HT) (median follow up 14 months, median PFS with T-DM1 14.2 vs 9.2 with HT).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>970, \"name\"=>\"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.\", \"citation\"=>\"Hurvitz et al., 2013, J. Clin. Oncol.\", \"pubmed_id\"=>\"23382472\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23382472\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>3, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1098, \"name\"=>\"EID1098\", \"description\"=>\"This phase II single arm study assessed trastuzumab monotherapy in HER2 positive endometrial cancers with tumor response as primary endpoint.  Participants had stage III, IV or recurrent HER2 positive endometrial cancer.  During the trial's initial phase, 23 of 132 patients screened met the criteria of IHC2+ or 3+ or FISH positivity for HER2 status.  In the absence of results, the trial entered phase B, where only patients with HER2 amplification by FISH were admitted.  The trial ended early due to poor accrual with 11 of 154 screened meeting the phase B criteria. No major objective tumor responses were observed in the study.  28% of the cancers were of the serous type that had shown trastuzumab response in case studies.  The investigators note that in other HER2 cancers, such as breast and gastrointestinal, trastuzumab in combination with chemotherapy has been found most effective, and could warrant more study.  Currently a clinical trial (NCT01367002) is evaluating carboplatin/paclitaxel with or without trastuzumab in uterine serous cancer.\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>757, \"name\"=>\"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.\", \"citation\"=>\"Fleming et al., 2010, Gynecol. Oncol.\", \"pubmed_id\"=>\"19840887\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19840887\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2804260\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>1}, \"journal\"=>\"Gynecol. Oncol.\", \"full_journal_title\"=>\"Gynecologic oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1077, \"name\"=>\"EID1077\", \"description\"=>\"CLEOPATRA (NCT00567190) was a Phase III, randomized and double-blind, placebo-controlled study of 808 patients with HER2-positive metastatic breast cancer.  Patients were HER2-positive by IHC3+ or FISH, and patients who had received prior hormonal treatment or adjuvant/neo-adjuvant therapy with or without trastuzumab for longer than 12 months before randomization were also eligible.  The two arms of the study were trastuzumab and docetaxel with either placebo or pertuzumab.  Median PFS in the placebo arm was 12.4 months while in the petuzumab arm 18.5 months was achieved.  Median OS in the control arm was 40.8 months and 56.5 months with pertuzumab.  These strong results make a case for dual antibody blockade in first line treatments of HER2-positive metastatic breast cancer.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>745, \"name\"=>\"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.\", \"citation\"=>\"Swain et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"25693012\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25693012\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>2, \"day\"=>19}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1096, \"name\"=>\"EID1096\", \"description\"=>\"In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient information.  Earlier deaths were seen with heavier HER2 expression.  Multivariate Cox regression indicated that shorter survival was associated with higher HER2 expression, and not with age or ethnicity, and that observed differences in survival rates between ethnicities can be ascribed to higher rates of HER2 overexpression in African American patients.  The authors conclude that high HER2 expression in USPC is associated with poor outcome and explains observed differences in outcome between ethnicities.\", \"disease\"=>{\"id\"=>185, \"name\"=>\"Uterine Corpus Serous Adenocarcinoma\", \"display_name\"=>\"Uterine Corpus Serous Adenocarcinoma\", \"doid\"=>\"5750\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5750\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>755, \"name\"=>\"Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.\", \"citation\"=>\"Santin et al., 2005, Am. J. Obstet. Gynecol.\", \"pubmed_id\"=>\"15746676\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15746676\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>3}, \"journal\"=>\"Am. J. Obstet. Gynecol.\", \"full_journal_title\"=>\"American journal of obstetrics and gynecology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1041, \"name\"=>\"EID1041\", \"description\"=>\"In this phase II trial with 2 arms, 103 patients with untreated stage IIIB/IV HER2 positive NSCLC were given gemcitabine-cisplatin with or without trastuzumab.  HER2 positivity was broadly defined as IHC2+/3+, positive by FISH, or increased circulating HER2 extracellular domain.  Significant differences between the treatment arms were not observed, but in a small subset of IHC3+/FISH positive patients, 5 of 6 responded to trastuzumab and had increased PFS of 8.5 months in comparison to 6.1 months in the IHC2+ group.  Although from 2004, this study remains cited in 2016 literature when discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC. The authors conclude that future studies of trastuzumab in HER2 positive NSCLC should focus on high expressing subjects.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>724, \"name\"=>\"Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.\", \"citation\"=>\"Gatzemeier et al., 2004, Ann. Oncol.\", \"pubmed_id\"=>\"14679114\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/14679114\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>1}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1122, \"name\"=>\"EID1122\", \"description\"=>\"HERA was a Phase III trial assessing application of trastuzumab in an extended adjuvant setting.  Patients were HER2 positive with completely excised invasive BC, node positive or negative, and having undergone prior adjuvant or neo-adjuvant chemotherapy.  In the 3 arm study patients were given trastuzumab courses of 1 year, 2 years, or untreated.  At the first planned interim analysis, trastuzumab treatment for one year was compared with observation alone.  A significant difference in disease-free survival was seen with 220 DFS events out of 1693 in the observation arm versus 127 DFS events out of 1694 in the 1 year trastuzumab arm.  1 year adjuvant trastuzumab is currently the standard of care.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>777, \"name\"=>\"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.\", \"citation\"=>\"Piccart-Gebhart et al., 2005, N. Engl. J. Med.\", \"pubmed_id\"=>\"16236737\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16236737\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>10, \"day\"=>20}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1561, \"name\"=>\"EID1561\", \"description\"=>\"In a panel of 47 breast cancer cell lines, HER2 overexpressing cells were among those more sensitive to CDK4/6 inhibitor Palbociclib (PD0332991). In the trastuzumab sensitive cell line Bt474, palbociclib synergized with trastuzumab in growth inhibition, while in 2 trastuzumab resistant cell lines, addition of trastuzumab to palbociclib treatment resulted in increased growth inhibition over palbociclib alone.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>48, \"name\"=>\"Palbociclib (PD0332991)\", \"pubchem_id\"=>\"\"}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1031, \"name\"=>\"PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.\", \"citation\"=>\"Finn et al., 2009, Breast Cancer Res.\", \"pubmed_id\"=>\"19874578\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19874578\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2790859\", \"publication_date\"=>{\"year\"=>2009}, \"journal\"=>\"Breast Cancer Res.\", \"full_journal_title\"=>\"Breast cancer research : BCR\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1613, \"name\"=>\"EID1613\", \"description\"=>\"In a panel of 31 breast cancer cell lines with varied mutation backgrounds, 10 cell lines harbored HER2 (ERBB2) amplification. Sensitivity to the mTORC1/2 inhibitor PP242 was assessed, and 8/10 HER2 positive cell lines were reported to be sensitive (IC50 < 1 micro molar PP242).  8/21 without HER2 amplification were reported as resistant (IC50 > 1 micro molar PP242). This pattern of HER2 positive cell sensitivity was not reported with the rapamycin analog  mTORC1 inhibitor everolimus.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>179, \"name\"=>\"PP242\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1066, \"name\"=>\"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.\", \"citation\"=>\"Weigelt et al., 2011, Oncogene\", \"pubmed_id\"=>\"21358673\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21358673\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>7, \"day\"=>21}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1022, \"name\"=>\"EID1022\", \"description\"=>\"ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer.\", \"disease\"=>{\"id\"=>147, \"name\"=>\"Gastric Adenocarcinoma\", \"display_name\"=>\"Gastric Adenocarcinoma\", \"doid\"=>\"3717\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3717\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>708, \"name\"=>\"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.\", \"citation\"=>\"Bang et al., 2010, Lancet\", \"pubmed_id\"=>\"20728210\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20728210\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>8, \"day\"=>28}, \"journal\"=>\"Lancet\", \"full_journal_title\"=>\"Lancet (London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1010, \"name\"=>\"EID1010\", \"description\"=>\"With multiple mechanisms of HER reprogramming thought to be behind trastuzumab resistance, including increased expression of ErbB members, afatinib, which broadly and irreversibly targets ErbB receptors was tested in a single arm phase II trial on advanced stage HER2 positive metastatic breast cancer. From 41 treated patients, 10% had partial response, 37% had stable disease as best response and 46% achieved clinical benefit.  Median progression free survival (PFS) was 15.1 weeks and median overall survival (OS) was 61.0 weeks. The authors conclude that Afatinib monotherapy shows promise in treatment of metastatic HER2 positive breast cancer that has progressed under trastuzumab.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>663, \"name\"=>\"A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.\", \"citation\"=>\"Lin et al., 2012, Breast Cancer Res. Treat.\", \"pubmed_id\"=>\"22418700\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22418700\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3387495\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>6}, \"journal\"=>\"Breast Cancer Res. Treat.\", \"full_journal_title\"=>\"Breast cancer research and treatment\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1009, \"name\"=>\"EID1009\", \"description\"=>\"This Phase III study (EGF104900) was motivated by preclinical and other data demonstrating synergistic activity between lapatinib and trastuzumab against HER2 positive breast cancer (BC) cells.  In this study of HER2 positive metastatic BC which had progressed on trastuzumab, two arms were compared: lapatinib vs. lapatinib + trastuzumab. Progression free survival (PFS) was the primary endpoint. For 296 patients, 148 in each arm, median PFS of 8.1 weeks for lapatinib and 12.0 for combination therapy was observed (P=0.008).  The authors conclude that in the context of metastatic trastuzumab-progressed HER2 positive BC, trastuzumab with lapatinib TKI addition is a favorable treatment.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>698, \"name\"=>\"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.\", \"citation\"=>\"Blackwell et al., 2010, J. Clin. Oncol.\", \"pubmed_id\"=>\"20124187\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20124187\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>962, \"name\"=>\"EID962\", \"description\"=>\"Afatinib was growth-inhibitory for three pancreatic cancer cell lines but cytotoxic only toward BxPC3 (KRAS wt) and Capan-2 (KRAS mut) cells, both of which express high levels of EGFR, ERBB2, and ERBB3 receptors. Afatinib increased the radiosensitivity of BxPC3 and Capan-2 cells. In comparison, Panc-1 cells (KRAS mut) expressing low levels of EGFR family receptors were resistant to afatinib-induced radiosensitization.\", \"disease\"=>{\"id\"=>158, \"name\"=>\"Pancreatic Adenocarcinoma\", \"display_name\"=>\"Pancreatic Adenocarcinoma\", \"doid\"=>\"4074\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4074\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>664, \"name\"=>\"Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.\", \"citation\"=>\"Huguet et al., 2016, Target Oncol\", \"pubmed_id\"=>\"26668065\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26668065\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Target Oncol\", \"full_journal_title\"=>\"Targeted oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>895, \"name\"=>\"EID895\", \"description\"=>\"141 patients were analyzed for ERBB2 (HER2) positivity by FISH and/or IHC. Only 6 (4.3%) were ERBB2 positive. These patients did not show a difference in outcome after capecitabine, oxaliplatin and chemoradiotherapy, with or without cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>32, \"name\"=>\"Capecitabine\", \"pubchem_id\"=>nil}, {\"id\"=>237, \"name\"=>\"Oxaliplatin\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>603, \"name\"=>\"HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.\", \"citation\"=>\"Sclafani et al., 2013, Ann. Oncol.\", \"pubmed_id\"=>\"24146218\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24146218\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>12}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>886, \"name\"=>\"EID886\", \"description\"=>\"Eight uterine cancer cell lines (four with ERBB2 amplification and four without) were treated with scalar concentrations of afatinib. Primary chemotherapy-resistant USC cell lines harbouring ERBB2 gene amplification were sensitive to afatinib exposure and significantly more sensitive than non-amplified cell lines.\", \"disease\"=>{\"id\"=>93, \"name\"=>\"Uterine Corpus Endometrial Carcinoma\", \"display_name\"=>\"Uterine Corpus Endometrial Carcinoma\", \"doid\"=>\"0050939\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050939\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>596, \"name\"=>\"Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.\", \"citation\"=>\"Schwab et al., 2014, Br. J. Cancer\", \"pubmed_id\"=>\"25268372\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25268372\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4453741\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>10, \"day\"=>28}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1023, \"name\"=>\"EID1023\", \"description\"=>\"TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer.  Primary endpoint was Overall Survival (OS).  Participants had progressed under previous treatment and only a small percentage had seen first line trastuzumab.  Patients were a mix of those having undergone gastrectomy and not.  OS was not significantly  different in the ITT population, but certain subpopulations showed significant differences.  In the subset of patients showing a stronger immunohistochemistry result for HER2 (IHC3+), progression free survival was significantly different at 5.6 months for lapatinib + pacitaxel vs. 4.2 months for pacitaxel alone.  The authors conclude that proof of concept for lapatanib addition to chemotherapy for certain subgroups is provided in this study.\", \"disease\"=>{\"id\"=>147, \"name\"=>\"Gastric Adenocarcinoma\", \"display_name\"=>\"Gastric Adenocarcinoma\", \"doid\"=>\"3717\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3717\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>709, \"name\"=>\"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.\", \"citation\"=>\"Satoh et al., 2014, J. Clin. Oncol.\", \"pubmed_id\"=>\"24868024\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24868024\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1006, \"name\"=>\"EID1006\", \"description\"=>\"In-vitro studies using ERBB2 over-expressing breast cancer cell lines BT474 and SKBR3 (with ERBB2 amplification) showed apoptosis under either labatinib or trastuzumab treatment.  A marked synergistic apoptotic effect under lapatinib and trastuzumab co-treatment was observed in BT474 cells, and a milder synergistic effect was observed in SKBR3 cells.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>695, \"name\"=>\"Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.\", \"citation\"=>\"Xia et al., 2005, Oncogene\", \"pubmed_id\"=>\"16091755\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16091755\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>9, \"day\"=>15}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>760, \"name\"=>\"EID760\", \"description\"=>\"Xenografts established from breast cancer cell lines with ERBB2 amplification and PIK3CA mutation (BT474) or PIK3CA mutation alone (MCF7) were effectively inhibited in-vivo with an AKT1/2-inhibitor (AKTi-1/2; naphthyridinone).\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>169, \"name\"=>\"AKTi-1/2\", \"pubchem_id\"=>\"\"}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>503, \"name\"=>\"Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.\", \"citation\"=>\"She et al., 2008, PLoS ONE\", \"pubmed_id\"=>\"18725974\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18725974\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2516933\", \"publication_date\"=>{\"year\"=>2008}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>761, \"name\"=>\"EID761\", \"description\"=>\"Oral neratinib showed objective response rates of 24 and 56% respectively in prior-trastuzumab and trastuzumab-naive cohorts in a Phase II trial with a primary endpoint of 16-week progression free survival.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>52, \"name\"=>\"Neratinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>504, \"name\"=>\"Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.\", \"citation\"=>\"Burstein et al., 2010, J. Clin. Oncol.\", \"pubmed_id\"=>\"20142587\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20142587\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>3, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}]}, {\"id\"=>214, \"entrez_name\"=>\"PTEN\", \"entrez_id\"=>5728, \"name\"=>\"LOSS\", \"description\"=>\"\", \"gene_id\"=>41, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>229.0, \"coordinates\"=>{\"chromosome\"=>\"10\", \"start\"=>89622870, \"stop\"=>89731687, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000371953.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/41/summary/variants/214/summary#variant\", \"evidence_items\"=>[{\"id\"=>5840, \"name\"=>\"EID5840\", \"description\"=>\"In a single-arm, open label phase 2 trial in PIK3CA amplified/mutated and/or PTEN loss encompassing 10 patients, no objective responses were observed but a stable disease response in 4 patients, resulting in a median PFS of 1.4 months. Everolimus failed to meet its enpoint.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2364, \"name\"=>\"Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.\", \"citation\"=>\"Kim et al., 2017, BMC Cancer\", \"pubmed_id\"=>\"28330462\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28330462\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5363054\", \"publication_date\"=>{\"year\"=>2017, \"month\"=>3, \"day\"=>23}, \"journal\"=>\"BMC Cancer\", \"full_journal_title\"=>\"BMC cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>5957, \"name\"=>\"EID5957\", \"description\"=>\"No objective responses were observed in the PTEN deficient cohort. Four out of 6 patients with stable disease (SD) had SD or better for â¥6 cycles, 2 of which had PTEN deficient tumors. Conclusion The addition of buparlisib to high dose carboplatin and paclitaxel was not tolerable. The combination did not reveal significant clinical activity amongst a small and heterogenous group of PTEN deficient tumors.\", \"disease\"=>{\"id\"=>2616, \"name\"=>\"Solid Tumor\", \"display_name\"=>\"Solid Tumor\", \"doid\"=>\"\", \"url\"=>\"http://www.disease-ontology.org/\"}, \"drugs\"=>[{\"id\"=>81, \"name\"=>\"Paclitaxel\", \"pubchem_id\"=>nil}, {\"id\"=>93, \"name\"=>\"Carboplatin\", \"pubchem_id\"=>nil}, {\"id\"=>116, \"name\"=>\"Buparlisib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2413, \"name\"=>\"A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.\", \"citation\"=>\"Smyth et al., 2017, Invest New Drugs\", \"pubmed_id\"=>\"28281183\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28281183\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5591764\", \"publication_date\"=>{\"year\"=>2017, \"month\"=>12}, \"journal\"=>\"Invest New Drugs\", \"full_journal_title\"=>\"Investigational new drugs\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT01297452\", \"name\"=>\"BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors\", \"description\"=>\"The purpose of this study is to find out the good and bad effects that occur when BKM120 is added to standard chemotherapy with carboplatin and paclitaxel.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT01297452\"}]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1502, \"name\"=>\"EID1502\", \"description\"=>\"In a panel of 182 cell lines (162 with PIK3CA mutation status known) from solid and hematological tumors, significant correlation was found between AZD5363 (pan-Akt inhibitor) sensitivity and PIK3CA mutation status (N=33, p=0.0059). In the subpopulation free of RAS mutation (N=19) the correlation was increased.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>112, \"name\"=>\"AZD5363\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1005, \"name\"=>\"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.\", \"citation\"=>\"Davies et al., 2012, Mol. Cancer Ther.\", \"pubmed_id\"=>\"22294718\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22294718\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1455, \"name\"=>\"EID1455\", \"description\"=>\"Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance. PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition, but co-treatment with trastuzumab and LY294002 induced growth inhibition comparable to trastuzumab alone in normal BT474 cells. BT474 mouse xenograft tumors were injected with PTEN antisense (AS) oligonucleotides and this resulted in trastuzumab resitance. Co-treatment of PTEN AS tumor mice with LY294002 and trastuzumab inhibited tumor growth in comparison to PTEN AS tumors treated with trastuzumab or LY294002 alone.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>115, \"name\"=>\"LY294002\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>983, \"name\"=>\"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.\", \"citation\"=>\"Nagata et al., 2004, Cancer Cell\", \"pubmed_id\"=>\"15324695\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15324695\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>8}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1493, \"name\"=>\"EID1493\", \"description\"=>\"Cancer and normal tissue samples were taken from 68 gastric cancer patients undergoing surgery without prior chemotherapy. Tissue samples were divided into high grade and low grade for phospho Akt (p-Akt) expression, and tested for PTEN LOH by sequencing. Patients with PTEN LOH were significantly more likely to have elevated p-Akt (p=0.0081), and high p-Akt samples were significantly less sensitive to chemotherapy agents 5-flourouracil, adriamycin, mitomycin and cis-platinum in MTT assay.\", \"disease\"=>{\"id\"=>1322, \"name\"=>\"Stomach Carcinoma\", \"display_name\"=>\"Stomach Carcinoma\", \"doid\"=>\"5517\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5517\"}, \"drugs\"=>[{\"id\"=>199, \"name\"=>\"Chemotherapy\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1000, \"name\"=>\"Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.\", \"citation\"=>\"Oki et al., 2005, Int. J. Cancer\", \"pubmed_id\"=>\"15900596\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15900596\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>11, \"day\"=>10}, \"journal\"=>\"Int. J. Cancer\", \"full_journal_title\"=>\"International journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1383, \"name\"=>\"EID1383\", \"description\"=>\"A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance. The most prominently enriched gene in trastuzumab resistant populations was PTEN. Subsequent knockdown of PTEN in BT-474 cells increased cell survival when treated with trastuzumab, and growth curves showed partial restoration of proliferation in PTEN knockdown BT-474 cells treated with trastuzumab.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>938, \"name\"=>\"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.\", \"citation\"=>\"Berns et al., 2007, Cancer Cell\", \"pubmed_id\"=>\"17936563\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17936563\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2007, \"month\"=>10}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1492, \"name\"=>\"EID1492\", \"description\"=>\"A cisplatin resistant derivative of ovarian cancer cell line OVCAR-3 was generated by long term passage with increasing cisplatin levels. Western blot showed decreased PTEN level in the resistant cell line, and siRNA against PTEN in parent OVCAR-3 cells induced cisplatin resistance.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>326, \"name\"=>\"Cisplatin\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>999, \"name\"=>\"Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.\", \"citation\"=>\"Lee et al., 2005, Gynecol. Oncol.\", \"pubmed_id\"=>\"15790433\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15790433\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>4}, \"journal\"=>\"Gynecol. Oncol.\", \"full_journal_title\"=>\"Gynecologic oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1385, \"name\"=>\"EID1385\", \"description\"=>\"A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and PTEN loss alone was found to be significantly associated with resistance to trastuzumab (p=0.028) and shorter overall survival (p=0.008).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>939, \"name\"=>\"PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.\", \"citation\"=>\"Esteva et al., 2010, Am. J. Pathol.\", \"pubmed_id\"=>\"20813970\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20813970\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2947262\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Am. J. Pathol.\", \"full_journal_title\"=>\"The American journal of pathology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1386, \"name\"=>\"EID1386\", \"description\"=>\"While some reports indicate PTEN loss is associated with resistance to trastuzumab, in a subgroup of HER2 breast cancer FFPE samples from patients receiving trastuzumab as later line therapy (second or greater line therapy), with 25 PTEN loss and and 25 normal samples, no association was seen between trastuzumab response and PTEN status (p=1.000) or overall survival and PTEN status (p=0.863).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>939, \"name\"=>\"PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.\", \"citation\"=>\"Esteva et al., 2010, Am. J. Pathol.\", \"pubmed_id\"=>\"20813970\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20813970\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2947262\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Am. J. Pathol.\", \"full_journal_title\"=>\"The American journal of pathology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1500, \"name\"=>\"EID1500\", \"description\"=>\"A patient derived mouse xenograft model was established with gastric cancer cells having PTEN loss. The xenograft was resistant to monotherapy with both the pan-Akt inhibitor AZD5363, and also to the commonly used gastric cancer chemotheraputic docetaxel. When used in combination, AZD5363 and docetaxel induced significant tumor growth inhibition in comparison to monotherapy and vehicle control.\", \"disease\"=>{\"id\"=>21, \"name\"=>\"Stomach Cancer\", \"display_name\"=>\"Stomach Cancer\", \"doid\"=>\"10534\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10534\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}, {\"id\"=>112, \"name\"=>\"AZD5363\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1004, \"name\"=>\"The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.\", \"citation\"=>\"Li et al., 2013, J Transl Med\", \"pubmed_id\"=>\"24088382\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24088382\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3850695\", \"publication_date\"=>{\"year\"=>2013}, \"journal\"=>\"J Transl Med\", \"full_journal_title\"=>\"Journal of translational medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1614, \"name\"=>\"EID1614\", \"description\"=>\"A panel of 24 endometroid endometrial cancer (EEC) cell lines was characterized for mutations and 18 cell lines were found to have mutations in PTEN or absence of expression. Cell lines were assessed for sensitivity to mTORC1 allosteric inhibitor temsirolimus, and it was reported that PTEN loss had significant association with temsirolimus sensitivity. .\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>83, \"name\"=>\"Temsirolimus\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1067, \"name\"=>\"PI3K pathway dependencies in endometrioid endometrial cancer cell lines.\", \"citation\"=>\"Weigelt et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23674493\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23674493\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3700760\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1297, \"name\"=>\"EID1297\", \"description\"=>\"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PTEN loss (as defined by IHC staining intensity and proportion of positive tumor cells) had a longer progression-free survival with everolimus compared to placebo (HR 0.54 (95%CI 0.31 to 0.96, P=0.04) whereas patients with PTEN normal status had a hazard ration of 1.00 (95%CI 0.8 to 1.26, P=0.97).\\nThe same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combined and analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>891, \"name\"=>\"Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.\", \"citation\"=>\"AndrÃ© et al., 2016, J. Clin. Oncol.\", \"pubmed_id\"=>\"27091708\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27091708\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1611, \"name\"=>\"EID1611\", \"description\"=>\"In a panel of 31 breast cancer cell lines, 11 had loss of PTEN function. Cells were tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/2 inhibitor PP242, and no significant correlation was found between PTEN status and sensitivity to mTORC inhibition.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}, {\"id\"=>179, \"name\"=>\"PP242\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1066, \"name\"=>\"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.\", \"citation\"=>\"Weigelt et al., 2011, Oncogene\", \"pubmed_id\"=>\"21358673\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21358673\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>7, \"day\"=>21}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>938, \"name\"=>\"EID938\", \"description\"=>\"Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.\", \"disease\"=>{\"id\"=>169, \"name\"=>\"Pancreatic Carcinoma\", \"display_name\"=>\"Pancreatic Carcinoma\", \"doid\"=>\"4905\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4905\"}, \"drugs\"=>[{\"id\"=>43, \"name\"=>\"MK-2206\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>641, \"name\"=>\"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.\", \"citation\"=>\"Yap et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"22025163\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22025163\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>12, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>864, \"name\"=>\"EID864\", \"description\"=>\"In 48 patients with advanced gastric cancer, retrospectively analyzed for PTEN expression using IHC, PTEN loss was associated with a shorter duration of response (median 4.2 vs. 6.1 months, p = 0.04) to HER2-targeted therapy (trastuzumab, N=39; lapatinib, N=9). Response rates did not differ between groups.\", \"disease\"=>{\"id\"=>147, \"name\"=>\"Gastric Adenocarcinoma\", \"display_name\"=>\"Gastric Adenocarcinoma\", \"doid\"=>\"3717\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3717\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>579, \"name\"=>\"PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.\", \"citation\"=>\"Zhang et al., 2015, Oncology\", \"pubmed_id\"=>\"25300346\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25300346\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"Oncology\", \"full_journal_title\"=>\"Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>893, \"name\"=>\"EID893\", \"description\"=>\"94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed.\\nNo predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss.\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>83, \"name\"=>\"Temsirolimus\", \"pubchem_id\"=>nil}, {\"id\"=>170, \"name\"=>\"Ridaforolimus\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>602, \"name\"=>\"Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.\", \"citation\"=>\"Mackay et al., 2014, Cancer\", \"pubmed_id\"=>\"24166148\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24166148\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>15}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>711, \"name\"=>\"EID711\", \"description\"=>\"Breast and prostate cancer cell lines responsive to AZD8186 were enriched for PTEN deficiency.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>114, \"name\"=>\"AZD8186\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>467, \"name\"=>\"Inhibition of PI3KÎ² signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.\", \"citation\"=>\"Hancox et al., 2015, Mol. Cancer Ther.\", \"pubmed_id\"=>\"25398829\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25398829\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>1}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>645, \"name\"=>\"EID645\", \"description\"=>\"PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free survival.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>406, \"name\"=>\"Therapeutic targeting of cancers with loss of PTEN function.\", \"citation\"=>\"Dillon et al., 2014, Curr Drug Targets\", \"pubmed_id\"=>\"24387334\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24387334\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4310752\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>1}, \"journal\"=>\"Curr Drug Targets\", \"full_journal_title\"=>\"Current drug targets\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>714, \"name\"=>\"EID714\", \"description\"=>\"All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>81, \"name\"=>\"Paclitaxel\", \"pubchem_id\"=>nil}, {\"id\"=>93, \"name\"=>\"Carboplatin\", \"pubchem_id\"=>nil}, {\"id\"=>116, \"name\"=>\"Buparlisib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>469, \"name\"=>\"Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.\", \"citation\"=>\"Hyman et al., 2015, Cancer Chemother. Pharmacol.\", \"pubmed_id\"=>\"25672916\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25672916\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>4}, \"journal\"=>\"Cancer Chemother. Pharmacol.\", \"full_journal_title\"=>\"Cancer chemotherapy and pharmacology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>716, \"name\"=>\"EID716\", \"description\"=>\"A case report described a responder to PI3K inhibitor BYL719 for a tumor with PIK3CA E542K mutation. After partial response for 9.5 months, resistance developed. Sequencing in this and other patients as well as preclinical models showed loss of PTEN as the probable mechanism of resistance.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>339, \"name\"=>\"BYL719 (Alpelisib)\", \"pubchem_id\"=>\"\"}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>471, \"name\"=>\"Convergent loss of PTEN leads to clinical resistance to a PI(3)KÎ± inhibitor.\", \"citation\"=>\"Juric et al., 2015, Nature\", \"pubmed_id\"=>\"25409150\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25409150\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4326538\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>2, \"day\"=>12}, \"journal\"=>\"Nature\", \"full_journal_title\"=>\"Nature\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>708, \"name\"=>\"EID708\", \"description\"=>\"Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor\\nGSK2141795B.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>111, \"name\"=>\"GSK2141795\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>465, \"name\"=>\"Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.\", \"citation\"=>\"Lassen et al., 2014, Mol. Cancer\", \"pubmed_id\"=>\"24735930\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24735930\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4021505\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Mol. Cancer\", \"full_journal_title\"=>\"Molecular cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>644, \"name\"=>\"EID644\", \"description\"=>\"PTEN loss is associated with reduced response to mTOR inhibitors in patients with bladder cancer.\", \"disease\"=>{\"id\"=>18, \"name\"=>\"Bladder Carcinoma\", \"display_name\"=>\"Bladder Carcinoma\", \"doid\"=>\"4007\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4007\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>407, \"name\"=>\"PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.\", \"citation\"=>\"Seront et al., 2013, Br. J. Cancer\", \"pubmed_id\"=>\"23989949\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23989949\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3777009\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>9, \"day\"=>17}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>643, \"name\"=>\"EID643\", \"description\"=>\"PTEN Loss (by FISH) is associated with poorer prognosis in patients with prostate cancer.\", \"disease\"=>{\"id\"=>46, \"name\"=>\"Prostate Cancer\", \"display_name\"=>\"Prostate Cancer\", \"doid\"=>\"10283\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10283\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>310, \"name\"=>\"FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.\", \"citation\"=>\"Yoshimoto et al., 2007, Br. J. Cancer\", \"pubmed_id\"=>\"17700571\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17700571\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2360375\", \"publication_date\"=>{\"year\"=>2007, \"month\"=>9, \"day\"=>3}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>507, \"name\"=>\"EID507\", \"description\"=>\"In prostate cancer xenographs, PTEN null tumors had a significant decrease in cell size and proliferation when treated with Temsirolimus (CCI-779).\", \"disease\"=>{\"id\"=>46, \"name\"=>\"Prostate Cancer\", \"display_name\"=>\"Prostate Cancer\", \"doid\"=>\"10283\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10283\"}, \"drugs\"=>[{\"id\"=>83, \"name\"=>\"Temsirolimus\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>312, \"name\"=>\"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.\", \"citation\"=>\"Neshat et al., 2001, Proc. Natl. Acad. Sci. U.S.A.\", \"pubmed_id\"=>\"11504908\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11504908\", \"open_access\"=>true, \"pmc_id\"=>\"PMC56958\", \"publication_date\"=>{\"year\"=>2001, \"month\"=>8, \"day\"=>28}, \"journal\"=>\"Proc. Natl. Acad. Sci. U.S.A.\", \"full_journal_title\"=>\"Proceedings of the National Academy of Sciences of the United States of America\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>506, \"name\"=>\"EID506\", \"description\"=>\"In 27 patients with chemotherapy-naive or chemotherapy-refractory metastatic colorectal cancer who were treated with cetuximab and chemotherapy, PTEN loss was associated with non-response.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>311, \"name\"=>\"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.\", \"citation\"=>\"De Roock et al., 2011, Lancet Oncol.\", \"pubmed_id\"=>\"21163703\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21163703\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>6}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}]}, {\"id\"=>55, \"entrez_name\"=>\"FLT3\", \"entrez_id\"=>2322, \"name\"=>\"ITD\", \"description\"=>\"FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.\", \"gene_id\"=>24, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>106, \"name\"=>\"inframe_insertion\", \"display_name\"=>\"Inframe Insertion\", \"so_id\"=>\"SO:0001821\", \"description\"=>\"An inframe non synonymous variant that inserts bases into in the coding sequence.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001821\"}], \"civic_actionability_score\"=>432.5, \"coordinates\"=>{\"chromosome\"=>\"13\", \"start\"=>28608219, \"stop\"=>28608351, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000241453.7\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/24/summary/variants/55/summary#variant\", \"evidence_items\"=>[{\"id\"=>1555, \"name\"=>\"EID1555\", \"description\"=>\"Six children with relapsed or refractory FLT3-ITD-positive AML received initial therapy with sorafenib (alone or in combination with clofarabine and cytarabine).  Four of the patients initially achieved morphological complete remission (bone marrow blasts <5%), however, 3 patients developed resistance within 14-37 weeks and and 1 required a bone marrow transplant.  Two patients did not have any clinical response to sorafenib upon initial treatment.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>6, \"name\"=>\"Sorafenib\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1028, \"name\"=>\"Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.\", \"citation\"=>\"Baker et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23969938\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23969938\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3878304\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>10, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>1109, \"name\"=>\"EID1109\", \"description\"=>\"In a study of 53 APL patients treated with combination ATRA/anthracycline chemotherapy, patients with the FLT3 ITD mutation (n=10) had higher rates of relapse (30% vs. 2.5%), lower rates of remission (70% vs 87.5%), and lower 3-year Leukemia-Free Survival (44.4% vs. 84.4%).\", \"disease\"=>{\"id\"=>379, \"name\"=>\"Acute Promyelocytic Leukemia\", \"display_name\"=>\"Acute Promyelocytic Leukemia\", \"doid\"=>\"0060318\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060318\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>765, \"name\"=>\"Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients.\", \"citation\"=>\"Hong et al., 2011, Korean J Hematol\", \"pubmed_id\"=>\"21461300\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21461300\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3065622\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>3}, \"journal\"=>\"Korean J Hematol\", \"full_journal_title\"=>\"The Korean journal of hematology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>1112, \"name\"=>\"EID1112\", \"description\"=>\"In a study of 171 APL patients treated with combination ATRA/anthracycline chemotherapy, FLT3 ITD mutations (n=35) were associated with lower 3-year OS compared to the FLT3 ITD-negative group (62% vs. 82%), as well as higher CR achievement failure and early death.\", \"disease\"=>{\"id\"=>379, \"name\"=>\"Acute Promyelocytic Leukemia\", \"display_name\"=>\"Acute Promyelocytic Leukemia\", \"doid\"=>\"0060318\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060318\"}, \"drugs\"=>[{\"id\"=>265, \"name\"=>\"All-trans Retinoic Acid\", \"pubchem_id\"=>nil}, {\"id\"=>278, \"name\"=>\"Anthracycline\", \"pubchem_id\"=>\"\"}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>767, \"name\"=>\"Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.\", \"citation\"=>\"Lucena-Araujo et al., 2014, Ann. Hematol.\", \"pubmed_id\"=>\"24981688\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24981688\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>12}, \"journal\"=>\"Ann. Hematol.\", \"full_journal_title\"=>\"Annals of hematology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>198, \"name\"=>\"EID198\", \"description\"=>\"Patients with NPM1 mutations and low (<25%, N=63), intermediate (25-50%, N=156) or high (>50%, N=66) levels of FLT3-ITD have worse overall survival (P<0.0001 for trend) and cumulative incidence of relapse (P<0.001) than those with NPM1 mutations alone (N=387) in young adult, intermediate risk AML patients.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>141, \"name\"=>\"Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.\", \"citation\"=>\"Linch et al., 2014, Blood\", \"pubmed_id\"=>\"24855211\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24855211\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>7, \"day\"=>10}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>128, \"name\"=>\"EID128\", \"description\"=>\"FLT3-ITD mutation without NPM1 was associated with increased relapse risk and reduced overall survival in young adult AML patients (median age 43).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>116, \"name\"=>\"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.\", \"citation\"=>\"Gale et al., 2008, Blood\", \"pubmed_id\"=>\"17957027\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17957027\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>1137, \"name\"=>\"EID1137\", \"description\"=>\"Forty-seven patients with relapsed/refractory AML or 60+ years old with untreated AML were enrolled on a phase II study. In FLT3 wild-type patients, six out of 36 (17%) had a response (1 PR, 3 MR, 2 uMR) that lasted a median of 58 days (range, 33â273 days). No patient with FLT3-ITD (n = 10) responded. One patient with unknown FLT3 status also had no response. Of note, this study did not meet its primary endpoint of 6 responses (CR, CRi, PR or MR) in the first 35 patients enrolled.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>787, \"name\"=>\"Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.\", \"citation\"=>\"Jain et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24178622\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24178622\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4310865\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>1, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>1515, \"name\"=>\"EID1515\", \"description\"=>\"In the absence of a FLT3 (ITD) mutation, a co-mutation of NPM1 and DNMT3A had a 50% 10-year survival rate, whereas triple-mutation of NPM1, DNMT3A, and FLT3 (ITD) had a 20% 10-year survival rate.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1009, \"name\"=>\"Genomic Classification and Prognosis in Acute Myeloid Leukemia.\", \"citation\"=>\"Papaemmanuil et al., 2016, N. Engl. J. Med.\", \"pubmed_id\"=>\"27276561\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27276561\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4979995\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>1040, \"name\"=>\"EID1040\", \"description\"=>\"13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients showed clearance or near clearance of bone marrow myeloblasts after 27 (range 21-84) days with evidence of differentiation of leukemia cells. Sorafenib response was lost in most patients after 72 (range 54-287) days.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>6, \"name\"=>\"Sorafenib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>172, \"name\"=>\"Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.\", \"citation\"=>\"Man et al., 2012, Blood\", \"pubmed_id\"=>\"22368270\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22368270\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>5, \"day\"=>31}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>129, \"name\"=>\"EID129\", \"description\"=>\"Increasing level of FLT3-ITD mutant correlated with reduced disease-free and overall survival as well as increased relapse rate.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>116, \"name\"=>\"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.\", \"citation\"=>\"Gale et al., 2008, Blood\", \"pubmed_id\"=>\"17957027\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17957027\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>372, \"name\"=>\"EID372\", \"description\"=>\"Simultaneous tandem repeat of FLT3 with loss of wild type FLT3 leads to poor survival and inferior disease free survival in patients with AML.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>226, \"name\"=>\"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.\", \"citation\"=>\"Whitman et al., 2001, Cancer Res.\", \"pubmed_id\"=>\"11585760\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11585760\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2001, \"month\"=>10, \"day\"=>1}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>371, \"name\"=>\"EID371\", \"description\"=>\"AML patients with internal tandem repeat of FLT3 has worse overall survival than patients with wild type FLT3.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>152, \"name\"=>\"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.\", \"citation\"=>\"Yamamoto et al., 2001, Blood\", \"pubmed_id\"=>\"11290608\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11290608\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2001, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>297, \"name\"=>\"EID297\", \"description\"=>\"CEP701 was effective in reducing blast counts of 5/14 heavily pre-treated AML patients with FLT3 mutations.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>260, \"name\"=>\"Lestaurtinib (CEP-701)\", \"pubchem_id\"=>\"\"}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>187, \"name\"=>\"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.\", \"citation\"=>\"Smith et al., 2004, Blood\", \"pubmed_id\"=>\"14726387\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/14726387\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>5, \"day\"=>15}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>298, \"name\"=>\"EID298\", \"description\"=>\"Sorafenib is effective in patients with FLT3 internal tandem repeats, but not in wild type or D835 mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>6, \"name\"=>\"Sorafenib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>173, \"name\"=>\"Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.\", \"citation\"=>\"Zhang et al., 2008, J. Natl. Cancer Inst.\", \"pubmed_id\"=>\"18230792\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18230792\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>2, \"day\"=>6}, \"journal\"=>\"J. Natl. Cancer Inst.\", \"full_journal_title\"=>\"Journal of the National Cancer Institute\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>299, \"name\"=>\"EID299\", \"description\"=>\"AG1296 is effective in triggering apoptosis in Ba/F3 and primary AML cells with FLT3 internal tandem repeat.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>58, \"name\"=>\"AG1296\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>188, \"name\"=>\"Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.\", \"citation\"=>\"Tse et al., 2002, Leukemia\", \"pubmed_id\"=>\"12357354\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/12357354\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2002, \"month\"=>10}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>222, \"name\"=>\"EID222\", \"description\"=>\"WBC counts were higher in AML patients with internal tandem repeat of Flt3 compared to wild type.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>152, \"name\"=>\"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.\", \"citation\"=>\"Yamamoto et al., 2001, Blood\", \"pubmed_id\"=>\"11290608\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11290608\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2001, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>195, \"name\"=>\"EID195\", \"description\"=>\"Coocurrence of FLT3-ITD mutations significantly reduced overall (N=74 vs 95, P=0.003) and disease-free survival (N=43 vs 67, P=0.02) of normal karyotype AML patients (<60 years old) compared to patients with NPM1 mutations alone.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>113, \"name\"=>\"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).\", \"citation\"=>\"Thiede et al., 2006, Blood\", \"pubmed_id\"=>\"16455956\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16455956\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>5, \"day\"=>15}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>191, \"name\"=>\"EID191\", \"description\"=>\"A ratio of >0.49 FLT3-ITD/FLT3 wildtype level was associated with reduced event-free and overall survival in old (>59) and younger patients (<60) with an NPM1 mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>134, \"name\"=>\"Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.\", \"citation\"=>\"Schnittger et al., 2011, Leukemia\", \"pubmed_id\"=>\"21537333\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21537333\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>8}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>192, \"name\"=>\"EID192\", \"description\"=>\"Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival compared to patients with wildtype FLT3.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>134, \"name\"=>\"Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.\", \"citation\"=>\"Schnittger et al., 2011, Leukemia\", \"pubmed_id\"=>\"21537333\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21537333\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>8}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>193, \"name\"=>\"EID193\", \"description\"=>\"Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable, a higher ratio was associated with reduced event-free survival in patients with an NPM1 mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>134, \"name\"=>\"Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.\", \"citation\"=>\"Schnittger et al., 2011, Leukemia\", \"pubmed_id\"=>\"21537333\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21537333\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>8}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>190, \"name\"=>\"EID190\", \"description\"=>\"Meta-analysis of studies involving cytogentically normal younger (<60) patients showed reduced overall and relapse-free survival for patients with FLT3-ITD.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>145, \"name\"=>\"Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.\", \"citation\"=>\"Port et al., 2014, Ann. Hematol.\", \"pubmed_id\"=>\"24801015\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24801015\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>8}, \"journal\"=>\"Ann. Hematol.\", \"full_journal_title\"=>\"Annals of hematology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>158, \"name\"=>\"EID158\", \"description\"=>\"FLT3-ITD duplication length did not effect prognosis in patients with an NPM1 mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>134, \"name\"=>\"Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.\", \"citation\"=>\"Schnittger et al., 2011, Leukemia\", \"pubmed_id\"=>\"21537333\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21537333\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>8}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>159, \"name\"=>\"EID159\", \"description\"=>\"Size of the FLT3-ITD mutant duplication had no impact on overall survival or relapse rate.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>116, \"name\"=>\"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.\", \"citation\"=>\"Gale et al., 2008, Blood\", \"pubmed_id\"=>\"17957027\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17957027\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>127, \"name\"=>\"EID127\", \"description\"=>\"ATRA treatment did not effect overall survival in patients <60 years old with FLT3-ITD mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>265, \"name\"=>\"All-trans Retinoic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>120, \"name\"=>\"The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.\", \"citation\"=>\"Burnett et al., 2010, Blood\", \"pubmed_id\"=>\"19965647\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19965647\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>2, \"day\"=>4}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>130, \"name\"=>\"EID130\", \"description\"=>\"Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to daunorubicin than cells with FLT3-ITD alone.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>2, \"name\"=>\"Daunorubicin\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>121, \"name\"=>\"FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).\", \"citation\"=>\"Bagrintseva et al., 2005, Blood\", \"pubmed_id\"=>\"15626738\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15626738\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>5, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>131, \"name\"=>\"EID131\", \"description\"=>\"Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>35, \"name\"=>\"SU5614\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>121, \"name\"=>\"FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).\", \"citation\"=>\"Bagrintseva et al., 2005, Blood\", \"pubmed_id\"=>\"15626738\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15626738\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>5, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>69, \"name\"=>\"EID69\", \"description\"=>\"In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations were associated with worse overall survival compared to those without DNMT3A mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>68, \"name\"=>\"DNMT3A mutations in acute myeloid leukemia.\", \"citation\"=>\"Ley et al., 2010, N. Engl. J. Med.\", \"pubmed_id\"=>\"21067377\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21067377\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3201818\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>12, \"day\"=>16}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}, {\"id\"=>52, \"name\"=>\"EID52\", \"description\"=>\"In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>54, \"name\"=>\"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.\", \"citation\"=>\"Ribeiro et al., 2012, Blood\", \"pubmed_id\"=>\"22490330\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22490330\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>14}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>55, \"phenotypes\"=>[]}]}, {\"id\"=>222, \"entrez_name\"=>\"TP53\", \"entrez_id\"=>7157, \"name\"=>\"MUTATION\", \"description\"=>\"\", \"gene_id\"=>45, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>103, \"name\"=>\"protein_altering_variant\", \"display_name\"=>\"Protein Altering Variant\", \"so_id\"=>\"SO:0001818\", \"description\"=>\"A sequence_variant which is predicted to change the protein encoded in the coding sequence.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001818\"}], \"civic_actionability_score\"=>375.0, \"coordinates\"=>{\"chromosome\"=>\"17\", \"start\"=>7571720, \"stop\"=>7590856, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000269305.4\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/45/summary/variants/222/summary#variant\", \"evidence_items\"=>[{\"id\"=>2999, \"name\"=>\"EID2999\", \"description\"=>\"In this Pooled Analysis, we explore the prognostic and predictive roles of TP53/KRAS and TP53/EGFR comutations in randomized trials of adjuvant chemotherapy versus observation.\\nResults of 3,533 patients with NSCLC: For TP53/KRAS mutation status, no prognostic effect was observed ( P = .61), whereas a borderline predictive effect ( P = .04) was observed with a deleterious effect of chemotherapy with TP53/KRAS comutations versus WT/WT. TP53/EGFR comutation in adenocarcinoma was neither prognostic ( P = .83), nor significantly predictive ( P = .86). Similar results were observed for both groups for disease-free survival.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1727, \"name\"=>\"Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.\", \"citation\"=>\"Shepherd et al., 2017, J. Clin. Oncol.\", \"pubmed_id\"=>\"28453411\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28453411\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>4, \"day\"=>28}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>2820, \"name\"=>\"EID2820\", \"description\"=>\"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044).\", \"disease\"=>{\"id\"=>1322, \"name\"=>\"Stomach Carcinoma\", \"display_name\"=>\"Stomach Carcinoma\", \"doid\"=>\"5517\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5517\"}, \"drugs\"=>[{\"id\"=>468, \"name\"=>\"EAP Protocol\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>2, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1557, \"name\"=>\"Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer.\", \"citation\"=>\"Bataille et al., 2003, MP, Mol. Pathol.\", \"pubmed_id\"=>\"14514923\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/14514923\", \"open_access\"=>true, \"pmc_id\"=>\"PMC1187340\", \"publication_date\"=>{\"year\"=>2003, \"month\"=>10}, \"journal\"=>\"MP, Mol. Pathol.\", \"full_journal_title\"=>\"Molecular pathology : MP\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>2784, \"name\"=>\"EID2784\", \"description\"=>\"In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31%, odds ratio (OR):0.22, 95CI:0.12-0.42, P<0.0001, univariate analysis; OR:0.29, 95% CI:0.12-0.42, P=0.0014, multivariate analysis). The median survival after start of therapy was shorter in patients with mutations in TP53 than for patients with wild-type TP53 (20mo vs. 29mo, HR:1.99,95% CI:1.43-2.75, P<0.001). Breast cancer patients with TP53 mutations also had a decrease in progression-free survival (HR:2.61, 95% CI:1.90-3.6, P<0.001).\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>53, \"name\"=>\"Tamoxifen\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1555, \"name\"=>\"Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.\", \"citation\"=>\"Berns et al., 2000, Cancer Res.\", \"pubmed_id\"=>\"10786679\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/10786679\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2000, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>1481, \"name\"=>\"EID1481\", \"description\"=>\"Thirty-six patients with CLL were treated with alemtuzumab. Partial or complete response was achieved in 6 of 15 patients with p53 mutations, compared to 4 of 21 without. These findings are not statistically significant, but the authors suggest that alemtuzumab is an effective therapy for patients with p53 mutations or deletions.\", \"disease\"=>{\"id\"=>52, \"name\"=>\"Chronic Lymphocytic Leukemia\", \"display_name\"=>\"Chronic Lymphocytic Leukemia\", \"doid\"=>\"1040\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1040\"}, \"drugs\"=>[{\"id\"=>358, \"name\"=>\"Alemtuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>993, \"name\"=>\"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.\", \"citation\"=>\"Lozanski et al., 2004, Blood\", \"pubmed_id\"=>\"14726385\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/14726385\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>5, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>1478, \"name\"=>\"EID1478\", \"description\"=>\"In the CLL4 trial assessing first line treatment with chlorambucil or fludarabine with or without cyclophosphamide, patients with TP53 mutations experienced poorer overall response rates (27% vs 83%), shorter progression free survival (5 year PFS 5% vs 17%), and overall survival (20% vs 59%) compared to patients without TP53 mutations.\", \"disease\"=>{\"id\"=>52, \"name\"=>\"Chronic Lymphocytic Leukemia\", \"display_name\"=>\"Chronic Lymphocytic Leukemia\", \"doid\"=>\"1040\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1040\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>991, \"name\"=>\"Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.\", \"citation\"=>\"Gonzalez et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21483000\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21483000\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>6, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>1145, \"name\"=>\"EID1145\", \"description\"=>\"A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Trp53 knockout mutant mice were resistant to docetaxel monotherapy but sensitive to combined treatment. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}, {\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>792, \"name\"=>\"A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.\", \"citation\"=>\"Chen et al., 2012, Nature\", \"pubmed_id\"=>\"22425996\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22425996\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3385933\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>3, \"day\"=>29}, \"journal\"=>\"Nature\", \"full_journal_title\"=>\"Nature\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>1485, \"name\"=>\"EID1485\", \"description\"=>\"In a multivariate analysis of 774 CLL patients, TP53 aberrations were significantly correlated with shorter time to first treatment (HR=2.081; 95% CI=1.431-3.021). This finding was independent of IGHV mutation status.\", \"disease\"=>{\"id\"=>52, \"name\"=>\"Chronic Lymphocytic Leukemia\", \"display_name\"=>\"Chronic Lymphocytic Leukemia\", \"doid\"=>\"1040\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1040\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>997, \"name\"=>\"Recurrent mutations refine prognosis in chronic lymphocytic leukemia.\", \"citation\"=>\"Baliakas et al., 2015, Leukemia\", \"pubmed_id\"=>\"24943832\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24943832\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>2}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>1452, \"name\"=>\"EID1452\", \"description\"=>\"The authors analyzed 328 patients with CLL, of which 28 were identified to have TP53 mutations. Patients with TP53 mutations were found to have significantly shorter progression-free (HR = 3.8; P < 0.001) and overall survival (HR = 7.2; P < 0.001).\", \"disease\"=>{\"id\"=>52, \"name\"=>\"Chronic Lymphocytic Leukemia\", \"display_name\"=>\"Chronic Lymphocytic Leukemia\", \"doid\"=>\"1040\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1040\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>980, \"name\"=>\"TP53 mutation and survival in chronic lymphocytic leukemia.\", \"citation\"=>\"Zenz et al., 2010, J. Clin. Oncol.\", \"pubmed_id\"=>\"20697090\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20697090\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>10, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>1146, \"name\"=>\"EID1146\", \"description\"=>\"A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Trp53 knockout mutant mice were resistant to docetaxel monotherapy but sensitive to combined treatment. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>792, \"name\"=>\"A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.\", \"citation\"=>\"Chen et al., 2012, Nature\", \"pubmed_id\"=>\"22425996\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22425996\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3385933\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>3, \"day\"=>29}, \"journal\"=>\"Nature\", \"full_journal_title\"=>\"Nature\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>1451, \"name\"=>\"EID1451\", \"description\"=>\"In a study of 126 patients with long-term follow-up, TP53 mutations were significantly associated with shorter median survival in patients (P = 0.002) from time of diagnosis. The median survival from the time of first observation of a TP53 mutation was much more pronounced (P = <0.001). These findings were statistically independent of 17p deletions.\", \"disease\"=>{\"id\"=>52, \"name\"=>\"Chronic Lymphocytic Leukemia\", \"display_name\"=>\"Chronic Lymphocytic Leukemia\", \"doid\"=>\"1040\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1040\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>979, \"name\"=>\"Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.\", \"citation\"=>\"Zenz et al., 2008, Blood\", \"pubmed_id\"=>\"18689542\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18689542\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>10, \"day\"=>15}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>1450, \"name\"=>\"EID1450\", \"description\"=>\"A study of 53 patients with B-CLL found a significant resistance to chemotherapy and corresponding poor clinical outcomes among the 7 treated patients with p53 mutations compared to the 29 treated patients without.\", \"disease\"=>{\"id\"=>52, \"name\"=>\"Chronic Lymphocytic Leukemia\", \"display_name\"=>\"Chronic Lymphocytic Leukemia\", \"doid\"=>\"1040\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1040\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>978, \"name\"=>\"p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.\", \"citation\"=>\"el Rouby et al., 1993, Blood\", \"pubmed_id\"=>\"8241511\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/8241511\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>1993, \"month\"=>12, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>519, \"name\"=>\"EID519\", \"description\"=>\"In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival.\", \"disease\"=>{\"id\"=>149, \"name\"=>\"Esophagus Squamous Cell Carcinoma\", \"display_name\"=>\"Esophagus Squamous Cell Carcinoma\", \"doid\"=>\"3748\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3748\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>322, \"name\"=>\"p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.\", \"citation\"=>\"Yamasaki et al., 2010, Ann. Surg. Oncol.\", \"pubmed_id\"=>\"19941080\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19941080\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>2}, \"journal\"=>\"Ann. Surg. Oncol.\", \"full_journal_title\"=>\"Annals of surgical oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>1018, \"name\"=>\"EID1018\", \"description\"=>\"In a study of 97 patients with AML  treated with HSCT, 40 had TP53 mutations comprising a total of 44 mutations. Patients with a TP53 mutation had a reduced three year probability of overall survival and event-free survival compared to patients with the wild-type TP53.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>705, \"name\"=>\"TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.\", \"citation\"=>\"Middeke et al., 2016, Br. J. Haematol.\", \"pubmed_id\"=>\"26771088\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26771088\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Br. J. Haematol.\", \"full_journal_title\"=>\"British journal of haematology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>851, \"name\"=>\"EID851\", \"description\"=>\"In this preclinical study, MMTV-Wnt1 mammary tumors with mutant TP53 showed a better clinical response to chemotherapy (doxorubicin) than TP53 wild-type tumors. This was mediated by wild-type TP53-induced cell-arrest under chemotherapy even in the context of heterozygous TP53 point mutations or absence of p21. Thus the status of both TP53 alleles should be assessed because even one copy of wild-type TP53 may contribute to poor response to chemotherapy.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>68, \"name\"=>\"Doxorubicin\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>199, \"name\"=>\"p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.\", \"citation\"=>\"Jackson et al., 2012, Cancer Cell\", \"pubmed_id\"=>\"22698404\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22698404\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3376352\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>12}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>850, \"name\"=>\"EID850\", \"description\"=>\"In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.704; 95% confidence intervals [CI] = 0.550-0.903; P = 0.006).\", \"disease\"=>{\"id\"=>147, \"name\"=>\"Gastric Adenocarcinoma\", \"display_name\"=>\"Gastric Adenocarcinoma\", \"doid\"=>\"3717\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3717\"}, \"drugs\"=>[{\"id\"=>199, \"name\"=>\"Chemotherapy\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>569, \"name\"=>\"Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis.\", \"citation\"=>\"Xu et al., 2014, PLoS ONE\", \"pubmed_id\"=>\"24740294\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24740294\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3989310\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>1028, \"name\"=>\"EID1028\", \"description\"=>\"TP53 mutation was shown to be associated with shorter overall survival in patients with adrenocortical tumors (log-rank test; P=0.098). Of 20 patients studied, 5 had coding mutation in TP53. Four of the 5 patients with a TP53 mutation had metastases at diagnosis or detected soon thereafter, and 3 of 4 died of disease within 12 months of surgical resection.\", \"disease\"=>{\"id\"=>154, \"name\"=>\"Adrenocortical Carcinoma\", \"display_name\"=>\"Adrenocortical Carcinoma\", \"doid\"=>\"3948\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3948\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>723, \"name\"=>\"Mutation and methylation analysis of TP53 in adrenal carcinogenesis.\", \"citation\"=>\"Sidhu et al., 2005, Eur J Surg Oncol\", \"pubmed_id\"=>\"15922892\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15922892\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>6}, \"journal\"=>\"Eur J Surg Oncol\", \"full_journal_title\"=>\"European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>523, \"name\"=>\"EID523\", \"description\"=>\"Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations, 21 of which were treated with surgery. Unlike those treated with radiotherapy, those treated with surgery did not show a significant difference in rates of loco-regional control between those with and without mutations in TP53.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>325, \"name\"=>\"TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.\", \"citation\"=>\"Alsner et al., 2001, Radiother Oncol\", \"pubmed_id\"=>\"11325447\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11325447\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2001, \"month\"=>5}, \"journal\"=>\"Radiother Oncol\", \"full_journal_title\"=>\"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>524, \"name\"=>\"EID524\", \"description\"=>\"Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations. Of the 93 patients treated with radiotherapy, patients with mutations in TP53 had lower rates of loco-regional control and shorter disease-free, disease-specific, and overall survival.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>325, \"name\"=>\"TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.\", \"citation\"=>\"Alsner et al., 2001, Radiother Oncol\", \"pubmed_id\"=>\"11325447\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11325447\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2001, \"month\"=>5}, \"journal\"=>\"Radiother Oncol\", \"full_journal_title\"=>\"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>521, \"name\"=>\"EID521\", \"description\"=>\"In patients with myelodysplastic syndrome, in a multivariate analysis those with mutations in TP53 had shorter overall survival than wild-type patients.\", \"disease\"=>{\"id\"=>34, \"name\"=>\"Myelodysplastic Syndrome\", \"display_name\"=>\"Myelodysplastic Syndrome\", \"doid\"=>\"0050908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050908\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>323, \"name\"=>\"Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.\", \"citation\"=>\"Bally et al., 2014, Leuk. Res.\", \"pubmed_id\"=>\"24836762\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24836762\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>7}, \"journal\"=>\"Leuk. Res.\", \"full_journal_title\"=>\"Leukemia research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>522, \"name\"=>\"EID522\", \"description\"=>\"In patients with myeloma, those with mutations in TP53 had worse overall survival than those without.\", \"disease\"=>{\"id\"=>224, \"name\"=>\"Myeloma\", \"display_name\"=>\"Myeloma\", \"doid\"=>\"0070004\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0070004\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>324, \"name\"=>\"Clinical significance of TP53 mutation in myeloma.\", \"citation\"=>\"Chng et al., 2007, Leukemia\", \"pubmed_id\"=>\"17215851\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17215851\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2007, \"month\"=>3}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>520, \"name\"=>\"EID520\", \"description\"=>\"In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, in multivariate analysis those with mutations in TP53 had worse event-free survival than patients without mutations.\", \"disease\"=>{\"id\"=>237, \"name\"=>\"Precursor B Lymphoblastic Lymphoma/leukemia\", \"display_name\"=>\"Precursor B Lymphoblastic Lymphoma/leukemia\", \"doid\"=>\"7061\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:7061\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>294, \"name\"=>\"Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.\", \"citation\"=>\"Krentz et al., 2013, Leukemia\", \"pubmed_id\"=>\"22699455\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22699455\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>2}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>640, \"name\"=>\"EID640\", \"description\"=>\"In relapsed B-ALL patients, TP53 mutations were associated with morphologic nonresponse to therapy (>5% blasts in the bone marrow after 9 weeks of treatment) as well as reduced event free and overall survival when compared to TP53 wildtype patients.\", \"disease\"=>{\"id\"=>237, \"name\"=>\"Precursor B Lymphoblastic Lymphoma/leukemia\", \"display_name\"=>\"Precursor B Lymphoblastic Lymphoma/leukemia\", \"doid\"=>\"7061\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:7061\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>403, \"name\"=>\"Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.\", \"citation\"=>\"Hof et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21747090\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21747090\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>8, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>518, \"name\"=>\"EID518\", \"description\"=>\"Unlike other studies, in this study of 110 patients with head and neck squamous cell carcinoma, there was no significant difference in the overall survival of patients with and without any TP53 mutations.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>321, \"name\"=>\"p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.\", \"citation\"=>\"Koch et al., 1996, J. Natl. Cancer Inst.\", \"pubmed_id\"=>\"8901856\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/8901856\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>1996, \"month\"=>11, \"day\"=>6}, \"journal\"=>\"J. Natl. Cancer Inst.\", \"full_journal_title\"=>\"Journal of the National Cancer Institute\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}, {\"id\"=>1507, \"name\"=>\"EID1507\", \"description\"=>\"In a cohort of 406 patients with CLL, those patients with clonal or sub-clonal mutations in TP53 had significantly shorter overall survival (HR: 1.71; 95% CI: 1.28-2.26; P = .0001).\", \"disease\"=>{\"id\"=>52, \"name\"=>\"Chronic Lymphocytic Leukemia\", \"display_name\"=>\"Chronic Lymphocytic Leukemia\", \"doid\"=>\"1040\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1040\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1006, \"name\"=>\"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.\", \"citation\"=>\"Nadeu et al., 2016, Blood\", \"pubmed_id\"=>\"26837699\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26837699\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4912011\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>28}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>222, \"phenotypes\"=>[]}]}, {\"id\"=>336, \"entrez_name\"=>\"KRAS\", \"entrez_id\"=>3845, \"name\"=>\"MUTATION\", \"description\"=>\"\", \"gene_id\"=>30, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>103, \"name\"=>\"protein_altering_variant\", \"display_name\"=>\"Protein Altering Variant\", \"so_id\"=>\"SO:0001818\", \"description\"=>\"A sequence_variant which is predicted to change the protein encoded in the coding sequence.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001818\"}], \"civic_actionability_score\"=>500.0, \"coordinates\"=>{\"chromosome\"=>\"12\", \"start\"=>25362365, \"stop\"=>25403737, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000256078.4\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/30/summary/variants/336/summary#variant\", \"evidence_items\"=>[{\"id\"=>4997, \"name\"=>\"EID4997\", \"description\"=>\"Of the 275 patients assessable for KRAS mutation status, 49 (18%) were positive for KRAS mutation. There were no differences between treatments in OS, PFS, or response rates according to KRAS mutation status, and no evidence that KRAS mutation is a predictive factor for a differential survival effect between gefitinib and docetaxel.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1501, \"name\"=>\"Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.\", \"citation\"=>\"Douillard et al., 2010, J. Clin. Oncol.\", \"pubmed_id\"=>\"20038723\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20038723\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>2, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>2998, \"name\"=>\"EID2998\", \"description\"=>\"A phase 3 study of selumetinib and docetaxel in KRAS mutant, previously treated NSCLC. 866 were enrolled and 510 randomized. Median progression-free survival was 3.9 months with selumetinibâ+âdocetaxel and 2.8 months with placeboâ+âdocetaxel. Median overall survival was 8.7 months with selumetinibâ+âdocetaxel and 7.9 months with placeboâ+âdocetaxel. Objective response rate was 20.1% with selumetinibâ+âdocetaxel and 13.7% with placeboâ+âdocetaxel.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}, {\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1726, \"name\"=>\"Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.\", \"citation\"=>\"JÃ¤nne et al., 2017, JAMA\", \"pubmed_id\"=>\"28492898\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28492898\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>5, \"day\"=>9}, \"journal\"=>\"JAMA\", \"full_journal_title\"=>\"JAMA\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>4842, \"name\"=>\"EID4842\", \"description\"=>\"In this multicenter phase I study of abemaciclib, a total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor-specific cohorts. Radiographic responses were achieved in previously treated patients with breast cancer, NSCLC, and melanoma. The disease control rate for the KRAS-mutant population was 55% (16/29) compared to 39% (13/33)  in KRAS wildtype cohort. Stable disease lasting â¥24 weeks was achieved for 31% (9/29) with KRAS-mutant disease vs 12% (4/33) with KRAS wild-type disease. Median PFS was 2.8 months and 1.9 months for the KRAS-mutant and KRAS wild-type populations, respectively.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>525, \"name\"=>\"Abemaciclib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2146, \"name\"=>\"Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.\", \"citation\"=>\"Patnaik et al., 2016, Cancer Discov\", \"pubmed_id\"=>\"27217383\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27217383\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>7}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>4867, \"name\"=>\"EID4867\", \"description\"=>\"In this phase II trial, trametinib or docetaxel was given to patients with advanced KRAS-mutant NSCLC. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (HR 1.14; p = 0.5197). Median OS, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P = 1.0000). These data suggest that trametinib is associated with similar PFS and response rates as docetaxel.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2164, \"name\"=>\"A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)â .\", \"citation\"=>\"Blumenschein et al., 2015, Ann. Oncol.\", \"pubmed_id\"=>\"25722381\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25722381\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4855243\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>5}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>4863, \"name\"=>\"EID4863\", \"description\"=>\"A meta-analysis of randomized trials to investigate if KRAS mutation status affects survival benefits of immune checkpoint inhibition (ICI) in patients with advanced NSCLC. Of 3 eligible studies using either nivolumab or atezolizumab, 138 patients with KRAS mutant NSCLC and 371 with KRAS wild-type were included. ICI improved overall survival over that with docetaxel in KRAS mutant, previously-treated advanced NSCLC (hazard ratio=0.64 [95% confidence interval, 0.43-0.96], P = 0.03) but not in those with KRAS wild-type tumor (HR = 0.88 [95% CI, 0.68-1.13], P = 0.30). These results suggest that KRAS mutation status may be a potential biomarker for survival benefits to ICIs.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}, {\"id\"=>261, \"name\"=>\"Atezolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2160, \"name\"=>\"Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A metaanalysis and review.\", \"citation\"=>\"Kim et al., 2017, Oncotarget\", \"pubmed_id\"=>\"28525386\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28525386\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>5, \"day\"=>3}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>4868, \"name\"=>\"EID4868\", \"description\"=>\"38 KRAS wild-type patients were randomized to erlotinib or combination of selumetinib with erlotinib. 41 KRAS mutant patients were randomized to selumetinib or the combination. The primary end points were progression-free survival (PFS) for the KRAS wild-type cohort and objective response rate (ORR) for the KRAS mutant cohort. Median PFS in the KRAS wild-type arm was 2.4 months for erlotinib alone and 2.1 months for the combination. The ORR in the KRAS mutant group was 0% for selumetinib alone and 10% for the combination. These data suggest no difference in ORR or PFS with combination therapy of over monotherapy in KRAS mutant and KRAS wild-type advanced NSCLC.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}, {\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2165, \"name\"=>\"Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.\", \"citation\"=>\"Carter et al., 2016, Ann. Oncol.\", \"pubmed_id\"=>\"26802155\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26802155\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4803455\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>4}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>4869, \"name\"=>\"EID4869\", \"description\"=>\"A preclinical study to investigate the efficacy of Binimetinib, Palbociclib and the combination on KRAS mutant colorectal cancer cell lines, cell line-derived and patient-derived xenografts.  \\nThe combination of MEK and CDK4/6 inhibition inhibited cancer cell growth and caused cell regression in a synergistic manner\\nCombination therapy markedly decreased levels of phosphorylated ribosomal protein S6 both in vitro and in vivo and decreased Ki67 staining in vivo.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>429, \"name\"=>\"Palbociclib\", \"pubchem_id\"=>nil}, {\"id\"=>485, \"name\"=>\"Binimetinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2022, \"name\"=>\"Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.\", \"citation\"=>\"Lee et al., 2016, Oncotarget\", \"pubmed_id\"=>\"27167191\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27167191\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5129956\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>28}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>4866, \"name\"=>\"EID4866\", \"description\"=>\"A phase I study  to determine the tolerability and pharmacokinetics of Selumetinib and Cetuximab with an expanded cohort in KRAS-mutant CRC. In the KRAS-mutant CRC dose expansion cohort 14 patients were evaluable for response. Five patients experienced stable disease, nine had progressive disease.  Minimal anti-tumor activity was observed in KRAS-mutant refractory metastatic CRC.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2163, \"name\"=>\"A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.\", \"citation\"=>\"Deming et al., 2016, Invest New Drugs\", \"pubmed_id\"=>\"26666244\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26666244\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4788533\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>4}, \"journal\"=>\"Invest New Drugs\", \"full_journal_title\"=>\"Investigational new drugs\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>4865, \"name\"=>\"EID4865\", \"description\"=>\"In this study we investigated the correlation between PD-L1 expression and KRAS mutation and the functional significance of PD-1/PD-L1 blockade in KRAS-mutant lung adenocarcinoma. We found that PD-L1 expression was associated with KRAS mutation both human  cell lines and tissues. KRAS-mediated up-regulation of PD-L1 induced the apoptosis of CD3-positive T cells which was reversed by anti-PD-1 antibody (Pembrolizumab) or ERK inhibitor. However, Pembrolizumab combined with ERK inhibitor did not show synergistic effect. The study demonstrated that KRAS mutation could induce PD-L1 expression through p-ERK signaling in lung adenocarcinoma. Blockade of PD-1/PD-L1 pathway may be a promising therapeutic strategy for human KRAS-mutant lung adenocarcinoma.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2162, \"name\"=>\"KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.\", \"citation\"=>\"Chen et al., 2017, Cancer Immunol. Immunother.\", \"pubmed_id\"=>\"28451792\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28451792\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>4, \"day\"=>27}, \"journal\"=>\"Cancer Immunol. Immunother.\", \"full_journal_title\"=>\"Cancer immunology, immunotherapy : CII\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>4862, \"name\"=>\"EID4862\", \"description\"=>\"This phase I/Ib two-part study evaluated trametinib in combination with anticancer agents docetaxel or pemetrexed in NSCLC with and without KRAS mutations. Confirmed partial response (PR) was observed in 21% (10/47) patients receiving trametinib/docetaxel. The ORR was 18% (4 PR in 22 patients) in KRAS wild-type versus 24% (six PR in 25 patients) in KRAS-mutant NSCLC. Of the 42 patients treated with trametinib/pemetrexed, 14% (6/42) had a PR; the ORR was 17% (4/23) in KRAS-mutated NSCLC versus 11% (2/19) in KRAS wild-type NSCLC.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}, {\"id\"=>156, \"name\"=>\"Pemetrexed\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2159, \"name\"=>\"A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With AdvancedÂ Non-Small Cell Lung Cancer.\", \"citation\"=>\"Gandara et al., 2017, J Thorac Oncol\", \"pubmed_id\"=>\"27876675\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27876675\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>3}, \"journal\"=>\"J Thorac Oncol\", \"full_journal_title\"=>\"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>4864, \"name\"=>\"EID4864\", \"description\"=>\"In this meta-analysis of nine studies querying the association between KRAS status and PD-L1expression, KRAS-mutant tumors were more likely to be PD-L1 positive than KRAS-wild type tumors (51% vs 36%; OR 1.69; 95% CI 1.01-2.84; p = 0.045).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predisposing\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2161, \"name\"=>\"Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis.\", \"citation\"=>\"Li et al., 2017, Eur J Surg Oncol\", \"pubmed_id\"=>\"28259530\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28259530\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>2, \"day\"=>21}, \"journal\"=>\"Eur J Surg Oncol\", \"full_journal_title\"=>\"European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>3715, \"name\"=>\"EID3715\", \"description\"=>\"Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherpy. The study was not powered for prognostic tests, but it was still found that KRAS Mutant status was a significant negative prognostic factor on progression free survival. (HR, 1.50; 95% CI, 1.06 to 2.12; P=0.20)\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1938, \"name\"=>\"Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.\", \"citation\"=>\"Brugger et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21969500\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21969500\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>3895, \"name\"=>\"EID3895\", \"description\"=>\"In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, KRAS mutation was assessed. In the KRAS wildtype group, erlotinib showed a significant benefit for progression free survival (PFS) over placebo (HR, 0.70; 95% CI, 0.57 to 0.87, P<0.001). No statistically significant improvement in PFS was seen with erlotinib in the KRAS mutant group over placebo. Significant difference in PFS between erlotinib treated KRAS WT and MUT patients was not seen.  Overall, in the intent to treat population erlotinib significantly improved PFS over placebo (HR, 0.71; 95% CI, 0.62 to 0.82; P<0.001).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1938, \"name\"=>\"Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.\", \"citation\"=>\"Brugger et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21969500\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21969500\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>5345, \"name\"=>\"EID5345\", \"description\"=>\"NCCN guidelines indicate colorectal cancer patients with KRAS mutations should not be treated with the anti-EGFR therapies cetuximab or panitumumab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2236, \"name\"=>nil, \"citation\"=>\"Benson et al., 2017, J Natl Compr Canc Netw\", \"pubmed_id\"=>\"28275037\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28275037\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{}, \"journal\"=>nil, \"full_journal_title\"=>nil, \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>1702, \"name\"=>\"EID1702\", \"description\"=>\"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1138, \"name\"=>\"A molecularly annotated platform of patient-derived xenografts (\\\"xenopatients\\\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.\", \"citation\"=>\"Bertotti et al., 2011, Cancer Discov\", \"pubmed_id\"=>\"22586653\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22586653\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>1642, \"name\"=>\"EID1642\", \"description\"=>\"Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was performed in 69 patients for KRAS, NRAS and BRAF mutations (BEAM technology). 4 patients were identified to harbor RAS mutations. 3 of whom still received study treatment at the cutoff date used for the final data analysis. These 3 patients had achieved confirmed PR, with duration responses ranging from 128 to 382 days. The fourth patient with a RAS mutation discontinued study treatment after 41 days on therapy due to PD. An overall of 4 (6 by modified RECIST) patients achieved PR.\", \"disease\"=>{\"id\"=>196, \"name\"=>\"Hepatocellular Carcinoma\", \"display_name\"=>\"Hepatocellular Carcinoma\", \"doid\"=>\"684\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:684\"}, \"drugs\"=>[{\"id\"=>6, \"name\"=>\"Sorafenib\", \"pubchem_id\"=>nil}, {\"id\"=>394, \"name\"=>\"Refametinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1088, \"name\"=>\"A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.\", \"citation\"=>\"Lim et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"25294897\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25294897\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>12, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>1700, \"name\"=>\"EID1700\", \"description\"=>\"In a study of 1036 patients with lung adenocarcinoma, patients with KRAS mutations (n=241) showed worse prognosis (OS: 19 months versus 23 months; HR=1.21; P=0.048).\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1148, \"name\"=>\"Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.\", \"citation\"=>\"Johnson et al., 2013, Cancer\", \"pubmed_id\"=>\"22810899\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22810899\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3966555\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>1, \"day\"=>15}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>1596, \"name\"=>\"EID1596\", \"description\"=>\"40 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and hypertermic intraperitoneal chemotherapy (HIPEC). KRAS mutations were found in 72% of samples and KRAS mutations were independently associated with PFS (p=0.012) after multivariate analysis.\", \"disease\"=>{\"id\"=>143, \"name\"=>\"Pseudomyxoma Peritonei\", \"display_name\"=>\"Pseudomyxoma Peritonei\", \"doid\"=>\"3559\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3559\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1058, \"name\"=>\"Towards the molecular dissection of peritoneal pseudomyxoma.\", \"citation\"=>\"Pietrantonio et al., 2016, Ann. Oncol.\", \"pubmed_id\"=>\"27502722\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27502722\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>8, \"day\"=>8}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>1218, \"name\"=>\"EID1218\", \"description\"=>\"In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival rates compared to previously untreated patients.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>307, \"name\"=>\"Farnesylthiosalicylic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>910, \"name\"=>\"A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.\", \"citation\"=>\"Riely et al., 2011, J Thorac Oncol\", \"pubmed_id\"=>\"21847063\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21847063\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>8}, \"journal\"=>\"J Thorac Oncol\", \"full_journal_title\"=>\"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>1220, \"name\"=>\"EID1220\", \"description\"=>\"In a phase 1 clinical trial for the use of trametinib for various advanced solid tumors, 22 out of 30 NSCLC patients harbored KRAS mutations. Of those 22 patients with mutant KRAS, 8 saw reductions in tumor size ranging from 6-52% including 2 partial responses.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>843, \"name\"=>\"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.\", \"citation\"=>\"Infante et al., 2012, Lancet Oncol.\", \"pubmed_id\"=>\"22805291\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22805291\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>8}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>1183, \"name\"=>\"EID1183\", \"description\"=>\"CDK1 was identified in a preclinical siRNA screen to identify targets in KRAS mutant tumors. Cell viability was evaluated following knockdown of 834 genes in isogenic LIM1215 colorectal cancer cell lines harboring wildtype (parental), G12S, G12D or G12V KRAS. 6 targets identified by this screen were evaluated in a second set of isogenic colorectal cancer cell lines (SW48) harboring wildtype (parental), G12S, G12D, G12V or G13D KRAS where only CDK1 knockdown more profoundly reduced survival in mutant cells compared to wildtype. Results were validated in 5 KRAS mutant (BRAF WT) and 10 KRAS WT colorectal cancer cell lines. Chemical inhibition of CDK1 by AZD5438 in KRAS mutant vs WT pancreatic and colorectal cancer cell lines showed increased efficacy in mutant cell lines. Finally, AZD5438 reduced tumor growth induced by SW620 (KRAS p.G12V) colorectal tumour cells xenografted into immunodeficient mice.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>299, \"name\"=>\"AZD5438\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>816, \"name\"=>\"CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.\", \"citation\"=>\"Costa-Cabral et al., 2016, PLoS ONE\", \"pubmed_id\"=>\"26881434\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26881434\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4755568\", \"publication_date\"=>{\"year\"=>2016}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>4996, \"name\"=>\"EID4996\", \"description\"=>\"In this study, KRAS was neither prognostic nor predictive of benefit for either docetaxel or erlotinib.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2189, \"name\"=>\"Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.\", \"citation\"=>\"Rulli et al., 2015, Ann. Oncol.\", \"pubmed_id\"=>\"26209642\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26209642\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>10}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>1140, \"name\"=>\"EID1140\", \"description\"=>\"Preclinical study analyzing the differential response to MEK Inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Efficacy of MEK inhibitors (GDC-0623 and G-573) in KRAS-driven tumours is mediated by a hydrogen-bond interaction with S212 in MEK that is critical for blocking MEK feedback phosphorylation by wild-type RAF. This mechanism was distinct from GDC-0973 which is less potent in KRAS mutant tumors. Overall, this work indicates that MEK inhibitors with this mechanism of action will be most effective in patients with both BRAF and KRAS mutations.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>284, \"name\"=>\"GDC-0623\", \"pubchem_id\"=>nil}, {\"id\"=>285, \"name\"=>\"G-573\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>790, \"name\"=>\"Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.\", \"citation\"=>\"Hatzivassiliou et al., 2013, Nature\", \"pubmed_id\"=>\"23934108\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23934108\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>9, \"day\"=>12}, \"journal\"=>\"Nature\", \"full_journal_title\"=>\"Nature\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>1139, \"name\"=>\"EID1139\", \"description\"=>\"Meta-Analysis of 12 studies with 2,266 patients (54 % were KRAS wt). The pooled response rates (RR) for KRAS wild-type (wt) versus mutated (mut) patients were 54.8 and 48.3 %, respectively (OR 1.42, P = 0.02). Median PFS in KRAS wild-type patients was significantly longer than in KRAS mut patients (HR = 0.85; 95 % confidence interval (CI) 0.74-0.98; P = 0.02). Median OS in wild-type KRAS patients compared was significantly better than in KRAS mut patients (HR = 0.65; 95 % CI 0.46-0.92; P = 0.01).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>33, \"name\"=>\"Bevacizumab\", \"pubchem_id\"=>nil}, {\"id\"=>199, \"name\"=>\"Chemotherapy\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>789, \"name\"=>\"KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.\", \"citation\"=>\"Petrelli et al., 2013, Med. Oncol.\", \"pubmed_id\"=>\"23828442\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23828442\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013}, \"journal\"=>\"Med. Oncol.\", \"full_journal_title\"=>\"Medical oncology (Northwood, London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>1182, \"name\"=>\"EID1182\", \"description\"=>\"Preclinical study in colorectal cancer xenografts. KRAS-G13D or KRAS-G12V mutations were introduced into KRAS-WT SW48 cell line. KRAS wild-type, but not KRAS mutant tumors were sensitive to proteasome inhibitor ixazomib\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>298, \"name\"=>\"Ixazomib\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>815, \"name\"=>\"KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.\", \"citation\"=>\"Chattopadhyay et al., 2015, PLoS ONE\", \"pubmed_id\"=>\"26709701\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26709701\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4692403\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>992, \"name\"=>\"EID992\", \"description\"=>\"An shDNA screen identified synergy between ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines. Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in colorectal and lung cancer cell lines. Induction of ERBB3 signalling was also identified in a patient with KRAS mutation after MEK inhibition with trametinib.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>686, \"name\"=>\"Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.\", \"citation\"=>\"Sun et al., 2014, Cell Rep\", \"pubmed_id\"=>\"24685132\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24685132\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>4, \"day\"=>10}, \"journal\"=>\"Cell Rep\", \"full_journal_title\"=>\"Cell reports\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>988, \"name\"=>\"EID988\", \"description\"=>\"SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling. This finding could be reproduced in colorectal and lung cancer cell lines in a second, independent screen.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}, {\"id\"=>233, \"name\"=>\"RAF265\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>685, \"name\"=>\"RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.\", \"citation\"=>\"Lamba et al., 2014, Cell Rep\", \"pubmed_id\"=>\"25199829\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25199829\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>9, \"day\"=>11}, \"journal\"=>\"Cell Rep\", \"full_journal_title\"=>\"Cell reports\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>989, \"name\"=>\"EID989\", \"description\"=>\"SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling. This finding was reproduced two NSCLC cell lines in a second, independent shRNA screen.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}, {\"id\"=>233, \"name\"=>\"RAF265\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>685, \"name\"=>\"RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.\", \"citation\"=>\"Lamba et al., 2014, Cell Rep\", \"pubmed_id\"=>\"25199829\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25199829\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>9, \"day\"=>11}, \"journal\"=>\"Cell Rep\", \"full_journal_title\"=>\"Cell reports\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>991, \"name\"=>\"EID991\", \"description\"=>\"An shDNA Screen identified synergy betwenn ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines. Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in colorectal and lung cancer cell lines. Induction of ERBB3 signalling was also identified in a patient with KRAS mutation after MEK inhibition with trametinib.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>686, \"name\"=>\"Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.\", \"citation\"=>\"Sun et al., 2014, Cell Rep\", \"pubmed_id\"=>\"24685132\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24685132\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>4, \"day\"=>10}, \"journal\"=>\"Cell Rep\", \"full_journal_title\"=>\"Cell reports\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>935, \"name\"=>\"EID935\", \"description\"=>\"In this screen of 218 solid cancer cell lines, KRAS and BRAF mutations were predictive of response to MEK inhibitor GSK1120212. 40 cell lines harbored a KRAS mutation. In RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic (9/10 cell lines) response rather than a cytotoxic response (1/10 cell lines).\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>640, \"name\"=>\"Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.\", \"citation\"=>\"Jing et al., 2012, Mol. Cancer Ther.\", \"pubmed_id\"=>\"22169769\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22169769\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>3}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>943, \"name\"=>\"EID943\", \"description\"=>\"TLR9 agonist immunomodulatory oligonucleotide (IMO) led to inhibited survival of LS174T colorectal cancer and AsPC1 pancreatic cancer cell lines with KRAS mutations.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>145, \"name\"=>\"EGFR Inhibitor\", \"pubchem_id\"=>nil}, {\"id\"=>182, \"name\"=>\"IMO\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>645, \"name\"=>\"Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.\", \"citation\"=>\"Rosa et al., 2011, Clin. Cancer Res.\", \"pubmed_id\"=>\"21890455\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21890455\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>10, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>947, \"name\"=>\"EID947\", \"description\"=>\"Combined treatment with dasatinib and cetuximab, but not either agent in monotherapy, had an antitumor efficacy in-vitro and in xenografts. These results were based on three KRAS mutant cell lines (LS180, LoVo and HCT116) and two KRAS wild-type cell lines (SW48 and CaCo2).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>20, \"name\"=>\"Dasatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>649, \"name\"=>\"Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.\", \"citation\"=>\"Dunn et al., 2011, Oncogene\", \"pubmed_id\"=>\"20956938\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20956938\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3025039\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>2, \"day\"=>3}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>820, \"name\"=>\"EID820\", \"description\"=>\"KRAS mutation or amplification predicted sensitivity to decitabine in ovarian cancer cell lines. The authors profiled the response of 45 ovarian, melanoma, and breast cancer cell lines over 9 days of treatment with decitabine. 4 ovarian lines with KRAS mutation were among the most sensitive to decitabine.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>155, \"name\"=>\"Decitabine\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>551, \"name\"=>\"KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.\", \"citation\"=>\"Stewart et al., 2015, Cancer Res.\", \"pubmed_id\"=>\"25968887\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25968887\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4506246\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>7, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>1003, \"name\"=>\"EID1003\", \"description\"=>\"Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either agent alone. Chemical library screen in two cell lines also identified mTOR, AKT Family Inhibitors (Temsirolimus, Everolimus) to act synergistically with ERK Inhibition.\", \"disease\"=>{\"id\"=>158, \"name\"=>\"Pancreatic Adenocarcinoma\", \"display_name\"=>\"Pancreatic Adenocarcinoma\", \"doid\"=>\"4074\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4074\"}, \"drugs\"=>[{\"id\"=>114, \"name\"=>\"AZD8186\", \"pubchem_id\"=>nil}, {\"id\"=>245, \"name\"=>\"SCH772984\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>692, \"name\"=>\"Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.\", \"citation\"=>\"Hayes et al., 2016, Cancer Cell\", \"pubmed_id\"=>\"26725216\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26725216\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4816652\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>1, \"day\"=>11}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>894, \"name\"=>\"EID894\", \"description\"=>\"94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. Mutations were found in 32 of 73 analyzed tumors, 10 of which were KRAS mutations. No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss.\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>83, \"name\"=>\"Temsirolimus\", \"pubchem_id\"=>nil}, {\"id\"=>170, \"name\"=>\"Ridaforolimus\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>602, \"name\"=>\"Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.\", \"citation\"=>\"Mackay et al., 2014, Cancer\", \"pubmed_id\"=>\"24166148\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24166148\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>15}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>1001, \"name\"=>\"EID1001\", \"description\"=>\"Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 4 patients with KRAS +/- PIK3CA mutant colorectal cancer. 3 with SD, 1 with PD.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>309, \"name\"=>\"BAY 86-9766\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>690, \"name\"=>\"Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.\", \"citation\"=>\"Weekes et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23434733\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23434733\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>999, \"name\"=>\"EID999\", \"description\"=>\"87 patients with KRAS mutant stage IIB-IV NSCLC after first line therapy were randomly assigned (1:1) to oral selumetunib and docetaxel or docetaxel and Placebo. Median OS was 9Â·4 months (6Â·8-13Â·6) in selumetinib group and 5Â·2 months (95% CI 3Â·8-non-calculable) in placebo group (hazard ratio [HR] for death 0Â·80, 80% CI 0Â·56-1Â·14; one-sided p=0Â·21). Median PFS was 5Â·3 months (4Â·6-6Â·4) in selumetinib group and 2Â·1 months (95% CI 1Â·4-3Â·7) in placebo group (HR for progression 0Â·58, 80% CI 0Â·42-0Â·79; one-sided p=0Â·014). An objective response was observed in 16 (37%) patients in the selumetinib group and none in the placebo group(p<0Â·0001).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}, {\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>689, \"name\"=>\"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.\", \"citation\"=>\"JÃ¤nne et al., 2013, Lancet Oncol.\", \"pubmed_id\"=>\"23200175\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23200175\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>1}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>1004, \"name\"=>\"EID1004\", \"description\"=>\"Preclinial data from KRAS mutant colorectal cancer cell lines show syngergistic effect on cell viability and apoptosis in vitro and in vivo when MEK and IGF-IR are inhibited concomitantly. In other cell lines, activation of other RTKs (such as MET) were observed upon MEK Inhibition and combination of RTKi and METi also showed synergistic activity. A total of 16 cell lines were used in this study. 6 were KRAS wild type, and 10 harbored various KRAS mutations (G12C, G12D, G12V, G13D, and Q61L). Additional data was obtained from xenografts.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}, {\"id\"=>246, \"name\"=>\"R1507\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>693, \"name\"=>\"Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.\", \"citation\"=>\"Ebi et al., 2011, J. Clin. Invest.\", \"pubmed_id\"=>\"21985784\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21985784\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3204842\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"J. Clin. Invest.\", \"full_journal_title\"=>\"The Journal of clinical investigation\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>998, \"name\"=>\"EID998\", \"description\"=>\"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). All 25 patients with KRAS mutant colorectal cancer experienced PD.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>243, \"name\"=>\"RO4987655\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>688, \"name\"=>\"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.\", \"citation\"=>\"Zimmer et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24947927\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24947927\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>8, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}, {\"id\"=>997, \"name\"=>\"EID997\", \"description\"=>\"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). 2 PR and 8 SD among 18 patients with KRAS Mutant NSCLC.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>243, \"name\"=>\"RO4987655\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>688, \"name\"=>\"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.\", \"citation\"=>\"Zimmer et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24947927\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24947927\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>8, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>336, \"phenotypes\"=>[]}]}, {\"id\"=>12, \"entrez_name\"=>\"BRAF\", \"entrez_id\"=>673, \"name\"=>\"V600E\", \"description\"=>\"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.\", \"gene_id\"=>5, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>47, \"name\"=>\"missense_variant\", \"display_name\"=>\"Missense Variant\", \"so_id\"=>\"SO:0001583\", \"description\"=>\"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001583\"}], \"civic_actionability_score\"=>841.5, \"coordinates\"=>{\"chromosome\"=>\"7\", \"start\"=>140453136, \"stop\"=>140453136, \"reference_bases\"=>\"A\", \"variant_bases\"=>\"T\", \"representative_transcript\"=>\"ENST00000288602.6\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/5/summary/variants/12/summary#variant\", \"evidence_items\"=>[{\"id\"=>5962, \"name\"=>\"EID5962\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant laryngeal cancer had a partial response with vemurafenib.\", \"disease\"=>{\"id\"=>124, \"name\"=>\"Laryngeal Squamous Cell Carcinoma\", \"display_name\"=>\"Laryngeal Squamous Cell Carcinoma\", \"doid\"=>\"2876\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2876\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>5961, \"name\"=>\"EID5961\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant anaplastic thyroid cancer had a complete response.\", \"disease\"=>{\"id\"=>155, \"name\"=>\"Thyroid Carcinoma\", \"display_name\"=>\"Thyroid Carcinoma\", \"doid\"=>\"3963\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3963\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>5960, \"name\"=>\"EID5960\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 2 patients with BRAF V600E mutant colorectal cancer, 1 had a partial response.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>5904, \"name\"=>\"EID5904\", \"description\"=>\"Dabrafenib and trametinib combination showed durable response for patients with standard chemotherapy refractory cholangiocarcinoma havoring BRAF V600E.\", \"disease\"=>{\"id\"=>29, \"name\"=>\"Cholangiocarcinoma\", \"display_name\"=>\"Cholangiocarcinoma\", \"doid\"=>\"4947\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4947\"}, \"drugs\"=>[{\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}, {\"id\"=>548, \"name\"=>\"Trametinib DMSO\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2379, \"name\"=>\"Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.\", \"citation\"=>\"Loaiza-Bonilla et al., 2014, Ecancermedicalscience\", \"pubmed_id\"=>\"25435907\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25435907\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4239128\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Ecancermedicalscience\", \"full_journal_title\"=>\"Ecancermedicalscience\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>5959, \"name\"=>\"EID5959\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.\\nAmong 4 patients with BRAF V600E mutant ovarian cancer, 2 had a partial response and one had stable disease > 120days.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>5906, \"name\"=>\"EID5906\", \"description\"=>\"Patients with metastatic cholangiocarcinoma havoring with BRAF V600E was treated with vemurafenib, panitumumab and irinotecan triplet therapy. Multiple lung metastasis was dramatically regressed and this treatment was continued.\", \"disease\"=>{\"id\"=>29, \"name\"=>\"Cholangiocarcinoma\", \"display_name\"=>\"Cholangiocarcinoma\", \"doid\"=>\"4947\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4947\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}, {\"id\"=>101, \"name\"=>\"Irinotecan\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2382, \"name\"=>\"Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.\", \"citation\"=>\"Silkin et al., 2016, J Gastrointest Cancer\", \"pubmed_id\"=>\"26687137\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26687137\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>12}, \"journal\"=>\"J Gastrointest Cancer\", \"full_journal_title\"=>\"Journal of gastrointestinal cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>5902, \"name\"=>\"EID5902\", \"description\"=>\"Chemotherapy-refractory, metastatic cholangiocarcinoma with BRAF V600E showed dramatically response for Dabrafenib and Trametinib combination.\", \"disease\"=>{\"id\"=>29, \"name\"=>\"Cholangiocarcinoma\", \"display_name\"=>\"Cholangiocarcinoma\", \"doid\"=>\"4947\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4947\"}, \"drugs\"=>[{\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}, {\"id\"=>548, \"name\"=>\"Trametinib DMSO\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2381, \"name\"=>\"Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion.\", \"citation\"=>\"Kocsis et al., 2017, J Gastrointest Oncol\", \"pubmed_id\"=>\"28480077\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28480077\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5401859\", \"publication_date\"=>{\"year\"=>2017, \"month\"=>4}, \"journal\"=>\"J Gastrointest Oncol\", \"full_journal_title\"=>\"Journal of gastrointestinal oncology\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>5903, \"name\"=>\"EID5903\", \"description\"=>\"Two cases of patients with BRAF V600E positive cholangiocarcinoma showed excellent response for Dabrafenib and Trametinib.\", \"disease\"=>{\"id\"=>29, \"name\"=>\"Cholangiocarcinoma\", \"display_name\"=>\"Cholangiocarcinoma\", \"doid\"=>\"4947\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4947\"}, \"drugs\"=>[{\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}, {\"id\"=>548, \"name\"=>\"Trametinib DMSO\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2380, \"name\"=>\"Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review.\", \"citation\"=>\"Lavingia et al., 2016, J Gastrointest Oncol\", \"pubmed_id\"=>\"28078132\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28078132\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5177579\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>12}, \"journal\"=>\"J Gastrointest Oncol\", \"full_journal_title\"=>\"Journal of gastrointestinal oncology\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3743, \"name\"=>\"EID3743\", \"description\"=>\"An anaplastic thyroid cancer patient harboring BRAF V600E mutation was associated with response to vemurafenib treatment. The patient was initially treated with paclitaxel, but experienced disease progression; subsequently, the patient was treated concurrently with vemurafenib and radiation therapy and achieved regression of metastatic disease.\", \"disease\"=>{\"id\"=>155, \"name\"=>\"Thyroid Carcinoma\", \"display_name\"=>\"Thyroid Carcinoma\", \"doid\"=>\"3963\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3963\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>nil, \"evidence_direction\"=>nil, \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1948, \"name\"=>\"BRAF V600E inhibition in anaplastic thyroid cancer.\", \"citation\"=>\"Rosove et al., 2013, N. Engl. J. Med.\", \"pubmed_id\"=>\"23406047\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23406047\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>2, \"day\"=>14}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>5958, \"name\"=>\"EID5958\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.\\nWithin the BRAF mutant group, fourteen patients had refractory BRAF V600E-mutated NSCLC (adenocarcinoma, n = 13; sarcomatoid, n = 1). Six patients (43%; 95% CI, 18% to 71%) had objective responses (one CR, five PR), and two additional patients had SD > 120 days. The median DOR was 5 months (range, 4 to 14 months).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3017, \"name\"=>\"EID3017\", \"description\"=>\"Patients with BRAF V600E-mutant NSCLC (n=57) were enrolled into a phase 2, multicentre, non-randomised, open-label study, administering dabrafenib plus trametinib. The overall response rate was 36/57 (63.2%, [95% CI 49.3-75.6]) and the median progression-free survival was 9.7 months (95% CI 6.9-19.6). At data cutoff (11.6 months of follow-up), 18/36  (50%) confirmed responses were ongoing and 23/57 (40%) of patients had died.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1296, \"name\"=>\"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.\", \"citation\"=>\"Planchard et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"27283860\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27283860\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4993103\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>7}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3737, \"name\"=>\"EID3737\", \"description\"=>\"In metastatic colorectal cancer patients with wildtype KRAS status who received cetuximab therapy, those with a BRAF V600E mutation had reduced progression-free survival (8.0wk vs. 31.4wk, P=0.001, log-rank test, univariate analysis) and reduced overall survival (6.5mo vs. 14.8mo, P=0.001, log-rank test, univariate analysis; HR:6.6, 95%CI:2.4-18.2, P<0.001, multivariate analysis. Similar associations have been found in independent studies.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1479, \"name\"=>\"Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.\", \"citation\"=>\"Souglakos et al., 2009, Br. J. Cancer\", \"pubmed_id\"=>\"19603024\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19603024\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2720232\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>8, \"day\"=>4}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>97, \"name\"=>\"EID97\", \"description\"=>\"Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>30, \"name\"=>\"PLX4720\", \"pubchem_id\"=>nil}, {\"id\"=>31, \"name\"=>\"Nutlin-3\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>107, \"name\"=>\"Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.\", \"citation\"=>\"Ji et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23812671\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23812671\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3777641\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>8, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2119, \"name\"=>\"EID2119\", \"description\"=>\"Among metastatic colorectal cancer patients treated with cetuximab and irinotecan, those with BRAF V600E mutations were less likely to achieve a complete or partial response to therapy (0% , P=0.016, Fisherï¿½s exact test) and had reduced median overall survival (4.1mo vs. 13.9mo, HR:0.51, 95%CI:0.18-0.95, P=0.037) than patients with wildtype BRAF.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>101, \"name\"=>\"Irinotecan\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1480, \"name\"=>\"KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.\", \"citation\"=>\"Loupakis et al., 2009, Br. J. Cancer\", \"pubmed_id\"=>\"19603018\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19603018\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2736831\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>8, \"day\"=>18}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3790, \"name\"=>\"EID3790\", \"description\"=>\"In a conjunctival malignant melanoma patient harboring a BRAF V600E mutation, BRAF V600E was associated with response to vemurafenib treatment. Prior to identification of the BRAF V600E mutation, the patient was treated with cryotherapy, standard chemotherapy and whole brain radiotherapy; the patient achieved a 4 month progression free survival with vemurafenib treatment prior to disease progression.\", \"disease\"=>{\"id\"=>2605, \"name\"=>\"Malignant Conjunctival Melanoma\", \"display_name\"=>\"Malignant Conjunctival Melanoma\", \"doid\"=>\"1751\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1751\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1986, \"name\"=>\"A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.\", \"citation\"=>\"Maleka et al., 2016, BMC Cancer\", \"pubmed_id\"=>\"27520988\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27520988\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4983009\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>8, \"day\"=>12}, \"journal\"=>\"BMC Cancer\", \"full_journal_title\"=>\"BMC cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3789, \"name\"=>\"EID3789\", \"description\"=>\"A primary central nervous system (CNS)-histiocytic sarcoma patient harboring BRAF V600E mutation was associated with improved response to vemurafenib treatment. The patient was treated with vemurafenib monotherapy and obtained a clinical, biological and radiologic response; subsequently, the patient developed progressive disease and died 6 months after initial treatment with vemurafenib.\", \"disease\"=>{\"id\"=>964, \"name\"=>\"Histiocytoma\", \"display_name\"=>\"Histiocytoma\", \"doid\"=>\"4231\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4231\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1985, \"name\"=>\"Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.\", \"citation\"=>\"Idbaih et al., 2014, Neurology\", \"pubmed_id\"=>\"25209580\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25209580\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>10, \"day\"=>14}, \"journal\"=>\"Neurology\", \"full_journal_title\"=>\"Neurology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3788, \"name\"=>\"EID3788\", \"description\"=>\"In a malignant peripheral nerve sheath tumor patient harboring a BRAF V600E mutation, response to vemurafenib monotherapy was reported. Upon identification of the BRAF V600E mutation, the patient was treated with sorafenib monotherapy, but quickly progressed; subsequently, the patient was treated with vemurafenib. 33 days after treatment was initiated, tumor response was reported, as evident by the disappearance of chest and abdominal skin lesions.\", \"disease\"=>{\"id\"=>326, \"name\"=>\"Malignant Peripheral Nerve Sheath Tumor\", \"display_name\"=>\"Malignant Peripheral Nerve Sheath Tumor\", \"doid\"=>\"5940\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5940\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1958, \"name\"=>\"Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.\", \"citation\"=>\"Kaplan, 2013, J Natl Compr Canc Netw\", \"pubmed_id\"=>\"24335681\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24335681\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>12, \"day\"=>1}, \"journal\"=>\"J Natl Compr Canc Netw\", \"full_journal_title\"=>\"Journal of the National Comprehensive Cancer Network : JNCCN\", \"status\"=>\"submitted\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3787, \"name\"=>\"EID3787\", \"description\"=>\"A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard chemotherapy, hormone therapy and bevacizumab prior to the identification of the BRAF V600E mutation; next, the patient was treated with paclitaxel and an anti-HER3 antibody and finally with vemurafenib, obtaining a partial response of greater than 1 year.\", \"disease\"=>{\"id\"=>816, \"name\"=>\"Ovarian Cystadenocarcinoma\", \"display_name\"=>\"Ovarian Cystadenocarcinoma\", \"doid\"=>\"3605\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3605\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1984, \"name\"=>\"Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.\", \"citation\"=>\"Combe et al., 2015, Invest New Drugs\", \"pubmed_id\"=>\"26490654\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26490654\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>12}, \"journal\"=>\"Invest New Drugs\", \"full_journal_title\"=>\"Investigational new drugs\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3786, \"name\"=>\"EID3786\", \"description\"=>\"An anaplastic pleomorphic xanthoastrocytoma patient harboring BRAF V600E mutation was associated with improved response to vemurafenib treatment. The patient was treated with radiation and temozolomide before experiencing disease progression; subsequent treatment with vemurafenib monotherapy, for a 12 week period, resulted in a near complete response.\", \"disease\"=>{\"id\"=>1124, \"name\"=>\"Pleomorphic Xanthoastrocytoma\", \"display_name\"=>\"Pleomorphic Xanthoastrocytoma\", \"doid\"=>\"4852\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4852\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1983, \"name\"=>\"Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.\", \"citation\"=>\"Lee et al., 2016, J. Clin. Oncol.\", \"pubmed_id\"=>\"25092772\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25092772\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3785, \"name\"=>\"EID3785\", \"description\"=>\"In an in vitro study, the BCPAP cell line expressing a BRAF V600E mutation was associated with sensitivity to vemurafenib treatment. Sensitivity was determined by assessing cell viability and apoptotic cell death. However, the 8505C cell line expressing a BRAF V600E mutation and high MET protein phosphorylation levels was reported to be insensitive to vemurafenib treatment.\", \"disease\"=>{\"id\"=>155, \"name\"=>\"Thyroid Carcinoma\", \"display_name\"=>\"Thyroid Carcinoma\", \"doid\"=>\"3963\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3963\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1982, \"name\"=>\"c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.\", \"citation\"=>\"Byeon et al., 2016, Mol. Carcinog.\", \"pubmed_id\"=>\"26456083\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26456083\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>11}, \"journal\"=>\"Mol. Carcinog.\", \"full_journal_title\"=>\"Molecular carcinogenesis\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3784, \"name\"=>\"EID3784\", \"description\"=>\"In an in vitro study, BRAF V600E expressing cell lines (BCPAP, OCUT1, K1 and SW1736) demonstrated increased sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells (FTC133, KAT18, Hth74 and WRO). Sensitivity was determined by assessing cell proliferation (OCUT1, IC50: 0.41uM; SW1736, IC50: 0.12 uM; K1, IC50: 0.83 uM; BCPAP, IC50: 1.16 uM vs. FTC133, IC50: 56.67 uM; KAT18, 541.66 uM; Hth74, IC50: 1349.79 uM; and WRO IC50: 943.73 uM) and ERK phosphorylation.\", \"disease\"=>{\"id\"=>155, \"name\"=>\"Thyroid Carcinoma\", \"display_name\"=>\"Thyroid Carcinoma\", \"doid\"=>\"3963\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3963\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1981, \"name\"=>\"The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).\", \"citation\"=>\"Xing et al., 2011, Biochem. Biophys. Res. Commun.\", \"pubmed_id\"=>\"21185263\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21185263\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4596240\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>1, \"day\"=>28}, \"journal\"=>\"Biochem. Biophys. Res. Commun.\", \"full_journal_title\"=>\"Biochemical and biophysical research communications\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3783, \"name\"=>\"EID3783\", \"description\"=>\"A stage IV lung adenocarcinoma patient harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patientï¿½s prior treatment regimens were complex, including radiotherapy, standard chemotherapy and erlotinib; subsequently, the BRAF V600E mutation was identified and the patient was treated with vemurafenib monotherapy, achieving a favorable response for greater than 24 months.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1980, \"name\"=>\"Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.\", \"citation\"=>\"Myall et al., 2016, Clin Lung Cancer\", \"pubmed_id\"=>\"26776917\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26776917\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Clin Lung Cancer\", \"full_journal_title\"=>\"Clinical lung cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3782, \"name\"=>\"EID3782\", \"description\"=>\"In a retrospective study of 35 lung adenocarcinoma patients (with chemotherapy previously administered in 86% of patients), patients harboring a BRAF V600E mutation and treated with vemurafenib monotherapy (n=29) were associated with an improved response rate; an overall survival (with 1st-line therapy) of 25.63 months, a 54% overall response rate and a 95% disease control rate were reported.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1979, \"name\"=>\"Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.\", \"citation\"=>\"Gautschi et al., 2015, J Thorac Oncol\", \"pubmed_id\"=>\"26200454\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26200454\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>10}, \"journal\"=>\"J Thorac Oncol\", \"full_journal_title\"=>\"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3781, \"name\"=>\"EID3781\", \"description\"=>\"In a stage IV non-small cell lung cancer patient with a BRAF V600E mutation, who developed adenocarcinoma, BRAF V600E was associated with sensitivity to vemurafenib treatment. The patient was initially treated with four cycles of standard chemotherapy (cisplatin and pemetrexed) and achieved a partial response, subsequently a complete radiologic response was observed with 11 cycle of maintenance chemotherapy. However, the patientï¿½s disease eventually progressed and lung adenocarcinoma and hepatic metastases were observed, the patient received radiotherapy, followed by the administration of vemurafenib monotherapy with concurrent radiotherapy, resulting in an excellent partial response followed by complete response.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1978, \"name\"=>\"Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.\", \"citation\"=>\"Peters et al., 2013, J. Clin. Oncol.\", \"pubmed_id\"=>\"23733758\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23733758\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>7, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3780, \"name\"=>\"EID3780\", \"description\"=>\"In a lung adenocarcinoma patient with brain metastases harboring BRAF V600E mutation, BRAF V600E was associated with sensitivity to vemurafenib treatment. Upon treatment with vemurafenib monotherapy, the patientï¿½s metastases demonstrated significant response and pleural right effusion improvement was observed; however, at 4 months the patientï¿½s disease progressed resulting in death.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1977, \"name\"=>\"BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.\", \"citation\"=>\"Robinson et al., 2014, Lung Cancer\", \"pubmed_id\"=>\"24888229\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24888229\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>8}, \"journal\"=>\"Lung Cancer\", \"full_journal_title\"=>\"Lung cancer (Amsterdam, Netherlands)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3779, \"name\"=>\"EID3779\", \"description\"=>\"In a case report, a clear cell sarcoma patient harboring BRAF V600E mutation with distant metastases was associated with a complete response to vemurafenib monotherapy at 8 weeks of treatment. Prior to the administration of vemurafenib, the patient had undergone surgery and was treated with radiation, and standard chemotherapy, but had developed progressive disease.\", \"disease\"=>{\"id\"=>966, \"name\"=>\"Clear Cell Sarcoma\", \"display_name\"=>\"Clear Cell Sarcoma\", \"doid\"=>\"4233\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4233\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1976, \"name\"=>\"BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.\", \"citation\"=>\"Protsenko et al., 2015, Invest New Drugs\", \"pubmed_id\"=>\"26286452\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26286452\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>10}, \"journal\"=>\"Invest New Drugs\", \"full_journal_title\"=>\"Investigational new drugs\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3778, \"name\"=>\"EID3778\", \"description\"=>\"A grade I refractory brainstem ganglioglioma patient harboring BRAF V600E mutation was associated with partial response to vemurafenib monotherapy. The patient experienced significant clinical improvement in response to vemurafenib and maintained a partial response for 12 months; however, disease progression occurred after vemurafenib was discontinued for three months, reintroduction of vemurafenib resulted in a rapid partial response, with continued response noted at time of publication.\", \"disease\"=>{\"id\"=>2604, \"name\"=>\"Ganglioglioma\", \"display_name\"=>\"Ganglioglioma\", \"doid\"=>\"5078\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5078\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1975, \"name\"=>\"Successful Retreatment of a Child with a Refractory Brainstem Ganglioglioma with Vemurafenib.\", \"citation\"=>\"Aguilera et al., 2016, Pediatr Blood Cancer\", \"pubmed_id\"=>\"26579623\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26579623\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Pediatr Blood Cancer\", \"full_journal_title\"=>\"Pediatric blood & cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3777, \"name\"=>\"EID3777\", \"description\"=>\"In a case report, a cervicomedullary ganglioglioma patient harboring BRAF V600E mutation was associated with radiological and clinical response to vemurafenib monotherapy after 3 months of treatment, which was sustained after 6 months of therapy. Prior to vemurafenib treatment, the patient had undergone tracheotomy, was treated with standard chemotherapy and underwent another surgery, but had developed progressive disease.\", \"disease\"=>{\"id\"=>2604, \"name\"=>\"Ganglioglioma\", \"display_name\"=>\"Ganglioglioma\", \"doid\"=>\"5078\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5078\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1974, \"name\"=>\"Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.\", \"citation\"=>\"del Bufalo et al., 2014, J Transl Med\", \"pubmed_id\"=>\"25524464\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25524464\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4279809\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>12, \"day\"=>19}, \"journal\"=>\"J Transl Med\", \"full_journal_title\"=>\"Journal of translational medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3776, \"name\"=>\"EID3776\", \"description\"=>\"In an in vitro study, WiDr, HT-29 and RKO cell lines expressing BRAF V600E mutation was associated with sensitivity to regorafenib treatment, as compared to Caco-2 and KM12SM cells expressing wild-type BRAF. Resistance was determined by assessing cell proliferation and migration.\", \"disease\"=>{\"id\"=>119, \"name\"=>\"Colon Cancer\", \"display_name\"=>\"Colon Cancer\", \"doid\"=>\"219\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:219\"}, \"drugs\"=>[{\"id\"=>27, \"name\"=>\"Regorafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1973, \"name\"=>\"Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.\", \"citation\"=>\"Takigawa et al., 2016, Cancer Sci.\", \"pubmed_id\"=>\"26865419\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26865419\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5001714\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>5}, \"journal\"=>\"Cancer Sci.\", \"full_journal_title\"=>\"Cancer science\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3775, \"name\"=>\"EID3775\", \"description\"=>\"In an in vitro study, K2, a papillary thyroid carcinoma cell line expressing the BRAFV600E mutation, was associated with sensitivity to dasatinib treatment. Sensitivity was determined by assessing cell growth inhibition. In an in vivo experiment, dasatinib also inhibited the growth of K2 thyroid carcinoma xenografts in 7 of 13 mice.\", \"disease\"=>{\"id\"=>156, \"name\"=>\"Papillary Thyroid Carcinoma\", \"display_name\"=>\"Papillary Thyroid Carcinoma\", \"doid\"=>\"3969\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3969\"}, \"drugs\"=>[{\"id\"=>20, \"name\"=>\"Dasatinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1972, \"name\"=>\"Src inhibitors in suppression of papillary thyroid carcinoma growth.\", \"citation\"=>\"Henderson et al., 2014, Head Neck\", \"pubmed_id\"=>\"23729178\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23729178\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4401074\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>3}, \"journal\"=>\"Head Neck\", \"full_journal_title\"=>\"Head & neck\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3774, \"name\"=>\"EID3774\", \"description\"=>\"In a clinical trial (NCT01286753) of 55 cancer patients with BRAF V600E mutation, patients with metastatic papillary thyroid cancer (n=3) were associated with sensitivity to vemurafenib treatment. One patient achieved partial response (31% reduction by RECIST) and two patients achieved stable disease (9% and 16% reduction by RECIST criteria), the time to progression for these three patients was 11.7, 13.2 and 11.4 months, and the overall survival was 15 months (patient was subsequently treated with radiation therapy), at least 31.7 months (patient subsequently underwent laryngectomy) and 24.9 months (patient was subsequently treated with sorafenib, followed by sunitinib monotherapy), respectively.\", \"disease\"=>{\"id\"=>156, \"name\"=>\"Papillary Thyroid Carcinoma\", \"display_name\"=>\"Papillary Thyroid Carcinoma\", \"doid\"=>\"3969\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3969\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1971, \"name\"=>\"Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.\", \"citation\"=>\"Kim et al., 2013, Thyroid\", \"pubmed_id\"=>\"23489023\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23489023\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3967415\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>10}, \"journal\"=>\"Thyroid\", \"full_journal_title\"=>\"Thyroid : official journal of the American Thyroid Association\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3773, \"name\"=>\"EID3773\", \"description\"=>\"In a retrospective study of 17 papillary thyroid cancer patients, patients with BRAF V600E mutation (n=6) were associated with a 47% (7/15) partial response rate and a 53% (8/15) stable disease rate.\", \"disease\"=>{\"id\"=>156, \"name\"=>\"Papillary Thyroid Carcinoma\", \"display_name\"=>\"Papillary Thyroid Carcinoma\", \"doid\"=>\"3969\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3969\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1970, \"name\"=>\"Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.\", \"citation\"=>\"Dadu et al., 2015, J. Clin. Endocrinol. Metab.\", \"pubmed_id\"=>\"25353071\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25353071\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4283003\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>1}, \"journal\"=>\"J. Clin. Endocrinol. Metab.\", \"full_journal_title\"=>\"The Journal of clinical endocrinology and metabolism\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3772, \"name\"=>\"EID3772\", \"description\"=>\"A pediatric pilocytic astrocytoma patient harboring BRAF V600E mutation, BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard chemotherapy regimens prior to the identification of the BRAF V600E mutation; subsequently, vemurafenib was administered (initially in combination with standard chemotherapy) and an overall regression achieved, with lack of disease progression noted at 15 months of vemurafenib therapy.\", \"disease\"=>{\"id\"=>166, \"name\"=>\"Pilocytic Astrocytoma\", \"display_name\"=>\"Pilocytic Astrocytoma\", \"doid\"=>\"4851\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4851\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1969, \"name\"=>\"Pilomyxoid astrocytoma treated successfully with vemurafenib.\", \"citation\"=>\"Skrypek et al., 2014, Pediatr Blood Cancer\", \"pubmed_id\"=>\"24821190\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24821190\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>11}, \"journal\"=>\"Pediatr Blood Cancer\", \"full_journal_title\"=>\"Pediatric blood & cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3771, \"name\"=>\"EID3771\", \"description\"=>\"In a case study, a pediatric grade IV glioblastoma multiforme patient harboring BRAF V600E mutation was associated with a complete response to vemurafenib monotherapy after 4 months of treatment, which was sustained at 6 month of therapy; the patient was undergoing the 7th cycle of therapy at the time of publication of this study.\", \"disease\"=>{\"id\"=>19, \"name\"=>\"Glioblastoma Multiforme\", \"display_name\"=>\"Glioblastoma Multiforme\", \"doid\"=>\"3068\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3068\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1968, \"name\"=>\"Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.\", \"citation\"=>\"Robinson et al., 2014, BMC Cancer\", \"pubmed_id\"=>\"24725538\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24725538\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3996187\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>4, \"day\"=>12}, \"journal\"=>\"BMC Cancer\", \"full_journal_title\"=>\"BMC cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3770, \"name\"=>\"EID3770\", \"description\"=>\"A hairy cell leukemia patient with extensive CNS involvement patient harboring BRAF V600E mutation was associated with complete response to vemurafenib monotherapy. Upon identification of the BRAF V600E mutation, the patient was treated with cytarabine, rituximab and methotrexate but quickly progressed; subsequently, the patient was treated with 2 rounds of vemurafenib and achieved complete response.\", \"disease\"=>{\"id\"=>665, \"name\"=>\"Hairy Cell Leukemia\", \"display_name\"=>\"Hairy Cell Leukemia\", \"doid\"=>\"285\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:285\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1967, \"name\"=>\"Response of relapsed central nervous system hairy cell leukemia to vemurafenib.\", \"citation\"=>\"McDowell et al., 2016, Leuk. Lymphoma\", \"pubmed_id\"=>\"27116997\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27116997\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>12}, \"journal\"=>\"Leuk. Lymphoma\", \"full_journal_title\"=>\"Leukemia & lymphoma\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3769, \"name\"=>\"EID3769\", \"description\"=>\"As a follow-up to a previous study (23300174), a hairy cell leukemia patient harboring BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was previously treated with vemurafenib and obtained a complete response, but then experienced disease progression. Subsequently, the patient was re-treated with vemurafenib and again achieved a complete hematological response.\", \"disease\"=>{\"id\"=>665, \"name\"=>\"Hairy Cell Leukemia\", \"display_name\"=>\"Hairy Cell Leukemia\", \"doid\"=>\"285\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:285\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1966, \"name\"=>\"Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib.\", \"citation\"=>\"Bailleux et al., 2015, Oncoscience\", \"pubmed_id\"=>\"25815361\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25815361\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4341463\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"Oncoscience\", \"full_journal_title\"=>\"Oncoscience\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3768, \"name\"=>\"EID3768\", \"description\"=>\"In a hairy cell leukemia patient harboring BRAF V600E mutation, BRAF V600E mutation was associated with improved response to vemurafenib treatment. The patient was treated with 3 lines of chemotherapy, including 6 cycles of pentostatin and rituximab combination therapy, but experience progressive disease; subsequently, the patient was treated with vemurafenib monotherapy for 58 days and achieved a partial response.\", \"disease\"=>{\"id\"=>665, \"name\"=>\"Hairy Cell Leukemia\", \"display_name\"=>\"Hairy Cell Leukemia\", \"doid\"=>\"285\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:285\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1965, \"name\"=>\"Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.\", \"citation\"=>\"Follows et al., 2013, Br. J. Haematol.\", \"pubmed_id\"=>\"23278307\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23278307\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>4}, \"journal\"=>\"Br. J. Haematol.\", \"full_journal_title\"=>\"British journal of haematology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3767, \"name\"=>\"EID3767\", \"description\"=>\"In a case report, a hairy cell leukemia (HCL) patient harboring BRAF V600E mutation was associated with a complete response to vemurafenib monotherapy after 3 months of treatment, which was sustained after 21 days of therapy. Prior to vemurafenib treatment, the patient had been diagnosed with HCL and achieved a complete hematologic response to splenectomy and interferon treatment, however, the patient subsequently relapsed and was treated with standard chemotherapy with further disease progression. As a follow-up to a previous study (23300174), a hairy cell leukemia patient harboring BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was previously treated with vemurafenib and obtained a complete response, but then experienced disease progression. Subsequently, the patient was re-treated with vemurafenib and again achieved a complete hematological response.\", \"disease\"=>{\"id\"=>665, \"name\"=>\"Hairy Cell Leukemia\", \"display_name\"=>\"Hairy Cell Leukemia\", \"doid\"=>\"285\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:285\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1964, \"name\"=>\"Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.\", \"citation\"=>\"Peyrade et al., 2013, Haematologica\", \"pubmed_id\"=>\"23300174\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23300174\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3561446\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>2}, \"journal\"=>\"Haematologica\", \"full_journal_title\"=>\"Haematologica\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3766, \"name\"=>\"EID3766\", \"description\"=>\"In a refractory hairy cell leukemia patient harboring BRAF V600E mutation, BRAF V600E was associated with sensitivity to vemurafenib treatment. The patient was initially treated with conventional treatments and failed to respond; subsequently, the patient was treated with vemurafenib monotherapy and achieved complete remission on day 43 with treatment being terminated at day 56.\", \"disease\"=>{\"id\"=>665, \"name\"=>\"Hairy Cell Leukemia\", \"display_name\"=>\"Hairy Cell Leukemia\", \"doid\"=>\"285\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:285\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1963, \"name\"=>\"BRAF inhibition in refractory hairy-cell leukemia.\", \"citation\"=>\"Dietrich et al., 2012, N. Engl. J. Med.\", \"pubmed_id\"=>\"22621641\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22621641\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>5, \"day\"=>24}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3765, \"name\"=>\"EID3765\", \"description\"=>\"In a study of low grade pediatric gliomas, 19 of 157 tumors had a BRAF V600E mutation. Tumors located in the cerebrum had a higher frequency of BRAF mutations than those in the cerebellum or midline (P<0.05). While it did not reach statistical significance, there was a trend between BRAF V600E mutation and reduced progression-free survival (HR:2.39, 95%CI:0.93-6.15, P=0.07, multivariate analysis).\", \"disease\"=>{\"id\"=>695, \"name\"=>\"Malignant Glioma\", \"display_name\"=>\"Malignant Glioma\", \"doid\"=>\"3070\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3070\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"rejected\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1499, \"name\"=>\"Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.\", \"citation\"=>\"Horbinski et al., 2012, Neuro-oncology\", \"pubmed_id\"=>\"22492957\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22492957\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3367847\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>6}, \"journal\"=>\"Neuro-oncology\", \"full_journal_title\"=>\"Neuro-oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3764, \"name\"=>\"EID3764\", \"description\"=>\"In a study of  pilocytic astrocytomas, presence of the BRAF V600E mutation was more frequently detected in extra-cerebellar pilocytic astrocytomas than cerebellar ones (20%  vs. 2% , P=0.009, Fisherï¿½s exact test).\", \"disease\"=>{\"id\"=>695, \"name\"=>\"Malignant Glioma\", \"display_name\"=>\"Malignant Glioma\", \"doid\"=>\"3070\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3070\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"rejected\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1962, \"name\"=>\"Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.\", \"citation\"=>\"Schindler et al., 2011, Acta Neuropathol.\", \"pubmed_id\"=>\"21274720\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21274720\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>3}, \"journal\"=>\"Acta Neuropathol.\", \"full_journal_title\"=>\"Acta neuropathologica\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3763, \"name\"=>\"EID3763\", \"description\"=>\"A study of pediatric malignant astrocytomas found that tumors with BRAF V600E mutations also had homozygous deletions of CDKN2A more frequently than those with wildtype BRAF (71%  vs. 8% , P=0.0016, Fisherï¿½s exact test).\", \"disease\"=>{\"id\"=>695, \"name\"=>\"Malignant Glioma\", \"display_name\"=>\"Malignant Glioma\", \"doid\"=>\"3070\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3070\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"rejected\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1961, \"name\"=>\"Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.\", \"citation\"=>\"Schiffman et al., 2010, Cancer Res.\", \"pubmed_id\"=>\"20068183\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20068183\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2851233\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>1, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3762, \"name\"=>\"EID3762\", \"description\"=>\"In a mouse xenograft model, tumors derived from the glioblastoma cell line AM-38 that were treated with vemurafenib had reduced tumor growth and improved survival compared to control treated mice (P=0.018 and 0.0002, respectively). In contrast, mice with wildtype BRAF xenografts did not respond vemurafenib compared to control treatment as measured by tumor size and survival (P=0.179 and P=0.225, respectively ). A malignant astrocytoma cell line that expressed BRAF V600E was more sensitive to growth inhibition by vemurafenib than a cell line with wildtype BRAF (EC50=1.75 vs. 31.2 umol/L).\", \"disease\"=>{\"id\"=>695, \"name\"=>\"Malignant Glioma\", \"display_name\"=>\"Malignant Glioma\", \"doid\"=>\"3070\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3070\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>348, \"name\"=>\"Targeted therapy for BRAFV600E malignant astrocytoma.\", \"citation\"=>\"Nicolaides et al., 2011, Clin. Cancer Res.\", \"pubmed_id\"=>\"22038996\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22038996\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3638050\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>12, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3758, \"name\"=>\"EID3758\", \"description\"=>\"In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V600E mutation and treated with vemurafenib (n=317) were associated with a 52% response rate, as compared to a 64% response rate in V600E mutation positive patients treated with dabrafenib and trametinib combination therapy (n=312).\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}, {\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>353, \"name\"=>\"Improved overall survival in melanoma with combined dabrafenib and trametinib.\", \"citation\"=>\"Robert et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"25399551\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25399551\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>1, \"day\"=>1}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3757, \"name\"=>\"EID3757\", \"description\"=>\"In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600E mutation (n=175) were associated with a 4.8% (8/167) complete response, a 58.1% (97/167) partial response and stable disease in 22.2% (37/167) of cases; however, 15% (25/167) of patients harboring BRAF V600E experienced progressive disease.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1957, \"name\"=>\"A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.\", \"citation\"=>\"Ugurel et al., 2015, Ann. Oncol.\", \"pubmed_id\"=>\"25524477\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25524477\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>3}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3761, \"name\"=>\"EID3761\", \"description\"=>\"In an in vitro study, the HCC364 cell line expressing a BRAF V600E mutation was associated with sensitivity to vemurafenib treatment. Sensitivity was determined by assessing cell viability, apoptosis and colony formation.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1960, \"name\"=>\"Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.\", \"citation\"=>\"Joshi et al., 2015, PLoS ONE\", \"pubmed_id\"=>\"25706985\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25706985\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4338247\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3760, \"name\"=>\"EID3760\", \"description\"=>\"Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to vemurafenib than those with wildtype BRAF (IC50: 0.115ï¿½ 1.156 uM vs. 56.674ï¿½1349.788 uM).\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1959, \"name\"=>\"BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.\", \"citation\"=>\"Sala et al., 2008, Mol. Cancer Res.\", \"pubmed_id\"=>\"18458053\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18458053\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>5}, \"journal\"=>\"Mol. Cancer Res.\", \"full_journal_title\"=>\"Molecular cancer research : MCR\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3759, \"name\"=>\"EID3759\", \"description\"=>\"In an in vitro study, a melanoma cell line, A375, expressing the BRAF V600E mutation was associated with resistance to dasatinib treatment, comparable to melanoma MEWO cells expressing wild-type BRAF. Resistance was determined by assessing cell viability.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>20, \"name\"=>\"Dasatinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>74, \"name\"=>\"Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.\", \"citation\"=>\"Woodman et al., 2009, Mol. Cancer Ther.\", \"pubmed_id\"=>\"19671763\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19671763\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3346953\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>8}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3756, \"name\"=>\"EID3756\", \"description\"=>\"In an in vitro study of 27 melanoma cell lines, 18 out of 20 cell lines expressing BRAF V600E mutation were associated with sensitivity to vemurafenib treatment (IC50: 0.01-1ï¿½M). Sensitivity was determined by assessing growth inhibition.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1956, \"name\"=>\"Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.\", \"citation\"=>\"Vergani et al., 2011, Neoplasia\", \"pubmed_id\"=>\"22241959\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22241959\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3257188\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>12}, \"journal\"=>\"Neoplasia\", \"full_journal_title\"=>\"Neoplasia (New York, N.Y.)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3755, \"name\"=>\"EID3755\", \"description\"=>\"In a  clinical study of Polish, stage IIIC/IV, melanoma patients with metastases (n=75) harboring BRAF V600 mutation (as detected by cobas 4800 BRAF V600 Mutation Test), patients were associated with a 61.9% (95% CI: 50.1-73.6) median overall survival, a 7.4 months (95% CI: 5.5-9.2) median progression free survival; a median duration response of 7.4 months was reported, with 3% (2/75) and 43% (29/75) of patients achieving a complete and partial response, respectively.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1955, \"name\"=>\"The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial.\", \"citation\"=>\"Rutkowski et al., 2015, Contemp Oncol (Pozn)\", \"pubmed_id\"=>\"26557775\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26557775\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4631301\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"Contemp Oncol (Pozn)\", \"full_journal_title\"=>\"Contemporary oncology (Poznan, Poland)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3754, \"name\"=>\"EID3754\", \"description\"=>\"In a stage I melanoma patient harboring a BRAF V600E mutation, response to vemurafenib monotherapy was reported. Upon identification of the BRAF V600E mutation, the patient enrolled in a clinical trial and was treated with vemurafenib monotherapy, a partial response was reported. However, novel hypermetabolic nodules developed and the patient enrolled in another clinical trial, undergoing combination therapy of vemurafenib and GDC-0973, but disease progression occurred at 5 months. Subsequently, the patient was treated with vemurafenib and ipilimumab, achieving a confirmed complete response.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1954, \"name\"=>\"Management of a patient with advanced BRAF-mutant melanoma.\", \"citation\"=>\"Ashworth et al., 2014, J Natl Compr Canc Netw\", \"pubmed_id\"=>\"24616537\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24616537\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"J Natl Compr Canc Netw\", \"full_journal_title\"=>\"Journal of the National Comprehensive Cancer Network : JNCCN\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3753, \"name\"=>\"EID3753\", \"description\"=>\"In an in vitro study, several cell lines (including MALME-3M, Colo829, Colo38, A375 and SK-MEK28) expressing BRAF V600E were associated with increased sensitivity to vemurafenib (RG7204) treatment, as compared to cell lines expressing BRAF wild-type. Sensitivity was determined by proliferation assay and by assessing MEK1/2 phosphorylation. Further, in an in vivo study, LOX, Colo829 and A375 xenografts were reportedly sensitive to vemurafenib treatment as assessed by tumor volume.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>351, \"name\"=>\"RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.\", \"citation\"=>\"Yang et al., 2010, Cancer Res.\", \"pubmed_id\"=>\"20551065\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20551065\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3752, \"name\"=>\"EID3752\", \"description\"=>\"In an in vitro study, a MBA72 cell line expressing BRAF V600E demonstrated improved sensitivity to vemurafenib treatment, compared to LND-1 cells expression BRAF wild-type. Sensitivity was determined by assessing cell proliferation (MBA72, IC50: 3.2uM; vs. LND-1, IC50: 32.2 uM).\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1953, \"name\"=>\"Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?\", \"citation\"=>\"Porcelli et al., 2015, Cancer Chemother. Pharmacol.\", \"pubmed_id\"=>\"26070258\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26070258\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>8}, \"journal\"=>\"Cancer Chemother. Pharmacol.\", \"full_journal_title\"=>\"Cancer chemotherapy and pharmacology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2504, \"name\"=>\"EID2504\", \"description\"=>\"In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, log-rank test). The presence of BRAF V600E was associated with poorer outcome as defined by persistent disease or death (Odds ratio:14.63, 95%CI:1.28-167.29, P=0.03, multivariate analysis.\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[{\"id\"=>6, \"name\"=>\"Sorafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1494, \"name\"=>\"BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.\", \"citation\"=>\"Elisei et al., 2008, J. Clin. Endocrinol. Metab.\", \"pubmed_id\"=>\"18682506\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18682506\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>10}, \"journal\"=>\"J. Clin. Endocrinol. Metab.\", \"full_journal_title\"=>\"The Journal of clinical endocrinology and metabolism\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2503, \"name\"=>\"EID2503\", \"description\"=>\"In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5%  vs. 12.8% ,  Risk ratio:2.14, 95%CI:1.67-2.74, P<0.00001).\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[{\"id\"=>6, \"name\"=>\"Sorafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1495, \"name\"=>\"The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.\", \"citation\"=>\"Kim et al., 2012, Cancer\", \"pubmed_id\"=>\"21882184\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21882184\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3751, \"name\"=>\"EID3751\", \"description\"=>\"In an in vitro study, BRAF V600E expressing cell lines (COLO205, A375 and COLO829) demonstrated improved sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells. Sensitivity was determined by assessing cell proliferation (COLO205, GI50: 0.31uM; A375, GI50: 0.50 uM; COLO829, GI50: 1.7 uM vs. BRAF expressing cells (n=9) GI50: 10-41uM) and ERK phosphorylation.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1952, \"name\"=>\"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.\", \"citation\"=>\"Tsai et al., 2008, Proc. Natl. Acad. Sci. U.S.A.\", \"pubmed_id\"=>\"18287029\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18287029\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2268581\", \"publication_date\"=>{\"year\"=>2008, \"month\"=>2, \"day\"=>26}, \"journal\"=>\"Proc. Natl. Acad. Sci. U.S.A.\", \"full_journal_title\"=>\"Proceedings of the National Academy of Sciences of the United States of America\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3750, \"name\"=>\"EID3750\", \"description\"=>\"In a phase 2 clinical trial (NCT00949702) of 132 BRAF mutation positive metastatic melanoma patients treated with vemurafenib monotherapy, patients harboring BRAF V600E (n=123) or V600K (n=9) mutations were associated with a favorable objective response rate (53% per RECIST v1.1 criteria, 70/132), with 6% (8/132) and 47% (62/132) of patients achieving complete response and partial response, respectively.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>60, \"name\"=>\"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.\", \"citation\"=>\"Trunzer et al., 2013, J. Clin. Oncol.\", \"pubmed_id\"=>\"23569304\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23569304\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>5, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3749, \"name\"=>\"EID3749\", \"description\"=>\"In a retrospective study of 30 metastatic melanoma patients with progressing metastases, patients with BRAF V600E mutation (n=8) treated with vemurafenib monotherapy achieved a partial response (n=5) and stable disease (n=1).\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1951, \"name\"=>\"BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.\", \"citation\"=>\"Rizos et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24463458\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24463458\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3748, \"name\"=>\"EID3748\", \"description\"=>\"An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1485, \"name\"=>\"Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.\", \"citation\"=>\"Hoeflich et al., 2006, Cancer Res.\", \"pubmed_id\"=>\"16424035\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16424035\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>1, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3744, \"name\"=>\"EID3744\", \"description\"=>\"In an anaplastic thyroid cancer patient harboring BRAF V600E and TP53 E180K co-mutations, BRAF V600E was associated with response to vemurafenib treatment. Prior to identification of the BRAF V600E mutation, the patient was treated with 6 cycles of standard chemotherapy plus radiation and experienced progressive disease; subsequently, the patient achieved a complete response with 61 weeks of vemurafenib monotherapy followed by disease progression.\", \"disease\"=>{\"id\"=>155, \"name\"=>\"Thyroid Carcinoma\", \"display_name\"=>\"Thyroid Carcinoma\", \"doid\"=>\"3963\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3963\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>nil, \"evidence_direction\"=>nil, \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1949, \"name\"=>\"Sustained Response to Vemurafenib in a BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma Patient.\", \"citation\"=>\"Prager et al., 2016, Thyroid\", \"pubmed_id\"=>\"27532222\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27532222\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>10}, \"journal\"=>\"Thyroid\", \"full_journal_title\"=>\"Thyroid : official journal of the American Thyroid Association\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3747, \"name\"=>\"EID3747\", \"description\"=>\"In an in vitro study, cell lines (including YUHUY and YUSAC2) expressing BRAF V600E were associated with increased sensitivity to vemurafenib (PLX4032) treatment, as compared to cell lines expressing wild-type BRAF. Sensitive was determined by assessing cellular proliferation, and ERK and MEK phosphorylation.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1482, \"name\"=>\"PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.\", \"citation\"=>\"Halaban et al., 2010, Pigment Cell Melanoma Res\", \"pubmed_id\"=>\"20149136\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20149136\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2848976\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>4}, \"journal\"=>\"Pigment Cell Melanoma Res\", \"full_journal_title\"=>\"Pigment cell & melanoma research\", \"status\"=>\"submitted\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3746, \"name\"=>\"EID3746\", \"description\"=>\"Acquired resistance to vemurafenib in BRAF V600E-positive melanomas frequently confound vemurafenib therapy. Proposed resistance mechanisms include PDGFRB upregulation or NRAS mutations resulting in MAPK pathway reactivation but not secondary mutations in BRAF. MEK inhibitors may demonstrate clinical benefit in vemurafenib resistant melanoma patients.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1491, \"name\"=>\"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.\", \"citation\"=>\"Nazarian et al., 2010, Nature\", \"pubmed_id\"=>\"21107323\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3143360\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>12, \"day\"=>16}, \"journal\"=>\"Nature\", \"full_journal_title\"=>\"Nature\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3745, \"name\"=>\"EID3745\", \"description\"=>\"Acquired resistance to vemurafenib in BRAF V600E-positive melanomas frequently confound vemurafenib therapy. Proposed resistance mechanisms include PDGFRB upregulation or NRAS mutations resulting in MAPK pathway reactivation but not secondary mutations in BRAF. MEK inhibitors may demonstrate clinical benefit in vemurafenib resistant melanoma patients.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1492, \"name\"=>\"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.\", \"citation\"=>\"Johannessen et al., 2010, Nature\", \"pubmed_id\"=>\"21107320\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21107320\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3058384\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>12, \"day\"=>16}, \"journal\"=>\"Nature\", \"full_journal_title\"=>\"Nature\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3739, \"name\"=>\"EID3739\", \"description\"=>\"In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with BRAF V600E (n=14) mutation treated with FOLFOX4 plus cetuximab were associated with a decreased progression free survival (7.2mo vs. 9.7mo, HR:0.39, 95% CI:0.21-0.72, P=0.0017), and decreased overall survival (11.7mo vs. 28.5mo, HR:0.23, 95% CI:0.12-0.41, P<0.0001), as compared to patients with wildtype BRAF.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1920, \"name\"=>\"FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.\", \"citation\"=>\"Kaczirek et al., 2015, Clin Colorectal Cancer\", \"pubmed_id\"=>\"25666295\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25666295\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>6}, \"journal\"=>\"Clin Colorectal Cancer\", \"full_journal_title\"=>\"Clinical colorectal cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3740, \"name\"=>\"EID3740\", \"description\"=>\"In a retrospective study of 53, KRAS exon 2 wild-type, metastatic colorectal cancer patients, patients harboring BRAF G466A (n=1), G469A (n=2), D594G (n=1), or V600E (n=2) mutations were reported to be non-responders to cetuximab in combination with irinotecan, (BRAF mutation positive: responders vs. non-responders = 0 vs. 6; BRAF wild-type: responders vs. non-responders 30 vs. 17; P=0.004), as compared to patients with wild-type BRAF.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1946, \"name\"=>\"Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.\", \"citation\"=>\"Hsu et al., 2016, Oncotarget\", \"pubmed_id\"=>\"26989027\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26989027\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5008360\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>19}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3738, \"name\"=>\"EID3738\", \"description\"=>\"Among metastatic colorectal cancer patients treated with cetuximab and irinotecan, those with BRAF V600E mutations were less likely to achieve a complete or partial response to therapy (0% , P=0.016, Fisherï¿½s exact test) and had shorter median overall survival (4.1mo vs. 13.9mo, HR:0.51, 95%CI:0.18-0.95, P=0.037) than patients with wildtype BRAF.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1480, \"name\"=>\"KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.\", \"citation\"=>\"Loupakis et al., 2009, Br. J. Cancer\", \"pubmed_id\"=>\"19603018\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19603018\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2736831\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>8, \"day\"=>18}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3742, \"name\"=>\"EID3742\", \"description\"=>\"In a clinical study of 122 cancer patients, including 37 previously treated colorectal cancer patients harboring BRAF V600 (V600E=32; V600 unknown=5) mutations, stable disease and progressive disease were reported in 50% of patients (n=5/10) treated with vemurafenib monotherapy, respectively.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1040, \"name\"=>\"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.\", \"citation\"=>\"Hyman et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"26287849\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26287849\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4971773\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>8, \"day\"=>20}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3741, \"name\"=>\"EID3741\", \"description\"=>\"In an in vitro study, WiDr, HT-29, LS411N, and SW1417 cell lines expressing BRAF V600E and treated with vemurafenib and erlotinib, or vemurafenib and gefitinib were associated with a reduction in cell viability (P<0.01), as compared to cells treated solely with vemurafenib or vehicle. WiDr and HT-29 cell lines expressing BRAF V600E were associated with a modest reduction in cell viability. Sensitivity was determined by assessing cell viability after 72h of vemurafenib treatement. In an in vivo study, WiDr and HT-29 xenografts expression BRAF V600E and treated with vemurafenib and erlotinib combination therapy were associated with reduced tumor volume (P<0.05) as compared to xenografts treated with vemurafenib alone, erlotinib alone, or vehicle alone.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1947, \"name\"=>\"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.\", \"citation\"=>\"Corcoran et al., 2012, Cancer Discov\", \"pubmed_id\"=>\"22448344\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22448344\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3308191\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>3}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>3736, \"name\"=>\"EID3736\", \"description\"=>\"In metastatic colorectal cancer patients with wildtype KRAS status who received cetuximab therapy, those with a BRAF V600E mutation had reduced progression-free survival (8.0wk vs. 31.4wk, P=0.001, log-rank test, univariate analysis) and reduced overall survival (6.5mo vs. 14.8mo, P=0.001, log-rank test, univariate analysis; HR:6.6, 95%CI:2.4-18.2, P<0.001, multivariate analysis. Similar associations have been found in independent studies.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1945, \"name\"=>\"Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.\", \"citation\"=>\"Laurent-Puig et al., 2009, J. Clin. Oncol.\", \"pubmed_id\"=>\"19884556\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19884556\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>12, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2894, \"name\"=>\"EID2894\", \"description\"=>\"Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>6, \"name\"=>\"Sorafenib\", \"pubchem_id\"=>nil}, {\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>100, \"name\"=>\"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.\", \"citation\"=>\"Di Nicolantonio et al., 2008, J. Clin. Oncol.\", \"pubmed_id\"=>\"19001320\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19001320\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>12, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>89, \"name\"=>\"EID89\", \"description\"=>\"Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>6, \"name\"=>\"Sorafenib\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>100, \"name\"=>\"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.\", \"citation\"=>\"Di Nicolantonio et al., 2008, J. Clin. Oncol.\", \"pubmed_id\"=>\"19001320\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19001320\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>12, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1940, \"name\"=>\"EID1940\", \"description\"=>\"In a study of 468 colorectal cancer samples, 61 patients had micro-satellite instability and there was a statistically significantly better prognosis for BRAF WT patients relative to BRAF (V600E)-mutated patients (Log-rank P=0.0903).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Negative\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1367, \"name\"=>\"A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.\", \"citation\"=>\"Schell et al., 2016, Nat Commun\", \"pubmed_id\"=>\"27302369\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27302369\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4912618\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>15}, \"journal\"=>\"Nat Commun\", \"full_journal_title\"=>\"Nature communications\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2116, \"name\"=>\"EID2116\", \"description\"=>\"In a study of metastatic colorectal cancer patients who received 5-FU-based first-line chemotherapy, those with BRAF V600E mutations had reduced progression-free survival (4.3mo vs. 12.5mo, HR:4.9, 95%CI:2.7-9.0, P<0.0001, univariate analysis; HR:4.0, 95%CI:2.2-7.4, P<0.0001, multivariate analysis) and reduced overall survival (10.9mo vs. 40.5mo, HR:4.5, 95%CI:2.4-8.4, P<0.0001, univariate analysis; HR:4.1, 95%CI:2.1-8.0, P<0.0001, multivariate analysis) compared to those with wildtype BRAF.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>458, \"name\"=>\"Fluorouracil\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1479, \"name\"=>\"Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.\", \"citation\"=>\"Souglakos et al., 2009, Br. J. Cancer\", \"pubmed_id\"=>\"19603024\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19603024\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2720232\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>8, \"day\"=>4}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1902, \"name\"=>\"EID1902\", \"description\"=>\"Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 patients with colorectal cancer (1 with appendiceal cancer). Six of 17 evaluable patients achieved an objective response, 15 patients total had either stable disease or radiographic response (the patient with appendiceal cancer had disease progression). Estimated median PFS was 7.7 months. Effect of the combined treatment was also observed in xenograft and cell line studies.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}, {\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>101, \"name\"=>\"Irinotecan\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1336, \"name\"=>\"Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.\", \"citation\"=>\"Hong et al., 2016, Cancer Discov\", \"pubmed_id\"=>\"27729313\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27729313\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>12}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2115, \"name\"=>\"EID2115\", \"description\"=>\"In metastatic colorectal cancer patients with wildtype KRAS status, those with a BRAF V600E mutation were less likely to respond to treatment with cetuximab or panitumumab than  those with wildtype BRAF (0%  vs. 32% , P=0.029). Regardless of KRAS status, patients with BRAF mutations had reduced progression-free and overall survival (P=0.0107 and P <0.0001, respectively). Transfection of the colorectal cancer cell line DiFi with a BRAF V600E expression vector conferred decreased sensitivity to cetuximab and panitumumab in comparison to cells transfected with empty vector.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>100, \"name\"=>\"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.\", \"citation\"=>\"Di Nicolantonio et al., 2008, J. Clin. Oncol.\", \"pubmed_id\"=>\"19001320\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19001320\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>12, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2146, \"name\"=>\"EID2146\", \"description\"=>\"In a phase 2 clinical trial  with 250 metastatic melanoma BRAF-V600E patients, treatment groups were randomly assigned to either dabrafenib, BRAF specific inhibitor, (n=187) or dacarbazine, a standard chemotherapeutic agent (n=63). Patients treated with dabrafenib were associated with improved progression-free survival (5.1mo vs. 2.7mo, HR:0.30, 95% CI:0.18-0.51, P<0.0001) compared with patients undergoing dacarbazine therapy.\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1500, \"name\"=>\"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.\", \"citation\"=>\"Hauschild et al., 2012, Lancet\", \"pubmed_id\"=>\"22735384\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22735384\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>7, \"day\"=>28}, \"journal\"=>\"Lancet\", \"full_journal_title\"=>\"Lancet (London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2145, \"name\"=>\"EID2145\", \"description\"=>\"In a study of pediatric low-grade gliomas, BRAF V600E mutation was associated with a strong trend toward reduced progression free survival (HR:2.39, 95%CI:0.93-6.15, P=0.07, multivariate analysis).\", \"disease\"=>{\"id\"=>695, \"name\"=>\"Malignant Glioma\", \"display_name\"=>\"Malignant Glioma\", \"doid\"=>\"3070\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3070\"}, \"drugs\"=>[{\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1499, \"name\"=>\"Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.\", \"citation\"=>\"Horbinski et al., 2012, Neuro-oncology\", \"pubmed_id\"=>\"22492957\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22492957\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3367847\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>6}, \"journal\"=>\"Neuro-oncology\", \"full_journal_title\"=>\"Neuro-oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2144, \"name\"=>\"EID2144\", \"description\"=>\"In a mouse xenograft model, tumors derived from pilocytic astrocytoma cells that expressed BRAF V600E experienced a complete response to treatment with selumetinib, whereas tumors derived from a wildtype BRAF pilocytic astrocytoma cell line were resistant to selumetinib.\", \"disease\"=>{\"id\"=>695, \"name\"=>\"Malignant Glioma\", \"display_name\"=>\"Malignant Glioma\", \"doid\"=>\"3070\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3070\"}, \"drugs\"=>[{\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1498, \"name\"=>\"Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.\", \"citation\"=>\"Kolb et al., 2010, Pediatr Blood Cancer\", \"pubmed_id\"=>\"20806365\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20806365\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3004092\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Pediatr Blood Cancer\", \"full_journal_title\"=>\"Pediatric blood & cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2143, \"name\"=>\"EID2143\", \"description\"=>\"In a genetic screen of 87 lung cancer cell lines, one MEK-dependent cell line HCC364 contained a BRAF-V600E mutation. In growth assays, the MEK inhibitor PD-0325901 reduced proliferation in growth assays of the HCC364 cell line (IC50=3.2 nmol/L). Additionally, cells exposed to PD-0325901 exhibited an increase in apoptosis, as measured by induction of PARP cleavage.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>459, \"name\"=>\"PD 0325901\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>341, \"name\"=>\"Genetic predictors of MEK dependence in non-small cell lung cancer.\", \"citation\"=>\"Pratilas et al., 2008, Cancer Res.\", \"pubmed_id\"=>\"19010912\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19010912\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2649746\", \"publication_date\"=>{\"year\"=>2008, \"month\"=>11, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2142, \"name\"=>\"EID2142\", \"description\"=>\"Following treatment with sorafenib, thyroid cancer cell lines with BRAF V600E mutations had severely reduced proliferation rates, but cells with wildtype BRAF were insensitive (P<0.0001).\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[{\"id\"=>6, \"name\"=>\"Sorafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1497, \"name\"=>\"BRAF is a therapeutic target in aggressive thyroid carcinoma.\", \"citation\"=>\"Salvatore et al., 2006, Clin. Cancer Res.\", \"pubmed_id\"=>\"16533790\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16533790\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2141, \"name\"=>\"EID2141\", \"description\"=>\"In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, log-rank test). The presence of BRAF V600E was associated with poorer outcome as defined by persistent disease or death (Odds ratio:14.63, 95%CI:1.28-167.29, P=0.03, multivariate analysis.\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[{\"id\"=>463, \"name\"=>\"RDEA 119\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1494, \"name\"=>\"BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.\", \"citation\"=>\"Elisei et al., 2008, J. Clin. Endocrinol. Metab.\", \"pubmed_id\"=>\"18682506\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18682506\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>10}, \"journal\"=>\"J. Clin. Endocrinol. Metab.\", \"full_journal_title\"=>\"The Journal of clinical endocrinology and metabolism\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1698, \"name\"=>\"EID1698\", \"description\"=>\"A 65-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and he received an autologous stem cell transplant. Sequencing of the recurrent tumor harbored BRAF V600E mutation and he was treated with vemurafenib.  After 7 weeks of treatment, the patient relapsed and died.\", \"disease\"=>{\"id\"=>41, \"name\"=>\"Multiple Myeloma\", \"display_name\"=>\"Multiple Myeloma\", \"doid\"=>\"9538\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9538\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1147, \"name\"=>\"Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.\", \"citation\"=>\"Sharman et al., 2014, Clin Lymphoma Myeloma Leuk\", \"pubmed_id\"=>\"24997557\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24997557\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>10}, \"journal\"=>\"Clin Lymphoma Myeloma Leuk\", \"full_journal_title\"=>\"Clinical lymphoma, myeloma & leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1699, \"name\"=>\"EID1699\", \"description\"=>\"A 54-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and received an autologous stem cell transplant.  Genomic profiling of the bone biopsy revealed BRAF V600E activating mutation and the patient was treated with vemurafenib.  At 4-months post treatment (time of case study report) the patient maintains near-resolution of hypermetabolic lesions.\", \"disease\"=>{\"id\"=>41, \"name\"=>\"Multiple Myeloma\", \"display_name\"=>\"Multiple Myeloma\", \"doid\"=>\"9538\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9538\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1147, \"name\"=>\"Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.\", \"citation\"=>\"Sharman et al., 2014, Clin Lymphoma Myeloma Leuk\", \"pubmed_id\"=>\"24997557\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24997557\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>10}, \"journal\"=>\"Clin Lymphoma Myeloma Leuk\", \"full_journal_title\"=>\"Clinical lymphoma, myeloma & leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1749, \"name\"=>\"EID1749\", \"description\"=>\"Multicenter, phase 1, dose-escalation trial of PLX4032 (Vemurafenib). Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. Patients without the V600E mutation had evidence of tumor regression.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>352, \"name\"=>\"Inhibition of mutated, activated BRAF in metastatic melanoma.\", \"citation\"=>\"Flaherty et al., 2010, N. Engl. J. Med.\", \"pubmed_id\"=>\"20818844\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20818844\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3724529\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>8, \"day\"=>26}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1552, \"name\"=>\"EID1552\", \"description\"=>\"In a study of 908 patients with colorectal cancer, 45 patients had BRAF V600E mutations and 589 patients were BRAF wild type.  BRAF V600E mutations were more likely to be proximal tumors (68.9%, 20.7%; p<0.0001), they were more likely to be poorly differentiated (17.7%, 1.9%; p<0.0001), they were more likely to be mucinous carcinoma type (20.0%, 4.2%; p=0.0003), they were more likely to have lymphatic invasion (77.6%, 49.9%; p=0.0003), and they had a shorter survival time (31.1 mo, 41.6 mo; p=0.001).  The 3-year survival rate was significantly poorer in the V600E group when compared to the wild type group (63.8%, 87.9%; p<0.0001).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1027, \"name\"=>\"Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.\", \"citation\"=>\"Amaki-Takao et al., 2016, Oncology\", \"pubmed_id\"=>\"27404270\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27404270\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>7, \"day\"=>13}, \"journal\"=>\"Oncology\", \"full_journal_title\"=>\"Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1005, \"name\"=>\"EID1005\", \"description\"=>\"49 BRAF-mutant melanoma cell lines from patients not previously treated with BRAF inhibition were analyzed. 21 exhibited primary resistance to BRAF inhibition using PLX4720. Inhibition of MEK1/2 (BEZ235) and PI3K/mTOR (AZD6244 [selumetinib]) was the most effective approach to counteract resistance in comparison to inhibition with the PLX4720-BEZ235 (where response was assessed by apoptosis, viability, p-ERK, p-Akt inhibition).\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}, {\"id\"=>343, \"name\"=>\"BEZ235 (NVP-BEZ235, Dactolisib)\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>694, \"name\"=>\"Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.\", \"citation\"=>\"Penna et al., 2016, Oncotarget\", \"pubmed_id\"=>\"26678033\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26678033\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4826182\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>1, \"day\"=>26}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1591, \"name\"=>\"EID1591\", \"description\"=>\"Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort 1) previously been treated with VEGFR inhibitors.\\n51 patients were enrolled (26 cohort 1, 25 cohort 2). In cohort 1, partial response was achieved in ten (38.5%) patients. Nine patients achieved stable disease for at least 6 months (35%). Median PFS was 18.2 months and median OS not reached after a median follow-up pf 18.8 months.\\nIn cohort 2, six patients (27.3%) achieved a partial response and another six patients achieved stable disease for at least six months. Median PFS was 8.9 months and median OS was 14.4. months.\", \"disease\"=>{\"id\"=>156, \"name\"=>\"Papillary Thyroid Carcinoma\", \"display_name\"=>\"Papillary Thyroid Carcinoma\", \"doid\"=>\"3969\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3969\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1052, \"name\"=>\"Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.\", \"citation\"=>\"Brose et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"27460442\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27460442\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>7, \"day\"=>22}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1428, \"name\"=>\"EID1428\", \"description\"=>\"In a mouse model of BRAF V600E colorectal cancer, western blots from tumors in mice treated with BRAF inhibitor GDC-0879 and PI3K/mTOR inhibitor BEZ235 showed stronger reduction in phospho-Akt and phospho-S6 than PI3K/mTOR inhibitor alone, and combination inhibition also resulted in stronger phospho-ERK inhibition in tumors than did BRAF inhibition alone. Increased apoptosis in tumors was seen in dual treatment conditions with increased TUNEL-positive cells. In vehicle treated mice, area of colon covered by tumor increased, while treatment with single agent inhibitors caused growth inhibition resulting in no change in colon area covered by tumors. Administration of dual inhibitors induced tumor regression apparent in a decrease of colonic area covered by tumors over the course of treatment.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>343, \"name\"=>\"BEZ235 (NVP-BEZ235, Dactolisib)\", \"pubchem_id\"=>nil}, {\"id\"=>344, \"name\"=>\"GDC-0879\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>967, \"name\"=>\"Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.\", \"citation\"=>\"Coffee et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23549875\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23549875\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3815598\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>5, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1421, \"name\"=>\"EID1421\", \"description\"=>\"In a randomized phase 3 study, previously untreated advanced or metastatic BRAF V600 mutation-positive melanoma patients treated with combination vemurafenib and cobimetinib showed improved progression free survival (9.9 vs 6.2 months), increased rate of complete or partial response (68% vs 45%), and improved overall survival at 9 months ( 81% vs 73%) compared to the vemurafenib and placebo control group.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}, {\"id\"=>342, \"name\"=>\"Cobimetinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>963, \"name\"=>\"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.\", \"citation\"=>\"Larkin et al., 2014, N. Engl. J. Med.\", \"pubmed_id\"=>\"25265494\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25265494\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>11, \"day\"=>13}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1579, \"name\"=>\"EID1579\", \"description\"=>\"Two clinical trials evaluated the effects of vemurafenib in 54 patients with BRAF (V600E) positive hairy-cell leukemia.  The overall response rate was 98% with 19/54 having a complete response and 34/54 having a partial response.  In the Italian study (n=25), the median relapse-free survival was 9 months and in the U.S. study (n=24), rate of progression-free survival was 73% with overall survival rate of 91%.\", \"disease\"=>{\"id\"=>665, \"name\"=>\"Hairy Cell Leukemia\", \"display_name\"=>\"Hairy Cell Leukemia\", \"doid\"=>\"285\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:285\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1043, \"name\"=>\"Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.\", \"citation\"=>\"Tiacci et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"26352686\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26352686\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4811324\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>10, \"day\"=>29}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>96, \"name\"=>\"EID96\", \"description\"=>\"Combined MEK inhibitor GDC0941 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>30, \"name\"=>\"PLX4720\", \"pubchem_id\"=>nil}, {\"id\"=>515, \"name\"=>\"GDC0941\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>106, \"name\"=>\"A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.\", \"citation\"=>\"Rad et al., 2013, Cancer Cell\", \"pubmed_id\"=>\"23845441\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23845441\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3706745\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>7, \"day\"=>8}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2140, \"name\"=>\"EID2140\", \"description\"=>\"In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5%  vs. 12.8% ,  Risk ratio:2.14, 95%CI:1.67-2.74, P<0.00001).\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[{\"id\"=>463, \"name\"=>\"RDEA 119\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1495, \"name\"=>\"The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.\", \"citation\"=>\"Kim et al., 2012, Cancer\", \"pubmed_id\"=>\"21882184\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21882184\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2139, \"name\"=>\"EID2139\", \"description\"=>\"Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MEK inhibitor RDEA119 than those with wildtype BRAF (IC50: 0.034-0.217 uM vs. 1.413-34.120 uM).\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[{\"id\"=>463, \"name\"=>\"RDEA 119\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1496, \"name\"=>\"BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.\", \"citation\"=>\"Liu et al., 2010, Int. J. Cancer\", \"pubmed_id\"=>\"21351275\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21351275\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2916062\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>12, \"day\"=>15}, \"journal\"=>\"Int. J. Cancer\", \"full_journal_title\"=>\"International journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2138, \"name\"=>\"EID2138\", \"description\"=>\"In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5%  vs. 12.8% ,  Risk ratio:2.14, 95%CI:1.67-2.74, P<0.00001).\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[{\"id\"=>462, \"name\"=>\"CI-1040\", \"pubchem_id\"=>\"\"}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1495, \"name\"=>\"The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.\", \"citation\"=>\"Kim et al., 2012, Cancer\", \"pubmed_id\"=>\"21882184\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21882184\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2137, \"name\"=>\"EID2137\", \"description\"=>\"In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, log-rank test). The presence of BRAF V600E was associated with poorer outcome as defined by persistent disease or death (Odds ratio:14.63, 95%CI:1.28-167.29, P=0.03, multivariate analysis.\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[{\"id\"=>462, \"name\"=>\"CI-1040\", \"pubchem_id\"=>\"\"}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1494, \"name\"=>\"BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.\", \"citation\"=>\"Elisei et al., 2008, J. Clin. Endocrinol. Metab.\", \"pubmed_id\"=>\"18682506\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18682506\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>10}, \"journal\"=>\"J. Clin. Endocrinol. Metab.\", \"full_journal_title\"=>\"The Journal of clinical endocrinology and metabolism\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1410, \"name\"=>\"EID1410\", \"description\"=>\"Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E mutation. \\nConfirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Median overall survival was 15.9 months (95% CI, 11.6 to 18.3).\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>354, \"name\"=>\"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.\", \"citation\"=>\"Sosman et al., 2012, N. Engl. J. Med.\", \"pubmed_id\"=>\"22356324\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22356324\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3724515\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>2, \"day\"=>23}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2136, \"name\"=>\"EID2136\", \"description\"=>\"Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MAPK inhibitor CI-1040 than those with wildtype BRAF (IC50: 0.031-1.251 uM vs. 44.376-278.286 uM). In a mouse xenograft model, the growth of tumors derived from KAT10 cells, which carries the BRAF V600E mutation, was inhibited following treatment with CI-1040 (P<0.01), but drug treatment had no effect on growth of tumors derived from the MRO cell line, which expresses wildtype BRAF.\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[{\"id\"=>462, \"name\"=>\"CI-1040\", \"pubchem_id\"=>\"\"}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1493, \"name\"=>\"Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.\", \"citation\"=>\"Liu et al., 2007, J. Clin. Endocrinol. Metab.\", \"pubmed_id\"=>\"17911174\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17911174\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2007, \"month\"=>12}, \"journal\"=>\"J. Clin. Endocrinol. Metab.\", \"full_journal_title\"=>\"The Journal of clinical endocrinology and metabolism\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1398, \"name\"=>\"EID1398\", \"description\"=>\"The BRIM-3 Phase III trial NCT01006980 assessed BRAF inhibitor vemurafenib versus dacarbazine in 598 patients with treatment naive metastatic melanoma and confirmed V600E mutation. Significant differences were seen in overall survival (13.3 months with vemurafenib vs. 10.0 months with dacarbazine) and median progression free survival (6.9 months  with vemurafenib vs. 1.6 months with dacarbazine)\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>947, \"name\"=>\"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.\", \"citation\"=>\"McArthur et al., 2014, Lancet Oncol.\", \"pubmed_id\"=>\"24508103\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24508103\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4382632\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>3}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1430, \"name\"=>\"EID1430\", \"description\"=>\"BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E). Two patients were treated with a combination of BRAF and MEK inhibition and exhibited durable response (beyond 7 and 9 months, respectively). Urinary BRAF V600E tumor DNA correlated with disease response in one of the patients. BRAF and MEK inhibition was either dabrafenib+trametinib (case 1) or vemurafenib+trametinib (case 2).\", \"disease\"=>{\"id\"=>53, \"name\"=>\"Gastrointestinal Neuroendocrine Tumor\", \"display_name\"=>\"Gastrointestinal Neuroendocrine Tumor\", \"doid\"=>\"0050626\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050626\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}, {\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>969, \"name\"=>\"BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.\", \"citation\"=>\"Klempner et al., 2016, Cancer Discov\", \"pubmed_id\"=>\"27048246\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27048246\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1414, \"name\"=>\"EID1414\", \"description\"=>\"A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the only genetic alteration on a near diploid genome with trisomy 1q. Vemurafenib treatment resulted in improvement of symptoms and considerable reductions in tumor mass, and after 23 months the patient remained on therapy with well controlled disease.\", \"disease\"=>{\"id\"=>156, \"name\"=>\"Papillary Thyroid Carcinoma\", \"display_name\"=>\"Papillary Thyroid Carcinoma\", \"doid\"=>\"3969\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3969\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>958, \"name\"=>\"Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib.\", \"citation\"=>\"Ali et al., 2014, Case Rep Oncol\", \"pubmed_id\"=>\"24987354\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24987354\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4067722\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>5}, \"journal\"=>\"Case Rep Oncol\", \"full_journal_title\"=>\"Case reports in oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2135, \"name\"=>\"EID2135\", \"description\"=>\"In a study of 322 advanced melanoma patients with BRAF-V600E or BRAF-V600K mutations, treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo, <0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR:0.54, 95% CI:0.32-0.92, P=0.01).\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1210, \"name\"=>\"Improved survival with MEK inhibition in BRAF-mutated melanoma.\", \"citation\"=>\"Flaherty et al., 2012, N. Engl. J. Med.\", \"pubmed_id\"=>\"22663011\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22663011\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>7, \"day\"=>12}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1411, \"name\"=>\"EID1411\", \"description\"=>\"Open-label, randomized phase 3 trial with 704 patients with metastatic melanoma with a BRAF V600 mutation. Patients were randomized to receive either a combination of dabrafenib and trametinib or vemurafenib orally as first-line therapy. At preplanned interim analysis the overall survival rate at 12 months was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P=0.005). Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001).\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>353, \"name\"=>\"Improved overall survival in melanoma with combined dabrafenib and trametinib.\", \"citation\"=>\"Robert et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"25399551\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25399551\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>1, \"day\"=>1}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1413, \"name\"=>\"EID1413\", \"description\"=>\"Treatment response to mutant BRAF inhibitor vemurafenib and EGFR inhibitor panitumumab was assayed in 12 patients with metastatic colorectal cancer (CRC) who had progressed on chemotherapy. Two patients had confirmed partial responses, and 2 showed stable disease over 6 months. The authors conclude that although some efficacy is seen, only a small subset of patients respond to this treatment and the responses are not durable.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>957, \"name\"=>\"Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.\", \"citation\"=>\"Yaeger et al., 2015, Clin. Cancer Res.\", \"pubmed_id\"=>\"25589621\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25589621\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>3, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1409, \"name\"=>\"EID1409\", \"description\"=>\"Phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. A relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression was observed with vemurafenib as compared with dacarbazine (P<0.001 for both comparisons).\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>954, \"name\"=>\"Improved survival with vemurafenib in melanoma with BRAF V600E mutation.\", \"citation\"=>\"Chapman et al., 2011, N. Engl. J. Med.\", \"pubmed_id\"=>\"21639808\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21639808\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3549296\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>6, \"day\"=>30}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1408, \"name\"=>\"EID1408\", \"description\"=>\"5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified EGFR as an enhancer for survival when exposed to vemurafenib.  Treatment with vemurafenib and EGFR inhibitor (cetuximab or gefitinib) in V600E CRC cells (WiDr, VACO432 and KM20) showed inhibited growth as well as induction of the cleaved PARP apoptotic marker. WiDr and VACO432 cells were injected into immunodeficient mice. Modest response was seen with vemurafenib treatment, while combination treatment showed considerable tumor growth inhibition as compared to control.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}, {\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}, {\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>344, \"name\"=>\"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.\", \"citation\"=>\"Prahallad et al., 2012, Nature\", \"pubmed_id\"=>\"22281684\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22281684\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"Nature\", \"full_journal_title\"=>\"Nature\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2134, \"name\"=>\"EID2134\", \"description\"=>\"An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1485, \"name\"=>\"Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.\", \"citation\"=>\"Hoeflich et al., 2006, Cancer Res.\", \"pubmed_id\"=>\"16424035\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16424035\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>1, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2133, \"name\"=>\"EID2133\", \"description\"=>\"Acquired resistance to vemurafenib in BRAF-V600E positive melanomas frequently confound vemurafenib therapy.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1492, \"name\"=>\"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.\", \"citation\"=>\"Johannessen et al., 2010, Nature\", \"pubmed_id\"=>\"21107320\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21107320\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3058384\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>12, \"day\"=>16}, \"journal\"=>\"Nature\", \"full_journal_title\"=>\"Nature\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2132, \"name\"=>\"EID2132\", \"description\"=>\"Proposed resistance mechanisms include PDGFRB upregulation or NRAS mutations resulting in MAPK pathway reactivation, but not secondary mutations in BRAF. MEK inhibitors may demonstrate clinical benefit in vemurafenib-resistant melanoma patients.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1491, \"name\"=>\"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.\", \"citation\"=>\"Nazarian et al., 2010, Nature\", \"pubmed_id\"=>\"21107323\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3143360\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>12, \"day\"=>16}, \"journal\"=>\"Nature\", \"full_journal_title\"=>\"Nature\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1406, \"name\"=>\"EID1406\", \"description\"=>\"In trial NCT00880321, dabrafenib was tested in various solid tumor types harboring mutant BRAF after establishing dosage of 150 mg twice daily. In nine colorectal cancer patients with established V600E mutation, 1 confirmed response, 7 instances of stable disease, and 1 case of progressive disease was seen, which contrasted strongly with a 56% confirmed response rate seen in metastatic V600E melanoma patients similarly treated in the same study.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>345, \"name\"=>\"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.\", \"citation\"=>\"Falchook et al., 2012, Lancet\", \"pubmed_id\"=>\"22608338\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22608338\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4109288\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>5, \"day\"=>19}, \"journal\"=>\"Lancet\", \"full_journal_title\"=>\"Lancet (London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2131, \"name\"=>\"EID2131\", \"description\"=>\"An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>461, \"name\"=>\"GSK 1120212\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1485, \"name\"=>\"Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.\", \"citation\"=>\"Hoeflich et al., 2006, Cancer Res.\", \"pubmed_id\"=>\"16424035\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16424035\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>1, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2130, \"name\"=>\"EID2130\", \"description\"=>\"An inducible BRAF-V600E mouse melanoma model has shown a tight correlation between activated BRAF and disease progression.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1485, \"name\"=>\"Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.\", \"citation\"=>\"Hoeflich et al., 2006, Cancer Res.\", \"pubmed_id\"=>\"16424035\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16424035\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>1, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1405, \"name\"=>\"EID1405\", \"description\"=>\"In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and seven patients had 8 week stable disease as best response. Median progression free survival was 2.1 months and median overall survival was 7.7 months. The authors conclude that single agent vemurafenib did not show meaningful activity in V600E CRC, in contrast to the significant vemurafenib activity against V600 in melanoma.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>953, \"name\"=>\"Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.\", \"citation\"=>\"Kopetz et al., 2015, J. Clin. Oncol.\", \"pubmed_id\"=>\"26460303\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26460303\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4669589\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>12, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2129, \"name\"=>\"EID2129\", \"description\"=>\"In a mouse in vivo study, the MEK protein inhibitor selumetinib suppressed the growth of 1205Lu xenograft tumors, which contains the BRAF-V600Emutation (0.91 +/- 0.10-fold volume increase vs. 9.47 +/- 2.14-fold for non-treated mice). These tumors had a concomitant reduction of BrdU positive cells (P=0.009) but no increase in apoptosis. Selumetinib, in combination with docetaxel, a chemotherapeutic agent, produced cycle arrest and elevated apoptosis.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>122, \"name\"=>\"Selumetinib (AZD6244)\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1489, \"name\"=>\"The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.\", \"citation\"=>\"Haass et al., 2008, Clin. Cancer Res.\", \"pubmed_id\"=>\"18172275\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18172275\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>1, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1141, \"name\"=>\"EID1141\", \"description\"=>\"Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Inhibition of active, phosphorylated MEK by GDC-0973 (cobimetinib) is required for strong inhibition of the MAPK pathway in BRAF-mutant tumours. This study provides mechanistic rationale for improved efficacy of cobimetinib in BRAF-mutant models compared to MEK inhibitors acting through an alternative mechanism (GDC-0623 and G-573).\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>342, \"name\"=>\"Cobimetinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>790, \"name\"=>\"Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.\", \"citation\"=>\"Hatzivassiliou et al., 2013, Nature\", \"pubmed_id\"=>\"23934108\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23934108\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>9, \"day\"=>12}, \"journal\"=>\"Nature\", \"full_journal_title\"=>\"Nature\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2128, \"name\"=>\"EID2128\", \"description\"=>\"An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1485, \"name\"=>\"Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.\", \"citation\"=>\"Hoeflich et al., 2006, Cancer Res.\", \"pubmed_id\"=>\"16424035\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16424035\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>1, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1127, \"name\"=>\"EID1127\", \"description\"=>\"In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the sequenced patients.\", \"disease\"=>{\"id\"=>665, \"name\"=>\"Hairy Cell Leukemia\", \"display_name\"=>\"Hairy Cell Leukemia\", \"doid\"=>\"285\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:285\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>780, \"name\"=>\"BRAF mutations in hairy-cell leukemia.\", \"citation\"=>\"Tiacci et al., 2011, N. Engl. J. Med.\", \"pubmed_id\"=>\"21663470\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21663470\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3689585\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>6, \"day\"=>16}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2127, \"name\"=>\"EID2127\", \"description\"=>\"Acquired resistance to vemurafenib in BRAF-V600E positive melanomas frequently confound vemurafenib therapy.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>352, \"name\"=>\"Inhibition of mutated, activated BRAF in metastatic melanoma.\", \"citation\"=>\"Flaherty et al., 2010, N. Engl. J. Med.\", \"pubmed_id\"=>\"20818844\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20818844\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3724529\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>8, \"day\"=>26}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2126, \"name\"=>\"EID2126\", \"description\"=>\"Patients with BRAF mutations who were treated with the specific RAF inhibitor dabrafenib had an improved overall survival (P<0.003) compared to untreated patients with BRAF mutations. Patients harboring BRAF mutations were associated with reduced overall survival (11.1mo vs. 46.1mo for wildtype, P=0.006).\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1488, \"name\"=>\"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.\", \"citation\"=>\"Long et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21343559\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21343559\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2125, \"name\"=>\"EID2125\", \"description\"=>\"An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>459, \"name\"=>\"PD 0325901\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1485, \"name\"=>\"Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.\", \"citation\"=>\"Hoeflich et al., 2006, Cancer Res.\", \"pubmed_id\"=>\"16424035\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16424035\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>1, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2124, \"name\"=>\"EID2124\", \"description\"=>\"In a mouse in vivo study of MEK protein inhibitor, PD-0325901, was able to suppress growth of SKMEL28 BRAF-V600E xenograft tumors (P<0.01). The reduction of growth was associated with loss of D-cyclin expression and induction of p27.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>459, \"name\"=>\"PD 0325901\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1487, \"name\"=>\"BRAF mutation predicts sensitivity to MEK inhibition.\", \"citation\"=>\"Solit et al., 2006, Nature\", \"pubmed_id\"=>\"16273091\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16273091\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3306236\", \"publication_date\"=>{\"year\"=>2006, \"month\"=>1, \"day\"=>19}, \"journal\"=>\"Nature\", \"full_journal_title\"=>\"Nature\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>99, \"name\"=>\"EID99\", \"description\"=>\"Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>108, \"name\"=>\"Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.\", \"citation\"=>\"Yang et al., 2012, Cancer Res.\", \"pubmed_id\"=>\"22180495\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22180495\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>86, \"name\"=>\"EID86\", \"description\"=>\"In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>29, \"name\"=>\"PD0325901\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>98, \"name\"=>\"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.\", \"citation\"=>\"Nissan et al., 2014, Cancer Res.\", \"pubmed_id\"=>\"24576830\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24576830\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4005042\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>757, \"name\"=>\"EID757\", \"description\"=>\"One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a partial response on treatment with pictilisib, a PI3K inhibitor, for 9.5 months. Study was a phase-1 with 60 patients enrolled.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>141, \"name\"=>\"Pictilisib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>500, \"name\"=>\"First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.\", \"citation\"=>\"Sarker et al., 2015, Clin. Cancer Res.\", \"pubmed_id\"=>\"25370471\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25370471\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4287394\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>1, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>82, \"name\"=>\"EID82\", \"description\"=>\"BRAF status does not predict outcome in patients treated with dacarbazine or temozolomide.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>11, \"name\"=>\"Temozolomide\", \"pubchem_id\"=>\"\"}, {\"id\"=>25, \"name\"=>\"Dacarbazine\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>96, \"name\"=>\"BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.\", \"citation\"=>\"Meckbach et al., 2014, PLoS ONE\", \"pubmed_id\"=>\"24586605\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24586605\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3930670\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2123, \"name\"=>\"EID2123\", \"description\"=>\"An inducible BRAF-V600E mouse melanoma model has shown a tight correlation between activated BRAF and disease progression.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>6, \"name\"=>\"Sorafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1485, \"name\"=>\"Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.\", \"citation\"=>\"Hoeflich et al., 2006, Cancer Res.\", \"pubmed_id\"=>\"16424035\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16424035\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>1, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2122, \"name\"=>\"EID2122\", \"description\"=>\"In a mouse in vivo study, the dual RAF and VEGF inhibitor sorafenib suppressed the growth of both UACC903 and 1205Lu cell line- generating  xenograft tumors harboring the BRAF-V600E mutation, which had a concomitant reduction of phosphorylated Erk-positive cells (P<0.05).\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>6, \"name\"=>\"Sorafenib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1484, \"name\"=>\"Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.\", \"citation\"=>\"Sharma et al., 2005, Cancer Res.\", \"pubmed_id\"=>\"15781657\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15781657\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>3, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2121, \"name\"=>\"EID2121\", \"description\"=>\"In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, and bevacizumab, those with BRAF V600E mutations had reduced progression-free survival (5.9mo vs. 12.2mo, P=0.003) and reduced overall survival (15.0mo vs. 24.6mo, P=0.002) compared to those with wildtype BRAF.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>33, \"name\"=>\"Bevacizumab\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1481, \"name\"=>\"BRAF mutation in metastatic colorectal cancer.\", \"citation\"=>\"Tol et al., 2009, N. Engl. J. Med.\", \"pubmed_id\"=>\"19571295\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19571295\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>7, \"day\"=>2}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>1589, \"name\"=>\"EID1589\", \"description\"=>\"Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subsequent disease progression.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1050, \"name\"=>\"MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.\", \"citation\"=>\"Pietrantonio et al., 2016, Cancer Discov\", \"pubmed_id\"=>\"27325282\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27325282\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>20}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2120, \"name\"=>\"EID2120\", \"description\"=>\"Of metastatic colorectal cancer patients treated with bevacizumab-based first-line therapy, those with BRAF V600E mutations had reduced progression-free survival compared to those with wildtype BRAF (4.2mo vs. 12.5mo, HR:5.1, 95%CI:2.4-11.1, P<0.0001).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>33, \"name\"=>\"Bevacizumab\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1479, \"name\"=>\"Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.\", \"citation\"=>\"Souglakos et al., 2009, Br. J. Cancer\", \"pubmed_id\"=>\"19603024\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19603024\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2720232\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>8, \"day\"=>4}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2118, \"name\"=>\"EID2118\", \"description\"=>\"The presence of BRAF V600E was associated with reduced progression-free survival in metastatic colorectal cancer patients treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to patients with wildtype BRAF.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>101, \"name\"=>\"Irinotecan\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1479, \"name\"=>\"Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.\", \"citation\"=>\"Souglakos et al., 2009, Br. J. Cancer\", \"pubmed_id\"=>\"19603024\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19603024\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2720232\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>8, \"day\"=>4}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>2117, \"name\"=>\"EID2117\", \"description\"=>\"Of metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, those with BRAF V600E mutations had reduced progression-free survival compared to those with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>237, \"name\"=>\"Oxaliplatin\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1479, \"name\"=>\"Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.\", \"citation\"=>\"Souglakos et al., 2009, Br. J. Cancer\", \"pubmed_id\"=>\"19603024\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19603024\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2720232\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>8, \"day\"=>4}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>91, \"name\"=>\"EID91\", \"description\"=>\"In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>101, \"name\"=>\"Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.\", \"citation\"=>\"Rudin et al., 2013, J Thorac Oncol\", \"pubmed_id\"=>\"23524406\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23524406\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3634121\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>5}, \"journal\"=>\"J Thorac Oncol\", \"full_journal_title\"=>\"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>463, \"name\"=>\"EID463\", \"description\"=>\"In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type.\", \"disease\"=>{\"id\"=>224, \"name\"=>\"Myeloma\", \"display_name\"=>\"Myeloma\", \"doid\"=>\"0070004\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0070004\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>278, \"name\"=>\"Targeting the BRAF V600E mutation in multiple myeloma.\", \"citation\"=>\"Andrulis et al., 2013, Cancer Discov\", \"pubmed_id\"=>\"23612012\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23612012\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>8}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>656, \"name\"=>\"EID656\", \"description\"=>\"In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no mutations in either gene.\", \"disease\"=>{\"id\"=>156, \"name\"=>\"Papillary Thyroid Carcinoma\", \"display_name\"=>\"Papillary Thyroid Carcinoma\", \"doid\"=>\"3969\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3969\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>413, \"name\"=>\"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.\", \"citation\"=>\"Xing et al., 2014, J. Clin. Oncol.\", \"pubmed_id\"=>\"25024077\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25024077\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4145183\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>9, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>126, \"name\"=>\"EID126\", \"description\"=>\"Chemotherapy-refractory patients with colorectal cancer harboring BRAF mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype BRAF.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>76, \"name\"=>\"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.\", \"citation\"=>\"De Roock et al., 2010, Lancet Oncol.\", \"pubmed_id\"=>\"20619739\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20619739\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>8}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>816, \"name\"=>\"EID816\", \"description\"=>\"This meta-analysis of 7 randomized control trials evaluating overall survival (OS) (8 for progression free survival) could not definitely state that survival benefit of anti-EGFR monoclonal antibodies is limited to patients with wild type BRAF. In other words, the authors believe that there is insufficient data to justify the exclusion of anti-EGFR monoclonal antibody therapy for patients with mutant BRAF. In these studies, mutant BRAF specifically meant the V600E mutation.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>548, \"name\"=>\"Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.\", \"citation\"=>\"Rowland et al., 2015, Br. J. Cancer\", \"pubmed_id\"=>\"25989278\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25989278\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4580381\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>6, \"day\"=>9}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>98, \"name\"=>\"EID98\", \"description\"=>\"Mouse xenografts using HT29 cells harboring the BRAF V600E mutation treated with combination therapy (capecitabine, vemurafenib, bevacizumab) showed increased survival and reduced tumor burden compared to single and double agent therapies.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}, {\"id\"=>32, \"name\"=>\"Capecitabine\", \"pubchem_id\"=>nil}, {\"id\"=>33, \"name\"=>\"Bevacizumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>108, \"name\"=>\"Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.\", \"citation\"=>\"Yang et al., 2012, Cancer Res.\", \"pubmed_id\"=>\"22180495\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22180495\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>90, \"name\"=>\"EID90\", \"description\"=>\"In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>4, \"name\"=>\"Vemurafenib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>98, \"name\"=>\"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.\", \"citation\"=>\"Nissan et al., 2014, Cancer Res.\", \"pubmed_id\"=>\"24576830\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24576830\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4005042\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>107, \"name\"=>\"EID107\", \"description\"=>\"V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo).\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>93, \"name\"=>\"Both BRAF V600E mutation and older age (â¥ 65 years) are associated with recurrent papillary thyroid cancer.\", \"citation\"=>\"Howell et al., 2011, Ann. Surg. Oncol.\", \"pubmed_id\"=>\"21594703\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21594703\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>12}, \"journal\"=>\"Ann. Surg. Oncol.\", \"full_journal_title\"=>\"Annals of surgical oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>106, \"name\"=>\"EID106\", \"description\"=>\"BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>112, \"name\"=>\"Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma.\", \"citation\"=>\"He et al., 2014, Oncol Lett\", \"pubmed_id\"=>\"24396464\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24396464\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3881916\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>2}, \"journal\"=>\"Oncol Lett\", \"full_journal_title\"=>\"Oncology letters\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>105, \"name\"=>\"EID105\", \"description\"=>\"BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts.\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>93, \"name\"=>\"Both BRAF V600E mutation and older age (â¥ 65 years) are associated with recurrent papillary thyroid cancer.\", \"citation\"=>\"Howell et al., 2011, Ann. Surg. Oncol.\", \"pubmed_id\"=>\"21594703\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21594703\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>12}, \"journal\"=>\"Ann. Surg. Oncol.\", \"full_journal_title\"=>\"Annals of surgical oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>104, \"name\"=>\"EID104\", \"description\"=>\"BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>111, \"name\"=>\"Prognostic value of BRAF mutations in localized cutaneous melanoma.\", \"citation\"=>\"Nagore et al., 2014, J. Am. Acad. Dermatol.\", \"pubmed_id\"=>\"24388723\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24388723\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>5}, \"journal\"=>\"J. Am. Acad. Dermatol.\", \"full_journal_title\"=>\"Journal of the American Academy of Dermatology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>103, \"name\"=>\"EID103\", \"description\"=>\"V600E is associated with adverse pathological features of colorectal cancer. This can be concluded as a marker of poor prognosis.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>110, \"name\"=>\"BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.\", \"citation\"=>\"Chen et al., 2014, PLoS ONE\", \"pubmed_id\"=>\"24594804\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24594804\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3940924\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>102, \"name\"=>\"EID102\", \"description\"=>\"Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer.\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>109, \"name\"=>\"The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?\", \"citation\"=>\"Walczyk et al., 2014, Clin. Endocrinol. (Oxf)\", \"pubmed_id\"=>\"24354346\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24354346\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>6}, \"journal\"=>\"Clin. Endocrinol. (Oxf)\", \"full_journal_title\"=>\"Clinical endocrinology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>95, \"name\"=>\"EID95\", \"description\"=>\"Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemotherapy) in patients with melanoma.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>22, \"name\"=>\"Dabrafenib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>105, \"name\"=>\"Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.\", \"citation\"=>\"Menzies et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24583796\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24583796\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>80, \"name\"=>\"EID80\", \"description\"=>\"Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>94, \"name\"=>\"Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.\", \"citation\"=>\"Crescenzi et al., 2014, Horm. Metab. Res.\", \"pubmed_id\"=>\"24570209\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24570209\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>5}, \"journal\"=>\"Horm. Metab. Res.\", \"full_journal_title\"=>\"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et meÌtabolisme\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}, {\"id\"=>79, \"name\"=>\"EID79\", \"description\"=>\"BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer.\", \"disease\"=>{\"id\"=>16, \"name\"=>\"Thyroid Cancer\", \"display_name\"=>\"Thyroid Cancer\", \"doid\"=>\"1781\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1781\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>93, \"name\"=>\"Both BRAF V600E mutation and older age (â¥ 65 years) are associated with recurrent papillary thyroid cancer.\", \"citation\"=>\"Howell et al., 2011, Ann. Surg. Oncol.\", \"pubmed_id\"=>\"21594703\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21594703\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>12}, \"journal\"=>\"Ann. Surg. Oncol.\", \"full_journal_title\"=>\"Annals of surgical oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>12, \"phenotypes\"=>[]}]}, {\"id\"=>32, \"entrez_name\"=>\"DNMT3A\", \"entrez_id\"=>1788, \"name\"=>\"R882\", \"description\"=>\"DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.\", \"gene_id\"=>18, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>47, \"name\"=>\"missense_variant\", \"display_name\"=>\"Missense Variant\", \"so_id\"=>\"SO:0001583\", \"description\"=>\"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001583\"}], \"civic_actionability_score\"=>525.0, \"coordinates\"=>{\"chromosome\"=>\"2\", \"start\"=>25457241, \"stop\"=>25457243, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000264709.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/18/summary/variants/32/summary#variant\", \"evidence_items\"=>[{\"id\"=>50, \"name\"=>\"EID50\", \"description\"=>\"In a large cohort (n=1770) of AML patients (18-60 years old), DNMT3A mutation status (65.4% of which were R882) had no prognostic value for overall, relapse free and event free survival. This was true for cytogenetically normal AML and the entire cohort.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>81, \"name\"=>\"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).\", \"citation\"=>\"Gaidzik et al., 2013, Blood\", \"pubmed_id\"=>\"23632886\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23632886\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>6, \"day\"=>6}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>189, \"name\"=>\"EID189\", \"description\"=>\"Young AML patients (415 patients; <60 years old) with DNMT3A R882 mutations (n=58) have shorter overall and relapse-free survival than patients with wildtype DNMT3A.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>54, \"name\"=>\"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.\", \"citation\"=>\"Ribeiro et al., 2012, Blood\", \"pubmed_id\"=>\"22490330\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22490330\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>14}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>186, \"name\"=>\"EID186\", \"description\"=>\"Complete remission rate was not different between young AML patients (<60 years old) with or without DNMT3A mutations (60% of which were R882).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>54, \"name\"=>\"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.\", \"citation\"=>\"Ribeiro et al., 2012, Blood\", \"pubmed_id\"=>\"22490330\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22490330\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>14}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>187, \"name\"=>\"EID187\", \"description\"=>\"DNMT3A mutations (62% of which were R882) were associated with reduced disease-free survival in patients with cytogenetically normal AML.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>86, \"name\"=>\"Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.\", \"citation\"=>\"Marcucci et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22291079\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22291079\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3295550\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>157, \"name\"=>\"EID157\", \"description\"=>\"Complete remission rates did not differ between patients with wildtype or mutant DNMT3A (62% of which affected R882) and cytogenetically normal AML.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>86, \"name\"=>\"Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.\", \"citation\"=>\"Marcucci et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22291079\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22291079\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3295550\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>170, \"name\"=>\"EID170\", \"description\"=>\"DNMT3A mutations were associated with achievement of complete remission in a large cohort of younger (18-60) AML patients.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>81, \"name\"=>\"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).\", \"citation\"=>\"Gaidzik et al., 2013, Blood\", \"pubmed_id\"=>\"23632886\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23632886\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>6, \"day\"=>6}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>110, \"name\"=>\"EID110\", \"description\"=>\"Therapy-related AML was less common in patients with DNMT3A mutations (64.5% of which were R882) than patients wildtype for DNMT3A in a large cohort of younger (18-60) AML patients.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Negative\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>81, \"name\"=>\"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).\", \"citation\"=>\"Gaidzik et al., 2013, Blood\", \"pubmed_id\"=>\"23632886\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23632886\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>6, \"day\"=>6}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>112, \"name\"=>\"EID112\", \"description\"=>\"DNMT3A mutations (59% of which were R882) were associated with an intermediate risk cytogenetic profile, normal cytogenetic profile, and M4 and M5 FAB subtypes.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>68, \"name\"=>\"DNMT3A mutations in acute myeloid leukemia.\", \"citation\"=>\"Ley et al., 2010, N. Engl. J. Med.\", \"pubmed_id\"=>\"21067377\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21067377\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3201818\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>12, \"day\"=>16}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>113, \"name\"=>\"EID113\", \"description\"=>\"DNMT3A mutations (59% of which were R882) were associated with intermediate risk cytogenetics (including normal karyotype).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>68, \"name\"=>\"DNMT3A mutations in acute myeloid leukemia.\", \"citation\"=>\"Ley et al., 2010, N. Engl. J. Med.\", \"pubmed_id\"=>\"21067377\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21067377\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3201818\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>12, \"day\"=>16}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>114, \"name\"=>\"EID114\", \"description\"=>\"DNMT3A mutations (64.5% R882) were associated with older age, higher white blood cell count and cytogenetically normal AML in a large cohort of younger (18-60) AML patients.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>81, \"name\"=>\"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).\", \"citation\"=>\"Gaidzik et al., 2013, Blood\", \"pubmed_id\"=>\"23632886\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23632886\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>6, \"day\"=>6}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>115, \"name\"=>\"EID115\", \"description\"=>\"DNMT3A R882 mutations were associated with cytogenetically normal AML in a large cohort of younger (18-60) AML patients.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>81, \"name\"=>\"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).\", \"citation\"=>\"Gaidzik et al., 2013, Blood\", \"pubmed_id\"=>\"23632886\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23632886\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>6, \"day\"=>6}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>61, \"name\"=>\"EID61\", \"description\"=>\"In a large cohort of young AML patients (18-60 years old), DNMT3A R882 mutations were associated with reduced relapse free survival in the entire cohort as well as the subset of patients with cytogenetically normal AML.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>81, \"name\"=>\"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).\", \"citation\"=>\"Gaidzik et al., 2013, Blood\", \"pubmed_id\"=>\"23632886\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23632886\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>6, \"day\"=>6}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>63, \"name\"=>\"EID63\", \"description\"=>\"DNMT3A R882 mutation was associated with reduced relapse free and overall survival in ELN-unfavorable, cytogenetically normal AMLs.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>81, \"name\"=>\"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).\", \"citation\"=>\"Gaidzik et al., 2013, Blood\", \"pubmed_id\"=>\"23632886\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23632886\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>6, \"day\"=>6}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>67, \"name\"=>\"EID67\", \"description\"=>\"In young AML patients (<60 years old), DNMT3A mutations were associated with significantly reduced overall survival and relapse free survival in patients wildtype for NPM1 and FLT3.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>54, \"name\"=>\"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.\", \"citation\"=>\"Ribeiro et al., 2012, Blood\", \"pubmed_id\"=>\"22490330\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22490330\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>14}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>68, \"name\"=>\"EID68\", \"description\"=>\"In younger cytogenetically normal AML patients (<60 years), DNMT3A mutations other than R882 are prognostic for shorter disease free survival and overall survival compared to patients without the mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>86, \"name\"=>\"Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.\", \"citation\"=>\"Marcucci et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22291079\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22291079\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3295550\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>66, \"name\"=>\"EID66\", \"description\"=>\"In older cytogenetically normal AML patients (>59 years), DNMT3A R882 mutation is prognostic for shorter disease free survival and overall survival compared to patients without the mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>86, \"name\"=>\"Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.\", \"citation\"=>\"Marcucci et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22291079\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22291079\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3295550\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>65, \"name\"=>\"EID65\", \"description\"=>\"In cytogenetically normal AML patients, DNMT3A R882 mutations are associated with lower overall and disease free survival as compared to patients with wild type DNMT3A.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>72, \"name\"=>\"DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.\", \"citation\"=>\"El Ghannam et al., Blood Cells Mol. Dis.\", \"pubmed_id\"=>\"24512939\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24512939\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{}, \"journal\"=>\"Blood Cells Mol. Dis.\", \"full_journal_title\"=>\"Blood cells, molecules & diseases\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>64, \"name\"=>\"EID64\", \"description\"=>\"In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations (including R882) were associated with worse overall survival compared to those without DNMT3A mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>68, \"name\"=>\"DNMT3A mutations in acute myeloid leukemia.\", \"citation\"=>\"Ley et al., 2010, N. Engl. J. Med.\", \"pubmed_id\"=>\"21067377\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21067377\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3201818\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>12, \"day\"=>16}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>62, \"name\"=>\"EID62\", \"description\"=>\"AML patients with DNMT3A mutations (59% of which were R882) showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>68, \"name\"=>\"DNMT3A mutations in acute myeloid leukemia.\", \"citation\"=>\"Ley et al., 2010, N. Engl. J. Med.\", \"pubmed_id\"=>\"21067377\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21067377\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3201818\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>12, \"day\"=>16}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>49, \"name\"=>\"EID49\", \"description\"=>\"In a large cohort of AML patients (mean = 48 years), DNMT3A mutation (64.5% of which were R882) had no prognostic value on overall, relapse free and event free survival.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>81, \"name\"=>\"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).\", \"citation\"=>\"Gaidzik et al., 2013, Blood\", \"pubmed_id\"=>\"23632886\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23632886\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>6, \"day\"=>6}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>51, \"name\"=>\"EID51\", \"description\"=>\"In young AML patients (<60 years old), DNMT3A mutation status (60% of which were R882) was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>54, \"name\"=>\"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.\", \"citation\"=>\"Ribeiro et al., 2012, Blood\", \"pubmed_id\"=>\"22490330\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22490330\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>14}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>3, \"name\"=>\"EID3\", \"description\"=>\"DNMT3A R882 mutations occur most often in de novo AML patients with intermediate risk cytogenetics (39/194 intermediate risk patients vs 0/89 low and high risk).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>53, \"name\"=>\"Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.\", \"citation\"=>\"LaRochelle et al., 2011, Oncotarget\", \"pubmed_id\"=>\"22081665\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22081665\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3260002\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>25, \"name\"=>\"EID25\", \"description\"=>\"De novo AML patients with DNMT3A D882 mutation showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>68, \"name\"=>\"DNMT3A mutations in acute myeloid leukemia.\", \"citation\"=>\"Ley et al., 2010, N. Engl. J. Med.\", \"pubmed_id\"=>\"21067377\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21067377\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3201818\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>12, \"day\"=>16}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>24, \"name\"=>\"EID24\", \"description\"=>\"There is no difference in the complete remission rate of de novo AML patients with DNMT3A mutation compared to those who are wild type for DNMT3A.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>53, \"name\"=>\"Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.\", \"citation\"=>\"LaRochelle et al., 2011, Oncotarget\", \"pubmed_id\"=>\"22081665\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22081665\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3260002\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>4, \"name\"=>\"EID4\", \"description\"=>\"Young AML patients (<60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>54, \"name\"=>\"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.\", \"citation\"=>\"Ribeiro et al., 2012, Blood\", \"pubmed_id\"=>\"22490330\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22490330\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>14}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>18, \"name\"=>\"EID18\", \"description\"=>\"Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>7, \"name\"=>\"Idarubicin\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>53, \"name\"=>\"Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.\", \"citation\"=>\"LaRochelle et al., 2011, Oncotarget\", \"pubmed_id\"=>\"22081665\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22081665\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3260002\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>31, \"name\"=>\"EID31\", \"description\"=>\"DNMT3A R882 mutations were associated with older age, higher white blood cell count, and FAB M4 and M5 subtypes compared to wildtype DNMT3A in a cohort of cytogenetically normal AML patients.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>72, \"name\"=>\"DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.\", \"citation\"=>\"El Ghannam et al., Blood Cells Mol. Dis.\", \"pubmed_id\"=>\"24512939\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24512939\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{}, \"journal\"=>\"Blood Cells Mol. Dis.\", \"full_journal_title\"=>\"Blood cells, molecules & diseases\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}, {\"id\"=>11, \"name\"=>\"EID11\", \"description\"=>\"Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>2, \"name\"=>\"Daunorubicin\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>53, \"name\"=>\"Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.\", \"citation\"=>\"LaRochelle et al., 2011, Oncotarget\", \"pubmed_id\"=>\"22081665\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22081665\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3260002\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>32, \"phenotypes\"=>[]}]}, {\"id\"=>33, \"entrez_name\"=>\"EGFR\", \"entrez_id\"=>1956, \"name\"=>\"L858R\", \"description\"=>\"EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.\", \"gene_id\"=>19, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>47, \"name\"=>\"missense_variant\", \"display_name\"=>\"Missense Variant\", \"so_id\"=>\"SO:0001583\", \"description\"=>\"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001583\"}], \"civic_actionability_score\"=>314.5, \"coordinates\"=>{\"chromosome\"=>\"7\", \"start\"=>55259515, \"stop\"=>55259515, \"reference_bases\"=>\"T\", \"variant_bases\"=>\"G\", \"representative_transcript\"=>\"ENST00000275493.2\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/19/summary/variants/33/summary#variant\", \"evidence_items\"=>[{\"id\"=>229, \"name\"=>\"EID229\", \"description\"=>\"There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib with EGFR L858R mutations (N=72/242; univariate: P=0.283; multivariate: P=0.250) compared to patients with Exon 19 mutations (N=170).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}, {\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>162, \"name\"=>\"Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.\", \"citation\"=>\"Lim et al., 2014, J Thorac Oncol\", \"pubmed_id\"=>\"24736073\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24736073\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>4}, \"journal\"=>\"J Thorac Oncol\", \"full_journal_title\"=>\"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>4284, \"name\"=>\"EID4284\", \"description\"=>\"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to erlotinib (IC50: 40nM vs. 110nM) compared to EGFR wild type cells.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1525, \"name\"=>\"BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.\", \"citation\"=>\"Li et al., 2008, Oncogene\", \"pubmed_id\"=>\"18408761\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18408761\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2748240\", \"publication_date\"=>{\"year\"=>2008, \"month\"=>8, \"day\"=>7}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>4860, \"name\"=>\"EID4860\", \"description\"=>\"We pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. For those (exon19/21), the median PFS was 14.6 months with dacomitinib and 9.6 months with erlotinib The median survival was 26.6 months with dacomitinib versus 23.2 months with erlotinib.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>44, \"name\"=>\"Dacomitinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>nil, \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2158, \"name\"=>\"Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.\", \"citation\"=>\"Ramalingam et al., 2016, Ann. Oncol.\", \"pubmed_id\"=>\"26768165\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26768165\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2634, \"name\"=>\"EID2634\", \"description\"=>\"In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1513, \"name\"=>\"First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.\", \"citation\"=>\"Han et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22370314\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22370314\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>4288, \"name\"=>\"EID4288\", \"description\"=>\"In a non-small cell lung cancer patient with an EGFR L858R mutation, EGFR L858R was reported to be refractory to 61-day crizotinib treatment.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>507, \"name\"=>\"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.\", \"citation\"=>\"Doebele et al., 2012, Clin. Cancer Res.\", \"pubmed_id\"=>\"22235099\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22235099\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3311875\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>4294, \"name\"=>\"EID4294\", \"description\"=>\"EGFR L858R mutation has been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to erlotinib (IC50: 8.0-11.0 nmol/L vs 108.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).\", \"disease\"=>{\"id\"=>217, \"name\"=>\"Hematologic Cancer\", \"display_name\"=>\"Hematologic Cancer\", \"doid\"=>\"2531\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2531\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>nil, \"evidence_direction\"=>nil, \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>665, \"name\"=>\"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.\", \"citation\"=>\"Cross et al., 2014, Cancer Discov\", \"pubmed_id\"=>\"24893891\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24893891\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4315625\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>9}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>4293, \"name\"=>\"EID4293\", \"description\"=>\"In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated an sensitivity to erlotinib (IC50: 8.0-11.0 nmol/L vs 108.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).\", \"disease\"=>{\"id\"=>174, \"name\"=>\"Lung Small Cell Carcinoma\", \"display_name\"=>\"Lung Small Cell Carcinoma\", \"doid\"=>\"5409\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5409\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>nil, \"evidence_direction\"=>nil, \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>665, \"name\"=>\"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.\", \"citation\"=>\"Cross et al., 2014, Cancer Discov\", \"pubmed_id\"=>\"24893891\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24893891\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4315625\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>9}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>4292, \"name\"=>\"EID4292\", \"description\"=>\"In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to cetuximab treatment. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation and EGFR auto-phosphorylation.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2086, \"name\"=>\"EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.\", \"citation\"=>\"Konduri et al., 2016, Cancer Discov\", \"pubmed_id\"=>\"27102076\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27102076\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4893907\", \"publication_date\"=>{\"year\"=>2016}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>4291, \"name\"=>\"EID4291\", \"description\"=>\"In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation, and EGFR auto-phosphorylation.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2086, \"name\"=>\"EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.\", \"citation\"=>\"Konduri et al., 2016, Cancer Discov\", \"pubmed_id\"=>\"27102076\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27102076\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4893907\", \"publication_date\"=>{\"year\"=>2016}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>4287, \"name\"=>\"EID4287\", \"description\"=>\"In an in vitro study, CHO and NCI-H3255 cells expressing EGFR L858R mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2070, \"name\"=>\"Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.\", \"citation\"=>\"Ray et al., 2016, Oncotarget\", \"pubmed_id\"=>\"27612423\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27612423\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5356576\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>10, \"day\"=>18}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>4286, \"name\"=>\"EID4286\", \"description\"=>\"In an in vitro study, Ba/F3 and NCI-H3255 cell lines expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment (IC50=0.006ï¿½M). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1230, \"name\"=>\"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.\", \"citation\"=>\"Yasuda et al., 2013, Sci Transl Med\", \"pubmed_id\"=>\"24353160\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24353160\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3954775\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>12, \"day\"=>18}, \"journal\"=>\"Sci Transl Med\", \"full_journal_title\"=>\"Science translational medicine\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>4285, \"name\"=>\"EID4285\", \"description\"=>\"In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib treatment, compared to MCF-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing YFP signal-EGFR relocation.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1993, \"name\"=>\"Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.\", \"citation\"=>\"Harada et al., 2011, Oncogene\", \"pubmed_id\"=>\"21132006\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21132006\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>14}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>4295, \"name\"=>\"EID4295\", \"description\"=>\"In an in vitro study, a Ba/F3 cell line expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.\", \"disease\"=>{\"id\"=>695, \"name\"=>\"Malignant Glioma\", \"display_name\"=>\"Malignant Glioma\", \"doid\"=>\"3070\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3070\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1608, \"name\"=>\"Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.\", \"citation\"=>\"Lee et al., 2006, PLoS Med.\", \"pubmed_id\"=>\"17177598\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17177598\", \"open_access\"=>true, \"pmc_id\"=>\"PMC1702556\", \"publication_date\"=>{\"year\"=>2006, \"month\"=>12}, \"journal\"=>\"PLoS Med.\", \"full_journal_title\"=>\"PLoS medicine\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>4290, \"name\"=>\"EID4290\", \"description\"=>\"In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR L858R mutation was associated with resistance to erlotinib treatment; the patient survived 3.9 months, as compared to the overall 24 months median overall survival of the other patients who were not resistant to erlotinib treatment.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2067, \"name\"=>\"Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).\", \"citation\"=>\"De GrÃ¨ve et al., 2016, PLoS ONE\", \"pubmed_id\"=>\"27032107\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27032107\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4816447\", \"publication_date\"=>{\"year\"=>2016}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>4265, \"name\"=>\"EID4265\", \"description\"=>\"MCF-7 cells were transduced with YFP tagged EGFR with E746_A750delELREA mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased p-Akt stain was seen with ectopic mutant EGFR over wildtype cells. Parallel erlotinib incubations of cells with wildtype EGFR induced recompartmentalization of ectopic EGFR protien only at high concentration (10uM). Addition of erlotinib to mutant EGFR cell incubations reduced p-Akt signal and induced recompartmentalization of ectopic EGFR protien at considerably lower conecntration (100 nM) erlotinib.  These results indicate the EGFR L858R variant as a growth pathway driver targetable by erlotinib.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1991, \"name\"=>\"Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.\", \"citation\"=>\"de Gunst et al., 2007, Mol. Cancer\", \"pubmed_id\"=>\"17877814\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17877814\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2064929\", \"publication_date\"=>{\"year\"=>2007, \"month\"=>9, \"day\"=>18}, \"journal\"=>\"Mol. Cancer\", \"full_journal_title\"=>\"Molecular cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2997, \"name\"=>\"EID2997\", \"description\"=>\"Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1725, \"name\"=>\"Afatinib: first global approval.\", \"citation\"=>\"Dungo et al., 2013, Drugs\", \"pubmed_id\"=>\"23982599\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23982599\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>9}, \"journal\"=>\"Drugs\", \"full_journal_title\"=>\"Drugs\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2621, \"name\"=>\"EID2621\", \"description\"=>\"In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1501, \"name\"=>\"Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.\", \"citation\"=>\"Douillard et al., 2010, J. Clin. Oncol.\", \"pubmed_id\"=>\"20038723\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20038723\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>2, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2632, \"name\"=>\"EID2632\", \"description\"=>\"In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patients had the del L858R mutation. One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1509, \"name\"=>\"EGF receptor gene mutations are common in lung cancers from \\\"never smokers\\\" and are associated with sensitivity of tumors to gefitinib and erlotinib.\", \"citation\"=>\"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.\", \"pubmed_id\"=>\"15329413\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15329413\", \"open_access\"=>true, \"pmc_id\"=>\"PMC516528\", \"publication_date\"=>{\"year\"=>2004, \"month\"=>9, \"day\"=>7}, \"journal\"=>\"Proc. Natl. Acad. Sci. U.S.A.\", \"full_journal_title\"=>\"Proceedings of the National Academy of Sciences of the United States of America\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2633, \"name\"=>\"EID2633\", \"description\"=>\"EGFR L858R mutation has been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib.In an in vitro study using PC9 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib  (IC50: 11.0-12.0 nmol/L vs 61.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>427, \"name\"=>\"MEDI4736\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>nil, \"evidence_direction\"=>nil, \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>665, \"name\"=>\"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.\", \"citation\"=>\"Cross et al., 2014, Cancer Discov\", \"pubmed_id\"=>\"24893891\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24893891\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4315625\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>9}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2631, \"name\"=>\"EID2631\", \"description\"=>\"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to canertinib (IC50: 1nM vs. 198nM) compared to wildtype EGFR cells.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>465, \"name\"=>\"Canertinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1525, \"name\"=>\"BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.\", \"citation\"=>\"Li et al., 2008, Oncogene\", \"pubmed_id\"=>\"18408761\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18408761\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2748240\", \"publication_date\"=>{\"year\"=>2008, \"month\"=>8, \"day\"=>7}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2629, \"name\"=>\"EID2629\", \"description\"=>\"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1525, \"name\"=>\"BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.\", \"citation\"=>\"Li et al., 2008, Oncogene\", \"pubmed_id\"=>\"18408761\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18408761\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2748240\", \"publication_date\"=>{\"year\"=>2008, \"month\"=>8, \"day\"=>7}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2623, \"name\"=>\"EID2623\", \"description\"=>\"In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, HR: 0.30, 95% CI: 0.22-0.41, P<0.001), compared to patients treated with carboplatin and paclitaxel combination therapy. The frequency of mutation of exon 19 deletion and L858R was 25.2% (58/230) and 21.3% (49/230), respectively.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1508, \"name\"=>\"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.\", \"citation\"=>\"Maemondo et al., 2010, N. Engl. J. Med.\", \"pubmed_id\"=>\"20573926\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20573926\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>6, \"day\"=>24}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2628, \"name\"=>\"EID2628\", \"description\"=>\"In an in vitro study using NCI-H1781 cells (EGFR wild-type) and NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to neratinib (IC50: 0.0049umol/L vs. 0.085umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug erlotinib (IC50: 0.031umol/L vs. wildtype >1umol/L).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>52, \"name\"=>\"Neratinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1526, \"name\"=>\"Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.\", \"citation\"=>\"Shimamura et al., 2006, Cancer Res.\", \"pubmed_id\"=>\"16818618\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16818618\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2630, \"name\"=>\"EID2630\", \"description\"=>\"In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors had an EGFR mutation, of which 76 (79%) were positive for either L858R or a deletion in exon 19. These mutations were associated with improved progression-free survival (median 3.3 months  vs 1.0 month ; HR:0.51, 95% CI:0.31-0.85, P<0.009) compared to placebo control.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1510, \"name\"=>\"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.\", \"citation\"=>\"Miller et al., 2012, Lancet Oncol.\", \"pubmed_id\"=>\"22452896\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22452896\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>5}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2627, \"name\"=>\"EID2627\", \"description\"=>\"In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to PF 00299804  (IC50: 0.007umol/L vs. >10umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug gefitinib (IC50: 0.075umol/L vs. wild-type >10umol/L).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>464, \"name\"=>\"PF 00299804\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1515, \"name\"=>\"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.\", \"citation\"=>\"Engelman et al., 2007, Cancer Res.\", \"pubmed_id\"=>\"18089823\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18089823\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2007, \"month\"=>12, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2626, \"name\"=>\"EID2626\", \"description\"=>\"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to lapatinib (IC50: 63nM vs. 534nM) compared to wildtype EGFR cells.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1525, \"name\"=>\"BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.\", \"citation\"=>\"Li et al., 2008, Oncogene\", \"pubmed_id\"=>\"18408761\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18408761\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2748240\", \"publication_date\"=>{\"year\"=>2008, \"month\"=>8, \"day\"=>7}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2625, \"name\"=>\"EID2625\", \"description\"=>\"In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib  (IC50: 23.0 nmol/L vs 200.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>665, \"name\"=>\"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.\", \"citation\"=>\"Cross et al., 2014, Cancer Discov\", \"pubmed_id\"=>\"24893891\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24893891\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4315625\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>9}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2624, \"name\"=>\"EID2624\", \"description\"=>\"Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 1 was L858R. The patient was a female former smoker who had lung adenocarcinoma histology, and demonstrated response for 5 months, with overall survival 8 months.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1509, \"name\"=>\"EGF receptor gene mutations are common in lung cancers from \\\"never smokers\\\" and are associated with sensitivity of tumors to gefitinib and erlotinib.\", \"citation\"=>\"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.\", \"pubmed_id\"=>\"15329413\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15329413\", \"open_access\"=>true, \"pmc_id\"=>\"PMC516528\", \"publication_date\"=>{\"year\"=>2004, \"month\"=>9, \"day\"=>7}, \"journal\"=>\"Proc. Natl. Acad. Sci. U.S.A.\", \"full_journal_title\"=>\"Proceedings of the National Academy of Sciences of the United States of America\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>3811, \"name\"=>\"EID3811\", \"description\"=>\"EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors Gefitinib, Erlotinib, or the the tool compound AEE788, and IC50 values were measured. L858R EGFR cells had very low IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib=12, Erlotinib=6, AEE788=6), indicating sensitivity to all three constructs.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}, {\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}, {\"id\"=>90, \"name\"=>\"AEE788\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1528, \"name\"=>\"Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.\", \"citation\"=>\"Kancha et al., 2009, Clin. Cancer Res.\", \"pubmed_id\"=>\"19147750\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19147750\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>1, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>2994, \"name\"=>\"EID2994\", \"description\"=>\"On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1724, \"name\"=>\"U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.\", \"citation\"=>\"Khozin et al., 2014, Oncologist\", \"pubmed_id\"=>\"24868098\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24868098\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4077454\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>7}, \"journal\"=>\"Oncologist\", \"full_journal_title\"=>\"The oncologist\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>1665, \"name\"=>\"EID1665\", \"description\"=>\"90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were  treated with gefitinib, and the L858R EGFR mutation was associated with longer time to treatment failure than those with wild-type EGFR(median 9.1 versus 2.1). In multivariate analysis, L858R mutations plus adenocarcinoma was a significant predictive factor for TTF (HR = 0.1030; P = .0004).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1127, \"name\"=>\"Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.\", \"citation\"=>\"Yang et al., 2008, J. Clin. Oncol.\", \"pubmed_id\"=>\"18509184\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18509184\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>6, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>982, \"name\"=>\"EID982\", \"description\"=>\"Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>679, \"name\"=>\"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.\", \"citation\"=>\"Wu et al., 2014, Lancet Oncol.\", \"pubmed_id\"=>\"24439929\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24439929\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>2}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>885, \"name\"=>\"EID885\", \"description\"=>\"A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>595, \"name\"=>\"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.\", \"citation\"=>\"Rosell et al., 2012, Lancet Oncol.\", \"pubmed_id\"=>\"22285168\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22285168\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>3}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>5922, \"name\"=>\"EID5922\", \"description\"=>\"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR L858R demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR \\n expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2081, \"name\"=>\"Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.\", \"citation\"=>\"Foster et al., 2010, World J Surg Oncol\", \"pubmed_id\"=>\"20942962\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20942962\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2970593\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>10, \"day\"=>13}, \"journal\"=>\"World J Surg Oncol\", \"full_journal_title\"=>\"World journal of surgical oncology\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>883, \"name\"=>\"EID883\", \"description\"=>\"In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>594, \"name\"=>\"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.\", \"citation\"=>\"Yang et al., 2012, Lancet Oncol.\", \"pubmed_id\"=>\"22452895\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22452895\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>5}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>968, \"name\"=>\"EID968\", \"description\"=>\"Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>669, \"name\"=>\"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.\", \"citation\"=>\"Hirano et al., 2015, Oncotarget\", \"pubmed_id\"=>\"26515464\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26515464\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4770737\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>11, \"day\"=>17}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>879, \"name\"=>\"EID879\", \"description\"=>\"A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>592, \"name\"=>\"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.\", \"citation\"=>\"Sequist et al., 2013, J. Clin. Oncol.\", \"pubmed_id\"=>\"23816960\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23816960\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>9, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>347, \"name\"=>\"EID347\", \"description\"=>\"Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>213, \"name\"=>\"Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.\", \"citation\"=>\"Douillard et al., 2014, J Thorac Oncol\", \"pubmed_id\"=>\"24662454\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24662454\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>5}, \"journal\"=>\"J Thorac Oncol\", \"full_journal_title\"=>\"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>276, \"name\"=>\"EID276\", \"description\"=>\"Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>181, \"name\"=>\"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.\", \"citation\"=>\"Paez et al., 2004, Science\", \"pubmed_id\"=>\"15118125\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15118125\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>6, \"day\"=>4}, \"journal\"=>\"Science\", \"full_journal_title\"=>\"Science (New York, N.Y.)\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}, {\"id\"=>275, \"name\"=>\"EID275\", \"description\"=>\"In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}, {\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>182, \"name\"=>\"Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.\", \"citation\"=>\"Fukihara et al., 2014, Oncology\", \"pubmed_id\"=>\"24457318\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24457318\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Oncology\", \"full_journal_title\"=>\"Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>33, \"phenotypes\"=>[]}]}, {\"id\"=>34, \"entrez_name\"=>\"EGFR\", \"entrez_id\"=>1956, \"name\"=>\"T790M\", \"description\"=>\"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.\", \"gene_id\"=>19, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>47, \"name\"=>\"missense_variant\", \"display_name\"=>\"Missense Variant\", \"so_id\"=>\"SO:0001583\", \"description\"=>\"A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001583\"}], \"civic_actionability_score\"=>373.25, \"coordinates\"=>{\"chromosome\"=>\"7\", \"start\"=>55249071, \"stop\"=>55249071, \"reference_bases\"=>\"C\", \"variant_bases\"=>\"T\", \"representative_transcript\"=>\"ENST00000275493.2\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/19/summary/variants/34/summary#variant\", \"evidence_items\"=>[{\"id\"=>6006, \"name\"=>\"EID6006\", \"description\"=>\"Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the pancreaticoduodenectomy was analysed, which revealed an activating mutation in exon 19 (L747_P753>S) of EGFR. Mutations were also detected in CDKN2A, TP53, and amplifications of PRKCI and TERC. He began erlotinib at 150mg daily. CT imaging  revealed a partial response by RECIST at 8, 24 and 32 weeks after starting erlotinib. At 40 weeks CT imaging revealed unequivocal disease progression. After disease progression to erlotinib, a repeat liver biopsy revealed an EGFR T790M mutation. He began treatment with osimertinib at 80mg daily. After 8 weeks of this treatment CT imaging revealed unequivocal disease progression.\", \"disease\"=>{\"id\"=>158, \"name\"=>\"Pancreatic Adenocarcinoma\", \"display_name\"=>\"Pancreatic Adenocarcinoma\", \"doid\"=>\"4074\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4074\"}, \"drugs\"=>[{\"id\"=>187, \"name\"=>\"Osimertinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2359, \"name\"=>\"EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.\", \"citation\"=>\"Cecchini et al., 2017, J Natl Compr Canc Netw\", \"pubmed_id\"=>\"28874593\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28874593\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>9}, \"journal\"=>\"J Natl Compr Canc Netw\", \"full_journal_title\"=>\"Journal of the National Comprehensive Cancer Network : JNCCN\", \"status\"=>\"submitted\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>5709, \"name\"=>\"EID5709\", \"description\"=>\"Recently, the development of the third-generation epidermal growth factor receptor-small molecule inhibitor (EGFR-TKI) rociletinib had failed. in May 2016, after receiving a negative reply from  the  FDAâs  Oncologic  Drugs  Advisory  Committee, \\nwhich voted 12â1 against the accelerated approval of rociletinib, Clovis Oncology decided to end the development of \\nrociletinib.\\nIn this review, the wide-ranging aspects of the evolution of EGFR-TKIs were collected, with a special focus on rociletinib.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>91, \"name\"=>\"Rociletinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2322, \"name\"=>\"New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?\", \"citation\"=>\"Van Der Steen et al., 2016, Onco Targets Ther\", \"pubmed_id\"=>\"27785053\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27785053\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5063481\", \"publication_date\"=>{\"year\"=>2016}, \"journal\"=>\"Onco Targets Ther\", \"full_journal_title\"=>\"OncoTargets and therapy\", \"status\"=>\"fully curated\", \"is_review\"=>true, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>2164, \"name\"=>\"EID2164\", \"description\"=>\"In an in vitro study using purified EGFR protein, kinase activity was assayed and compared for wildtype EGFR, EGFR-T790M and EGFR-T790M/L858R using both reversible and irreversible TKI drugs. EFGR proteins with T790M or T790M/L858R mutations were more sensitive to afatinib treatment (IC50: 9.8nM and 24nM, respectively vs. IC50: >1000nM and >1000nM, respectively) compared to treatment with erlotinib or lapatinib treatment. In an in vitro study using NCI-H358 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (GI50: 42.0nM vs. >1000nM) compared to the same cells treated with erlotinib. However, IC50s were intermediate compared to a more potent pan-HER inhibitor.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1527, \"name\"=>\"Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.\", \"citation\"=>\"Cha et al., 2012, Int. J. Cancer\", \"pubmed_id\"=>\"21732342\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21732342\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>5, \"day\"=>15}, \"journal\"=>\"Int. J. Cancer\", \"full_journal_title\"=>\"International journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>2165, \"name\"=>\"EID2165\", \"description\"=>\"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to canertinib (IC50: 101nM vs. >4000nM) compared to the same cells treated with erlotinib. IC50 values of canertinib were comparable to afatinib.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>465, \"name\"=>\"Canertinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1525, \"name\"=>\"BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.\", \"citation\"=>\"Li et al., 2008, Oncogene\", \"pubmed_id\"=>\"18408761\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18408761\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2748240\", \"publication_date\"=>{\"year\"=>2008, \"month\"=>8, \"day\"=>7}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>2157, \"name\"=>\"EID2157\", \"description\"=>\"In a lung adenocarcinoma patient harboring an EGFR E746_A750 mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with gefitinib and achieved a partial response, but subsequently tumor progression occurred; however, osimertinib treatment resulted a favorable tumor response with the extinguishment of the EGFR T790M mutation. In a stage IV lung adenocarcinoma patient harboring an EGFR L858R mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with erlotinib, followed by gefitinib for 12 months and achieved stable disease, but subsequently metastasis occurred; the EGFR T790M was then identified and subsequent 10 month treatment with osimertinib monotherapy resulted in a 45% disease regression.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>187, \"name\"=>\"Osimertinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1516, \"name\"=>\"EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.\", \"citation\"=>\"Planchard et al., 2015, Ann. Oncol.\", \"pubmed_id\"=>\"26269204\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26269204\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>10}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>965, \"name\"=>\"EID965\", \"description\"=>\"This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and were subsequently treated with Osimertinib (AZD9291). The overall objective tumor response rate was 51%. Among 127 patients with EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70). In contrast, among 61 patients without EGFR T790M, the response rate was 21% (95% CI, 12 to 34). The median progression-free survival was 9.6 months in EGFR T790M-positive patients and 2.8 months in EGFR T790M-negative patients.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>187, \"name\"=>\"Osimertinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>667, \"name\"=>\"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.\", \"citation\"=>\"JÃ¤nne et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"25923549\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25923549\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>4, \"day\"=>30}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>4836, \"name\"=>\"EID4836\", \"description\"=>\"Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance to Osimertinib. In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo. The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibodies Ceutximab or Panitumumab because of the decrease of surface and total EGFR expression. Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>524, \"name\"=>\"Brigatinib, Panitumumab, Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2142, \"name\"=>\"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.\", \"citation\"=>\"Uchibori et al., 2017, Nat Commun\", \"pubmed_id\"=>\"28287083\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28287083\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5355811\", \"publication_date\"=>{\"year\"=>2017, \"month\"=>3, \"day\"=>13}, \"journal\"=>\"Nat Commun\", \"full_journal_title\"=>\"Nature communications\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>277, \"name\"=>\"EID277\", \"description\"=>\"In an NSCLC patient initially with L858R mutation, pemetrexed and cisplatin combination treatment was followed by erlotinib treatment. A slow progression developed which was found to be positive for L858R as well as T790M mutation which confers resistance to tyrosine kinase inhibitors. Due to slow tumor growth erlotinib was continued despite T790M, with re-addition of premetrexed, and this reduced tumor size and resulted in stable disease.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}, {\"id\"=>156, \"name\"=>\"Pemetrexed\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>183, \"name\"=>\"Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.\", \"citation\"=>\"Li et al., 2014, Lung Cancer\", \"pubmed_id\"=>\"24636847\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24636847\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>5}, \"journal\"=>\"Lung Cancer\", \"full_journal_title\"=>\"Lung cancer (Amsterdam, Netherlands)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>3810, \"name\"=>\"EID3810\", \"description\"=>\"Experimental - Associated drug effects EGFR T790M mutation has been associated with resistance to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study, Ba/F3 cells stably expressing EGFR T790M demonstrated  resistance to gefitinib and erlotinib (greater than 100-fold decreased sensitivity) compared to Ba/F3 expressing wild-type EGFR.\", \"disease\"=>{\"id\"=>217, \"name\"=>\"Hematologic Cancer\", \"display_name\"=>\"Hematologic Cancer\", \"doid\"=>\"2531\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2531\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>nil, \"evidence_direction\"=>nil, \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1528, \"name\"=>\"Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.\", \"citation\"=>\"Kancha et al., 2009, Clin. Cancer Res.\", \"pubmed_id\"=>\"19147750\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19147750\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>1, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>3812, \"name\"=>\"EID3812\", \"description\"=>\"In an in vitro study, the recombinant EGFR T790M mutation kinase was associated with reduced sensitivity to bosutinib(IC50: 491nM), as compared to wild-type EGFR kinase (IC50: 53nM). Resistance was assessed by analyzing kinase inhibition.\", \"disease\"=>{\"id\"=>4, \"name\"=>\"Chronic Myeloid Leukemia\", \"display_name\"=>\"Chronic Myeloid Leukemia\", \"doid\"=>\"8552\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8552\"}, \"drugs\"=>[{\"id\"=>520, \"name\"=>\"Bosutinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1994, \"name\"=>\"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.\", \"citation\"=>\"Remsing Rix et al., 2009, Leukemia\", \"pubmed_id\"=>\"19039322\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19039322\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>3}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>3809, \"name\"=>\"EID3809\", \"description\"=>\"In an in vitro study, a MCF-7 cell line expressing EGFR L858R and T790M co-mutation demonstrated resistance to erlotinib treatment, compared to MCF-7 cells expressing a known erlotinib sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing YFP signal-EGFR relocation.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1993, \"name\"=>\"Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.\", \"citation\"=>\"Harada et al., 2011, Oncogene\", \"pubmed_id\"=>\"21132006\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21132006\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>14}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>3808, \"name\"=>\"EID3808\", \"description\"=>\"In an in vitro study, a NCI-H1975 cell line expressing EGFR L858R and EGFR T790M co-mutation, EGFR T790M was associated with reduced sensitivity to erlotinib treatment compared to QG56 cells expressing EGFR wild-type. Sensitivity was determined by assessing cell viability (mean IC50 of erlotinib for cells expressing EGFR L858R and EGFR T790M co-mutations was 4.3 ï¿½M vs. 8.9 ï¿½M for EGFR wild-type expressing cells).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1992, \"name\"=>\"Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET.\", \"citation\"=>\"Abourbeh et al., 2015, EJNMMI Res\", \"pubmed_id\"=>\"25853010\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25853010\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4385014\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"EJNMMI Res\", \"full_journal_title\"=>\"EJNMMI research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>3807, \"name\"=>\"EID3807\", \"description\"=>\"In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 2 patients acquired a new EGFR-T790M mutation.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1520, \"name\"=>\"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.\", \"citation\"=>\"Pao et al., 2005, PLoS Med.\", \"pubmed_id\"=>\"15737014\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15737014\", \"open_access\"=>true, \"pmc_id\"=>\"PMC549606\", \"publication_date\"=>{\"year\"=>2005, \"month\"=>3}, \"journal\"=>\"PLoS Med.\", \"full_journal_title\"=>\"PLoS medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>3806, \"name\"=>\"EID3806\", \"description\"=>\"In a lung adenocarcinoma patient with EGFR E746_A751>A (a known erlotinib sensitizing mutation) and EGFR T790M co-mutation treated with erlotinib monotherapy, EGFR T790M was associated with disease progression. The patient was treated with erlotinib monotherapy and achieved a 10 month response rate, but subsequently developed disease progression upon emergence of the EGFR T790M mutation.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1331, \"name\"=>\"Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.\", \"citation\"=>\"Balak et al., 2006, Clin. Cancer Res.\", \"pubmed_id\"=>\"17085664\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17085664\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>11, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>3801, \"name\"=>\"EID3801\", \"description\"=>\"In an in vitro study, a Ba/F3 cell line expressing EGFR S752_I759del demonstrated increased sensitivity to erlotinib treatment (IC50=33nM), comparable to Ba/F3 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors; IC50=16nM). Sensitivity was determined by assessing IL-3 independent cell survival.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1991, \"name\"=>\"Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.\", \"citation\"=>\"de Gunst et al., 2007, Mol. Cancer\", \"pubmed_id\"=>\"17877814\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17877814\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2064929\", \"publication_date\"=>{\"year\"=>2007, \"month\"=>9, \"day\"=>18}, \"journal\"=>\"Mol. Cancer\", \"full_journal_title\"=>\"Molecular cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>2163, \"name\"=>\"EID2163\", \"description\"=>\"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib. In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts. However, no complete responses were observed with afatinib alone.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1525, \"name\"=>\"BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.\", \"citation\"=>\"Li et al., 2008, Oncogene\", \"pubmed_id\"=>\"18408761\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18408761\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2748240\", \"publication_date\"=>{\"year\"=>2008, \"month\"=>8, \"day\"=>7}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>2166, \"name\"=>\"EID2166\", \"description\"=>\"In a prospective study (NCT01802632) of 253 locally advanced or metastatic, non-small cell lung cancer patients, patients with EGFR T790M mutations treated with osimertinib were associated with improved progression free survival (9.6mo, 95% CI:8.3-not reached vs. 2.8mo, 95% CI: 2.4-4.3), improved objective response rate (61% (78/127), 95% CI: 52-70 vs. 21% (37/61), 95% CI:12-34) and improved disease control rate (95% (121/127), 95% CI:90-98 vs. 61%, (37/61), 95% CI: 47-73), as compared to patients that did not harbor EGFR T790M mutations.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>466, \"name\"=>\"Mereletinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"rejected\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>667, \"name\"=>\"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.\", \"citation\"=>\"JÃ¤nne et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"25923549\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25923549\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>4, \"day\"=>30}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>2162, \"name\"=>\"EID2162\", \"description\"=>\"The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 Î¼mol/L).\\nIn an in vitro study Ba/F3 cells transfected with either EGFR-L858R or EGFR-L858R/T790M were used to assay cell growth. Ba/F3 cells require IL-3 in order to proliferate, but cells transfected with an activated oncogene are IL-3 independent. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to neratinib (IC50: 0.185umol/L vs. >10umol/L) compared to the same cells treated with erlotinib.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>52, \"name\"=>\"Neratinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1526, \"name\"=>\"Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.\", \"citation\"=>\"Shimamura et al., 2006, Cancer Res.\", \"pubmed_id\"=>\"16818618\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16818618\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>2161, \"name\"=>\"EID2161\", \"description\"=>\"In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. PF00299804 inhibited the growth of Ba/F3 cell lines containing the EFGR T790M resistance mutation as well as H1975 and H3255 cell lines that contain both EGFR L858R and T790M mutations and H820 containing an EGFR exon 19 deletion (Del 747_L751, Ins S) and a T790M mutation. All three cell lines were resistant to gefitinib in vitro, but sensitive to PF00299804 (IC50 <1 Î¼mol/L for all three cell lines).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>464, \"name\"=>\"PF 00299804\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1515, \"name\"=>\"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.\", \"citation\"=>\"Engelman et al., 2007, Cancer Res.\", \"pubmed_id\"=>\"18089823\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18089823\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2007, \"month\"=>12, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>2160, \"name\"=>\"EID2160\", \"description\"=>\"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated a reduced response to lapatinib (IC50: >4000nM vs. 534nM) compared to wildtype EGFR cells. Similarly, NIH-3T3 ectopically expression EGFR-L858R/T790M showed reduced sensistivity to lapatinib compared to EGFR wt or L585R mutant cells. These results were further confirmed in a Ba/F3 cell line model\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1525, \"name\"=>\"BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.\", \"citation\"=>\"Li et al., 2008, Oncogene\", \"pubmed_id\"=>\"18408761\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18408761\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2748240\", \"publication_date\"=>{\"year\"=>2008, \"month\"=>8, \"day\"=>7}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>2159, \"name\"=>\"EID2159\", \"description\"=>\"In a study of 14 patients with progressive non-small cell lung cancer during gefitinib,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 7 patients acquired a new EGFR-T790M mutation.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1524, \"name\"=>\"Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.\", \"citation\"=>\"Kosaka et al., 2006, Clin. Cancer Res.\", \"pubmed_id\"=>\"17020982\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17020982\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>10, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>2158, \"name\"=>\"EID2158\", \"description\"=>\"In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 2 patients acquired a new EGFR-T790M mutation.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1520, \"name\"=>\"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.\", \"citation\"=>\"Pao et al., 2005, PLoS Med.\", \"pubmed_id\"=>\"15737014\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15737014\", \"open_access\"=>true, \"pmc_id\"=>\"PMC549606\", \"publication_date\"=>{\"year\"=>2005, \"month\"=>3}, \"journal\"=>\"PLoS Med.\", \"full_journal_title\"=>\"PLoS medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>1667, \"name\"=>\"EID1667\", \"description\"=>\"48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (NGS failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 79%, or 31 out of the 39 patients,  had the T790M EGFR mutation present, indicating its importance in the development of resistance.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}, {\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}, {\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1128, \"name\"=>\"Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma.\", \"citation\"=>\"Belchis et al., 2016, Oncotarget\", \"pubmed_id\"=>\"27304188\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27304188\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5216719\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>7, \"day\"=>19}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>1867, \"name\"=>\"EID1867\", \"description\"=>\"Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy. Patients were randomized, in a 2:1 ratio, to oral osimertinib or chemotherapy (pemetrexed plus either carboplatin or cisplatin every 3 weeks for up to six cycles, maintenance pemetrexed was allowed). Primary end point was PFS, which was significantly longer with osimertinib than with chemotherapy (10.1 months vs. 4.4 months; HR 0.30; 95% CI: 0.23 to 0.41; P<0.001). Objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with chemotherapy (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>187, \"name\"=>\"Osimertinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1286, \"name\"=>\"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.\", \"citation\"=>\"Mok et al., 2016, N. Engl. J. Med.\", \"pubmed_id\"=>\"27959700\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27959700\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>12, \"day\"=>6}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>1863, \"name\"=>\"EID1863\", \"description\"=>\"Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1282, \"name\"=>\"Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.\", \"citation\"=>\"Sun et al., 2013, Lung Cancer\", \"pubmed_id\"=>\"24035188\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24035188\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>11}, \"journal\"=>\"Lung Cancer\", \"full_journal_title\"=>\"Lung cancer (Amsterdam, Netherlands)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>642, \"name\"=>\"EID642\", \"description\"=>\"Lung cancers can accumulate activating mutations in oncogenes such as EGFR. The common L858R EGFR mutation has been shown previously to be sensitive to small molecular tyrosine kinase inhibitors (ie. erlotinib). In response, tumors may accumulate an additional 'gatekeeper' mutation in EGFR, T790M. Authors show that T790M retain low affinity for gefitinib and that introduction of T790M in the presence of L858R mutant increases the ATP affinity of L858R and activates wild-type EGFR, thus showing that increased ATP affinity is the primary mode of resistance in tumors with T790M, though irreversible ATP inhibitors (ie. HKI-272) are able to overcome this resistance via covalent bonding.\", \"disease\"=>{\"id\"=>23, \"name\"=>\"Lung Cancer\", \"display_name\"=>\"Lung Cancer\", \"doid\"=>\"1324\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1324\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}, {\"id\"=>90, \"name\"=>\"AEE788\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Sequential\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>405, \"name\"=>\"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.\", \"citation\"=>\"Yun et al., 2008, Proc. Natl. Acad. Sci. U.S.A.\", \"pubmed_id\"=>\"18227510\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18227510\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2538882\", \"publication_date\"=>{\"year\"=>2008, \"month\"=>2, \"day\"=>12}, \"journal\"=>\"Proc. Natl. Acad. Sci. U.S.A.\", \"full_journal_title\"=>\"Proceedings of the National Academy of Sciences of the United States of America\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>1397, \"name\"=>\"EID1397\", \"description\"=>\"Case report of a patient with stage IV lung adenocarcinoma and a 15âbase pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>187, \"name\"=>\"Osimertinib\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>946, \"name\"=>\"Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.\", \"citation\"=>\"Yu et al., 2015, JAMA Oncol\", \"pubmed_id\"=>\"26181354\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26181354\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4665629\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>10}, \"journal\"=>\"JAMA Oncol\", \"full_journal_title\"=>\"JAMA oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>1391, \"name\"=>\"EID1391\", \"description\"=>\"155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 98 patients were found to have developed EGFR T790M mutations.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}, {\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>943, \"name\"=>\"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.\", \"citation\"=>\"Yu et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23470965\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23470965\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3630270\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>1592, \"name\"=>\"EID1592\", \"description\"=>\"Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>187, \"name\"=>\"Osimertinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1053, \"name\"=>\"Osimertinib: First Global Approval.\", \"citation\"=>\"Greig, 2016, Drugs\", \"pubmed_id\"=>\"26729184\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26729184\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>2}, \"journal\"=>\"Drugs\", \"full_journal_title\"=>\"Drugs\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>762, \"name\"=>\"EID762\", \"description\"=>\"CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of mouse xenografts harboring the T790M than those with wildtype EGFR.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>91, \"name\"=>\"Rociletinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>505, \"name\"=>\"Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.\", \"citation\"=>\"Walter et al., 2013, Cancer Discov\", \"pubmed_id\"=>\"24065731\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24065731\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4048995\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>12}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>967, \"name\"=>\"EID967\", \"description\"=>\"For cell harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compared to erlotinib or afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>91, \"name\"=>\"Rociletinib\", \"pubchem_id\"=>nil}, {\"id\"=>187, \"name\"=>\"Osimertinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>669, \"name\"=>\"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.\", \"citation\"=>\"Hirano et al., 2015, Oncotarget\", \"pubmed_id\"=>\"26515464\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26515464\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4770737\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>11, \"day\"=>17}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>963, \"name\"=>\"EID963\", \"description\"=>\"Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the drug inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild-type EGFR lines. Sustained tumor regression was observed in EGFR-mutant tumor xenograft and transgenic models. Treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC was reported as proof of principle.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>187, \"name\"=>\"Osimertinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>665, \"name\"=>\"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.\", \"citation\"=>\"Cross et al., 2014, Cancer Discov\", \"pubmed_id\"=>\"24893891\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24893891\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4315625\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>9}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>966, \"name\"=>\"EID966\", \"description\"=>\"This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632). 8 were T790M-positive prior to treatment with osimertinib. 6 transitioned directly from rociletinib to osimertinib. 3 patients achieved PR and 4 achieved SD. The median PFS was 208 days (95% CI, 41-208 days). Among 6 patients who transitioned directly from rociletinib to osimertinib all derived clinical benefit from osimertinib with either prolonged SD or PR.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>187, \"name\"=>\"Osimertinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>668, \"name\"=>\"Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.\", \"citation\"=>\"Sequist et al., 2016, JAMA Oncol\", \"pubmed_id\"=>\"26720284\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26720284\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4}, \"journal\"=>\"JAMA Oncol\", \"full_journal_title\"=>\"JAMA oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>370, \"name\"=>\"EID370\", \"description\"=>\"Patients with NSCLC harboring EGFR T790M mutation have statistically worse overall survival compared to patients with L858R or other exon 19 activating mutations.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>225, \"name\"=>\"Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.\", \"citation\"=>\"Li et al., 2014, Onco Targets Ther\", \"pubmed_id\"=>\"24729716\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24729716\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3979794\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Onco Targets Ther\", \"full_journal_title\"=>\"OncoTargets and therapy\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>369, \"name\"=>\"EID369\", \"description\"=>\"In NSCLC patients with T790M and another activating mutations, their progression free survival is shorter compared to those who do not possess T790M mutation.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>224, \"name\"=>\"The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis.\", \"citation\"=>\"Ding et al., 2014, Onco Targets Ther\", \"pubmed_id\"=>\"24623981\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24623981\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3949752\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Onco Targets Ther\", \"full_journal_title\"=>\"OncoTargets and therapy\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>278, \"name\"=>\"EID278\", \"description\"=>\"In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>51, \"name\"=>\"Staurosporine\", \"pubchem_id\"=>\"\"}], \"rating\"=>1, \"evidence_level\"=>\"E\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>184, \"name\"=>\"A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.\", \"citation\"=>\"Ai et al., 2014, Amino Acids\", \"pubmed_id\"=>\"24658966\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24658966\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>7}, \"journal\"=>\"Amino Acids\", \"full_journal_title\"=>\"Amino acids\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>238, \"name\"=>\"EID238\", \"description\"=>\"The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>167, \"name\"=>\"EGFR T790M resistance mutation in non small-cell lung carcinoma.\", \"citation\"=>\"Denis et al., 2015, Clin. Chim. Acta\", \"pubmed_id\"=>\"25668228\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25668228\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Clin. Chim. Acta\", \"full_journal_title\"=>\"Clinica chimica acta; international journal of clinical chemistry\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>240, \"name\"=>\"EID240\", \"description\"=>\"In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>44, \"name\"=>\"Dacomitinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>169, \"name\"=>\"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.\", \"citation\"=>\"Sequist et al., 2011, Sci Transl Med\", \"pubmed_id\"=>\"21430269\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21430269\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3132801\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>3, \"day\"=>23}, \"journal\"=>\"Sci Transl Med\", \"full_journal_title\"=>\"Science translational medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>239, \"name\"=>\"EID239\", \"description\"=>\"In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>168, \"name\"=>\"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.\", \"citation\"=>\"Kobayashi et al., 2005, N. Engl. J. Med.\", \"pubmed_id\"=>\"15728811\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15728811\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>2, \"day\"=>24}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}, {\"id\"=>646, \"name\"=>\"EID646\", \"description\"=>\"In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>91, \"name\"=>\"Rociletinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>408, \"name\"=>\"Rociletinib in EGFR-mutated non-small-cell lung cancer.\", \"citation\"=>\"Sequist et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"25923550\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25923550\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>4, \"day\"=>30}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>34, \"phenotypes\"=>[]}]}, {\"id\"=>86, \"entrez_name\"=>\"NPM1\", \"entrez_id\"=>4869, \"name\"=>\"EXON 12 MUTATION\", \"description\"=>\"NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.\", \"gene_id\"=>35, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>99, \"name\"=>\"exon_variant\", \"display_name\"=>\"Exon Variant\", \"so_id\"=>\"SO:0001791\", \"description\"=>\"A sequence variant that changes exon sequence.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001791\"}], \"civic_actionability_score\"=>454.0, \"coordinates\"=>{\"chromosome\"=>\"5\", \"start\"=>170837531, \"stop\"=>170837569, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000517671.1\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/35/summary/variants/86/summary#variant\", \"evidence_items\"=>[{\"id\"=>149, \"name\"=>\"EID149\", \"description\"=>\"NSC348884 combined with ATRA treatment induces apoptosis in primary AML cells harboring mutant NPM1 but not in cells with wildtype NPM1 or both mutant NPM1 and FLT3-ITD.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>38, \"name\"=>\"NSC348884\", \"pubchem_id\"=>nil}, {\"id\"=>265, \"name\"=>\"All-trans Retinoic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>128, \"name\"=>\"Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.\", \"citation\"=>\"Balusu et al., 2011, Blood\", \"pubmed_id\"=>\"21719597\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21719597\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>9, \"day\"=>15}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>1369, \"name\"=>\"EID1369\", \"description\"=>\"In normal karyotype patients with AML (15-65 years old), complete remission rates and overall, event-free and relapse-free survival were not different for patients harboring NPM1 exon 12 mutations (N=50) than those wildtype for NPM1 (N=56).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>930, \"name\"=>\"Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.\", \"citation\"=>\"Boissel et al., 2005, Blood\", \"pubmed_id\"=>\"16046528\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16046528\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>11, \"day\"=>15}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>181, \"name\"=>\"EID181\", \"description\"=>\"NPM1 mutation (N=724) was associated with higher complete remission rates (92% vs 82%; P < 0.0001), lower cumulative incidence of relapse (42% vs 58%; P < 0.0001) and higher overall survival (48% vs 27%; P < .0001) than NPM1 wildtype status (N=885) in intermediate risk, young adult AML patients (median age 46 years).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>141, \"name\"=>\"Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.\", \"citation\"=>\"Linch et al., 2014, Blood\", \"pubmed_id\"=>\"24855211\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24855211\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>7, \"day\"=>10}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>174, \"name\"=>\"EID174\", \"description\"=>\"Patients with NPM1 mutations were associated with improved complete remission rates as well as overall and disease free survival when all ages and karyotype were analyzed; however, when only normal karyotype patients were analyzed, only complete remission rates were improved.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>117, \"name\"=>\"Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.\", \"citation\"=>\"Schlenk et al., 2009, Haematologica\", \"pubmed_id\"=>\"19059939\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19059939\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2625424\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>1}, \"journal\"=>\"Haematologica\", \"full_journal_title\"=>\"Haematologica\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>1102, \"name\"=>\"EID1102\", \"description\"=>\"Peripheral blood from NPM1 mutated AMLs was assessed for NPM1 mutation status at multiple time points using RT-qPCR with primers designed to amplify different mutant NPM1 transcripts. The test development cohort consisted of 194 cases and an independent validation cohort consisted of 91 cases. Persistence of NPM1-mutated transcripts in blood was present in 15% of the patients after the second chemotherapy cycle. This persistence was associated with a greater risk of relapse after 3 years of follow-up than was an absence of such transcripts (82% vs. 30%; hazard ratio, 4.80; 95% confidence interval [CI], 2.95 to 7.80; P<0.001) and a lower rate of survival (24% vs. 75%; hazard ratio for death, 4.38; 95% CI, 2.57 to 7.47; P<0.001). The presence of minimal residual disease was the only independent prognostic factor for death in multivariate analysis (hazard ratio, 4.84; 95% CI, 2.57 to 9.15; P<0.001). On sequential monitoring of minimal residual disease, relapse was reliably predicted by a rising level of NPM1-mutated transcripts.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>760, \"name\"=>\"Assessment of Minimal Residual Disease in Standard-Risk AML.\", \"citation\"=>\"Ivey et al., 2016, N. Engl. J. Med.\", \"pubmed_id\"=>\"26789727\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26789727\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>2, \"day\"=>4}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>183, \"name\"=>\"EID183\", \"description\"=>\"In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, NPM1 mutation without FLT3-ITD was significantly associated with complete remission in multivariate analysis (odds ratio, 1.48; 95% CI, 1.21 to 1.80). Multivariate analysis was performed on all patients that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study. 130 patients had NPM1 mutations without FLT3-ITD. NPM1 mutations were evaluated in 570 patients (310 mutated).  FLT3-ITD was evaluated in 531 patients (164 mutated).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>137, \"name\"=>\"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.\", \"citation\"=>\"Schlenk et al., 2008, N. Engl. J. Med.\", \"pubmed_id\"=>\"18450602\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18450602\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>5, \"day\"=>1}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>175, \"name\"=>\"EID175\", \"description\"=>\"Complete remission rates were higher (P<0.001) and both disease-free survival (N=205 vs 352, P=0.041) and overall survival (N=372 vs 956, P=0.022) were longer for AML patients with Exon 12 NPM1 mutations (irrespective of FLT3 status) than those with wildtype NPM1. Improved CR rates were also higher for those with NPM1 exon 12 mutations and normal karyotype. In multivariate analysis, NPM1 mutation alone (FLT3 wildtype) was associated with improved overall survival (but not DFS) in the entire cohort and in normal karyotype patients <60 years old.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>113, \"name\"=>\"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).\", \"citation\"=>\"Thiede et al., 2006, Blood\", \"pubmed_id\"=>\"16455956\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16455956\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>5, \"day\"=>15}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>176, \"name\"=>\"EID176\", \"description\"=>\"Complete remission rates were higher (70.5% vs 54.7%, P = 0.003) and event-free survival was longer (median, 428 vs 336 days; P = 0.012) for normal karyotype AML patients (median age 60.3 years) with Exon 12 NPM1 mutations (N=212) compared to those with wildtype NPM1 (N=189).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>114, \"name\"=>\"Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.\", \"citation\"=>\"Schnittger et al., 2005, Blood\", \"pubmed_id\"=>\"16076867\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16076867\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>12, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>179, \"name\"=>\"EID179\", \"description\"=>\"Intermediate risk patients with mutant NPM1 had improved overall survival with the presence of either IDH1 or IDH2 mutations than those wildtype for both IDH1 and IDH2.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>126, \"name\"=>\"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.\", \"citation\"=>\"Patel et al., 2012, N. Engl. J. Med.\", \"pubmed_id\"=>\"22417203\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22417203\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3545649\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>3, \"day\"=>22}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>180, \"name\"=>\"EID180\", \"description\"=>\"Normal karyotype patients with NPM1 mutation and without FLT3-ITD had improved overall and relapse-free survival, complete remission rates and remission duration compared to all other combinations of mutants.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>140, \"name\"=>\"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.\", \"citation\"=>\"BÃ¼chner et al., 2009, J. Clin. Oncol.\", \"pubmed_id\"=>\"19047294\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19047294\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>1, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>182, \"name\"=>\"EID182\", \"description\"=>\"NPM1 mutation was associated with increased overall, event-free and relapse-free survival and remission after induction therapy in the entire cohort and in the cytogenetically normal subset of patients.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>142, \"name\"=>\"TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.\", \"citation\"=>\"Gaidzik et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22430270\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22430270\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>184, \"name\"=>\"EID184\", \"description\"=>\"NPM1 mutations were associated with increased complete remission rates as well as longer overall disease free survival in normal karyotype AML patients >59 years old, particularly in those >69 years old.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>143, \"name\"=>\"Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.\", \"citation\"=>\"Becker et al., 2010, J. Clin. Oncol.\", \"pubmed_id\"=>\"20026798\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20026798\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2815994\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>185, \"name\"=>\"EID185\", \"description\"=>\"Younger (16-60), normal karyotype AML patients with Exon 12 NPM1 mutation and without FLT3-ITD have increased overall survival (N=74, P = .001), relapse-free survival (N=86, P < .001) and response to induction chemotherapy. Multivariate analysis identified NPM1 mutation in the absence of FLT3-ITD as a prognostic marker for the achievement of CR (P=0.004).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>144, \"name\"=>\"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.\", \"citation\"=>\"DÃ¶hner et al., 2005, Blood\", \"pubmed_id\"=>\"16051734\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16051734\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>12, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>196, \"name\"=>\"EID196\", \"description\"=>\"Monitoring NPM1 mutation by cDNA-based RT-PCR effectively predicted relapse in 62/93 patients by >1 log increase in NPM1 levels (N=57) or lack of reduction in NPM1 levels following first line therapy (N=15).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>146, \"name\"=>\"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.\", \"citation\"=>\"Schnittger et al., 2009, Blood\", \"pubmed_id\"=>\"19587375\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19587375\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>9, \"day\"=>10}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>199, \"name\"=>\"EID199\", \"description\"=>\"TET2 mutation reduces overall survival of normal karyotype patients with either an NPM1 mutation or NPM1 mutation without FLT3-ITD.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>147, \"name\"=>\"TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.\", \"citation\"=>\"Tian et al., 2014, Int. J. Hematol.\", \"pubmed_id\"=>\"24859829\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24859829\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>7}, \"journal\"=>\"Int. J. Hematol.\", \"full_journal_title\"=>\"International journal of hematology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>177, \"name\"=>\"EID177\", \"description\"=>\"Cytoplasmic localization of NPM in AML patients was an independent prognositic factor associated with complete remission in response to induction therapy in a multivariate analysis (p=0.019) but not in a univariate analysis (p=0.07).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>130, \"name\"=>\"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.\", \"citation\"=>\"Falini et al., 2005, N. Engl. J. Med.\", \"pubmed_id\"=>\"15659725\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15659725\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>1, \"day\"=>20}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>146, \"name\"=>\"EID146\", \"description\"=>\"ATRA treatment improved overall and relapse-free survival in older (>60) patients with mutant NPM1 and without FLT3-ITD.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>265, \"name\"=>\"All-trans Retinoic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>117, \"name\"=>\"Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.\", \"citation\"=>\"Schlenk et al., 2009, Haematologica\", \"pubmed_id\"=>\"19059939\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19059939\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2625424\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>1}, \"journal\"=>\"Haematologica\", \"full_journal_title\"=>\"Haematologica\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>148, \"name\"=>\"EID148\", \"description\"=>\"For patients with NPM1 mutation that achieved CR following induction therapy, relapse-free survival was improved following treatment with valproic acid.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>37, \"name\"=>\"Valproic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>127, \"name\"=>\"Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.\", \"citation\"=>\"Tassara et al., 2014, Blood\", \"pubmed_id\"=>\"24797300\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24797300\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>6, \"day\"=>26}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>151, \"name\"=>\"EID151\", \"description\"=>\"CD33 expression was significantly increased in patients with NPM1 mutation with or without FLT3-ITD, indicating these patients may respond to anti-CD33 therapy.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>268, \"name\"=>\"Anti-CD33\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"E\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>129, \"name\"=>\"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.\", \"citation\"=>\"Ehninger et al., 2014, Blood Cancer J\", \"pubmed_id\"=>\"24927407\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24927407\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4080210\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Blood Cancer J\", \"full_journal_title\"=>\"Blood cancer journal\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>173, \"name\"=>\"EID173\", \"description\"=>\"NPM1 mutation without FLT3-ITD was associated with reduced relapse risk and increased overall survival in young adult acute myeloid leukemia patients (median age 43).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>116, \"name\"=>\"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.\", \"citation\"=>\"Gale et al., 2008, Blood\", \"pubmed_id\"=>\"17957027\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17957027\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>150, \"name\"=>\"EID150\", \"description\"=>\"CD33 and CD123 expression was significantly increased in patients with NPM1 mutation with FLT3-ITD, indicating these patients may respond to combined anti-CD33 and anti-CD123 therapy.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>268, \"name\"=>\"Anti-CD33\", \"pubchem_id\"=>nil}, {\"id\"=>269, \"name\"=>\"Anti-CD123\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"E\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>129, \"name\"=>\"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.\", \"citation\"=>\"Ehninger et al., 2014, Blood Cancer J\", \"pubmed_id\"=>\"24927407\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24927407\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4080210\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Blood Cancer J\", \"full_journal_title\"=>\"Blood cancer journal\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>147, \"name\"=>\"EID147\", \"description\"=>\"Young patients (18-60) with NPM1 mutations had improved overall survival following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis. However, the adjusted p-value for multiple testing is 0.11.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>2, \"name\"=>\"Daunorubicin\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>126, \"name\"=>\"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.\", \"citation\"=>\"Patel et al., 2012, N. Engl. J. Med.\", \"pubmed_id\"=>\"22417203\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22417203\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3545649\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>3, \"day\"=>22}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>119, \"name\"=>\"EID119\", \"description\"=>\"NPM1 mutations were associated with M5a and M5b FAB subtypes of acute myeloid leukemia.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>113, \"name\"=>\"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).\", \"citation\"=>\"Thiede et al., 2006, Blood\", \"pubmed_id\"=>\"16455956\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16455956\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>5, \"day\"=>15}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>120, \"name\"=>\"EID120\", \"description\"=>\"NPM1 mutations were associated with normal karyotype in older (>60) patients.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>117, \"name\"=>\"Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.\", \"citation\"=>\"Schlenk et al., 2009, Haematologica\", \"pubmed_id\"=>\"19059939\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19059939\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2625424\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>1}, \"journal\"=>\"Haematologica\", \"full_journal_title\"=>\"Haematologica\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>137, \"name\"=>\"EID137\", \"description\"=>\"ATRA treatment did not effect overall survival in patients <60 years old with NPM1 mutation regardless of FLT3-ITD status.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>265, \"name\"=>\"All-trans Retinoic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>120, \"name\"=>\"The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.\", \"citation\"=>\"Burnett et al., 2010, Blood\", \"pubmed_id\"=>\"19965647\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19965647\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>2, \"day\"=>4}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>117, \"name\"=>\"EID117\", \"description\"=>\"NPM1 mutations were associated with de novo AML as well as M4 and M5 FAB subtypes.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>116, \"name\"=>\"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.\", \"citation\"=>\"Gale et al., 2008, Blood\", \"pubmed_id\"=>\"17957027\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17957027\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>118, \"name\"=>\"EID118\", \"description\"=>\"NPM1 mutations were associated with M4, M5a and M5b FAB subtypes of acute myeloid leukemia.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>114, \"name\"=>\"Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.\", \"citation\"=>\"Schnittger et al., 2005, Blood\", \"pubmed_id\"=>\"16076867\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16076867\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>12, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>111, \"name\"=>\"EID111\", \"description\"=>\"NPM1 mutations were not associated with the M2 FAB subtype of acute myeloid leukemia.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Negative\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>114, \"name\"=>\"Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.\", \"citation\"=>\"Schnittger et al., 2005, Blood\", \"pubmed_id\"=>\"16076867\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16076867\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>12, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>108, \"name\"=>\"EID108\", \"description\"=>\"NPM1 mutations were not associated with the M3 acute myeloid leukemia FAB subtype (0/55).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>113, \"name\"=>\"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).\", \"citation\"=>\"Thiede et al., 2006, Blood\", \"pubmed_id\"=>\"16455956\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16455956\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>5, \"day\"=>15}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}, {\"id\"=>116, \"name\"=>\"EID116\", \"description\"=>\"AML with mutated NPM1 is a provisional entity in the World Health Organization (WHO) classification of acute myeloid leukemia (AML). This mutation should be tested for in clinical trials and is recommended for testing in patients with cytogentically normal AML.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>19, \"name\"=>\"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.\", \"citation\"=>\"Vardiman et al., 2009, Blood\", \"pubmed_id\"=>\"19357394\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19357394\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>7, \"day\"=>30}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>86, \"phenotypes\"=>[]}]}, {\"id\"=>133, \"entrez_name\"=>\"EGFR\", \"entrez_id\"=>1956, \"name\"=>\"EXON 19 DELETION\", \"description\"=>\"Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.\", \"gene_id\"=>19, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>107, \"name\"=>\"inframe_deletion\", \"display_name\"=>\"Inframe Deletion\", \"so_id\"=>\"SO:0001822\", \"description\"=>\"An inframe non synonymous variant that deletes bases from the coding sequence.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001822\"}], \"civic_actionability_score\"=>263.0, \"coordinates\"=>{\"chromosome\"=>\"7\", \"start\"=>55242415, \"stop\"=>55242513, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000275493.2\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/19/summary/variants/133/summary#variant\", \"evidence_items\"=>[{\"id\"=>4859, \"name\"=>\"EID4859\", \"description\"=>\"Non-small cell cancer patients from two studies [The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)] with exon 19 deletion and L858R EGFR (Exon 21) mutations were pooled to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. Median progression-free survival and median survival were better following dacomitinib treatment (14.6 and 26.6 months, N=53) than erlotinib (9.6 and 23.2, P = 0.146 and P = 0.265, N=48). In exon 19 mutated patients (N=32 and 36) PFS was better for dacomitinib treated patients (HR of 0.585 [95% CI 0.335â1.024], two-sided log-rank, P = 0.058) but did not reach significance.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}, {\"id\"=>44, \"name\"=>\"Dacomitinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2158, \"name\"=>\"Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.\", \"citation\"=>\"Ramalingam et al., 2016, Ann. Oncol.\", \"pubmed_id\"=>\"26768165\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26768165\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>2519, \"name\"=>\"EID2519\", \"description\"=>\"In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1513, \"name\"=>\"First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.\", \"citation\"=>\"Han et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22370314\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22370314\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>4766, \"name\"=>\"EID4766\", \"description\"=>\"In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1990, \"name\"=>\"Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma.\", \"citation\"=>\"Kanemaru et al., 2016, Respir Investig\", \"pubmed_id\"=>\"27566387\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27566387\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>9}, \"journal\"=>\"Respir Investig\", \"full_journal_title\"=>\"Respiratory investigation\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>2996, \"name\"=>\"EID2996\", \"description\"=>\"Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1725, \"name\"=>\"Afatinib: first global approval.\", \"citation\"=>\"Dungo et al., 2013, Drugs\", \"pubmed_id\"=>\"23982599\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23982599\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>9}, \"journal\"=>\"Drugs\", \"full_journal_title\"=>\"Drugs\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>2995, \"name\"=>\"EID2995\", \"description\"=>\"On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1724, \"name\"=>\"U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.\", \"citation\"=>\"Khozin et al., 2014, Oncologist\", \"pubmed_id\"=>\"24868098\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24868098\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4077454\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>7}, \"journal\"=>\"Oncologist\", \"full_journal_title\"=>\"The oncologist\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>413, \"name\"=>\"EID413\", \"description\"=>\"NSCLC patients with exon 19 deletions in EGFR had longer overall survival than patients with an L858R mutation when treated with gefitinib or erlotinib (38 versus 17 months; P = 0.04).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}, {\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>243, \"name\"=>\"Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.\", \"citation\"=>\"Jackman et al., 2006, Clin. Cancer Res.\", \"pubmed_id\"=>\"16818686\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16818686\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>1666, \"name\"=>\"EID1666\", \"description\"=>\"90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and exon 19 deletion of EGFR was associated with longer time to treatment failure than those with wild-type EGFR (median 8.9 versus 2.1). In multivariate analysis, exon 19 deletion was a significant predictive factor for TTF (HR = 0.0320; P < .0001).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1127, \"name\"=>\"Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.\", \"citation\"=>\"Yang et al., 2008, J. Clin. Oncol.\", \"pubmed_id\"=>\"18509184\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18509184\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>6, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>981, \"name\"=>\"EID981\", \"description\"=>\"Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>679, \"name\"=>\"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.\", \"citation\"=>\"Wu et al., 2014, Lancet Oncol.\", \"pubmed_id\"=>\"24439929\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24439929\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>2}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>983, \"name\"=>\"EID983\", \"description\"=>\"In analysis of LUX-Lung 3 and LUX-Lung 6 trials (NCT00949650 and NCT01121393), of EGFR mutant NSCLC, median overall survival with afatinib treatment was seen to be significantly improved over chemotherapy (33.3 vs 21.1 and 31.4 vs 18.4 months in LUX-Lung 3 and LUX-Lung 6 respectively).  This effect was observed in the EGFR exon 19 deletion subgroup, but not in the L858R mutant subgroup.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>680, \"name\"=>\"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.\", \"citation\"=>\"Yang et al., 2015, Lancet Oncol.\", \"pubmed_id\"=>\"25589191\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25589191\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>2}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>969, \"name\"=>\"EID969\", \"description\"=>\"Cells harboring an exon 19 deletion were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>669, \"name\"=>\"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.\", \"citation\"=>\"Hirano et al., 2015, Oncotarget\", \"pubmed_id\"=>\"26515464\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26515464\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4770737\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>11, \"day\"=>17}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>884, \"name\"=>\"EID884\", \"description\"=>\"A randomized phase 3 trial involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>595, \"name\"=>\"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.\", \"citation\"=>\"Rosell et al., 2012, Lancet Oncol.\", \"pubmed_id\"=>\"22285168\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22285168\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>3}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>881, \"name\"=>\"EID881\", \"description\"=>\"Stable HEK293 cell lines expressing mutant EGFR cDNAs were created (using a pQCLIN retroviral vector) and their drug sensitivities to afatinib were examined by MTT assay. Phorphorylation of EGFR was assayed by Western blot. The 50% inhibitory concentration (IC50) of afatinib was significantly lower in cells harboring EGFR exon 19 deletion than in cells harboring EGFR L858R.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>593, \"name\"=>\"Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.\", \"citation\"=>\"Banno et al., 2015, Anticancer Res.\", \"pubmed_id\"=>\"25862853\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25862853\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>4}, \"journal\"=>\"Anticancer Res.\", \"full_journal_title\"=>\"Anticancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>880, \"name\"=>\"EID880\", \"description\"=>\"A phase III clinical trial (NCT00949650) found that median progression free survival among patients with EGFR exon 19 deletion was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = .001). 308 patients had either exon 19 or L858 mutations.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>592, \"name\"=>\"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.\", \"citation\"=>\"Sequist et al., 2013, J. Clin. Oncol.\", \"pubmed_id\"=>\"23816960\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23816960\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>9, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>882, \"name\"=>\"EID882\", \"description\"=>\"In a phase 2 study (NCT00525148), patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib, were assessed by objective response. In total, 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (exon 19 deletion or L858R) had an objective response compared to 39% of 23 patients with less common EGFR mutations.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>594, \"name\"=>\"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.\", \"citation\"=>\"Yang et al., 2012, Lancet Oncol.\", \"pubmed_id\"=>\"22452895\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22452895\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>5}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}, {\"id\"=>273, \"name\"=>\"EID273\", \"description\"=>\"Exon 19 deletion has been shown to be correlated with gefitinib response.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>180, \"name\"=>\"The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.\", \"citation\"=>\"Ji et al., 2006, Cancer Cell\", \"pubmed_id\"=>\"16730237\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16730237\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>6}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>133, \"phenotypes\"=>[]}]}]"
      ]
     },
     "execution_count": 149,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#pull in CIViC API for DNA-based variants \n",
    "url_DNA = 'https://civicdb.org/api/panels/DNA-based/qualifying_variants?minimum_score=200'\n",
    "resp_DNA = Net::HTTP.get_response(URI.parse(url_DNA))\n",
    "variants_DNA = JSON.parse(resp_DNA.body)['records']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 158,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       ":get_exons"
      ]
     },
     "execution_count": 158,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def get_exons(gene_id, chromosome)\n",
    "  server='http://grch37.rest.ensembl.org'\n",
    "  path = \"/overlap/id/#{gene_id}?feature=exon;expand=1;utr=0\"\n",
    "  print path\n",
    "  url = URI.parse(server)\n",
    "  http = Net::HTTP.new(url.host, url.port)\n",
    "  request = Net::HTTP::Get.new(path, {'Content-Type' => 'application/json'})\n",
    "\n",
    "  response = http.request(request)\n",
    "  result = JSON.parse(response.body)\n",
    "  exons = []\n",
    "  for item in result\n",
    "    stop = item[\"end\"]\n",
    "    start = item[\"start\"]\n",
    "    exons << [chromosome, start, stop]\n",
    "  end\n",
    "  \n",
    "  ###NEED TO SORT EXONS AND MERGE\n",
    "  \n",
    "  return exons\n",
    "end"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 159,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "AMPLIFICATION\n",
      "/overlap/id/ENST00000269571.5?feature=exon;expand=1;utr=0LOSS\n",
      "/overlap/id/ENST00000371953.3?feature=exon;expand=1;utr=0ITD\n",
      "MUTATION\n",
      "/overlap/id/ENST00000269305.4?feature=exon;expand=1;utr=0MUTATION\n",
      "/overlap/id/ENST00000256078.4?feature=exon;expand=1;utr=0V600E\n",
      "R882\n",
      "L858R\n",
      "T790M\n",
      "EXON 12 MUTATION\n",
      "EXON 19 DELETION\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 672, 17, 37883942, 37884614]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 337, 17, 37873573, 37873910]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 973, 17, 37883942, 37884915]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 973, 17, 37883942, 37884915]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 335, 17, 37856229, 37856564]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 390, 17, 37883942, 37884332]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 310, 17, 37856254, 37856564]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 973, 17, 37883942, 37884915]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 287, 17, 37856277, 37856564]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 355, 17, 37883942, 37884297]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 237, 17, 37856327, 37856564]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 10, 17, 37872554, 37872564]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 237, 17, 37856327, 37856564]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 865, 17, 37871993, 37872858]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 335, 17, 37873573, 37873908]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 231, 17, 37856333, 37856564]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 214, 17, 37863243, 37863457]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 888, 17, 37883942, 37884830]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 231, 17, 37856333, 37856564]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 973, 17, 37883942, 37884915]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 84, 17, 37856480, 37856564]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 402, 17, 37868181, 37868583]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 234, 17, 37859447, 37859681]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 171, 17, 37864574, 37864745]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 148, 17, 37863002, 37863150]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 67, 17, 37865571, 37865638]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 148, 17, 37863002, 37863150]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 333, 17, 37873573, 37873906]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 1130, 17, 37863657, 37864787]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 865, 17, 37871993, 37872858]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 1302, 17, 37881302, 37882604]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 208, 17, 37865497, 37865705]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 70, 17, 37866593, 37866663]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 125, 17, 37866609, 37866734]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 116, 17, 37869406, 37869522]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 6, 17, 37871539, 37871545]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 54, 17, 37872804, 37872858]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 86, 17, 37879791, 37879877]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 38, 17, 37880165, 37880203]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 506, 17, 37873227, 37873733]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 56, 17, 37880165, 37880221]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 137, 17, 37873596, 37873733]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 510, 17, 37876040, 37876550]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 51, 17, 37873682, 37873733]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 154, 17, 37881302, 37881456]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 66, 17, 37882748, 37882814]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 95, 17, 37884639, 37884734]\n",
      "[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 1998, 17, 37884749, 37886747]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 4276, 10, 89618918, 89623194]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 1435, 10, 89622870, 89624305]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 84, 10, 89653782, 89653866]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 44, 10, 89685270, 89685314]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 43, 10, 89690803, 89690846]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 238, 10, 89692770, 89693008]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 141, 10, 89711875, 89712016]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 166, 10, 89717610, 89717776]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 224, 10, 89720651, 89720875]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 6643, 10, 89725044, 89731687]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 99, 10, 89624206, 89624305]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 376, 10, 89626430, 89626806]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 80, 10, 89624225, 89624305]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 301, 10, 89653782, 89654083]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 331, 10, 89638449, 89638780]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 38, 10, 89639829, 89639867]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 127, 10, 89640057, 89640184]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 34, 10, 89685280, 89685314]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 43, 10, 89690803, 89690846]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 474, 10, 89692770, 89693244]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 522, 10, 89705259, 89705781]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 60, 10, 89711956, 89712016]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 166, 10, 89717610, 89717776]\n",
      "[\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 415, 10, 89720651, 89721066]\n",
      "[\"FLT3\", \"ITD\", \"small_variant\", \"DNA-based\", 132, 13, 28608219, 28608351]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7579839, 7579912]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7579839, 7579912]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 440, 17, 7578371, 7578811]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 59, 17, 7576525, 7576584]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1288, 17, 7571720, 7573008]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 440, 17, 7578371, 7578811]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 132, 17, 7576525, 7576657]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1288, 17, 7571720, 7573008]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 440, 17, 7578371, 7578811]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1288, 17, 7571720, 7573008]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 161, 17, 7590695, 7590856]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1288, 17, 7571720, 7573008]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 104, 17, 7590695, 7590799]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 59, 17, 7576525, 7576584]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1286, 17, 7571722, 7573008]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 104, 17, 7590695, 7590799]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 132, 17, 7576525, 7576657]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1286, 17, 7571722, 7573008]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 110, 17, 7590695, 7590805]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 98, 17, 7579839, 7579937]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1269, 17, 7571739, 7573008]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 52, 17, 7576853, 7576905]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 121, 17, 7572887, 7573008]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 110, 17, 7590695, 7590805]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 50, 17, 7590695, 7590745]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7577535, 7577608]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 66, 17, 7578371, 7578437]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 36, 17, 7577572, 7577608]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 110, 17, 7590695, 7590805]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 240, 17, 7579700, 7579940]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 445, 17, 7577844, 7578289]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7580643, 7580752]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 120, 17, 7578434, 7578554]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 110, 17, 7590695, 7590805]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 53, 17, 7578480, 7578533]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 50, 17, 7590695, 7590745]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 102, 17, 7580643, 7580745]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 7, 17, 7578547, 7578554]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1111, 17, 7588578, 7589689]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 153, 17, 7589389, 7589542]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 2778, 17, 7589619, 7592397]\n",
      "[\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 163, 17, 7590758, 7590921]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 450, 12, 25362129, 25362579]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 180, 12, 25403685, 25403865]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 121, 12, 25398208, 25398329]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 178, 12, 25380168, 25380346]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 159, 12, 25378548, 25378707]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 5122, 12, 25357723, 25362845]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 185, 12, 25403685, 25403870]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 121, 12, 25398208, 25398329]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 743, 12, 25362102, 25362845]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 52, 12, 25403685, 25403737]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 121, 12, 25398208, 25398329]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 178, 12, 25380168, 25380346]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 159, 12, 25378548, 25378707]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 123, 12, 25368371, 25368494]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 480, 12, 25362365, 25362845]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 57, 12, 25381515, 25381572]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 26, 12, 25384952, 25384978]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 25, 12, 25390815, 25390840]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 165, 12, 25403698, 25403863]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 121, 12, 25398208, 25398329]\n",
      "[\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1407, 12, 25386753, 25388160]\n",
      "[\"BRAF\", \"V600E\", \"SNV/indel\", \"DNA-based\", 0, 7, 140453136, 140453136]\n",
      "[\"DNMT3A\", \"R882\", \"SNV/indel\", \"DNA-based\", 2, 2, 25457241, 25457243]\n",
      "[\"EGFR\", \"L858R\", \"SNV/indel\", \"DNA-based\", 0, 7, 55259515, 55259515]\n",
      "[\"EGFR\", \"T790M\", \"SNV/indel\", \"DNA-based\", 0, 7, 55249071, 55249071]\n",
      "[\"NPM1\", \"EXON 12 MUTATION\", \"small_variant\", \"DNA-based\", 38, 5, 170837531, 170837569]\n",
      "[\"EGFR\", \"EXON 19 DELETION\", \"small_variant\", \"DNA-based\", 98, 7, 55242415, 55242513]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[[\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 672, 17, 37883942, 37884614], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 337, 17, 37873573, 37873910], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 973, 17, 37883942, 37884915], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 973, 17, 37883942, 37884915], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 335, 17, 37856229, 37856564], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 390, 17, 37883942, 37884332], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 310, 17, 37856254, 37856564], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 973, 17, 37883942, 37884915], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 287, 17, 37856277, 37856564], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 355, 17, 37883942, 37884297], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 237, 17, 37856327, 37856564], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 10, 17, 37872554, 37872564], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 237, 17, 37856327, 37856564], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 865, 17, 37871993, 37872858], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 335, 17, 37873573, 37873908], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 231, 17, 37856333, 37856564], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 214, 17, 37863243, 37863457], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 888, 17, 37883942, 37884830], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 231, 17, 37856333, 37856564], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 155, 17, 37881302, 37881457], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 75, 17, 37881580, 37881655], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 146, 17, 37881960, 37882106], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 97, 17, 37882815, 37882912], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 188, 17, 37883068, 37883256], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 252, 17, 37883548, 37883800], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 973, 17, 37883942, 37884915], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 84, 17, 37856480, 37856564], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 402, 17, 37868181, 37868583], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 234, 17, 37859447, 37859681], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 171, 17, 37864574, 37864745], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 148, 17, 37863002, 37863150], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 67, 17, 37865571, 37865638], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 148, 17, 37863002, 37863150], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 151, 17, 37863243, 37863394], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 213, 17, 37864574, 37864787], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 199, 17, 37871993, 37872192], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 132, 17, 37872554, 37872686], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37872768, 37872858], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 333, 17, 37873573, 37873906], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 1130, 17, 37863657, 37864787], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 134, 17, 37865571, 37865705], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 141, 17, 37866593, 37866734], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 73, 17, 37871539, 37871612], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 90, 17, 37871699, 37871789], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 865, 17, 37871993, 37872858], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 1302, 17, 37881302, 37882604], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 208, 17, 37865497, 37865705], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 68, 17, 37866066, 37866134], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 115, 17, 37866339, 37866454], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 70, 17, 37866593, 37866663], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 125, 17, 37866609, 37866734], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 119, 17, 37868181, 37868300], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 126, 17, 37868575, 37868701], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 116, 17, 37869406, 37869522], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 6, 17, 37871539, 37871545], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 54, 17, 37872804, 37872858], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 160, 17, 37873573, 37873733], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 86, 17, 37879791, 37879877], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 38, 17, 37880165, 37880203], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 506, 17, 37873227, 37873733], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 47, 17, 37876040, 37876087], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 56, 17, 37880165, 37880221], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 137, 17, 37873596, 37873733], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 510, 17, 37876040, 37876550], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 51, 17, 37873682, 37873733], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 138, 17, 37879572, 37879710], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 122, 17, 37879791, 37879913], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 98, 17, 37880165, 37880263], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 185, 17, 37880979, 37881164], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 154, 17, 37881302, 37881456], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 66, 17, 37882748, 37882814], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 95, 17, 37884639, 37884734], [\"ERBB2\", \"AMPLIFICATION\", \"exon_coding\", \"DNA-based\", 1998, 17, 37884749, 37886747], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 4276, 10, 89618918, 89623194], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 1435, 10, 89622870, 89624305], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 84, 10, 89653782, 89653866], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 44, 10, 89685270, 89685314], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 43, 10, 89690803, 89690846], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 238, 10, 89692770, 89693008], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 141, 10, 89711875, 89712016], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 166, 10, 89717610, 89717776], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 224, 10, 89720651, 89720875], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 6643, 10, 89725044, 89731687], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 99, 10, 89624206, 89624305], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 376, 10, 89626430, 89626806], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 80, 10, 89624225, 89624305], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 301, 10, 89653782, 89654083], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 331, 10, 89638449, 89638780], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 38, 10, 89639829, 89639867], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 127, 10, 89640057, 89640184], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 34, 10, 89685280, 89685314], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 43, 10, 89690803, 89690846], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 474, 10, 89692770, 89693244], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 522, 10, 89705259, 89705781], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 60, 10, 89711956, 89712016], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 166, 10, 89717610, 89717776], [\"PTEN\", \"LOSS\", \"exon_coding\", \"DNA-based\", 415, 10, 89720651, 89721066], [\"FLT3\", \"ITD\", \"small_variant\", \"DNA-based\", 132, 13, 28608219, 28608351], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7579839, 7579912], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7579839, 7579912], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 440, 17, 7578371, 7578811], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 59, 17, 7576525, 7576584], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1288, 17, 7571720, 7573008], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 440, 17, 7578371, 7578811], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 132, 17, 7576525, 7576657], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1288, 17, 7571720, 7573008], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 440, 17, 7578371, 7578811], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1288, 17, 7571720, 7573008], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 161, 17, 7590695, 7590856], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1288, 17, 7571720, 7573008], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 104, 17, 7590695, 7590799], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 59, 17, 7576525, 7576584], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1286, 17, 7571722, 7573008], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 104, 17, 7590695, 7590799], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 132, 17, 7576525, 7576657], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1286, 17, 7571722, 7573008], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 110, 17, 7590695, 7590805], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 98, 17, 7579839, 7579937], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 106, 17, 7573927, 7574033], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1269, 17, 7571739, 7573008], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 52, 17, 7576853, 7576905], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 121, 17, 7572887, 7573008], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 110, 17, 7590695, 7590805], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7577499, 7577608], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 136, 17, 7577019, 7577155], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7576853, 7576926], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 50, 17, 7590695, 7590745], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 112, 17, 7578177, 7578289], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 73, 17, 7577535, 7577608], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 66, 17, 7578371, 7578437], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 36, 17, 7577572, 7577608], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 110, 17, 7590695, 7590805], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 240, 17, 7579700, 7579940], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 183, 17, 7578371, 7578554], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 445, 17, 7577844, 7578289], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 109, 17, 7580643, 7580752], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 120, 17, 7578434, 7578554], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 110, 17, 7590695, 7590805], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 53, 17, 7578480, 7578533], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 50, 17, 7590695, 7590745], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 102, 17, 7580643, 7580745], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 101, 17, 7579839, 7579940], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 21, 17, 7579700, 7579721], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 278, 17, 7579312, 7579590], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 7, 17, 7578547, 7578554], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1111, 17, 7588578, 7589689], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 153, 17, 7589389, 7589542], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 2778, 17, 7589619, 7592397], [\"TP53\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 163, 17, 7590758, 7590921], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 450, 12, 25362129, 25362579], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 180, 12, 25403685, 25403865], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 121, 12, 25398208, 25398329], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 178, 12, 25380168, 25380346], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 159, 12, 25378548, 25378707], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 5122, 12, 25357723, 25362845], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 185, 12, 25403685, 25403870], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 121, 12, 25398208, 25398329], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 743, 12, 25362102, 25362845], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 52, 12, 25403685, 25403737], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 121, 12, 25398208, 25398329], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 178, 12, 25380168, 25380346], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 159, 12, 25378548, 25378707], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 123, 12, 25368371, 25368494], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 480, 12, 25362365, 25362845], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 57, 12, 25381515, 25381572], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 26, 12, 25384952, 25384978], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 25, 12, 25390815, 25390840], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 165, 12, 25403698, 25403863], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 121, 12, 25398208, 25398329], [\"KRAS\", \"MUTATION\", \"exon_coding\", \"DNA-based\", 1407, 12, 25386753, 25388160], [\"BRAF\", \"V600E\", \"SNV/indel\", \"DNA-based\", 0, 7, 140453136, 140453136], [\"DNMT3A\", \"R882\", \"SNV/indel\", \"DNA-based\", 2, 2, 25457241, 25457243], [\"EGFR\", \"L858R\", \"SNV/indel\", \"DNA-based\", 0, 7, 55259515, 55259515], [\"EGFR\", \"T790M\", \"SNV/indel\", \"DNA-based\", 0, 7, 55249071, 55249071], [\"NPM1\", \"EXON 12 MUTATION\", \"small_variant\", \"DNA-based\", 38, 5, 170837531, 170837569], [\"EGFR\", \"EXON 19 DELETION\", \"small_variant\", \"DNA-based\", 98, 7, 55242415, 55242513]]"
      ]
     },
     "execution_count": 159,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#set list for DNA-based capture\n",
    "capture_DNA = []\n",
    "\n",
    "## For variants listed in the DNA-based API, create bed-like files for capture design\n",
    "pipeline = 'DNA-based' #set pipeline\n",
    "blank = ' ' #set blanks\n",
    "\n",
    "#iterate through evidence items\n",
    "for item in variants_DNA\n",
    "  exons1 = []\n",
    "  exons2 = []\n",
    "  flag = false\n",
    "  \n",
    "  #Get Gene Information from JSON\n",
    "  gene = item['entrez_name']  #Call Gene name\n",
    "  variant = item['name'] #call variant\n",
    "  puts variant\n",
    "  chrom = item['coordinates']['chromosome'].to_i #call chrom\n",
    "  start = item['coordinates']['start'].to_i #call start\n",
    "  stop = item['coordinates']['stop'].to_i\n",
    "  gene_ENST = item['coordinates'][\"representative_transcript\"]\n",
    "  \n",
    "  #If there are 2 sets of coordiantes pull them\n",
    "  if item['coordinates']['chromosome2'] and item['coordinates']['start2'] and item['coordinates']['stop2'] #determine if there is a second set of coordinates\n",
    "    gene_ENST2 = item['coordinates'][\"representative_transcript2\"]\n",
    "    chrom2 = item['coordinates']['chromosome2'].to_i  # call chrom2\n",
    "    start2 = item['coordinates']['start2'].to_i  # call start2\n",
    "    stop2 = item['coordinates']['stop2'].to_i  # call stop2\n",
    "    flag = true #set flag for coordinates; true = second set of coordinates available\n",
    "  end\n",
    "\n",
    "  #If there is a coordinates flag pull both genes and get the exons\n",
    "  if flag\n",
    "    flag2 = true\n",
    "    exons1 = get_exons(gene_ENST, chrom)\n",
    "    exons2 = get_exons(gene_ENST2, chrom2)\n",
    "    probe_type = 'exon_coding'\n",
    "\n",
    "  #Evaluate for SNVs/Indels\n",
    "  elsif (start - stop).abs < 25\n",
    "    probe_type = 'SNV/indel'\n",
    "    region_length = (start - stop).abs \n",
    "\n",
    "  #Evaluate for small variants\n",
    "  elsif (start - stop).abs  < 1000\n",
    "    flag2 = true\n",
    "    probe_type = 'small_variant'\n",
    "    region_length = (start - stop).abs\n",
    "\n",
    "  #Evaluate for Exon Coding\n",
    "  elsif (start - stop).abs  > 1000\n",
    "    exons1 = get_exons(gene_ENST, chrom)\n",
    "    probe_type = 'exon_coding'\n",
    "  end\n",
    "\n",
    "  #Print to lists\n",
    "  if exons1.any? #if there is two sets of coordinates\n",
    "    for item in exons1\n",
    "      start = item[1].to_i\n",
    "      stop = item[2].to_i\n",
    "      region_length = (start - stop).abs\n",
    "      chrom = item[0]\n",
    "      capture_DNA << [gene, variant, probe_type, pipeline, region_length, chrom, start, stop] #append to list\n",
    "    end\n",
    "  if exons2.any?\n",
    "      start = item[1].to_i\n",
    "      stop = item[2].to_i\n",
    "      region_length = (start - stop).abs\n",
    "      chrom = item[0]\n",
    "      capture_DNA << [gene, variant, probe_type, pipeline, region_length, chrom, start, stop] #append to list\n",
    "    end\n",
    "  end\n",
    "\n",
    "  if exons1.empty? and exons2.empty? #if there is only one set of coordinates\n",
    "    capture_DNA << [gene, variant, probe_type, pipeline, region_length, chrom, start, stop] #append to list\n",
    "  end\n",
    "end \n",
    "\n",
    "for item in capture_DNA\n",
    "  puts item\n",
    "end"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{\"id\"=>20, \"entrez_name\"=>\"CCND1\", \"entrez_id\"=>595, \"name\"=>\"OVEREXPRESSION\", \"description\"=>\"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.\", \"gene_id\"=>8, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>183, \"name\"=>\"N/A\", \"display_name\"=>\"N/A\", \"so_id\"=>\"N/A\", \"description\"=>\"No suitable Sequence Ontology term exists.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/N/A\"}], \"civic_actionability_score\"=>106.0, \"coordinates\"=>{\"chromosome\"=>\"11\", \"start\"=>69455855, \"stop\"=>69469242, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000227507.2\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/8/summary/variants/20/summary#variant\", \"evidence_items\"=>[{\"id\"=>1536, \"name\"=>\"EID1536\", \"description\"=>\"A pharmacodynamic study (NCT00420056) of 17 mantle cell lymphoma MCL patients was performed using the CDK4/6 inhibitor palbociclib (PD0332991). Patients were verified by IHC, FISH or molecular testing for the t(11:14) rearrangement  causing Cyclin D overexpression in MCL. 1 patient demonstrated complete response, and 2 showed partial response for an 18% overall response rate. 7 patients showed stable disease. Patient population was heavily pretreated.\", \"disease\"=>{\"id\"=>38, \"name\"=>\"Mantle Cell Lymphoma\", \"display_name\"=>\"Mantle Cell Lymphoma\", \"doid\"=>\"0050746\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050746\"}, \"drugs\"=>[{\"id\"=>48, \"name\"=>\"Palbociclib (PD0332991)\", \"pubchem_id\"=>\"\"}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1023, \"name\"=>\"Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.\", \"citation\"=>\"Leonard et al., 2012, Blood\", \"pubmed_id\"=>\"22383795\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22383795\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>5, \"day\"=>17}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}, {\"id\"=>1563, \"name\"=>\"EID1563\", \"description\"=>\"In Mantle Cell Lymphoma (MCL), t(11:14)-induced overexpression of cyclin D1 was targeted by CDK4/6 inhibitor Palbociclib (PD0332991). Palbociclib caused Rb dephosphorylation in MCL cell lines and patient derived tumor cells. MCL cell lines overexpressing cyclin D1 showed growth inhibition with Palbociclib. The VAL DLBCL cell line was used as control to verify cyclin D1 overexpression but was not used as a control in Palbociclib inhibitor experiments. Instead, the investigators report that other publications report cell lines without cyclin D1 overexpression had higher IC50 values for palbociclib, suggesting overexpresssed cyclin D1 targetability in MCL.\", \"disease\"=>{\"id\"=>38, \"name\"=>\"Mantle Cell Lymphoma\", \"display_name\"=>\"Mantle Cell Lymphoma\", \"doid\"=>\"0050746\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050746\"}, \"drugs\"=>[{\"id\"=>48, \"name\"=>\"Palbociclib (PD0332991)\", \"pubchem_id\"=>\"\"}], \"rating\"=>1, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1032, \"name\"=>\"Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.\", \"citation\"=>\"Marzec et al., 2006, Blood\", \"pubmed_id\"=>\"16690963\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16690963\", \"open_access\"=>true, \"pmc_id\"=>\"PMC1895502\", \"publication_date\"=>{\"year\"=>2006, \"month\"=>9, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}, {\"id\"=>856, \"name\"=>\"EID856\", \"description\"=>\"The authors performed a tissue microarray analysis of 167 postmenopausal breast cancers that had been randomized to treatment with or without tamoxifen.  ER +ve patients with high CCND1 tumor expression did not show any difference in survival between tamoxifen and no treatment.\", \"disease\"=>{\"id\"=>28, \"name\"=>\"Estrogen-receptor Positive Breast Cancer\", \"display_name\"=>\"Estrogen-receptor Positive Breast Cancer\", \"doid\"=>\"0060075\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060075\"}, \"drugs\"=>[{\"id\"=>53, \"name\"=>\"Tamoxifen\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>573, \"name\"=>\"Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.\", \"citation\"=>\"Stendahl et al., 2004, Br. J. Cancer\", \"pubmed_id\"=>\"15138475\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15138475\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2409465\", \"publication_date\"=>{\"year\"=>2004, \"month\"=>5, \"day\"=>17}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}, {\"id\"=>358, \"name\"=>\"EID358\", \"description\"=>\"Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma.\", \"disease\"=>{\"id\"=>38, \"name\"=>\"Mantle Cell Lymphoma\", \"display_name\"=>\"Mantle Cell Lymphoma\", \"doid\"=>\"0050746\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050746\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>219, \"name\"=>\"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.\", \"citation\"=>\"Jares et al., 2007, Nat. Rev. Cancer\", \"pubmed_id\"=>\"17891190\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17891190\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2007, \"month\"=>10}, \"journal\"=>\"Nat. Rev. Cancer\", \"full_journal_title\"=>\"Nature reviews. Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}, {\"id\"=>357, \"name\"=>\"EID357\", \"description\"=>\"Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>218, \"name\"=>\"Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.\", \"citation\"=>\"Thomas et al., 2005, Int J Exp Pathol\", \"pubmed_id\"=>\"16309541\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16309541\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2517451\", \"publication_date\"=>{\"year\"=>2005, \"month\"=>12}, \"journal\"=>\"Int J Exp Pathol\", \"full_journal_title\"=>\"International journal of experimental pathology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}, {\"id\"=>356, \"name\"=>\"EID356\", \"description\"=>\"In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>157, \"name\"=>\"Cyclin D1 in breast cancer pathogenesis.\", \"citation\"=>\"Arnold et al., 2005, J. Clin. Oncol.\", \"pubmed_id\"=>\"15961768\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15961768\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>6, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}, {\"id\"=>221, \"name\"=>\"EID221\", \"description\"=>\"Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>157, \"name\"=>\"Cyclin D1 in breast cancer pathogenesis.\", \"citation\"=>\"Arnold et al., 2005, J. Clin. Oncol.\", \"pubmed_id\"=>\"15961768\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15961768\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>6, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}]}, {\"id\"=>85, \"entrez_name\"=>\"MGMT\", \"entrez_id\"=>4255, \"name\"=>\"PROMOTER METHYLATION\", \"description\"=>\"MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.\", \"gene_id\"=>34, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>183, \"name\"=>\"N/A\", \"display_name\"=>\"N/A\", \"so_id\"=>\"N/A\", \"description\"=>\"No suitable Sequence Ontology term exists.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/N/A\"}], \"civic_actionability_score\"=>136.0, \"coordinates\"=>{\"chromosome\"=>\"10\", \"start\"=>131264495, \"stop\"=>131265656, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000306010.7\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/34/summary/variants/85/summary#variant\", \"evidence_items\"=>[{\"id\"=>490, \"name\"=>\"EID490\", \"description\"=>\"In a study of 152 anaplastic oligodendroglial tumors, 121 samples had MGMT promoter methylation. Those with promoter methylation had better progression-free and overall survival.\", \"disease\"=>{\"id\"=>241, \"name\"=>\"Anaplastic Oligodendroglioma\", \"display_name\"=>\"Anaplastic Oligodendroglioma\", \"doid\"=>\"3181\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3181\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>298, \"name\"=>\"MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.\", \"citation\"=>\"van den Bent et al., 2009, J. Clin. Oncol.\", \"pubmed_id\"=>\"19901104\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19901104\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2793037\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>12, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>85, \"phenotypes\"=>[]}, {\"id\"=>491, \"name\"=>\"EID491\", \"description\"=>\"In patients with glioblastoma, those with methylated MGMT promoters have better overall survival than those with unmethylated promoters.\", \"disease\"=>{\"id\"=>19, \"name\"=>\"Glioblastoma Multiforme\", \"display_name\"=>\"Glioblastoma Multiforme\", \"doid\"=>\"3068\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3068\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>299, \"name\"=>\"MGMT gene silencing and benefit from temozolomide in glioblastoma.\", \"citation\"=>\"Hegi et al., 2005, N. Engl. J. Med.\", \"pubmed_id\"=>\"15758010\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15758010\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>3, \"day\"=>10}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>85, \"phenotypes\"=>[]}, {\"id\"=>309, \"name\"=>\"EID309\", \"description\"=>\"In patients lacking MGMT promoter methylation, the use of an MGMT inhibitor, such as O(6)-benzylguanine, in combination with alkylating agents (Carmustine) may be useful in treating patients with initial resistance to alkylating agents.\", \"disease\"=>{\"id\"=>19, \"name\"=>\"Glioblastoma Multiforme\", \"display_name\"=>\"Glioblastoma Multiforme\", \"doid\"=>\"3068\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3068\"}, \"drugs\"=>[{\"id\"=>65, \"name\"=>\"O(6)-benzylguanine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"E\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>139, \"name\"=>\"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.\", \"citation\"=>\"Esteller et al., 2000, N. Engl. J. Med.\", \"pubmed_id\"=>\"11070098\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11070098\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2000, \"month\"=>11, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>85, \"phenotypes\"=>[]}, {\"id\"=>308, \"name\"=>\"EID308\", \"description\"=>\"MGMT promoter methylation has been shown to confer sensitivity to alkylating agents, such as carmustine, in glioblastoma cells.\", \"disease\"=>{\"id\"=>19, \"name\"=>\"Glioblastoma Multiforme\", \"display_name\"=>\"Glioblastoma Multiforme\", \"doid\"=>\"3068\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3068\"}, \"drugs\"=>[{\"id\"=>64, \"name\"=>\"Carmustine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>139, \"name\"=>\"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.\", \"citation\"=>\"Esteller et al., 2000, N. Engl. J. Med.\", \"pubmed_id\"=>\"11070098\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11070098\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2000, \"month\"=>11, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>85, \"phenotypes\"=>[]}, {\"id\"=>307, \"name\"=>\"EID307\", \"description\"=>\"In a randomized clinical trial, patients with MGMT promoter methyaltion benefitted from temozolomide. This benefit was also methylation status dependent, as those without methylation did not see increased survival.\", \"disease\"=>{\"id\"=>19, \"name\"=>\"Glioblastoma Multiforme\", \"display_name\"=>\"Glioblastoma Multiforme\", \"doid\"=>\"3068\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3068\"}, \"drugs\"=>[{\"id\"=>11, \"name\"=>\"Temozolomide\", \"pubchem_id\"=>\"\"}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>194, \"name\"=>\"MGMT gene silencing and benefit from temozolomide in glioblastoma.\", \"citation\"=>\"Hegi et al., 2005, N. Engl. J. Med.\", \"pubmed_id\"=>\"15758010\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15758010\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>3, \"day\"=>10}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>85, \"phenotypes\"=>[]}, {\"id\"=>172, \"name\"=>\"EID172\", \"description\"=>\"MGMT promoter methylation was associated with increased overall and disease-free survival as well as tumor regression in patients with gliomas.\", \"disease\"=>{\"id\"=>19, \"name\"=>\"Glioblastoma Multiforme\", \"display_name\"=>\"Glioblastoma Multiforme\", \"doid\"=>\"3068\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3068\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>139, \"name\"=>\"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.\", \"citation\"=>\"Esteller et al., 2000, N. Engl. J. Med.\", \"pubmed_id\"=>\"11070098\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11070098\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2000, \"month\"=>11, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>85, \"phenotypes\"=>[]}]}, {\"id\"=>193, \"entrez_name\"=>\"EGFR\", \"entrez_id\"=>1956, \"name\"=>\"OVEREXPRESSION\", \"description\"=>\"\", \"gene_id\"=>19, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>183, \"name\"=>\"N/A\", \"display_name\"=>\"N/A\", \"so_id\"=>\"N/A\", \"description\"=>\"No suitable Sequence Ontology term exists.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/N/A\"}], \"civic_actionability_score\"=>130.0, \"coordinates\"=>{\"chromosome\"=>\"7\", \"start\"=>55086794, \"stop\"=>55279321, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000275493.2\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/19/summary/variants/193/summary#variant\", \"evidence_items\"=>[{\"id\"=>3797, \"name\"=>\"EID3797\", \"description\"=>\"A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1938, \"name\"=>\"Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.\", \"citation\"=>\"Brugger et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21969500\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21969500\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>5827, \"name\"=>\"EID5827\", \"description\"=>\"A total of 57 patients with HER1/EGFR positive non-small cell lung cancer were treated with erlotinib therapy. Two patients achieved a complete response, five had a partial response, and 22/57 patients (39%) had stable disease. Median duration of response was 19.7 weeks, median progression-free survival was 9 weeks (95% CI, 8-15 weeks), median overall survival was 8.4 months (95% CI, 4.8-13.9 months), and 1-year survival rate was 40% (95% CI, 28%-54%).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2173, \"name\"=>\"Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.\", \"citation\"=>\"PÃ©rez-Soler et al., 2004, J. Clin. Oncol.\", \"pubmed_id\"=>\"15310767\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15310767\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>8, \"day\"=>15}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"submitted\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>784, \"name\"=>\"EID784\", \"description\"=>\"55 tumor samples were analyzed for EGFR expression using IHC.\\nPFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8 Â± 0.5 vs. 11.0 Â± 2.8 months, P = 0.007; OS: 9.7 Â± 0.5 vs. 21.5 Â± 1.5 months, P = 0.03.\", \"disease\"=>{\"id\"=>149, \"name\"=>\"Esophagus Squamous Cell Carcinoma\", \"display_name\"=>\"Esophagus Squamous Cell Carcinoma\", \"doid\"=>\"3748\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3748\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>522, \"name\"=>\"The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.\", \"citation\"=>\"Jia et al., 2016, Clin Transl Oncol\", \"pubmed_id\"=>\"26459251\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26459251\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Clin Transl Oncol\", \"full_journal_title\"=>\"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>834, \"name\"=>\"EID834\", \"description\"=>\"Overexpression of EGFR in 55 samples of esophageal squamous cell carcinoma as assesesed by IHC, was related to poor OS and PFS  (PFS: 5.8 Â± 0.5 vs. 11.0 Â± 2.8 months, P = 0.007; OS: 9.7 Â± 0.5 vs. 21.5 Â± 1.5 months, P = 0.03).\", \"disease\"=>{\"id\"=>149, \"name\"=>\"Esophagus Squamous Cell Carcinoma\", \"display_name\"=>\"Esophagus Squamous Cell Carcinoma\", \"doid\"=>\"3748\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3748\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"rejected\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>522, \"name\"=>\"The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.\", \"citation\"=>\"Jia et al., 2016, Clin Transl Oncol\", \"pubmed_id\"=>\"26459251\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26459251\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Clin Transl Oncol\", \"full_journal_title\"=>\"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>783, \"name\"=>\"EID783\", \"description\"=>\"55 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to moderate groups (37 pts).\", \"disease\"=>{\"id\"=>149, \"name\"=>\"Esophagus Squamous Cell Carcinoma\", \"display_name\"=>\"Esophagus Squamous Cell Carcinoma\", \"doid\"=>\"3748\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3748\"}, \"drugs\"=>[{\"id\"=>188, \"name\"=>\"Nimotuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>522, \"name\"=>\"The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.\", \"citation\"=>\"Jia et al., 2016, Clin Transl Oncol\", \"pubmed_id\"=>\"26459251\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26459251\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Clin Transl Oncol\", \"full_journal_title\"=>\"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>954, \"name\"=>\"EID954\", \"description\"=>\"82 patients treated with gefitinib were retrospectively analyzed for EGFR mRNA expression (rt-PCR in 64 patients). Patients with high EGFR mRNA expression (>5.01) had 43% response probability, whereas patients with low EGFR mRNA expression had 8% response probability (P = 0.006). PFS but not OS was also longer in patients with high EGFR mRNA expression.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>656, \"name\"=>\"Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.\", \"citation\"=>\"Dziadziuszko et al., 2006, Clin. Cancer Res.\", \"pubmed_id\"=>\"16707605\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16707605\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>5, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>833, \"name\"=>\"EID833\", \"description\"=>\"Expression of EGFR in 55 samples of esophageal squamous cell carcinoma with IHC was not predictive of response to EGFR inhibitor nimotuzumab. EGFR overexpression was related to poor OS and PFS.\", \"disease\"=>{\"id\"=>149, \"name\"=>\"Esophagus Squamous Cell Carcinoma\", \"display_name\"=>\"Esophagus Squamous Cell Carcinoma\", \"doid\"=>\"3748\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3748\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"rejected\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>522, \"name\"=>\"The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.\", \"citation\"=>\"Jia et al., 2016, Clin Transl Oncol\", \"pubmed_id\"=>\"26459251\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26459251\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Clin Transl Oncol\", \"full_journal_title\"=>\"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>782, \"name\"=>\"EID782\", \"description\"=>\"Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>521, \"name\"=>\"Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.\", \"citation\"=>\"Rubin Grandis et al., 1998, J. Natl. Cancer Inst.\", \"pubmed_id\"=>\"9625170\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/9625170\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>1998, \"month\"=>6, \"day\"=>3}, \"journal\"=>\"J. Natl. Cancer Inst.\", \"full_journal_title\"=>\"Journal of the National Cancer Institute\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>693, \"name\"=>\"EID693\", \"description\"=>\"EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>145, \"name\"=>\"EGFR Inhibitor\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>452, \"name\"=>\"EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.\", \"citation\"=>\"Pirker et al., 2012, Lancet Oncol.\", \"pubmed_id\"=>\"22056021\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22056021\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>1}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>737, \"name\"=>\"EID737\", \"description\"=>\"In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison to MET expression were correlated with longer PFS.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>145, \"name\"=>\"EGFR Inhibitor\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>485, \"name\"=>\"Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer.\", \"citation\"=>\"Park et al., 2015, Oncotarget\", \"pubmed_id\"=>\"26439803\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26439803\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4741578\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>10, \"day\"=>13}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>692, \"name\"=>\"EID692\", \"description\"=>\"EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcinoma.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>451, \"name\"=>\"Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.\", \"citation\"=>\"Licitra et al., 2013, Eur. J. Cancer\", \"pubmed_id\"=>\"23265711\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23265711\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>4}, \"journal\"=>\"Eur. J. Cancer\", \"full_journal_title\"=>\"European journal of cancer (Oxford, England : 1990)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>474, \"name\"=>\"EID474\", \"description\"=>\"In patients with glioblastoma multiforme, those with overespression of wild-type EGFR had shorter overall survival.\", \"disease\"=>{\"id\"=>231, \"name\"=>\"Supratentorial Glioblastoma Multiforme\", \"display_name\"=>\"Supratentorial Glioblastoma Multiforme\", \"doid\"=>\"3073\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3073\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>288, \"name\"=>\"Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.\", \"citation\"=>\"Shinojima et al., 2003, Cancer Res.\", \"pubmed_id\"=>\"14583498\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/14583498\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2003, \"month\"=>10, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}]}, {\"id\"=>272, \"entrez_name\"=>\"CDKN2A\", \"entrez_id\"=>1029, \"name\"=>\"p16 EXPRESSION\", \"description\"=>\"CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.\", \"gene_id\"=>14, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>183, \"name\"=>\"N/A\", \"display_name\"=>\"N/A\", \"so_id\"=>\"N/A\", \"description\"=>\"No suitable Sequence Ontology term exists.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/N/A\"}], \"civic_actionability_score\"=>180.0, \"coordinates\"=>{\"chromosome\"=>\"9\", \"start\"=>21968055, \"stop\"=>21974865, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000498124.1\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/14/summary/variants/272/summary#variant\", \"evidence_items\"=>[{\"id\"=>4873, \"name\"=>\"EID4873\", \"description\"=>\"A preclinical study to explore the efficacy of CDK4/6 inhibition with palbociclib, in a panel of sarcoma cell lines and sarcoma tumor xenografts (PDXs). The responsiveness of these cell lines/PDX correlated with CDK4 mRNA levels but not in those showing high p16ink4a. High levels of CDKN2A predicted poorer efficacy.\", \"disease\"=>{\"id\"=>105, \"name\"=>\"Sarcoma\", \"display_name\"=>\"Sarcoma\", \"doid\"=>\"1115\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1115\"}, \"drugs\"=>[{\"id\"=>429, \"name\"=>\"Palbociclib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>nil, \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2168, \"name\"=>\"Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.\", \"citation\"=>\"Perez et al., 2015, Oncotarget\", \"pubmed_id\"=>\"26528855\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26528855\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4747352\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>12, \"day\"=>1}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>1155, \"name\"=>\"EID1155\", \"description\"=>\"Phase III trial to compare afatinib or metothrexate in recurrent or metastatic head and neck squamous cell carcinoma. 483 patients were randomized to either afatinib (n=322) or methotrexate (n=161). 285 patients were assessed for p16 Status (IHC). In the post-hoc analysis, benefit of afatinib compared with methotrexate was more pronounced in p16-negative disease (HR 0Â·69 [95% CI 0Â·50â0Â·96], p=0.022) than in p16-positive disease (HR 0Â·95 [CI 0Â·51â1Â·75], p=0.67, interaction test p=0Â·32).\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>795, \"name\"=>\"Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.\", \"citation\"=>\"Machiels et al., 2015, Lancet Oncol.\", \"pubmed_id\"=>\"25892145\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25892145\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>5}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>1314, \"name\"=>\"EID1314\", \"description\"=>\"In a cohort of 73 patients with stage I or stage II NSCLC it was discovered that the CDKN2A protein (p16-INK4A) retrospectively evaluated via IHC was associated with adverse outcomes (p=0.004).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>904, \"name\"=>\"Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer.\", \"citation\"=>\"Zhao et al., 2012, J Oncol\", \"pubmed_id\"=>\"22619677\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22619677\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3350860\", \"publication_date\"=>{\"year\"=>2012}, \"journal\"=>\"J Oncol\", \"full_journal_title\"=>\"Journal of oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>758, \"name\"=>\"EID758\", \"description\"=>\"720 patients with stage III/IV oropharyngeal cancer were retrospectively analyzed for p16 and HPV status. p16 and HPV-positivity correlated well and both showed improved overall-survival compared to patients with HPV-negative/p16 negative tumors. HPV/p16 status was shown to be a strong and independent risk factor in oropharyngeal carcinoma.\", \"disease\"=>{\"id\"=>204, \"name\"=>\"Oropharynx Cancer\", \"display_name\"=>\"Oropharynx Cancer\", \"doid\"=>\"8557\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8557\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>501, \"name\"=>\"Human papillomavirus and survival of patients with oropharyngeal cancer.\", \"citation\"=>\"Ang et al., 2010, N. Engl. J. Med.\", \"pubmed_id\"=>\"20530316\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20530316\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2943767\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>804, \"name\"=>\"EID804\", \"description\"=>\"Patients from three studies (RTOG 0129, 0234, and 0522; 85, 95 and 142 patients, respectively) were retrospectively analyzed for p16 (CDKN2A) expression (IHC) and HPV-high risk status (ISH). p16 expression in non-oropharyngeal HNSSC was also prognostic and associated with a better outcome. However, p16-positive oropharyngeal HNSSC still had better PFS and OS than p16-positive non-oropharyngeal HNSSC.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>538, \"name\"=>\"p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.\", \"citation\"=>\"Chung et al., 2014, J. Clin. Oncol.\", \"pubmed_id\"=>\"25267748\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25267748\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4251957\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>12, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>697, \"name\"=>\"EID697\", \"description\"=>\"In this study response to EGFR-inhibition by cetuximab was independent of HPV-status, represented by expression of p16 (CDKN2A, an established biomarker of HPV infection). Expression of p16 was assayed in 69 HNSCC patients by IHC.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>456, \"name\"=>\"Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.\", \"citation\"=>\"Pogorzelski et al., 2014, Cell Death Dis\", \"pubmed_id\"=>\"24577089\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24577089\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3944273\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Cell Death Dis\", \"full_journal_title\"=>\"Cell death & disease\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>695, \"name\"=>\"EID695\", \"description\"=>\"p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>454, \"name\"=>\"Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.\", \"citation\"=>\"Argiris et al., 2014, Ann. Oncol.\", \"pubmed_id\"=>\"24799460\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24799460\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4071756\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>7}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>696, \"name\"=>\"EID696\", \"description\"=>\"In this retrospective analysis of p16 status as surrogate marker for HPV in the SPECTRUM trial, p16 (CDKN2A) expression was not associated with improved response to EGFR-directed therapy (Panitumumab) in combination with chemotherapy compared to chemotherapy alone.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>455, \"name\"=>\"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.\", \"citation\"=>\"Vermorken et al., 2013, Lancet Oncol.\", \"pubmed_id\"=>\"23746666\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23746666\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>7}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>759, \"name\"=>\"EID759\", \"description\"=>\"This study shows that benefit of EGFR inhibition in addition to radiotherapy was independent of p16/HPV status. 182 patients were evaluated.\", \"disease\"=>{\"id\"=>204, \"name\"=>\"Oropharynx Cancer\", \"display_name\"=>\"Oropharynx Cancer\", \"doid\"=>\"8557\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8557\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>502, \"name\"=>\"Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.\", \"citation\"=>\"Rosenthal et al., 2016, J. Clin. Oncol.\", \"pubmed_id\"=>\"26712222\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26712222\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>694, \"name\"=>\"EID694\", \"description\"=>\"In this retrospective analysis of the SPECTRUM trial, p16 (CDKN2A) expression (and HPV-infection) was not predictive of response to EGFR-targeted therapy in combination with chemotherapy (n = 416 patient tumors).\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>145, \"name\"=>\"EGFR Inhibitor\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>453, \"name\"=>\"Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.\", \"citation\"=>\"Vermorken et al., 2014, Ann. Oncol.\", \"pubmed_id\"=>\"24577117\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24577117\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3969553\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>4}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>753, \"name\"=>\"EID753\", \"description\"=>\"p16-negative patients (HPV negative) have a longer overall survival under panitumumab/chemotherapy in comparison to chemotherapy alone.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>455, \"name\"=>\"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.\", \"citation\"=>\"Vermorken et al., 2013, Lancet Oncol.\", \"pubmed_id\"=>\"23746666\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23746666\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>7}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}]}, {\"id\"=>276, \"entrez_name\"=>\"CD274\", \"entrez_id\"=>29126, \"name\"=>\"EXPRESSION\", \"description\"=>\"\", \"gene_id\"=>11335, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>183, \"name\"=>\"N/A\", \"display_name\"=>\"N/A\", \"so_id\"=>\"N/A\", \"description\"=>\"No suitable Sequence Ontology term exists.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/N/A\"}], \"civic_actionability_score\"=>315.0, \"coordinates\"=>{\"chromosome\"=>\"9\", \"start\"=>5450525, \"stop\"=>5470547, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000381577.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/11335/summary/variants/276/summary#variant\", \"evidence_items\"=>[{\"id\"=>5507, \"name\"=>\"EID5507\", \"description\"=>\"A meta analysis of 60 research studies involving 10,310 solid tumors indicated that CD274 over expression results in poor overall survival (HRâ=â1.58, Pâ<.001) and poor disease free/progression free survival (DFS/PFS) (HRâ=â1.72, Pâ=0â.001). When split into sub groups by cancer type overall survival  was poor for breast (HRâ=â1.98, Pâ=0â.014), urothelial (HRâ=â2.24, Pâ<0.001), renal (HRâ=â3.30,  Pâ<0.001), and gastric cancers (HRâ=â1.56, Pâ=0â.040). DFS/PFS was poor in patients with hepatocellular carcinoma (HRâ=â1.72,  Pâ=â0.003), melanoma (HRâ=â3.39,  Pâ<0.001), and renal carcinoma, (HRâ=â5.04,  Pâ<0.001).\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2256, \"name\"=>\"Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.\", \"citation\"=>\"Wang et al., 2017, Medicine (Baltimore)\", \"pubmed_id\"=>\"28471952\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28471952\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5419898\", \"publication_date\"=>{\"year\"=>2017, \"month\"=>5}, \"journal\"=>\"Medicine (Baltimore)\", \"full_journal_title\"=>\"Medicine\", \"status\"=>\"fully curated\", \"is_review\"=>true, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>4856, \"name\"=>\"EID4856\", \"description\"=>\"PD-L1 is not only expressed in tumor cells (TCs) but also upregulated in tumor-infiltrating immune cells (TIICs). This meta-analysis evaluated the prognostic value of PD-L1 expression in TIICs in different types of cancers. 18 studies involving 3674 patients were included. PD-L1 positivity in TIICs related to a lower risk of death (HR = 0.784, p=0.047), and TIICs indicated a better prognosis especially in breast cancer patients (HR = 0.359, p=0.002).\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2155, \"name\"=>\"Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.\", \"citation\"=>\"Zhao et al., 2017, PLoS ONE\", \"pubmed_id\"=>\"28453554\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28453554\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5409185\", \"publication_date\"=>{\"year\"=>2017}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>4844, \"name\"=>\"EID4844\", \"description\"=>\"A meta-analysis of the role of PD-L1 expression in breast cancer found nine relevant studies with a total 8583 patients. PD-L1 expression was found to be associated with several poor prognostic indicators, such as ductal cancer, high tumor grade, ER negativity, PR negativity, HER2 positivity and aggressive molecular subtypes. PD-L1 overexpression had no significant impact on metastasis-free survival (HR 0.924, 95% CI = 0.747-1.141, p = 0.462), disease-free survival (HR 1.122, 95% CI = 0.878-1.434, p = 0.357) and overall specific survival (HR 0.837, 95% CI = 0.640-1.093, p = 0.191), but significantly correlated with shortened overall survival (HR 1.573, 95% CI = 1.010-2.451, p = 0.045).\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2148, \"name\"=>\"Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.\", \"citation\"=>\"Wang et al., 2017, Breast J\", \"pubmed_id\"=>\"28079291\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28079291\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>1, \"day\"=>12}, \"journal\"=>\"Breast J\", \"full_journal_title\"=>\"The breast journal\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>4855, \"name\"=>\"EID4855\", \"description\"=>\"In this meta-analysis, 5 studies totalling 2,546 cases were combined to assess the prognostic association of PD-L1 expression in breast cancer. The combined hazard ratio (HR) for PD-L1 overexpression was 1.76 (OS). The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with positive lymph node metastasis, higher histological grades, estrogen receptor (ER)-negativity, and triple-negative breast cancer (TNBC).\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2154, \"name\"=>\"Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.\", \"citation\"=>\"Zhang et al., 2017, Oncotarget\", \"pubmed_id\"=>\"28430626\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28430626\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>5, \"day\"=>9}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>4857, \"name\"=>\"EID4857\", \"description\"=>\"In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}, {\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}, {\"id\"=>261, \"name\"=>\"Atezolizumab\", \"pubchem_id\"=>nil}, {\"id\"=>296, \"name\"=>\"Avelumab\", \"pubchem_id\"=>nil}, {\"id\"=>530, \"name\"=>\"Durvalumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2156, \"name\"=>\"PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.\", \"citation\"=>\"Aguiar et al., 2017, Immunotherapy\", \"pubmed_id\"=>\"28472902\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28472902\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>5}, \"journal\"=>\"Immunotherapy\", \"full_journal_title\"=>\"Immunotherapy\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>3000, \"name\"=>\"EID3000\", \"description\"=>\"Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamous cell carcinoma patient samples evaluated with different methods [reverse phase protein array (N=68), mRNA expression array (N=97) or immunohistochemistry (N=114), respectively], increased expression of PD-L1 was also correlated with local failure following radiotherapy as compared to the PD-L1âlow expression group (P = 0.01, 1.9 Ã 10â3, and 9 Ã 10â4, respectively).\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>360, \"name\"=>\"Radiation\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1728, \"name\"=>\"Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.\", \"citation\"=>\"Skinner et al., 2017, Clin. Cancer Res.\", \"pubmed_id\"=>\"28476872\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28476872\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>5, \"day\"=>5}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1733, \"name\"=>\"EID1733\", \"description\"=>\"This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of EGFR or translocation of ALK. Patients in the pembrolizumab group exhibited significantly better progression-free survival and overall survival compared to patients in the chemotherapy group.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1176, \"name\"=>\"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.\", \"citation\"=>\"Reck et al., 2016, N. Engl. J. Med.\", \"pubmed_id\"=>\"27718847\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27718847\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>11, \"day\"=>10}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1615, \"name\"=>\"EID1615\", \"description\"=>\"A clinical trial of 86 patients evaluated concurrent (n=53) or sequential (n=33) treatment of ipilimumab (anti-CTLA4) and nivolumab (anti-PD1). In the concurrent regimen cohort, 65% of patients showed clinical activity with no correlation between PD-L1 expression and response (6 of 13 patients were PD-L1 positive versus 9 of 22 patients were PD-L1 negative). In the sequential regimen cohort, 20% of patients had an objective response with a potential correlation between PD-L1 expression and response (4 of 8 patients were PD-L1 positive versus 1 of 13 patients were PD-L1 negative).\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}, {\"id\"=>365, \"name\"=>\"Ipilimumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1068, \"name\"=>\"Nivolumab plus ipilimumab in advanced melanoma.\", \"citation\"=>\"Wolchok et al., 2013, N. Engl. J. Med.\", \"pubmed_id\"=>\"23724867\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23724867\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>7, \"day\"=>11}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1578, \"name\"=>\"EID1578\", \"description\"=>\"Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab. Of these patients, 25 were evaluated for response rate to pembrolizumab and PD-L1 (CD274) expression.  The response rate to pembrolizumab was 56% (95%CI: 35-76%), however, there was no correlation between PD-L1 expression (cutoff >1%) on tumor cells or on infiltrating immune cells and clinical response to pembrolizumab (P=0.61).\", \"disease\"=>{\"id\"=>311, \"name\"=>\"Merkel Cell Carcinoma\", \"display_name\"=>\"Merkel Cell Carcinoma\", \"doid\"=>\"3965\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3965\"}, \"drugs\"=>[{\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1042, \"name\"=>\"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.\", \"citation\"=>\"Nghiem et al., 2016, N. Engl. J. Med.\", \"pubmed_id\"=>\"27093365\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27093365\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4927341\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>30}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1517, \"name\"=>\"EID1517\", \"description\"=>\"Trial NCT00730639 tested monoclonal antibody nivolumab against the PD-1 immune checkpoint receptor in pretreated patients with various cancer types. PD-L1 expression was tested in 42 patients by ICH from tumor FFPE biopsies. (18 melanoma, 10 NSCLC, 7 colorectal cancer, 5 renal cell cancer, 2 prostate cancer). 9 of 25 PD-L1 expressing patients showed objective response, and zero of 17 PD-L1 negative patients showed objective response (p=0.006). Biopsies were optional, and therefore not fully randomized.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1010, \"name\"=>\"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.\", \"citation\"=>\"Topalian et al., 2012, N. Engl. J. Med.\", \"pubmed_id\"=>\"22658127\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22658127\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3544539\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>28}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1274, \"name\"=>\"EID1274\", \"description\"=>\"Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE surgical tissues (66 benign thyroid nodules and 185 papillary thyroid carcinomas PTC, E1L3N antibody). Patients with increased PD-L1 protein had significantly shorter median DFS (36 months [membranous staining] and 49 months [cytoplasmic staining] vs. 186 months [negative], p < 0.001 and p < 0.01, respectively).\", \"disease\"=>{\"id\"=>156, \"name\"=>\"Papillary Thyroid Carcinoma\", \"display_name\"=>\"Papillary Thyroid Carcinoma\", \"doid\"=>\"3969\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3969\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>880, \"name\"=>\"Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.\", \"citation\"=>\"Chowdhury et al., 2016, Oncotarget\", \"pubmed_id\"=>\"27086918\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27086918\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>12}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1275, \"name\"=>\"EID1275\", \"description\"=>\"465 gastric cancer samples and 15 corresponding liver metastases underwent IHC for PD1/PD-L1 protein expression. PD-L1 positivity in tumor cells was defined by at least 2% tumor cells with membranous positivity, PD-L1 positivity in immune cells by at least 10% PD-L1 positive immune cells. Patients with PD-L1 positive tumor cells had a significant better overall (p=0.028) and tumor specific survival (p=0.018). The same applied for patients with PD-L1 positive immune cells (p<0.001 each).\", \"disease\"=>{\"id\"=>1322, \"name\"=>\"Stomach Carcinoma\", \"display_name\"=>\"Stomach Carcinoma\", \"doid\"=>\"5517\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5517\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>881, \"name\"=>\"PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.\", \"citation\"=>\"BÃ¶ger et al., 2016, Oncotarget\", \"pubmed_id\"=>\"27009855\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27009855\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>26}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1172, \"name\"=>\"EID1172\", \"description\"=>\"Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and docetaxel in previously treated, advanced or metastatic non-small cell lung cancer. Baseline PD-L1 expression (IHC) was assessed in tumour cells (as percentage of PD-L1-expressing tumour cells TC3â¥50%, TC2â¥5% and <50%, TC1â¥1% and <5%, and TC0<1%) and tumour-infiltrating immune cells (as percentage of tumour area: IC3â¥10%, IC2â¥5% and <10%, IC1â¥1% and <5%, and IC0<1%). Increasing PD-L1 Expression was associated with improved overall survival (TC3 or IC3 HR 0Â·49 [0Â·22-1Â·07; p=0Â·068], TC2/3 or IC2/3 HR 0Â·54 [0Â·33-0Â·89; p=0Â·014], TC1/2/3 or IC1/2/3 HR 0Â·59 [0Â·40-0Â·85; p=0Â·005], TC0 and IC0 HR 1Â·04 [0Â·62-1Â·75; p=0Â·871]) but not progression free survival or overall response rate.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>261, \"name\"=>\"Atezolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>809, \"name\"=>\"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.\", \"citation\"=>\"Fehrenbacher et al., 2016, Lancet\", \"pubmed_id\"=>\"26970723\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26970723\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>30}, \"journal\"=>\"Lancet\", \"full_journal_title\"=>\"Lancet (London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1167, \"name\"=>\"EID1167\", \"description\"=>\"Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1/PD-L1 monoclonal antibodies. Patients with PD-L1 positive tumors (PD-L1 tumor cell staining â¥1%), had a significantly higher ORR, compared to patients with PD-L1 negative tumors (OR: 2.44; 95% CIs: 1.61-3.68).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}, {\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}, {\"id\"=>261, \"name\"=>\"Atezolizumab\", \"pubchem_id\"=>nil}, {\"id\"=>296, \"name\"=>\"Avelumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>804, \"name\"=>\"PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.\", \"citation\"=>\"Passiglia et al., 2016, Oncotarget\", \"pubmed_id\"=>\"26918451\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26918451\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>12}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>975, \"name\"=>\"EID975\", \"description\"=>\"74 patients with stage III NSCLC treated with concurrent chemoradiotherapy were retrospectively analyzed for PD-L1 expression and CD8+ tumour-infiltrating lymphocytes (TILs) density (IHC). CD8+ TIL density was an independent predictor of progression free survival (PFS) and overall survival (OS). Only when both TIL density and PD-L1 expression were both considered, was PD-L1 expression associated with survival. The subgroup, PD-L1+/CD8 low tumors had the shortest PFS (8.6 months, p = 0.02) and shortest, but not significantly different, OS (13.9 months, p = 0.11).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>674, \"name\"=>\"Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.\", \"citation\"=>\"Tokito et al., 2016, Eur. J. Cancer\", \"pubmed_id\"=>\"26771872\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26771872\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Eur. J. Cancer\", \"full_journal_title\"=>\"European journal of cancer (Oxford, England : 1990)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>743, \"name\"=>\"EID743\", \"description\"=>\"Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}, {\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>462, \"name\"=>\"Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.\", \"citation\"=>\"Carbognin et al., 2015, PLoS ONE\", \"pubmed_id\"=>\"26086854\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26086854\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4472786\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>702, \"name\"=>\"EID702\", \"description\"=>\"In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study).\", \"disease\"=>{\"id\"=>153, \"name\"=>\"Lung Squamous Cell Carcinoma\", \"display_name\"=>\"Lung Squamous Cell Carcinoma\", \"doid\"=>\"3907\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3907\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>460, \"name\"=>\"PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.\", \"citation\"=>\"Schmidt et al., 2015, PLoS ONE\", \"pubmed_id\"=>\"26313362\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26313362\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4552388\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>701, \"name\"=>\"EID701\", \"description\"=>\"This meta-analysis did not find a significant connection between expression of PD-L1 and overall survival in patients with NSCLC.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>459, \"name\"=>\"Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.\", \"citation\"=>\"Zhong et al., 2015, Onco Targets Ther\", \"pubmed_id\"=>\"26664143\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26664143\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4671817\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"Onco Targets Ther\", \"full_journal_title\"=>\"OncoTargets and therapy\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>704, \"name\"=>\"EID704\", \"description\"=>\"Based on a meta-analysis of 20 trials (1475 patients), of which 7 studies (636 patients) included melanoma, PD-L1 expression was associated with a higher ORR rate in patients with melanoma. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}, {\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>462, \"name\"=>\"Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.\", \"citation\"=>\"Carbognin et al., 2015, PLoS ONE\", \"pubmed_id\"=>\"26086854\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26086854\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4472786\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>703, \"name\"=>\"EID703\", \"description\"=>\"High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases).\", \"disease\"=>{\"id\"=>87, \"name\"=>\"Ovarian Serous Carcinoma\", \"display_name\"=>\"Ovarian Serous Carcinoma\", \"doid\"=>\"0050933\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050933\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>461, \"name\"=>\"Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.\", \"citation\"=>\"Darb-Esfahani et al., 2016, Oncotarget\", \"pubmed_id\"=>\"26625204\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26625204\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4811475\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>1, \"day\"=>12}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>5811, \"name\"=>\"EID5811\", \"description\"=>\"PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2351, \"name\"=>\"Pembrolizumab for the treatment of non-small-cell lung cancer.\", \"citation\"=>\"Garon et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"25891174\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25891174\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>5, \"day\"=>21}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT01295827\", \"name\"=>\"Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)\", \"description\"=>\"This study will be done in 6 parts. In Part A the dose of intravenous (IV) pembrolizumab (MK-3475) will be escalated to find the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for participants with a histologically or cytologically confirmed diagnosis of any type of carcinoma or melanoma (MEL). Part B of the study will explore the safety, tolerability, and efficacy of the drug in participants with advanced or metastatic MEL and compare every 2 week to every 3 week dosing. Part C of the study will explore the safety, tolerability, and efficacy of the drug in participants with non-small cell lung carcinoma (NSCLC) that is locally advanced or metastatic. Part D of the study will explore the low and high doses of study drug identified in Parts A and B in participants with advanced or metastatic MEL. Part E (closed with Amendment 7) will explore low, medium, and high doses of study drug in combination with standard chemotherapy in participants with locally advanced or metastatic NSCLC. Part F will explore low and high doses of study drug in treatment-naive and previously-treated participants with NSCLC with programmed cell death 1 ligand (PD-L1) gene expression. In Parts D and F and some of Part B participants will be randomized to one dose level. The primary hypotheses are the following: that pembrolizumab has acceptable safety and tolerability; and that pembrolizumab shows a clinically meaningful response rate (RR) or disease-control rate (DCR) in participants with melanoma (ipilimumab-refractory or not), and a clinically meaningful RR in participants with NSCLC, especially a clinically meaningful RR in those participants with either cancer, whose tumors express PD-L1.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT01295827\"}]}, \"variant_id\"=>276, \"phenotypes\"=>[]}]}, {\"id\"=>29, \"entrez_name\"=>\"CEBPA\", \"entrez_id\"=>1050, \"name\"=>\"MUTATION\", \"description\"=>\"CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.\", \"gene_id\"=>15, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>42, \"name\"=>\"transcript_variant\", \"display_name\"=>\"Transcript Variant\", \"so_id\"=>\"SO:0001576\", \"description\"=>\"A sequence variant that changes the structure of the transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001576\"}, {\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>105.0, \"coordinates\"=>{\"chromosome\"=>\"19\", \"start\"=>33790840, \"stop\"=>33793470, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000498907.2\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/15/summary/variants/29/summary#variant\", \"evidence_items\"=>[{\"id\"=>167, \"name\"=>\"EID167\", \"description\"=>\"In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, CEBPA mutation was significantly associated with complete remission in multivariate analysis (odds ratio, 1.33; 95% confidence interval [CI], 1.01 to 1.74). Multivariate analysis was performed on all patients  that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study. Only 509 patients in the study were evaluated for CEBPA, 67 of which had a mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>137, \"name\"=>\"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.\", \"citation\"=>\"Schlenk et al., 2008, N. Engl. J. Med.\", \"pubmed_id\"=>\"18450602\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18450602\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>5, \"day\"=>1}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>29, \"phenotypes\"=>[]}, {\"id\"=>122, \"name\"=>\"EID122\", \"description\"=>\"In a randomized trial of previously untreated younger (<60) patients with acute myeloid leukemia (excluding acute promyelocytic leukemia) and high-risk myelodysplastic syndrome CEBPA mutation status had no significant impact on patient response to ATRA (N=20) compared to randomized control (N=15).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>265, \"name\"=>\"All-trans Retinoic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>118, \"name\"=>\"The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.\", \"citation\"=>\"Burnett et al., 2010, Blood\", \"pubmed_id\"=>\"19965647\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19965647\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>2, \"day\"=>4}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>29, \"phenotypes\"=>[]}, {\"id\"=>467, \"name\"=>\"EID467\", \"description\"=>\"In children with acute myeloid leukemia, those with mutations in CEBPA had better overall and event-free survival and decreased cummulative incidence of relapse.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>281, \"name\"=>\"Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.\", \"citation\"=>\"Ho et al., 2009, Blood\", \"pubmed_id\"=>\"19304957\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19304957\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2943755\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>6, \"day\"=>25}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>29, \"phenotypes\"=>[]}, {\"id\"=>468, \"name\"=>\"EID468\", \"description\"=>\"In a set of 315 pediatric patients with acute myeloid leukemia, 47 had mutations in CEBPA. Those with mutations had better overall survival than wild-type patients.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>282, \"name\"=>\"Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.\", \"citation\"=>\"Matsuo et al., 2014, Blood Cancer J\", \"pubmed_id\"=>\"25014773\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25014773\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4219441\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Blood Cancer J\", \"full_journal_title\"=>\"Blood cancer journal\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>29, \"phenotypes\"=>[]}, {\"id\"=>168, \"name\"=>\"EID168\", \"description\"=>\"Overall survival and remission duration were significantly longer (p=0.01 and p=0.05, respectively) in younger (16-60), cytogenetically normal acute myeloid leukemia patients with CEBPA mutations (21/236 patients).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>133, \"name\"=>\"CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.\", \"citation\"=>\"FrÃ¶hling et al., 2004, J. Clin. Oncol.\", \"pubmed_id\"=>\"14726504\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/14726504\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>2, \"day\"=>15}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>29, \"phenotypes\"=>[]}, {\"id\"=>166, \"name\"=>\"EID166\", \"description\"=>\"In a group of young (<60 years old) acute myeloid leukemia (exclude acute promyelocytic leukemia) and high-risk MDS patients, those with CEBPA mutations (35/423) showed marginally improved overall survival (36% vs 31%; P = .04) than those with wildtype CEBPA.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>118, \"name\"=>\"The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.\", \"citation\"=>\"Burnett et al., 2010, Blood\", \"pubmed_id\"=>\"19965647\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19965647\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>2, \"day\"=>4}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>29, \"phenotypes\"=>[]}]}, {\"id\"=>155, \"entrez_name\"=>\"RUNX1\", \"entrez_id\"=>861, \"name\"=>\"MUTATION\", \"description\"=>\"RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.\", \"gene_id\"=>43, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>42, \"name\"=>\"transcript_variant\", \"display_name\"=>\"Transcript Variant\", \"so_id\"=>\"SO:0001576\", \"description\"=>\"A sequence variant that changes the structure of the transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001576\"}, {\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>110.0, \"coordinates\"=>{\"chromosome\"=>\"21\", \"start\"=>36160098, \"stop\"=>36421641, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000300305.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/43/summary/variants/155/summary#variant\", \"evidence_items\"=>[{\"id\"=>429, \"name\"=>\"EID429\", \"description\"=>\"In 878 non-APL patients with AML, those who had mutations in RUNX1 (N=53) had higher rates of refractory disease than those without (30% versus 19%; P = 0.047).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>241, \"name\"=>\"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.\", \"citation\"=>\"Gaidzik et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21343560\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21343560\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>155, \"phenotypes\"=>[]}, {\"id\"=>509, \"name\"=>\"EID509\", \"description\"=>\"In a study of patients with cytogenically normal acute myeloid leukemia, RUNX1 mutations were more frequent in patients 60 years old or older. Patients with RUNX1 mutations had shorter disease-free (younger, P = 0.058; older, P < 0.001), event-free (both, P < 0.001), and overall survival (younger, P = 0.003; older, P < 0.001) as well as lower complete remission rates (younger, P = 0.005; older, P = 0.006).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>313, \"name\"=>\"RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.\", \"citation\"=>\"Mendler et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22753902\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22753902\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3732007\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>9, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>155, \"phenotypes\"=>[]}, {\"id\"=>430, \"name\"=>\"EID430\", \"description\"=>\"In 878 non-APL patients with AML (18-60 years), those who had mutations in RUNX1 (N=53) had shorter event-free survival (8% vs 30%, P<0.0001) and relapse-free survival (26% vs 44%, P=0.022) relative to wild-type. EFS was also shorter for the cytogenetically normal (CN) subgroup with RUNX1 mutations (N=34; 10% vs 34%; P<0.0001) compared to wild-type (N=499), but only trending for relapse-free survival (29% vs 43%; P=0.21). For multivariate analysis, RUNX1 was a significant marker of inferior EFS in the entire cohort (P=0.011) and the intermediate-risk (P=0.005) subgroup but not the CN subgroup.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>241, \"name\"=>\"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.\", \"citation\"=>\"Gaidzik et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21343560\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21343560\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>155, \"phenotypes\"=>[]}, {\"id\"=>1558, \"name\"=>\"EID1558\", \"description\"=>\"In patients with acute myeloid leukemia, those with RUNX1 mutations (n=245) had significantly worse outcomes when compared to those with RUNX1 wild-type alleles (n=2,194).  The complete remission rate for patients with RUNX1 mutations was significantly lower (48.4% vs. 68.1%; p <0.0001), the refractory disease rate was significantly higher (40.6% 23.4%; p=0.03), the 5-year event free survival rate was significantly lower (9%, 24%; p<0.0001), the 5-year relapse free survival rate was significantly lower (22%, 36%; p=0.0007), and the 5-year overall survival rate was significantly lower (22%, 37%; p=0.0001).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1029, \"name\"=>\"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.\", \"citation\"=>\"Gaidzik et al., 2016, Leukemia\", \"pubmed_id\"=>\"27137476\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27137476\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>10}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>155, \"phenotypes\"=>[]}, {\"id\"=>508, \"name\"=>\"EID508\", \"description\"=>\"In univariate analysis, mutations in RUNX1 were significantly associated with shorter overall survival compared to wildtype RUNX1 in adult (18-87 years old) T-cell acute lymphoblastic leukemia (N=9 mutated, 62 wild type patients; P=0.014) and the early subtype (N=7 mutated, 23 wild type patients; P=0.027). RUNX1 mutations were associated with other poor-risk parameters, early subtype and older age.\", \"disease\"=>{\"id\"=>43, \"name\"=>\"Acute Lymphocytic Leukemia\", \"display_name\"=>\"Acute Lymphocytic Leukemia\", \"doid\"=>\"9952\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9952\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>283, \"name\"=>\"The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.\", \"citation\"=>\"Grossmann et al., 2013, Genes Chromosomes Cancer\", \"pubmed_id\"=>\"23341344\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23341344\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>4}, \"journal\"=>\"Genes Chromosomes Cancer\", \"full_journal_title\"=>\"Genes, chromosomes & cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>155, \"phenotypes\"=>[]}, {\"id\"=>411, \"name\"=>\"EID411\", \"description\"=>\"In non-APL patients with AML (age 18-60), those who had mutations in RUNX1 had significantly shorter relapse-free survival following conventional post-remission treatment (repetitive cycles of high-dose cytarabine) than those treated with an allogeneic hematopoietic stem-cell transplantation (N=32) at first remission (4-year RFS; 0% vs 52%; P<0.0001).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>173, \"name\"=>\"Cytarabine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>241, \"name\"=>\"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.\", \"citation\"=>\"Gaidzik et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21343560\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21343560\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>155, \"phenotypes\"=>[]}]}, {\"id\"=>189, \"entrez_name\"=>\"DNMT3A\", \"entrez_id\"=>1788, \"name\"=>\"MUTATION\", \"description\"=>\"DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.\", \"gene_id\"=>18, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>42, \"name\"=>\"transcript_variant\", \"display_name\"=>\"Transcript Variant\", \"so_id\"=>\"SO:0001576\", \"description\"=>\"A sequence variant that changes the structure of the transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001576\"}], \"civic_actionability_score\"=>115.0, \"coordinates\"=>{\"chromosome\"=>\"2\", \"start\"=>25455845, \"stop\"=>25565459, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000264709.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/18/summary/variants/189/summary#variant\", \"evidence_items\"=>[{\"id\"=>2926, \"name\"=>\"EID2926\", \"description\"=>\"A subset of patients receiving PD1/PD-L1 inhibition appear to be \\\"hyper-progressors,\\\" with a greatly accelerated rate of tumor growth and clinical deterioration compared to pre-therapy. The current study investigated potential genomic markers associated with \\\"hyper-progression\\\". Consecutive stage IV cancer patients who received immunotherapies (CTLA-4, PD-1/PD-L1 inhibitors or other [investigational] agents) and had their tumor evaluated by next-generation sequencing Amongst 155 patients, TTF (time to treatment failure) <2 months was seen in 4/5 individuals harbouring DNMT3A alteration.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}, {\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}, {\"id\"=>261, \"name\"=>\"Atezolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1679, \"name\"=>\"Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.\", \"citation\"=>\"Kato et al., 2017, Clin. Cancer Res.\", \"pubmed_id\"=>\"28351930\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28351930\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>3, \"day\"=>28}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}, {\"id\"=>1587, \"name\"=>\"EID1587\", \"description\"=>\"Among 46 AML patients treated with decitabine, the response rate was 75% (6/8) among DNMT3A mutated and 34% (13/38) among DNMT3A wild-type patients (P=.008)\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>155, \"name\"=>\"Decitabine\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1049, \"name\"=>\"DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.\", \"citation\"=>\"Metzeler et al., 2012, Leukemia\", \"pubmed_id\"=>\"22124213\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22124213\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3696987\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>5}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}, {\"id\"=>1586, \"name\"=>\"EID1586\", \"description\"=>\"DNMT3A mutations associate with adverse overall survival in acute myeloid leukemia patients if they occur in the context of mutated NPM1 and  FLT3-ITD (NPM1-FLT3ITD-DNMT3A phenotype), and in the context of IDH2 codon R140 mutations.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1009, \"name\"=>\"Genomic Classification and Prognosis in Acute Myeloid Leukemia.\", \"citation\"=>\"Papaemmanuil et al., 2016, N. Engl. J. Med.\", \"pubmed_id\"=>\"27276561\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27276561\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4979995\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}, {\"id\"=>1585, \"name\"=>\"EID1585\", \"description\"=>\"In AML patients aged <60years, presence of a DNMT3A mutation associated with inferior CR rate (HR, 0.54; P=.05) and shorter OS (HR, 1.84; P<.001) in multivariate analyses. Mutated DNMT3A associated with shorter RFS (HR 1.38; P=.034) irrespective of patient age.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1048, \"name\"=>\"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.\", \"citation\"=>\"Metzeler et al., 2016, Blood\", \"pubmed_id\"=>\"27288520\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27288520\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>8, \"day\"=>4}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}, {\"id\"=>1238, \"name\"=>\"EID1238\", \"description\"=>\"12/150 patients with de novo myelodysplastic syndrome screened for DNMT3A mutations (bone marrow and paired normal skin) had heterozygous mutations with predicted translational consequences. 1 patient was identified with 2 nonsynonymous coding mutations. R882 mutations accounted for 4/13 reported mutations, P904L for 2/13 mutations and the remaining had not been previously reported at the time of this report. Overall and event-free survival were worse for DNMT3A mutant patients although transplantation status was not considered (log-rank p=0.005 and p=0.009). Transformation to AML was increased for mutant 7/12 (58%) versus wildtype 39/138 (28%) patients (p=0.007). The authors note larger cohorts will be required to confirm these results.\", \"disease\"=>{\"id\"=>34, \"name\"=>\"Myelodysplastic Syndrome\", \"display_name\"=>\"Myelodysplastic Syndrome\", \"doid\"=>\"0050908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050908\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>785, \"name\"=>\"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.\", \"citation\"=>\"Walter et al., 2011, Leukemia\", \"pubmed_id\"=>\"21415852\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21415852\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3202965\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>7}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}, {\"id\"=>469, \"name\"=>\"EID469\", \"description\"=>\"In adult patients with early (n = 30), cortical (n = 30), mature (n = 3) or unknown (n = 8) T-cell acute lymphoblastic leukemia, those with mutations in DNMT3A (n=12) had shorter overall survival than wild-type patients (n=59; p=0.011). This was also true for the subset of patients with early T-ALL DNMT3A-mutated (n = 8) compared to wild-type patients (n = 22; p=0.005).\", \"disease\"=>{\"id\"=>227, \"name\"=>\"T-cell Acute Lymphoblastic Leukemia\", \"display_name\"=>\"T-cell Acute Lymphoblastic Leukemia\", \"doid\"=>\"5603\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5603\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>283, \"name\"=>\"The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.\", \"citation\"=>\"Grossmann et al., 2013, Genes Chromosomes Cancer\", \"pubmed_id\"=>\"23341344\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23341344\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>4}, \"journal\"=>\"Genes Chromosomes Cancer\", \"full_journal_title\"=>\"Genes, chromosomes & cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}, {\"id\"=>188, \"name\"=>\"EID188\", \"description\"=>\"Young AML patients (415 patients; <60 years old) with any DNMT3A mutation (n=96) have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>54, \"name\"=>\"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.\", \"citation\"=>\"Ribeiro et al., 2012, Blood\", \"pubmed_id\"=>\"22490330\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22490330\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>14}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}]}, {\"id\"=>208, \"entrez_name\"=>\"NRAS\", \"entrez_id\"=>4893, \"name\"=>\"MUTATION\", \"description\"=>\"\", \"gene_id\"=>36, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>42, \"name\"=>\"transcript_variant\", \"display_name\"=>\"Transcript Variant\", \"so_id\"=>\"SO:0001576\", \"description\"=>\"A sequence variant that changes the structure of the transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001576\"}, {\"id\"=>160, \"name\"=>\"gain_of_function_variant\", \"display_name\"=>\"Gain Of Function Variant\", \"so_id\"=>\"SO:0002053\", \"description\"=>\"A sequence variant whereby new or enhanced function is conferred on the gene product.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002053\"}], \"civic_actionability_score\"=>198.0, \"coordinates\"=>{\"chromosome\"=>\"1\", \"start\"=>115247090, \"stop\"=>115259515, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000369535.4\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/36/summary/variants/208/summary#variant\", \"evidence_items\"=>[{\"id\"=>5344, \"name\"=>\"EID5344\", \"description\"=>\"NCCN guidelines indicate colorectal cancer patients with NRAS mutations should not be treated with EGFR inhibitors cetuximab or panitumumab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2236, \"name\"=>nil, \"citation\"=>\"Benson et al., 2017, J Natl Compr Canc Netw\", \"pubmed_id\"=>\"28275037\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28275037\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{}, \"journal\"=>nil, \"full_journal_title\"=>nil, \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1429, \"name\"=>\"EID1429\", \"description\"=>\"In six NRAS mutant melanoma cell lines, concomitant use of MEK inhibitor and PI3K/mTOR inhibitor resulted in greater decrease in cell viability than either alone, with the synergistic effect being marked in 4/6 cell lines. MEK inhibitor JTP-74057 and PI3K/mTOR inhibitor GSK2126458 together induced synergistic increase in apoptotic Annexin V+/PI+ cells in these cell lines. Tumor xenografts in nude mice were established with 5 of the 6 cell lines. Effects of single agent treatment with JTP-74057 or GSK2126458 ranged from minor inhibition to tumor stasis, while dual inhibitor treatment showed synergistic effects in each case, with marked tumor reductions in 2/5 cases and the authors report one compete response in a MaMel301 cell line xenograft mouse.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>346, \"name\"=>\"Omipalisib (GSK2126458)\", \"pubchem_id\"=>\"\"}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>968, \"name\"=>\"Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.\", \"citation\"=>\"Posch et al., 2013, Proc. Natl. Acad. Sci. U.S.A.\", \"pubmed_id\"=>\"23431193\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23431193\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3593920\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>3, \"day\"=>5}, \"journal\"=>\"Proc. Natl. Acad. Sci. U.S.A.\", \"full_journal_title\"=>\"Proceedings of the National Academy of Sciences of the United States of America\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>2937, \"name\"=>\"EID2937\", \"description\"=>\"NEMO is an ongoing, randomised, open-label phase 3 study of patients with advanced, unresectable, AJCC IIIC/IV NRAS-mutant melanoma. 402 patients that were previously untreated or progressed on or after previous immunotherapy were randomised to receive either binimetinib (269) or dacarbazine (133). The study's primary endpoint was progression free survival. Median follow-up was 1.7 months (IQR 1.4-4.1). Median progression-free survival was 2.8 months (95% CI 2.8-3.6) in the binimetinib group and 1.5 months (1.5-1.7) in the dacarbazine group, demonstrating improved progression-free survival of binimetinib compared with dacarbazine.\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>485, \"name\"=>\"Binimetinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1686, \"name\"=>\"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.\", \"citation\"=>\"Dummer et al., 2017, Lancet Oncol.\", \"pubmed_id\"=>\"28284557\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28284557\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>4}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>2931, \"name\"=>\"EID2931\", \"description\"=>\"Inhibition of CDK4 and 6, regulators of the G1/S cell cycle checkpoint, arrests the cell cycle in the G1 phase, suppresses DNA synthesis, and inhibits cancer cell growth. There is an ongoing phase 1/2 trial of binimetinib with the CDK4/6 inhibitor ribociclib (LEE011) in mutant NRAS melanoma patients (NCT01781572). Early results from the 21 evaluable patients were very promising, with 7 patients achieving a partial response (33%) and 11 patients with stable disease (52%)\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>381, \"name\"=>\"Ribociclib\", \"pubchem_id\"=>nil}, {\"id\"=>485, \"name\"=>\"Binimetinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1682, \"name\"=>\"Targeting mutant NRAS signaling pathways in melanoma.\", \"citation\"=>\"Vu et al., 2016, Pharmacol. Res.\", \"pubmed_id\"=>\"26987942\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26987942\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4867277\", \"publication_date\"=>{\"year\"=>2016}, \"journal\"=>\"Pharmacol. Res.\", \"full_journal_title\"=>\"Pharmacological research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1703, \"name\"=>\"EID1703\", \"description\"=>\"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1138, \"name\"=>\"A molecularly annotated platform of patient-derived xenografts (\\\"xenopatients\\\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.\", \"citation\"=>\"Bertotti et al., 2011, Cancer Discov\", \"pubmed_id\"=>\"22586653\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22586653\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1509, \"name\"=>\"EID1509\", \"description\"=>\"In a panel of 7 NRAS mutant melanoma cell lines, all 7 were found to be sensitive to the MEK inhibitor MEK162, whereas 3 of 5 melanoma cell lines that were wild type for BRAF and NRAS were not sensitive to MEK162. In further tests using two of the seven NRAS mutant cell lines (YUDOSO Q16K/wt and YUKIM Q16R), colony forming capacity was reduced with increased MEK162 treatment, and MEK162 induced apoptotic markers in these cells.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>355, \"name\"=>\"Binimetinib (MEK162)\", \"pubchem_id\"=>\"\"}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1008, \"name\"=>\"MEK targeting in N-RAS mutated metastatic melanoma.\", \"citation\"=>\"Thumar et al., 2014, Mol. Cancer\", \"pubmed_id\"=>\"24588908\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24588908\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3945937\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Mol. Cancer\", \"full_journal_title\"=>\"Molecular cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1227, \"name\"=>\"EID1227\", \"description\"=>\"Phase 1 trial in 97 patients with melanoma (81 cutaneous or unknown, 16 uveal). Seven patients were found to harbor an NRAS mutation and two of them experienced stable disease (one 48 weeks on treatment). Patients with concurrent BRAFV600wt/NRASwt (n=20) had a trend of higher response rates (20%) than BRAFV600wt/NRAS-mutant patients (n=11; RR=0%; p=0.27), as well as a trend of higher percentage of patients on study at Week 24 or at 1 year (40% vs. 18% [p=0.26] and 30% vs. 0% [p=0.07], respectively).\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>850, \"name\"=>\"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.\", \"citation\"=>\"Falchook et al., 2012, Lancet Oncol.\", \"pubmed_id\"=>\"22805292\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22805292\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4109286\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>8}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1225, \"name\"=>\"EID1225\", \"description\"=>\"Phase 1 trial of trametinib and docetaxel in patients with advanced melanoma lacking BRAF V600 mutations. 15 patients were enrolled (14 BRAF wt). Six patients had a partial response, including four out of eight patients with NRAS mutations.\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>848, \"name\"=>\"PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.\", \"citation\"=>\"Coupe et al., 2015, Eur. J. Cancer\", \"pubmed_id\"=>\"25542057\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25542057\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>2}, \"journal\"=>\"Eur. J. Cancer\", \"full_journal_title\"=>\"European journal of cancer (Oxford, England : 1990)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1476, \"name\"=>\"EID1476\", \"description\"=>\"Preclinical study in melanoma cell lines. Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growth inhibition, tyrosine phosphorylation inhibition, cell cycle and apoptotic (Annexin V) assays.\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>384, \"name\"=>\"Amuvatinib\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>989, \"name\"=>\"Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.\", \"citation\"=>\"Fedorenko et al., 2014, Melanoma Res.\", \"pubmed_id\"=>\"24950457\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24950457\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4384823\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>10}, \"journal\"=>\"Melanoma Res.\", \"full_journal_title\"=>\"Melanoma research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1472, \"name\"=>\"EID1472\", \"description\"=>\"Phase II study in 71 patients with NRAS or BRAF V600 mutant melanoma treated with MEK162. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed).\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>355, \"name\"=>\"Binimetinib (MEK162)\", \"pubchem_id\"=>\"\"}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>849, \"name\"=>\"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.\", \"citation\"=>\"Ascierto et al., 2013, Lancet Oncol.\", \"pubmed_id\"=>\"23414587\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23414587\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>3}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1230, \"name\"=>\"EID1230\", \"description\"=>\"Preclinical study in 16 NRAS mutant cell lines (melanoma, lung carcinoma, neuroblastoma with various Q61, G13, G12 mutations). The combination of metformin and trametinib shown synergistic effects in most tested cell lines (no antagonistic effects observed) and a melanoma xenograft model. Metformin-induced PI3K pathway suppression was identified as a potential mechanism.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>308, \"name\"=>\"Metformin\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>851, \"name\"=>\"Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.\", \"citation\"=>\"Vujic et al., 2015, Oncotarget\", \"pubmed_id\"=>\"25504439\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25504439\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4359268\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>1, \"day\"=>20}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>996, \"name\"=>\"EID996\", \"description\"=>\"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). Among 8 patients with NRAS mutated melanoma, 4 experienced SD or PR (1 Patient received study treatment for 323 days).\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>243, \"name\"=>\"RO4987655\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>688, \"name\"=>\"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.\", \"citation\"=>\"Zimmer et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24947927\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24947927\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>8, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>496, \"name\"=>\"EID496\", \"description\"=>\"In patients with multiple myeloma, the presence of a mutation in NRAS was not significantly associated with progression-free or overall survival.\", \"disease\"=>{\"id\"=>41, \"name\"=>\"Multiple Myeloma\", \"display_name\"=>\"Multiple Myeloma\", \"doid\"=>\"9538\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9538\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>297, \"name\"=>\"Clinical and biological significance of RAS mutations in multiple myeloma.\", \"citation\"=>\"Chng et al., 2008, Leukemia\", \"pubmed_id\"=>\"18528420\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18528420\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3864109\", \"publication_date\"=>{\"year\"=>2008, \"month\"=>12}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>71, \"name\"=>\"EID71\", \"description\"=>\"In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>87, \"name\"=>\"NRAS mutation status is an independent prognostic factor in metastatic melanoma.\", \"citation\"=>\"Jakob et al., 2012, Cancer\", \"pubmed_id\"=>\"22180178\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22180178\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3310961\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>8, \"day\"=>15}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>56, \"name\"=>\"EID56\", \"description\"=>\"The presence of NRAS mutation in AML patients does not impact diease prognosis (resistant disease, disease-free survival, complete remission rate, relapse rate, induction death).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>83, \"name\"=>\"RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.\", \"citation\"=>\"Bowen et al., 2005, Blood\", \"pubmed_id\"=>\"15951308\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15951308\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>9, \"day\"=>15}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>27, \"name\"=>\"EID27\", \"description\"=>\"Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>70, \"name\"=>\"The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.\", \"citation\"=>\"Therkildsen et al., 2014, Acta Oncol\", \"pubmed_id\"=>\"24666267\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24666267\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>7}, \"journal\"=>\"Acta Oncol\", \"full_journal_title\"=>\"Acta oncologica (Stockholm, Sweden)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}]}, {\"id\"=>311, \"entrez_name\"=>\"PIK3CA\", \"entrez_id\"=>5290, \"name\"=>\"MUTATION\", \"description\"=>\"PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance ( trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.\", \"gene_id\"=>37, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>42, \"name\"=>\"transcript_variant\", \"display_name\"=>\"Transcript Variant\", \"so_id\"=>\"SO:0001576\", \"description\"=>\"A sequence variant that changes the structure of the transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001576\"}, {\"id\"=>160, \"name\"=>\"gain_of_function_variant\", \"display_name\"=>\"Gain Of Function Variant\", \"so_id\"=>\"SO:0002053\", \"description\"=>\"A sequence variant whereby new or enhanced function is conferred on the gene product.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002053\"}], \"civic_actionability_score\"=>124.0, \"coordinates\"=>{\"chromosome\"=>\"3\", \"start\"=>178866311, \"stop\"=>178957881, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000263967.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/37/summary/variants/311/summary#variant\", \"evidence_items\"=>[{\"id\"=>3040, \"name\"=>\"EID3040\", \"description\"=>\"In a study of 37 patients with AKT1 (E13K) mutations, 5 patients harbored a concurrent PI3K/mTOR pathway alteration. The PFS of patients with a concurrent PI3K/mTOR pathway alteration was significantly longer than those without when treated with AZD-5363 (median PFS, not reached v 4.3 months, respectively; HR, 0.21; P = 0.045).\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1745, \"name\"=>\"AKT Inhibition in Solid Tumors With AKT1 Mutations.\", \"citation\"=>\"Hyman et al., 2017, J. Clin. Oncol.\", \"pubmed_id\"=>\"28489509\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28489509\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>5, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1705, \"name\"=>\"EID1705\", \"description\"=>\"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab and only 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1138, \"name\"=>\"A molecularly annotated platform of patient-derived xenografts (\\\"xenopatients\\\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.\", \"citation\"=>\"Bertotti et al., 2011, Cancer Discov\", \"pubmed_id\"=>\"22586653\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22586653\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1384, \"name\"=>\"EID1384\", \"description\"=>\"The HER2 overexpressing breast cancer cell line BT-474 transduced with mutant PIK3CA H1047R demonstrated essentially normal proliferation under trastuzumab, while control cells showed negligible proliferation with trastuzumab. Sequencing of 55 HER2 breast cancer samples revealed 25% PIK3CA mutation rate and Kaplan Meier curves showed decreased time to progression for mutant PIK3CA at borderline statistical significance (p=0.052). This was potentially explained by presence of PTEN loss in wild-type PIK3CA sample and combining PTEN loss with PIK3CA mutation resulted in significant differences in time to progression (p=0.007).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>938, \"name\"=>\"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.\", \"citation\"=>\"Berns et al., 2007, Cancer Cell\", \"pubmed_id\"=>\"17936563\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17936563\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2007, \"month\"=>10}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1501, \"name\"=>\"EID1501\", \"description\"=>\"In a panel of 22 gastric cancer cell lines, 4 of 6 cell lines having the highest sensitivity to AZD5363 contained a PIK3CA mutation (E542K, E453K, E545K). A patient derived gastric cancer xenograft mouse model was established with PIK3CA H1047R mutant cells, and treatment with AZD5363 induced significant tumor growth inhibition in comparison to vehicle control.\", \"disease\"=>{\"id\"=>21, \"name\"=>\"Stomach Cancer\", \"display_name\"=>\"Stomach Cancer\", \"doid\"=>\"10534\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10534\"}, \"drugs\"=>[{\"id\"=>112, \"name\"=>\"AZD5363\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1004, \"name\"=>\"The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.\", \"citation\"=>\"Li et al., 2013, J Transl Med\", \"pubmed_id\"=>\"24088382\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24088382\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3850695\", \"publication_date\"=>{\"year\"=>2013}, \"journal\"=>\"J Transl Med\", \"full_journal_title\"=>\"Journal of translational medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1503, \"name\"=>\"EID1503\", \"description\"=>\"Sensitivity to pan-Akt inhibitor AZD5363 was assessed in a panel of 182 cell lines (160 with PTEN evaluated) derived from solid and hematological tumors. PTEN loss of function due to loss or mutation (N=32) was found to be significantly correlated with AZD5363 sensitivity (p=0.0099), and correlation improved in the subpopulation free of RAS mutation. Mouse xenografts with 786-0 (PTEN-null renal cancer) cells were established. 75 mg/kg twice daily AZD5363 caused tumor growth inhibition while 150 mg/kg twice daily induced moderate tumor regression.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>112, \"name\"=>\"AZD5363\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1005, \"name\"=>\"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.\", \"citation\"=>\"Davies et al., 2012, Mol. Cancer Ther.\", \"pubmed_id\"=>\"22294718\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22294718\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1600, \"name\"=>\"EID1600\", \"description\"=>\"Three PI3K mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941), and a panel of 42 inhibitor compounds was tested on the cells for ability to resensitize the cells to PI3K inhibition. The CDK4/6 inhibitor ribociclib (LEE011) acted synergistically with PI3K inhibitor to reduce viability in all three resistant cell lines. In a panel of 12 PIK3CA mutant and 10 wild type cell lines, synergistic effects between P110alpha inhibitor BYL719 and ribociclib were significantly stronger (weighted synergy score calculation, ANOVA, p=0.012) in PIK3CA mutant cells, indicating variant specific sensitization. Mouse xenografts of 4 different PIK3CA mutant breast cancer cells resistant to PI3K inhibitor showed stronger regression under dual PI3K inhibitor and ribociclib treatment than with either treatment alone.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>381, \"name\"=>\"Ribociclib\", \"pubchem_id\"=>nil}, {\"id\"=>382, \"name\"=>\"PI3K Inhibitor\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>178, \"name\"=>\"CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.\", \"citation\"=>\"Vora et al., 2014, Cancer Cell\", \"pubmed_id\"=>\"25002028\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25002028\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4155598\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>7, \"day\"=>14}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1402, \"name\"=>\"EID1402\", \"description\"=>\"A set of 474 cell lines from the Cancer Cell Line Encyclopedia was tested for responsiveness to the PI3Kalpha specific inhibitor BYL719 (Alpelisib). In the PIK3CA wild type subroup of cell lines, 22% were assessed as responsive, while in the subgroup of cell lines with PIK3CA mutations, 64% were labeled as responders. 7 patient derived xenografts with PIK3CA mutations (H1047R, E545K, M1043I, C420R, Q546K) were transplanted into mice and treated with BYL719. 6/7 mice responded with strong tumor growth inhibition or regression, while one (H1047R) responded with weak growth inhibition.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>339, \"name\"=>\"BYL719 (Alpelisib)\", \"pubchem_id\"=>\"\"}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>950, \"name\"=>\"Characterization of the novel and specific PI3KÎ± inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.\", \"citation\"=>\"Fritsch et al., 2014, Mol. Cancer Ther.\", \"pubmed_id\"=>\"24608574\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24608574\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>5}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1360, \"name\"=>\"EID1360\", \"description\"=>\"Preclinical analysis of the predicitive value of PIK3CA mutations for mTOR/PI3K Inhibition with BEZ-235. Two cell lines with PIK3CA Mutation (H1047R) were more sensitive to BEZ-235 than two cell lines with wild-type PIK3CA (in-vitro, results from one cell line also confirmed in-vivo). Two patient-derived xenografts with PIK3CA mutations (E110K, E542K) showed sensitivity to BEZ-235.\", \"disease\"=>{\"id\"=>453, \"name\"=>\"Head And Neck Cancer\", \"display_name\"=>\"Head And Neck Cancer\", \"doid\"=>\"11934\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:11934\"}, \"drugs\"=>[{\"id\"=>343, \"name\"=>\"BEZ235 (NVP-BEZ235, Dactolisib)\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>927, \"name\"=>\"Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.\", \"citation\"=>\"Lui et al., 2013, Cancer Discov\", \"pubmed_id\"=>\"23619167\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23619167\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3710532\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>7}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1358, \"name\"=>\"EID1358\", \"description\"=>\"Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to class I PI3K inhibitor GDC-0941 (p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines).\\nIC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the sanger cell line screening but these results could not be reproduced in the cancer cell line encyclopedia screening.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>10, \"name\"=>\"17-AAG\", \"pubchem_id\"=>nil}, {\"id\"=>141, \"name\"=>\"Pictilisib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>926, \"name\"=>\"Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.\", \"citation\"=>\"Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg\", \"pubmed_id\"=>\"25855885\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25855885\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4474763\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>6}, \"journal\"=>\"JAMA Otolaryngol Head Neck Surg\", \"full_journal_title\"=>\"JAMA otolaryngology-- head & neck surgery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1296, \"name\"=>\"EID1296\", \"description\"=>\"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PI3K mutations had longer progression-free survival with everolimus compared to placebo (HR 0.67 95%CI 0.45 to 1.00, P=0.05) whereas patients with PI3K wild type status did not benefit significantly (HR 1.1, 95%CI 0.83 to 1.46, P=0.5). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combinedly analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>891, \"name\"=>\"Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.\", \"citation\"=>\"AndrÃ© et al., 2016, J. Clin. Oncol.\", \"pubmed_id\"=>\"27091708\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27091708\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1364, \"name\"=>\"EID1364\", \"description\"=>\"6 head and neck cancer cell lines were tested for Response to 17-AAG, GDC-0941. Two of the cell lines did not carry PIK3CA mutations. No clear difference was shown between PIK3CA-mutant and wild-type cell lines and there was a trend towards increased resistance. SCC25 cell line was lentivirally transduced with PIK3CA E545K or H1047R mutation. Engineered cells, compared to the parental cell line, showed decreased sensitivity to 17-AAG, GDC-0941 or trametinib.\", \"disease\"=>{\"id\"=>453, \"name\"=>\"Head And Neck Cancer\", \"display_name\"=>\"Head And Neck Cancer\", \"doid\"=>\"11934\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:11934\"}, \"drugs\"=>[{\"id\"=>10, \"name\"=>\"17-AAG\", \"pubchem_id\"=>nil}, {\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>141, \"name\"=>\"Pictilisib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>926, \"name\"=>\"Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.\", \"citation\"=>\"Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg\", \"pubmed_id\"=>\"25855885\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25855885\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4474763\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>6}, \"journal\"=>\"JAMA Otolaryngol Head Neck Surg\", \"full_journal_title\"=>\"JAMA otolaryngology-- head & neck surgery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1607, \"name\"=>\"EID1607\", \"description\"=>\"Three PIK3CA mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941) by chronic exposure. Co-treatment of all three cell lines with PI3K inhibitor and CDK4/6 inhibitor palbociclib resulted in synergistic reductions in cell viability which were not seen with treatment of either compound alone, and resulted in similar suppression to viability as seen in the respective PI3K inhibitor sensitive parental cell lines.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>48, \"name\"=>\"Palbociclib (PD0332991)\", \"pubchem_id\"=>\"\"}, {\"id\"=>382, \"name\"=>\"PI3K Inhibitor\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>178, \"name\"=>\"CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.\", \"citation\"=>\"Vora et al., 2014, Cancer Cell\", \"pubmed_id\"=>\"25002028\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25002028\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4155598\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>7, \"day\"=>14}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>771, \"name\"=>\"EID771\", \"description\"=>\"20 patient-derived colorectal cancer xenografts were treated with cabozantinib, a c-MET and VEGFR2 inhibitor. 16 xenografts showed sensitivity (as defined by TGII: tumor growth of treated compared to controlââ¤â20%). Among the genes tested for mutations (KRAS, TP53, PIK3CA, MET, VEGFR2, RET and AXL), PIK3CA mutations (4 PDTX) showed a significant enrichment in sensitive xenografts. PIK3CA mutations were observed in 4/5 of the most responsive tumors. Treating xenografts derived from isogenic PIK3CA wildtype or mutant cell lines corroborated this finding with PIK3CA mutant xenografts showing greater sensitivity to cabozantinib.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>144, \"name\"=>\"Cabozantinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>510, \"name\"=>\"Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.\", \"citation\"=>\"Song et al., 2015, Int. J. Cancer\", \"pubmed_id\"=>\"25242168\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25242168\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4323738\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Int. J. Cancer\", \"full_journal_title\"=>\"International journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1616, \"name\"=>\"EID1616\", \"description\"=>\"A panel of 24 endometrioid endometrial cancer (EEC) cell lines was characterized for a set of mutations and sensitivity to pan PI3K class I inhibitor GDC-0941 (pictilisib) was assessed. EEC cell lines with PIK3CA mutations were significantly more sensitive to GDC-0941 (Fisherâs exact test, two-tailed, P=0.038). Some of the PIK3CA mutant cells contained PTEN and KRAS mutations, but in these cells, these mutations did not effect sensitivity.\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>141, \"name\"=>\"Pictilisib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1067, \"name\"=>\"PI3K pathway dependencies in endometrioid endometrial cancer cell lines.\", \"citation\"=>\"Weigelt et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23674493\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23674493\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3700760\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1610, \"name\"=>\"EID1610\", \"description\"=>\"A panel of 31 breast cancer cell lines was tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/mTORC2 inhibitor PP242. Inhibitor concentrations for 50% survival fraction (SF50) were measured and SF50 less than one micro molar was considered sensitive. PIK3CA mutant cell lines were significantly more sensitive to both everolimus and PP242 than PIK3CA wild type cell lines. Apoptotic indicators and cell cycle analysis indicated that the mTOR inhibitors induced G1 arrest instead of apoptosis in the cell lines.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}, {\"id\"=>179, \"name\"=>\"PP242\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1066, \"name\"=>\"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.\", \"citation\"=>\"Weigelt et al., 2011, Oncogene\", \"pubmed_id\"=>\"21358673\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21358673\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>7, \"day\"=>21}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>915, \"name\"=>\"EID915\", \"description\"=>\"A meta-analysis of 8 metastatic colorectal cancer studies (839 patients) was performed. PIK3CA mutations were significantly associated with shorter PFS and OS following therapy with anti-EGFR monoclonal antibodies (PFS: 8 studies, 839 patients; HR = 1.53; 95 % confidence interval (CI) 1.28-1.84; P < 0.001; OS: 5 studies; 587 patients; HR = 1.28; 95 % CI 1.05-1.56; P = 0.015).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>252, \"name\"=>\"Anti-EGFR Monoclonal Antibody\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>622, \"name\"=>\"PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.\", \"citation\"=>\"Wu et al., 2013, J. Cancer Res. Clin. Oncol.\", \"pubmed_id\"=>\"23435830\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23435830\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>5}, \"journal\"=>\"J. Cancer Res. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of cancer research and clinical oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>892, \"name\"=>\"EID892\", \"description\"=>\"94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed.\\nNo predictive biomarkers were identified, including PIK3CA mutations (N=21/73), KRAS mutations (10/73) or PTEN loss.\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>83, \"name\"=>\"Temsirolimus\", \"pubchem_id\"=>nil}, {\"id\"=>170, \"name\"=>\"Ridaforolimus\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>602, \"name\"=>\"Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.\", \"citation\"=>\"Mackay et al., 2014, Cancer\", \"pubmed_id\"=>\"24166148\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24166148\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>15}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1490, \"name\"=>\"EID1490\", \"description\"=>\"A panel of 26 HNSCC cell lines was tested for efficacy of the p110 alpha, delta and gamma isoform inhibitor taselisib (GDC-0032). Cell lines with PIK3CA mutation or amplification were the most sensitive. Four HNSCC cell lines with activating PIK3CA alterations showed synergistic cell death response to the combination of drug with radiation treatment. This synergism was not apparent in 4 tested HNSCC cell lines with wild-type PIK3CA or PTEN mutation. Nude mouse xenografts were established with Cal-33 PIK3CA H1047R cells. Radiation and taselisib treatments alone showed some growth inhibition in comparison to control, but only the combined treatment led durable tumor regressions.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>351, \"name\"=>\"Taselisib (GDC-0032)\", \"pubchem_id\"=>nil}, {\"id\"=>360, \"name\"=>\"Radiation\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>984, \"name\"=>\"Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.\", \"citation\"=>\"Zumsteg et al., 2016, Clin. Cancer Res.\", \"pubmed_id\"=>\"26589432\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26589432\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4870591\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1504, \"name\"=>\"EID1504\", \"description\"=>\"HER2 overexpressing breast cancer cell lines with PIK3CA mutation BT474c (K111N) and HCC-1954 (H1047R) were used to establish mouse tumor xenografts. In BT474c xenografts, three dosing schedules of AZD5363 caused significant tumor inhibition (200 mg/kg twice daily > 200 mg/kg once daily > 100 mg/kg once daily). In HCC-1954 xenografts two doses of AZD5363 induced significant tumor inhibition (150 mg/kg twice daily > 75 mg/kg twice daily) while 30 mg/kg twice weekly trastuzumab was inactive.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>112, \"name\"=>\"AZD5363\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1005, \"name\"=>\"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.\", \"citation\"=>\"Davies et al., 2012, Mol. Cancer Ther.\", \"pubmed_id\"=>\"22294718\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22294718\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}]}, {\"id\"=>1, \"entrez_name\"=>\"ABL1\", \"entrez_id\"=>25, \"name\"=>\"BCR-ABL\", \"description\"=>\"The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.\", \"gene_id\"=>4, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>120, \"name\"=>\"transcript_fusion\", \"display_name\"=>\"Transcript Fusion\", \"so_id\"=>\"SO:0001886\", \"description\"=>\"A feature fusion where the deletion brings together transcript regions.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001886\"}], \"civic_actionability_score\"=>238.0, \"coordinates\"=>{\"chromosome\"=>\"22\", \"start\"=>23522397, \"stop\"=>23632600, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000305877.8\", \"chromosome2\"=>\"9\", \"start2\"=>133729451, \"stop2\"=>133763063, \"representative_transcript2\"=>\"ENST00000318560.5\", \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/4/summary/variants/1/summary#variant\", \"evidence_items\"=>[{\"id\"=>344, \"name\"=>\"EID344\", \"description\"=>\"BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens.\", \"disease\"=>{\"id\"=>4, \"name\"=>\"Chronic Myeloid Leukemia\", \"display_name\"=>\"Chronic Myeloid Leukemia\", \"doid\"=>\"8552\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8552\"}, \"drugs\"=>[{\"id\"=>5, \"name\"=>\"Imatinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>156, \"name\"=>\"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.\", \"citation\"=>\"An et al., 2010, Leuk. Res.\", \"pubmed_id\"=>\"20537386\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20537386\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Leuk. Res.\", \"full_journal_title\"=>\"Leukemia research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}, {\"id\"=>259, \"name\"=>\"EID259\", \"description\"=>\"Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>5, \"name\"=>\"Imatinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>164, \"name\"=>\"Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.\", \"citation\"=>\"Nimmanapalli et al., 2002, Oncogene\", \"pubmed_id\"=>\"12476305\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/12476305\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2002, \"month\"=>12, \"day\"=>9}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}, {\"id\"=>260, \"name\"=>\"EID260\", \"description\"=>\"The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML.\", \"disease\"=>{\"id\"=>4, \"name\"=>\"Chronic Myeloid Leukemia\", \"display_name\"=>\"Chronic Myeloid Leukemia\", \"doid\"=>\"8552\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8552\"}, \"drugs\"=>[{\"id\"=>5, \"name\"=>\"Imatinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>156, \"name\"=>\"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.\", \"citation\"=>\"An et al., 2010, Leuk. Res.\", \"pubmed_id\"=>\"20537386\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20537386\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Leuk. Res.\", \"full_journal_title\"=>\"Leukemia research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}, {\"id\"=>213, \"name\"=>\"EID213\", \"description\"=>\"Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML.\", \"disease\"=>{\"id\"=>4, \"name\"=>\"Chronic Myeloid Leukemia\", \"display_name\"=>\"Chronic Myeloid Leukemia\", \"doid\"=>\"8552\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8552\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>151, \"name\"=>\"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.\", \"citation\"=>\"Schmidt et al., 2014, Leukemia\", \"pubmed_id\"=>\"25212276\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25212276\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>12}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}, {\"id\"=>232, \"name\"=>\"EID232\", \"description\"=>\"BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>5, \"name\"=>\"Imatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>164, \"name\"=>\"Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.\", \"citation\"=>\"Nimmanapalli et al., 2002, Oncogene\", \"pubmed_id\"=>\"12476305\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/12476305\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2002, \"month\"=>12, \"day\"=>9}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}, {\"id\"=>220, \"name\"=>\"EID220\", \"description\"=>\"The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease.\", \"disease\"=>{\"id\"=>4, \"name\"=>\"Chronic Myeloid Leukemia\", \"display_name\"=>\"Chronic Myeloid Leukemia\", \"doid\"=>\"8552\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8552\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>156, \"name\"=>\"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.\", \"citation\"=>\"An et al., 2010, Leuk. Res.\", \"pubmed_id\"=>\"20537386\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20537386\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Leuk. Res.\", \"full_journal_title\"=>\"Leukemia research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}, {\"id\"=>261, \"name\"=>\"EID261\", \"description\"=>\"The use of nilotinib and dasatinib, second-generation BCR-ABL targeted therapies, has been effective in patients resistant to imatinib, leading to their FDA-approval.\", \"disease\"=>{\"id\"=>4, \"name\"=>\"Chronic Myeloid Leukemia\", \"display_name\"=>\"Chronic Myeloid Leukemia\", \"doid\"=>\"8552\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8552\"}, \"drugs\"=>[{\"id\"=>13, \"name\"=>\"Nilotinib\", \"pubchem_id\"=>nil}, {\"id\"=>20, \"name\"=>\"Dasatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>156, \"name\"=>\"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.\", \"citation\"=>\"An et al., 2010, Leuk. Res.\", \"pubmed_id\"=>\"20537386\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20537386\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Leuk. Res.\", \"full_journal_title\"=>\"Leukemia research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}]}, {\"id\"=>108, \"entrez_name\"=>\"PML\", \"entrez_id\"=>5371, \"name\"=>\"PML-RARA\", \"description\"=>\"The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.\", \"gene_id\"=>39, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>120, \"name\"=>\"transcript_fusion\", \"display_name\"=>\"Transcript Fusion\", \"so_id\"=>\"SO:0001886\", \"description\"=>\"A feature fusion where the deletion brings together transcript regions.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001886\"}], \"civic_actionability_score\"=>132.5, \"coordinates\"=>{\"chromosome\"=>\"15\", \"start\"=>74287058, \"stop\"=>74325755, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000268058.3\", \"chromosome2\"=>\"17\", \"start2\"=>38504568, \"stop2\"=>38513048, \"representative_transcript2\"=>\"ENST00000254066.5\", \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/39/summary/variants/108/summary#variant\", \"evidence_items\"=>[{\"id\"=>1519, \"name\"=>\"EID1519\", \"description\"=>\"A 39-year old woman who presented with acute myeloid leukemia revealed a complicated genetic profile using conventional metaphase cytogenetics and FISH analysis.  Whole genome sequencing elucidated a PML-RARA fusion, which can be successfully treated with ATRA. Uncovering this mutation prevented an unnecessary allogeneic transplant and the patient remained in remission 15 months post-treatment (date of publication).\", \"disease\"=>{\"id\"=>379, \"name\"=>\"Acute Promyelocytic Leukemia\", \"display_name\"=>\"Acute Promyelocytic Leukemia\", \"doid\"=>\"0060318\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060318\"}, \"drugs\"=>[{\"id\"=>265, \"name\"=>\"All-trans Retinoic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1012, \"name\"=>\"Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.\", \"citation\"=>\"Welch et al., 2011, JAMA\", \"pubmed_id\"=>\"21505136\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21505136\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3156695\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>20}, \"journal\"=>\"JAMA\", \"full_journal_title\"=>\"JAMA\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>108, \"phenotypes\"=>[]}, {\"id\"=>1091, \"name\"=>\"EID1091\", \"description\"=>\"ATRA/Arsenic combined with standard chemotherapy has been shown to induce a complete remission rate of greater than 75% of patients with acute promyelocytic leukemia harboring the PML-RARa fusion.\", \"disease\"=>{\"id\"=>379, \"name\"=>\"Acute Promyelocytic Leukemia\", \"display_name\"=>\"Acute Promyelocytic Leukemia\", \"doid\"=>\"0060318\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060318\"}, \"drugs\"=>[{\"id\"=>47, \"name\"=>\"Arsenic Trioxide\", \"pubchem_id\"=>nil}, {\"id\"=>265, \"name\"=>\"All-trans Retinoic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>750, \"name\"=>\"All trans retinoic acid in acute promyelocytic leukemia.\", \"citation\"=>\"Degos et al., 2001, Oncogene\", \"pubmed_id\"=>\"11704842\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11704842\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2001, \"month\"=>10, \"day\"=>29}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>108, \"phenotypes\"=>[]}, {\"id\"=>1090, \"name\"=>\"EID1090\", \"description\"=>\"The presence of the PML-RARa fusion protein is a diagnostic marker of Acute Promyelocytic Leukemia, or M3 AML.\", \"disease\"=>{\"id\"=>379, \"name\"=>\"Acute Promyelocytic Leukemia\", \"display_name\"=>\"Acute Promyelocytic Leukemia\", \"doid\"=>\"0060318\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060318\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>749, \"name\"=>\"The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia.\", \"citation\"=>\"Diverio et al., Haematologica\", \"pubmed_id\"=>\"7628753\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/7628753\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{}, \"journal\"=>\"Haematologica\", \"full_journal_title\"=>\"Haematologica\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>108, \"phenotypes\"=>[]}, {\"id\"=>316, \"name\"=>\"EID316\", \"description\"=>\"Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations.\", \"disease\"=>{\"id\"=>379, \"name\"=>\"Acute Promyelocytic Leukemia\", \"display_name\"=>\"Acute Promyelocytic Leukemia\", \"doid\"=>\"0060318\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060318\"}, \"drugs\"=>[{\"id\"=>265, \"name\"=>\"All-trans Retinoic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>197, \"name\"=>\"Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.\", \"citation\"=>\"Yoshida et al., 1996, Cancer Res.\", \"pubmed_id\"=>\"8674046\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/8674046\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>1996, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>108, \"phenotypes\"=>[]}]}, {\"id\"=>499, \"entrez_name\"=>\"ALK\", \"entrez_id\"=>238, \"name\"=>\"ALK FUSIONS\", \"description\"=>\"Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer. \\n\\nIn a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response. \\n\\nDue to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib â a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.   \\n\\nALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.\", \"gene_id\"=>1, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>120, \"name\"=>\"transcript_fusion\", \"display_name\"=>\"Transcript Fusion\", \"so_id\"=>\"SO:0001886\", \"description\"=>\"A feature fusion where the deletion brings together transcript regions.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001886\"}], \"civic_actionability_score\"=>440.5, \"coordinates\"=>{\"chromosome\"=>\"2\", \"start\"=>29415640, \"stop\"=>29446394, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000389048.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/1/summary/variants/499/summary#variant\", \"evidence_items\"=>[{\"id\"=>4858, \"name\"=>\"EID4858\", \"description\"=>\"In a randomized, open-label phase 3 trial 303 patients with ALK-positive, previously untreated NSCLC (including asympt. CNS disease) were randomized to reiceive either Alectinib or Crizotinib. During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression/death occurred in 41% (62/152  pt) in the alectinib group and 68% (102/151 patients) in the crizotinib group. 12-month event-free survival rate 68.4% with alectinib vs. 48.7% with crizotinib. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, compared to 68 patients (45%) in the crizotinib group. Response rates were 82.9% (Alectinib) and 75.5% (crizotinib).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}, {\"id\"=>526, \"name\"=>\"Alectinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2157, \"name\"=>\"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.\", \"citation\"=>\"Peters et al., 2017, N. Engl. J. Med.\", \"pubmed_id\"=>\"28586279\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28586279\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>6, \"day\"=>6}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>4835, \"name\"=>\"EID4835\", \"description\"=>\"In a phase II randomized trial we evaluated two regimens of Brigatinib in Crizotinib-refractory ALK-pos. NSCLC. They were randomly assigned (1:1) to oral Brigatinib 90 mg once daily (arm A) or 180 mg once daily with a 7-day lead-in at 90 mg. Of 222 patients enrolled (arm A: n = 112, arm B: n = 110), 154 (69%) had baseline brain metastases and 164 of 222 (74%) had received prior chemotherapy. investigator-assessed confirmed ORR was 45 (arm A) and 54% (B). Investigator-assessed median PFS was 9.2 months (A) and 12.9 months (B). Independent review committee-assessed intracranial ORR in patients with measurable brain metastases at baseline was 42% (11/26, A) and 67% (12/18, B). Brigatinib yielded substantial whole-body and intracranial responses as well as robust PFS; 180 mg (with lead-in) showed consistently better efficacy than 90 mg, with acceptable safety.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>318, \"name\"=>\"Brigatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2141, \"name\"=>\"Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.\", \"citation\"=>\"Kim et al., 2017, J. Clin. Oncol.\", \"pubmed_id\"=>\"28475456\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28475456\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>5, \"day\"=>5}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>2952, \"name\"=>\"EID2952\", \"description\"=>\"Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>426, \"name\"=>\"Entrectinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1689, \"name\"=>\"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).\", \"citation\"=>\"Drilon et al., 2017, Cancer Discov\", \"pubmed_id\"=>\"28183697\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28183697\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5380583\", \"publication_date\"=>{\"year\"=>2017, \"month\"=>4}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1264, \"name\"=>\"EID1264\", \"description\"=>\"A 27 year old female patient with advanced-stage IV, CD20 negative diffuse large B cell lymphoma (DLBCL). ALK rearrangement was determined by FISH, but the ALK fusion partner was not determined due to limited tissue. The patient underwent treatment with CHOP chemotherapy regimen and radiation but did not respond. The patient progressed following salvage chemotherapy and autologous stem cell transplant. Crizotinib was then administered at 250 mg twice daily, and LDH levels rapidly dropped along with disappearance of palpable lymphadenopathy, but progression ensued after 21 days and the patient died soon after. The authors attribute the short response to crizotinib to the possibility of this tumor having an ALK fusion variant less responsive to ALK inhibition and to a high Ki-67 index in the patient, and deem that despite the brief response, crizotinib shows promise in ALK rearranged DLBCL.\", \"disease\"=>{\"id\"=>45, \"name\"=>\"Diffuse Large B-cell Lymphoma\", \"display_name\"=>\"Diffuse Large B-cell Lymphoma\", \"doid\"=>\"0050745\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050745\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>874, \"name\"=>\"Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.\", \"citation\"=>\"Wass et al., 2014, Eur. J. Haematol.\", \"pubmed_id\"=>\"24330038\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24330038\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>3}, \"journal\"=>\"Eur. J. Haematol.\", \"full_journal_title\"=>\"European journal of haematology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1202, \"name\"=>\"EID1202\", \"description\"=>\"In this study, heavily pretreated advanced NSCLC patients with various molecular tumor makeup were treated with Hsp90 inhibitor IPI-504 to assess overall response rate. The study did not reach the targeted endpoint of 20% ORR. However, of 3/12 patients found to be ALK-rearranged via break apart FISH assay, 2 showed a partial response and the third stable disease, which was durable for 7.2 months. The authors note that the break apart FISH assay used to determine ALK-rearrangement status does not determine the identity of the ALK fusion partner and the promising results shown here may be dependent on the nature of the ALK fusion partner.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>303, \"name\"=>\"IPI-504\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>831, \"name\"=>\"Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.\", \"citation\"=>\"Sequist et al., 2010, J. Clin. Oncol.\", \"pubmed_id\"=>\"20940188\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20940188\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4676802\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>11, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1273, \"name\"=>\"EID1273\", \"description\"=>\"In this case study of a critically ill 29 year old male nonsmoker with advanced metastatic ALK-positive NSCLC, alectinib (CH5424802), was administered as first line treatment. Where most clinical trials only admit patients with Eastern Cooperative Oncology Performance status (PS) of 0 or 1, this patient had PS 4 due to respiratory failure, multiple bone metastases and complications from disseminated intravascular coagulation (DIC). Administration of alectinib at 300 mg twice daily was followed by marked improvement seen in tests associated with DIC, pulmonary metastasis and change in PS from 4 to 0. Further improvements after a couple of months suggested a rapid complete response. Alectinib was well tolerated in this first line treatment of a critically ill ALK-positive NSCLC patient.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>17, \"name\"=>\"CH5424802\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>879, \"name\"=>\"Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.\", \"citation\"=>\"Yoshida et al., 2016, Anticancer Drugs\", \"pubmed_id\"=>\"26938871\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26938871\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>7}, \"journal\"=>\"Anticancer Drugs\", \"full_journal_title\"=>\"Anti-cancer drugs\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1691, \"name\"=>\"EID1691\", \"description\"=>\"In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an EML4-ALK-E13;A20 rearrangement was identified using CGP.  The patient attained a reduction in the target lesions by 14.2%, however, the patient relapsed 17 months later.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1141, \"name\"=>\"Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.\", \"citation\"=>\"Le et al., 2015, Clin Lung Cancer\", \"pubmed_id\"=>\"25922291\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25922291\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4418215\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>9}, \"journal\"=>\"Clin Lung Cancer\", \"full_journal_title\"=>\"Clinical lung cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1577, \"name\"=>\"EID1577\", \"description\"=>\"A phase-3 clinical trial evaluated 347 patients with ALK-positive lung cancer.  The study compared crizotinib treatment (n=173) with chemotherapy treatment of either pemetrexed or docetaxel (n=174).  In the crizotinib arm, the response rate was significantly higher (65% vs 20%; P<0.001), the progression-free survival was increased (7.7 months vs. 3.0 months; HR=0.49, 95%CI:14 months-26 months; p<0.001), however, there was no significant improvement in overall survival (HR=1.02; 95%CI:0.68-1.54; P=0.54).  Of the patients on crizotinib treatment, global quality of life was improved relative to baseline when compared to chemotherapy patients (+5 mean change, -5 mean change; P<0.001).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1041, \"name\"=>\"Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.\", \"citation\"=>\"2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"26466010\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26466010\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>10, \"day\"=>15}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1200, \"name\"=>\"EID1200\", \"description\"=>\"This retrospective study of patients from the PROFILE 1001 and 1005 studies of crizotinib in advanced ALK-rearranged NSCLC assessed the potential benefit of crizotinib beyond progressive disease (CBPD), defined as continuation of crizotinib for 3 or more weeks after disease progression on crizotinib. 194 patients who had developed PD by data cutoff were studied, where 120 received crizotinib for a median duration of 19.4 weeks and 74 discontinued crizotinib after PD. No gross imbalances in clinicopathologic features of the two groups were evident.  Significantly longer overall survival was observed in the crizotinib continuing group from time of PD (16.4 vs. 3.9 months; hazard ratio 0.27, 95% CI: 0.17â0.42; P < 0.0001), and from the time of initial crizotinib (29.6 vs. 10.8 months; HR 0.30, 95% CI: 0.19â0.46; P < 0.0001).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>829, \"name\"=>\"Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.\", \"citation\"=>\"Ou et al., 2014, Ann. Oncol.\", \"pubmed_id\"=>\"24478318\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24478318\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>2}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1783, \"name\"=>\"EID1783\", \"description\"=>\"Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 and immunohistochemistry revealed ALK expression, suggesting ALK fusions in three cases of IMT.\", \"disease\"=>{\"id\"=>12, \"name\"=>\"Inflammatory Myofibroblastic Tumor\", \"display_name\"=>\"Inflammatory Myofibroblastic Tumor\", \"doid\"=>\"0050905\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050905\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1245, \"name\"=>\"Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.\", \"citation\"=>\"Griffin et al., 1999, Cancer Res.\", \"pubmed_id\"=>\"10383129\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/10383129\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>1999, \"month\"=>6, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1282, \"name\"=>\"EID1282\", \"description\"=>\"In this Phase II trial of 87 patients (NCT01871805), alectinib was assayed for safety and efficacy in ALK positive NSCLC that had progressed on crizotinib. Of 69 patients with measurable disease, 35 achieved objective response, with median duration of response 13.5 months. Of 16 patients with measurable CNS disease, four achieved CNS complete response and 8 showed CNS partial response. median duration of CNS response was 11.1 months. 2 deaths were observed, and 1 was judged related to study treatment. In early 2016, alectinib was approved by the FDA partly based on this study for treatment of crizotinib-progressed ALK positive NSCLC\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>321, \"name\"=>\"Alectinib (CH5424802)\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>886, \"name\"=>\"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.\", \"citation\"=>\"Shaw et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"26708155\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26708155\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4752892\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>2}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1279, \"name\"=>\"EID1279\", \"description\"=>\"In this Phase I trial (NCT01588028) in 47 patients, alectinib was assessed for its effectiveness in treating locally advanced or metastatic ALK-positive NSCLC that had progressed or been resistant to crizotinib treatment. ALK rearrangement was assessed via approved break apart FISH kit, and patients with asymptomatic CNS metastases were also included. Patients were divided into different cohorts receiving different doses of alectinib. In the 600 mg cohort (N=13), there were 4 confirmed partial responses, 3 unconfirmed partial responses and 3 instances of stable disease. Also, five of nine patients throughout the cohorts with measurable baseline CNS lesions showed partial response to alectinib. Cerebrospinal fluid levels of alectinib increased linearly with blood alectinib levels, indicating it effectively crossed the blood-brain barrier.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>321, \"name\"=>\"Alectinib (CH5424802)\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>884, \"name\"=>\"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.\", \"citation\"=>\"Gadgeel et al., 2014, Lancet Oncol.\", \"pubmed_id\"=>\"25153538\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25153538\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>9}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1334, \"name\"=>\"EID1334\", \"description\"=>\"26 colorectal adenocarcinoma samples were run on Affymetrix human Exon 1.0 arrays and a computational method that assessed differential 5' and 3' gene expression for each gene was used to find potential rearrangements.  One sample showed potential rearrangement and RT-PCR demonstrated an EML4-ALK fusion where EML4 exon 21 was fused to ALK exon 13. This EML4-ALK variant is different from those commonly found in NSCLC. Genomic PCR verified the existence of the fusion breakpoint in intronic space, indicating that some colorectal adenocarcinoma may have targetable ALK-fusion driver mutations.\", \"disease\"=>{\"id\"=>57, \"name\"=>\"Colorectal Adenocarcinoma\", \"display_name\"=>\"Colorectal Adenocarcinoma\", \"doid\"=>\"0050861\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050861\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"E\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>920, \"name\"=>\"Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.\", \"citation\"=>\"Lin et al., 2009, Mol. Cancer Res.\", \"pubmed_id\"=>\"19737969\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19737969\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>9}, \"journal\"=>\"Mol. Cancer Res.\", \"full_journal_title\"=>\"Molecular cancer research : MCR\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1335, \"name\"=>\"EID1335\", \"description\"=>\"84 breast cancer samples acquired from commercial sources were assayed on Affymetrix human exon 1.0 arrays. A computational method was used to find potential gene fusions which assessed differential exon expression between the 3' and 5' ends of each gene. Two potential fusions were found and assessed using RNA ligase mediated rapid amplifiation of cDNA ends and RT-PCR. The fusions were EML4-ALK variants 1 and 2. Genomic PCR identified fusion breakpoints, and these differed from breakpoints for these EML4-ALK variants reported in NSCLC.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"E\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>920, \"name\"=>\"Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.\", \"citation\"=>\"Lin et al., 2009, Mol. Cancer Res.\", \"pubmed_id\"=>\"19737969\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19737969\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>9}, \"journal\"=>\"Mol. Cancer Res.\", \"full_journal_title\"=>\"Molecular cancer research : MCR\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1419, \"name\"=>\"EID1419\", \"description\"=>\"In a retrospective study comparing survival outcomes in a subgroup of 82 ALK-positive crizotinib-treated patients enrolled in a phase 1 clinical trial (NCT00585195), crizotinib therapy was associated with improved survival. For the crizotinib-treated, ALK-positive patient group, 1 year survival was 74% and 2 year overall survival was 54%, compared with 72% and 36% for the control group (ALK-positive crizotinib naive patients).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>961, \"name\"=>\"Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.\", \"citation\"=>\"Shaw et al., 2011, Lancet Oncol.\", \"pubmed_id\"=>\"21933749\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21933749\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3328296\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>10}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1240, \"name\"=>\"EID1240\", \"description\"=>\"Crizotinib at 250mg daily was given to two patients with relapsed ALK-rearranged anaplastic large cell lymphoma (ALCL). Patient one, 26 yrs old, had been treated with the CHOP-15 chemotherapy regimen, then salvage chemotherapy to prepare for autologous bone marrow transplant but ultimately relapsed. After initiation of crizotinib, PET, CT and bone marrow aspirates showed complete remission of previous lesions at 28 days. At time of publication the patient continued to show persistent response at 6 months. A 20 year old patient relapsed after one month of CHOP, and was treated with further chemotherapy and autologous bone marrow transplantation resulting in partial response of 1 month. Crizotinib was initialized, and after 12 days PET scan showed complete regression of all lesions. On day 60 bone marrow aspirates were ALK-negative (pretreatment evaluation showed 8% ALK-positive). The authors conclude these two cases indicate sensitivity to crizotinib of relapsed ALK-rearranged ALCL.\", \"disease\"=>{\"id\"=>348, \"name\"=>\"Anaplastic Large Cell Lymphoma\", \"display_name\"=>\"Anaplastic Large Cell Lymphoma\", \"doid\"=>\"0050744\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050744\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>858, \"name\"=>\"Crizotinib in anaplastic large-cell lymphoma.\", \"citation\"=>\"Gambacorti-Passerini et al., 2011, N. Engl. J. Med.\", \"pubmed_id\"=>\"21345110\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21345110\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>2, \"day\"=>24}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1272, \"name\"=>\"EID1272\", \"description\"=>\"In this initial report of a single-arm Phase I and II study (JapicCTI-101264) of alectinib (CH5424802), 46 patients with advanced or metastatic ALK-rearranged non small cell lung cancer (NSCLC) were assessed for objective response during phase II. ALK positivity was assessed via IHC and verified with FISH or RT-PCR. Patients had received one or more rounds of previous chemotherapy, but no prior targeted therapy towards ALK. From the 46 patients, 41 showed partial response, and 2 showed complete response. CNS metastases in three patients which had not received prior brain irradiation showed response to alectinib. Alectinib was generally well tolerated, and the authors conclude that alectinib compared favorably to crizotinib and could be an effective and safe option in ALK-rearranged NSCLC.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>321, \"name\"=>\"Alectinib (CH5424802)\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>878, \"name\"=>\"CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.\", \"citation\"=>\"Seto et al., 2013, Lancet Oncol.\", \"pubmed_id\"=>\"23639470\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23639470\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>6}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1323, \"name\"=>\"EID1323\", \"description\"=>\"Development of second generation ALK inhibitors has been underway in order to address resistance to first line treatments such as crizotinib in ALK-rearranged NSCLC.  Brigatinib is a potent dual inhibitor against ALK and EGFR.  In an update from the Phase I/II trial NCT01449461 of brigatinib in ALK+ NSCLC, patients were given 90 mg/day, 180 mg/day, or 90 followed by 180 mg/day. In crizotinib-naive patients, overall response rate (ORR) was 7/7 patients with progression free survival (PFS) of 56 weeks. In patients who failed on crizotinib treatment ORR was 69% (45/65 patients) with PFS of 47 weeks, and activity against CNS metastases was seen with ORR 37% in 38 patients with PFS 97 weeks indicating substantial brigatinib activity in crizotinib-progressed patients, as well as promise in CNS metastases.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>318, \"name\"=>\"Brigatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"rejected\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>912, \"name\"=>\"Second- and third-generation ALK inhibitors for non-small cell lung cancer.\", \"citation\"=>\"Wu et al., 2016, J Hematol Oncol\", \"pubmed_id\"=>\"26951079\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26951079\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4782349\", \"publication_date\"=>{\"year\"=>2016}, \"journal\"=>\"J Hematol Oncol\", \"full_journal_title\"=>\"Journal of hematology & oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1242, \"name\"=>\"EID1242\", \"description\"=>\"Four adult ALK-rearranged anaplastic large cell lymphoma (ALCL) patients were resistant to chemotherapy after 3 or more lines of treatment.  The patients were administered 250 mg crizotinib twice daily. Normalization of symptoms was observed at a median time of 5 days, with an overall response rate of 100% (3 complete responses and one partial response)\", \"disease\"=>{\"id\"=>348, \"name\"=>\"Anaplastic Large Cell Lymphoma\", \"display_name\"=>\"Anaplastic Large Cell Lymphoma\", \"doid\"=>\"0050744\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050744\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"rejected\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>860, \"name\"=>\"Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.\", \"citation\"=>\"Foyil et al., Cancer J\", \"pubmed_id\"=>\"23006951\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23006951\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{}, \"journal\"=>\"Cancer J\", \"full_journal_title\"=>\"Cancer journal (Sudbury, Mass.)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1243, \"name\"=>\"EID1243\", \"description\"=>\"As part of a phase 1 dose-escalation trial (NCT00939770), seven patients between ages 12 months and 22 years with relapsed or refractory inflammatory myofibroblastic tumors with ALK-rearrangement were given crizotinib. In six patients with measurable disease, responses included 3 with partial response and 3 with stable disease. One patient with evaluable disease had stable disease with treatment ongoing at the time of publication. Crizotinib was well tolerated in this group of pediatric patients.\", \"disease\"=>{\"id\"=>12, \"name\"=>\"Inflammatory Myofibroblastic Tumor\", \"display_name\"=>\"Inflammatory Myofibroblastic Tumor\", \"doid\"=>\"0050905\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050905\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>859, \"name\"=>\"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.\", \"citation\"=>\"MossÃ© et al., 2013, Lancet Oncol.\", \"pubmed_id\"=>\"23598171\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23598171\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3730818\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>5}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1201, \"name\"=>\"EID1201\", \"description\"=>\"This prospective Phase III study named Profile 1014 on NSCLC ALK-rearranged patients assessed intracranial disease control rate (IC-DCR) in the subset of patients entering the study with preexisting treated brain metastasis (tBM). IC-DCR was significantly improved in the tBM group given crizotinib (N=39) over chemotherapy (pemetrexed + cisplatin or carboplatin; N=40) at 12 weeks (85% vs. 45%, P<0.001), and at 24 weeks (56% vs. 25%, P=0.006). Progression free survival was also significantly improved with crizotinib over chemotherapy in the tBM subgroup (9.0 vs. 4.0 months; HR 0.40; P<0.001), where in the intent to treat population it was 10.9 vs. 7.0 months (HR 0.45; P<0.001), indicating that the difficult to treat BM population obtained benefit from crizotinib at both the brain and systemic level.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>830, \"name\"=>\"Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.\", \"citation\"=>\"Solomon et al., 2016, J. Clin. Oncol.\", \"pubmed_id\"=>\"27022118\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27022118\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>8, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1199, \"name\"=>\"EID1199\", \"description\"=>\"This phase 3 trial named PROFILE 1014 (NCT01154140) compared crizotinib to established chemotherapy in first-line treatment for this disease. The study consisted of 343 patients with advanced or metastatic NSCLC that tested positive for ALK rearrangement via break-apart FISH assay, and had no prior systemic treatment. Patients were assigned in a 1:1 ratio to crizotinib (N=172) or pemetrexed with cisplatin or carboplatin (N=171). Progression free survival was significantly longer with crizotinib treatment than chemotherapy (10.9 vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% CI, 0.35 to 0.60;P<0.001), and objective response rate was higher with crizotinib treatment than chemotherapy (75% vs. 45%, P<0.001). Improvement in quality of life was also reported.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>828, \"name\"=>\"First-line crizotinib versus chemotherapy in ALK-positive lung cancer.\", \"citation\"=>\"Solomon et al., 2014, N. Engl. J. Med.\", \"pubmed_id\"=>\"25470694\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25470694\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>12, \"day\"=>4}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1175, \"name\"=>\"EID1175\", \"description\"=>\"Updated results from ASCEND-1 trial assessing safety and activity of ceritinib in ALK rearranged locally advanced or metastatic NSCLC. 255 patients were enrolled and received at least one dose of ceritinib 750 mg/day, of whom 246 had ALK-rearranged NSCLC (Median follow-up: 11.1 months). Overall response rate was 72% [95% CI 61-82] of 83 ALK inhibitor-naive patients and 56% [49-64] of 163 ALK inhibitor-pretreated patients. Median duration of response was 17Â·0 months (95% CI 11.3-non-estimable [NE]) in ALK inhibitor-naive patients and 8.3 months (6.8-9.7) in ALK inhibitor-pretreated patients. Median progression-free survival was 18.4 months (95% CI 11.1-NE) in ALK inhibitor-naive patients and 6.9 months (5.6-8.7) in ALK inhibitor-pretreated patients. Brain metastases control was reported in 79% [95% CI 54-94] of 19 ALK inhibitor-naive patients and in 65% [54-76] of 75 ALK inhibitor-pretreated patients.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>159, \"name\"=>\"Ceritinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>812, \"name\"=>\"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.\", \"citation\"=>\"Kim et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"26973324\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26973324\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1187, \"name\"=>\"EID1187\", \"description\"=>\"In the Phase I study PROFILE 1001 (NCT00585195), a recommended crizotinib dose of 250 mg twice daily for 28 day cycles was established. Among 1,500 advanced NSCLC patients who were screened for ALK-rearrangement using a break-apart FISH assay, 82 patients were eligible for crizotinib treatment.  Overall response rate was 57%, with 46 partial responses and one complete response.  Since crizotinib inhibits MET, 33 patients with available tissue were screened for MET amplification and were found negative, further indicating that patient response was due to ALK inhibition.  31 patients were tested via RT-PCR for known EML4-ALK fusions, and 13 were shown to have EML4-ALK variant 1, four cases had variant 3, and one instance of variants 2, 3b and 5 were seen.  9 were unidentified, suggesting other fusion partners in these instances.  On the basis of this and a Phase II study, accelerated approval for crizotinib in ALK-positive advanced NSCLC was granted.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>819, \"name\"=>\"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.\", \"citation\"=>\"Kwak et al., 2010, N. Engl. J. Med.\", \"pubmed_id\"=>\"20979469\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20979469\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3014291\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>10, \"day\"=>28}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1198, \"name\"=>\"EID1198\", \"description\"=>\"This two arm Phase III study named PROFILE 1007 (NCT00932893) was performed to assess crizotinib vs. established chemotherapy in non-small cell lung cancer patients positive for ALK rearrangement (assessed by break-apart FISH) with locally advanced or metastatic disease. 347 patients with disease progression after one round of platinum-based chemotherapy were randomized to receive crizotinib (N=173) or chemotherapy (N=174) consisting of pemetrexed in pemetrexed-naive patients and docetaxel for patients previously treated with pemetrexed. The primary endpoint - progression free survival (PFS) - was found to be significantly better for patients treated with crizotinib (median 7.7 months) than with chemotherapy (median 3.0 months) (hazard ratio for disease progression or death with crizotinib, 0.49; 95% CI, 0.37 to 0.64; P<0.001). Response rates were 65% for crizotinib treatment and 20% for chemotherapy (P<0.001). Improvements in quality of life were also reported.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>827, \"name\"=>\"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.\", \"citation\"=>\"Shaw et al., 2013, N. Engl. J. Med.\", \"pubmed_id\"=>\"23724913\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23724913\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>6, \"day\"=>20}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>945, \"name\"=>\"EID945\", \"description\"=>\"Among 95 patients with NSCLC in this study, 15 had an ALK translocation. ORR of these patients compared to EGFR mutated or wild-type tumors was superior (46.7 versus 4.7 versus 16.2%, p = 0.001). TYMS expression was lower in ALK-positive cells.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>156, \"name\"=>\"Pemetrexed\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>647, \"name\"=>\"Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.\", \"citation\"=>\"Lee et al., 2011, J Thorac Oncol\", \"pubmed_id\"=>\"21642865\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21642865\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>9}, \"journal\"=>\"J Thorac Oncol\", \"full_journal_title\"=>\"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}]}, {\"id\"=>190, \"entrez_name\"=>\"EGFR\", \"entrez_id\"=>1956, \"name\"=>\"AMPLIFICATION\", \"description\"=>\"\", \"gene_id\"=>19, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>123, \"name\"=>\"transcript_amplification\", \"display_name\"=>\"Transcript Amplification\", \"so_id\"=>\"SO:0001889\", \"description\"=>\"A feature amplification of a region containing a transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001889\"}], \"civic_actionability_score\"=>133.0, \"coordinates\"=>{\"chromosome\"=>\"7\", \"start\"=>55086794, \"stop\"=>55279321, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000275493.2\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/19/summary/variants/190/summary#variant\", \"evidence_items\"=>[{\"id\"=>3015, \"name\"=>\"EID3015\", \"description\"=>\"Evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment. This study reports that the Src-AKT pathway contributes to acquired resistance to third generation EGFR TKIs. In addition, amplification of EGFR wild-type alleles but not mutant alleles was sufficient to confer acquired resistance.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>91, \"name\"=>\"Rociletinib\", \"pubchem_id\"=>nil}, {\"id\"=>187, \"name\"=>\"Osimertinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1733, \"name\"=>\"Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.\", \"citation\"=>\"Nukaga et al., 2017, Cancer Res.\", \"pubmed_id\"=>\"28202511\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28202511\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>691, \"name\"=>\"EID691\", \"description\"=>\"EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}, {\"id\"=>395, \"name\"=>\"5-fluorouracil\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>450, \"name\"=>\"Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.\", \"citation\"=>\"Licitra et al., 2011, Ann. Oncol.\", \"pubmed_id\"=>\"21048039\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21048039\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3082162\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>5}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>977, \"name\"=>\"EID977\", \"description\"=>\"In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib). EGFR amplification (Multiplex ligation-dependent probe amplification; MLPA) and Mutation (PCR) were analzed. EGFR amplification was associated with EGFR mutation but not independently with patient benefit from EGFR TKI (overall and progression-free survival).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}, {\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>676, \"name\"=>\"Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.\", \"citation\"=>\"Fiala et al., 2016, Anticancer Res.\", \"pubmed_id\"=>\"26722081\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26722081\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>1}, \"journal\"=>\"Anticancer Res.\", \"full_journal_title\"=>\"Anticancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>948, \"name\"=>\"EID948\", \"description\"=>\"A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy number), 10 (822 patients, 290 with increased gene copy number) and 5 studies (294 patients, 129 with increased gene copy number) were analyzed for overall survival (OS), progression-free survival (PFS) and time-to-progression (TTP) meta-analyses respectively. EGFR amplification was associated with increased OS (HR = 0.77; 95% CI 0.66-0.89; P = 0.001), PFS (HR = 0.60; 95% CI 0.46-0.79; P<0.001) and TTP (HR = 0.50; 95% CI 0.28-0.91; P = 0.02). This effect was shown to influence survival in predominantly white patient populations but not patients of Asian descent.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>145, \"name\"=>\"EGFR Inhibitor\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>650, \"name\"=>\"EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.\", \"citation\"=>\"Dahabreh et al., 2011, Ann. Oncol.\", \"pubmed_id\"=>\"20826716\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20826716\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>3}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>911, \"name\"=>\"EID911\", \"description\"=>\"87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and overall survival independent of KRAS status.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>618, \"name\"=>\"Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.\", \"citation\"=>\"Personeni et al., 2008, Clin. Cancer Res.\", \"pubmed_id\"=>\"18794099\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18794099\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>9, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>473, \"name\"=>\"EID473\", \"description\"=>\"The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tumors.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>287, \"name\"=>\"Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.\", \"citation\"=>\"Chung et al., 2006, J. Clin. Oncol.\", \"pubmed_id\"=>\"16943533\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16943533\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>9, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>854, \"name\"=>\"EID854\", \"description\"=>\"In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regardless of KRAS status. For the pooled analysis, the objective response rate (ORR) was 65.2% (167/256) in patients with high EFGR GCN, while in patients with low EFGR GCN, the pooled ORR was 12.2% (44/361). The odds ratio (OR) was 6.905 (95% CI: 4.489-10.620; Z=8.79, P=0.000). In wild type KRAS patients, the pooled OR was 8.133 (95% CI: 4.316-15.326; Z=6.48, P=0.000).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>571, \"name\"=>\"EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.\", \"citation\"=>\"Shen et al., 2014, Chin. J. Cancer Res.\", \"pubmed_id\"=>\"24653627\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24653627\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3937753\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>2}, \"journal\"=>\"Chin. J. Cancer Res.\", \"full_journal_title\"=>\"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>471, \"name\"=>\"EID471\", \"description\"=>\"In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival.\", \"disease\"=>{\"id\"=>148, \"name\"=>\"Cervical Squamous Cell Carcinoma\", \"display_name\"=>\"Cervical Squamous Cell Carcinoma\", \"doid\"=>\"3744\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3744\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>285, \"name\"=>\"EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.\", \"citation\"=>\"Iida et al., 2011, Br. J. Cancer\", \"pubmed_id\"=>\"21730982\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21730982\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3172895\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>7, \"day\"=>26}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>470, \"name\"=>\"EID470\", \"description\"=>\"In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial.\", \"disease\"=>{\"id\"=>228, \"name\"=>\"Barrett's Adenocarcinoma\", \"display_name\"=>\"Barrett's Adenocarcinoma\", \"doid\"=>\"7941\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:7941\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>284, \"name\"=>\"Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.\", \"citation\"=>\"Marx et al., 2010, Histopathology\", \"pubmed_id\"=>\"20840671\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20840671\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>9}, \"journal\"=>\"Histopathology\", \"full_journal_title\"=>\"Histopathology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}]}, {\"id\"=>267, \"entrez_name\"=>\"FGFR1\", \"entrez_id\"=>2260, \"name\"=>\"AMPLIFICATION\", \"description\"=>\"FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).\", \"gene_id\"=>1885, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>123, \"name\"=>\"transcript_amplification\", \"display_name\"=>\"Transcript Amplification\", \"so_id\"=>\"SO:0001889\", \"description\"=>\"A feature amplification of a region containing a transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001889\"}], \"civic_actionability_score\"=>158.0, \"coordinates\"=>{\"chromosome\"=>\"8\", \"start\"=>38268656, \"stop\"=>38325363, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000425967.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/1885/summary/variants/267/summary#variant\", \"evidence_items\"=>[{\"id\"=>1908, \"name\"=>\"EID1908\", \"description\"=>\"Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. In the subgroup of FGFR1-amplified NSCLC, 36 patients were treated at doses >100mg and disease control was achieved in 50% of patients (4 PR and 14 SD) with 6 patients receiving treatment after 16 weeks.\", \"disease\"=>{\"id\"=>153, \"name\"=>\"Lung Squamous Cell Carcinoma\", \"display_name\"=>\"Lung Squamous Cell Carcinoma\", \"doid\"=>\"3907\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3907\"}, \"drugs\"=>[{\"id\"=>151, \"name\"=>\"BGJ398\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1337, \"name\"=>\"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.\", \"citation\"=>\"Nogova et al., 2017, J. Clin. Oncol.\", \"pubmed_id\"=>\"27870574\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27870574\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>3027, \"name\"=>\"EID3027\", \"description\"=>\"Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications. Objective response for the cohort was 11.5%, disease control rate was 50%. 11.5% of patients exhibited partial response, 38.5% exhibited stable disease. Median PFS was 2.9 months, median OS was 5 months, this trend was worse with increases in FGFR1 amplification above average.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>228, \"name\"=>\"Dovitinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1342, \"name\"=>\"Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.\", \"citation\"=>\"Lim et al., 2016, Cancer\", \"pubmed_id\"=>\"27315356\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27315356\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>10}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1909, \"name\"=>\"EID1909\", \"description\"=>\"Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Among the 26 patients with breast cancer and FGFR1/2 amplification (n=25,  n= 21 with FGFR1 amplification only) or FGFR3 mutation (n=1) four (15.4%) had a reduced tumor burden. In total, 10 of 32 patients with breast cancer treated at doses >100mg had a best response of SD.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>433, \"name\"=>\"BGJ-398\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>nil, \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1337, \"name\"=>\"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.\", \"citation\"=>\"Nogova et al., 2017, J. Clin. Oncol.\", \"pubmed_id\"=>\"27870574\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27870574\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1911, \"name\"=>\"EID1911\", \"description\"=>\"Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. One patient with FGFR1 amplified bladder/urothelial carcinoma was treated with 125 mg and progressed rapidly in cycle 1 after 11 days of treatment.\", \"disease\"=>{\"id\"=>18, \"name\"=>\"Bladder Carcinoma\", \"display_name\"=>\"Bladder Carcinoma\", \"doid\"=>\"4007\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4007\"}, \"drugs\"=>[{\"id\"=>433, \"name\"=>\"BGJ-398\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1337, \"name\"=>\"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.\", \"citation\"=>\"Nogova et al., 2017, J. Clin. Oncol.\", \"pubmed_id\"=>\"27870574\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27870574\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1991, \"name\"=>\"EID1991\", \"description\"=>\"Activity of the FGFR-selective inhibitor AZD4547 in FGFR1-amplified breast cancer and FGFR2-amplified gastroesophageal cancer was analyzed in this study. 341 patients with advanced cancer were screened by FISH, identifying FGFR1 amplification in 18% of advanced HER2-negative breast cancers and FGFR2 amplification in 9% of advanced gastroesophageal cancer. 1 patient had a confirmed response among 8 patients treated with FGFR1-amplified breast cancer. In a preclinical model, FGFR1 amplification in breast cancer cell lines was less pronounced than FGFR2-amplifications in gastroesophageal cancers, which also had a higher response rate in the trial, indicating that high level amplification is associated with response and less common in FGFR1-amplified breast cancer.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>452, \"name\"=>\"AZD4547\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1397, \"name\"=>\"High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.\", \"citation\"=>\"Pearson et al., 2016, Cancer Discov\", \"pubmed_id\"=>\"27179038\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27179038\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5338732\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>8}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1604, \"name\"=>\"EID1604\", \"description\"=>\"Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study.\\nDovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines. Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model.\\n81 patients were enrolled in the trial and treated with dovitinib. Unconfirmed response or stable disease >6 months was observed in 25% of FGFR1-amplified/HR-positive vs. 3% FGFR1-nonamplified/HR-positive breast cancer patientes. When FGF3 and FGFR2 amplifications were also assessed, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>228, \"name\"=>\"Dovitinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1064, \"name\"=>\"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.\", \"citation\"=>\"AndrÃ© et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23658459\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23658459\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1767, \"name\"=>\"EID1767\", \"description\"=>\"In MDA-MB-134 cells (ER-positive breast cancer cells with amplified FGFR1) ponatinib potently inhibited cell growth with a GI50 value of 23 nmol/L and inhibited FGFR1 phosphorylation with an IC50 value of 7 nmol/L.\", \"disease\"=>{\"id\"=>28, \"name\"=>\"Estrogen-receptor Positive Breast Cancer\", \"display_name\"=>\"Estrogen-receptor Positive Breast Cancer\", \"doid\"=>\"0060075\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060075\"}, \"drugs\"=>[{\"id\"=>55, \"name\"=>\"Ponatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1233, \"name\"=>\"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.\", \"citation\"=>\"Gozgit et al., 2012, Mol. Cancer Ther.\", \"pubmed_id\"=>\"22238366\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22238366\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>3}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1247, \"name\"=>\"EID1247\", \"description\"=>\"116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines.\", \"disease\"=>{\"id\"=>135, \"name\"=>\"Bone Ewing's Sarcoma\", \"display_name\"=>\"Bone Ewing's Sarcoma\", \"doid\"=>\"3368\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3368\"}, \"drugs\"=>[{\"id\"=>55, \"name\"=>\"Ponatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>446, \"name\"=>\"Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.\", \"citation\"=>\"Agelopoulos et al., 2015, Clin. Cancer Res.\", \"pubmed_id\"=>\"26179511\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26179511\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>11, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>682, \"name\"=>\"EID682\", \"description\"=>\"In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates with cigarette smoking.\", \"disease\"=>{\"id\"=>153, \"name\"=>\"Lung Squamous Cell Carcinoma\", \"display_name\"=>\"Lung Squamous Cell Carcinoma\", \"doid\"=>\"3907\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3907\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>436, \"name\"=>\"Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.\", \"citation\"=>\"Kim et al., 2013, J. Clin. Oncol.\", \"pubmed_id\"=>\"23182986\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23182986\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>2, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>684, \"name\"=>\"EID684\", \"description\"=>\"This study shows a reduction in the risk of death for patients with FGFR1 copy-number between 4 and 6. No difference in survival is seen between amplified and non-amplified patients in general.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>438, \"name\"=>\"Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.\", \"citation\"=>\"Tran et al., 2013, Lung Cancer\", \"pubmed_id\"=>\"23806793\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23806793\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>9}, \"journal\"=>\"Lung Cancer\", \"full_journal_title\"=>\"Lung cancer (Amsterdam, Netherlands)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>685, \"name\"=>\"EID685\", \"description\"=>\"Meta-Analysis on prognostic value of FGFR1 amplification in different types of cancer shows significantly worse overall survival for patients with FGFR1 and FGFR2 amplification.\\nHowever, larger studies are warranted for confirmation.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>439, \"name\"=>\"Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis.\", \"citation\"=>\"Chang et al., 2014, PLoS ONE\", \"pubmed_id\"=>\"25171497\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25171497\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4149366\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>687, \"name\"=>\"EID687\", \"description\"=>\"Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metastasis.\", \"disease\"=>{\"id\"=>153, \"name\"=>\"Lung Squamous Cell Carcinoma\", \"display_name\"=>\"Lung Squamous Cell Carcinoma\", \"doid\"=>\"3907\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3907\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>441, \"name\"=>\"FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis.\", \"citation\"=>\"Jiang et al., 2015, Lung Cancer\", \"pubmed_id\"=>\"25433983\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25433983\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>1}, \"journal\"=>\"Lung Cancer\", \"full_journal_title\"=>\"Lung cancer (Amsterdam, Netherlands)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>683, \"name\"=>\"EID683\", \"description\"=>\"This study shows an association of FGFR1 amplification with shorter overall and disease-free survival. However, no statistically significant association is seen on multivariate analysis.\", \"disease\"=>{\"id\"=>153, \"name\"=>\"Lung Squamous Cell Carcinoma\", \"display_name\"=>\"Lung Squamous Cell Carcinoma\", \"doid\"=>\"3907\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3907\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>437, \"name\"=>\"FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer.\", \"citation\"=>\"Seo et al., 2014, Virchows Arch.\", \"pubmed_id\"=>\"25086725\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25086725\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>11}, \"journal\"=>\"Virchows Arch.\", \"full_journal_title\"=>\"Virchows Archiv : an international journal of pathology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>680, \"name\"=>\"EID680\", \"description\"=>\"Preclinical (in-vitro, in-vivo) evidence suggests predictive value of FGFR1 amplification for treatment with FGFR1-inhibitors. 4 of 83 cell lines exhibited FGFR1 amplification, and 3 of these were highly sensitive to PD173074. This sensitivity was confirmed in a mouse xenograft. Clinical trials are currently ongoing.\", \"disease\"=>{\"id\"=>153, \"name\"=>\"Lung Squamous Cell Carcinoma\", \"display_name\"=>\"Lung Squamous Cell Carcinoma\", \"doid\"=>\"3907\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3907\"}, \"drugs\"=>[{\"id\"=>36, \"name\"=>\"PD173074\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>434, \"name\"=>\"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.\", \"citation\"=>\"Weiss et al., 2010, Sci Transl Med\", \"pubmed_id\"=>\"21160078\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21160078\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3990281\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>12, \"day\"=>15}, \"journal\"=>\"Sci Transl Med\", \"full_journal_title\"=>\"Science translational medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1105, \"name\"=>\"EID1105\", \"description\"=>\"FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>277, \"name\"=>\"4-hydroxytamoxifen\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>763, \"name\"=>\"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.\", \"citation\"=>\"Turner et al., 2010, Cancer Res.\", \"pubmed_id\"=>\"20179196\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20179196\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2832818\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>686, \"name\"=>\"EID686\", \"description\"=>\"Preclinical study showing FGFR1 amplification in NSCLC and efficacy of FGFR-1 inhibition in one amplified cell line.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>36, \"name\"=>\"PD173074\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>440, \"name\"=>\"Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.\", \"citation\"=>\"Dutt et al., 2011, PLoS ONE\", \"pubmed_id\"=>\"21666749\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21666749\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3110189\", \"publication_date\"=>{\"year\"=>2011}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}]}, {\"id\"=>306, \"entrez_name\"=>\"ERBB2\", \"entrez_id\"=>2064, \"name\"=>\"AMPLIFICATION\", \"description\"=>\"Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.\", \"gene_id\"=>20, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>123, \"name\"=>\"transcript_amplification\", \"display_name\"=>\"Transcript Amplification\", \"so_id\"=>\"SO:0001889\", \"description\"=>\"A feature amplification of a region containing a transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001889\"}], \"civic_actionability_score\"=>822.5, \"coordinates\"=>{\"chromosome\"=>\"17\", \"start\"=>37856333, \"stop\"=>37884915, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000269571.5\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/20/summary/variants/306/summary#variant\", \"evidence_items\"=>[{\"id\"=>1011, \"name\"=>\"EID1011\", \"description\"=>\"This Phase II trial (LUX-Breast 3 - NCT01441596) compared afatinib, afatinib plus vinorelbine, or investigator's choice of treatment.  121 patients with HER2 overexpressing breast cancer with CNS recurrence or regression who had previously progressed on trastuzumab or lapatinib were assigned to 3 arms, with endpoint in the intention-to-treat population being patient benefit at 12 weeks defined as absence of CNS or extra CNS progression, no tumor related worsening of neurological symptoms and no increase in corticosteroid dose. Benefit was seen in 30% of 40 patients assigned to afatinib alone, 34.2% of 38 assigned to afatinib plus vinorelbine, and 41.9% of 43 assigned to investigator's treatment choice.  Differences were not statistically significant, and afatanib patients experienced more adverse effects.  While Afatanib did show response in HER2 breast cancer patients, it was not better than investigator's treatment choice and the investigators state that no further development of afatinib for HER2 breast cancer will be planned.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>699, \"name\"=>\"Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.\", \"citation\"=>\"CortÃ©s et al., 2015, Lancet Oncol.\", \"pubmed_id\"=>\"26596672\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26596672\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>12}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1013, \"name\"=>\"EID1013\", \"description\"=>\"Trastuzumab resistance is thought to consist of multiple compensatory mechanisms involving ErbB family members such as increased signaling through ErbB family heterodimers.  The irreversible TKI afatinib blocks EGFR, HER2, ErbB3 and ErbB4.  Thus afatinib was studied in this Phase I trial of trastuzumab-progressed HER2 positive metastatic BC (MBC) in combination with continued trastuzumab treatment, where trastuzumab is still the perferred treatment for trastuzumab-progressed MBC.  Objective response and disease control rates were 11% and 39%.  The authors conclude that the clinical activity observed in this trial warrants further work with afatinib and trastuzumab combination therapy.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>701, \"name\"=>\"Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.\", \"citation\"=>\"Ring et al., 2015, Clin. Cancer Res.\", \"pubmed_id\"=>\"25370464\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25370464\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>6, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1159, \"name\"=>\"EID1159\", \"description\"=>\"The Phase III trial, TH3RESA (NCT01419197), was performed in patients with advanced HER2 breast cancer that was heavily pretreated.  Patients were required to have prior exposure to trastuzumab and lapatinib as well as a taxane.  This patient population has not seen many studies, responds poorly to late-line treatment with trastuzumab, and in this study was treated with trastuzumab emtansine (T-DM1, n=404) vs. physician's choice (usually trastuzumab plus chemotherapy, n=198).  Results showed progression free survival was 6.2 months in T-DM1 treatment vs. 3.3 months under physician's choice, along with lower incidence of grade 3 or worse events with T-DM1.  The authors conclude that their findings in this heavily pretreated population, along with findings in the EMILIA trial, indicate promise for antibody-drug conjugates.  The NCI-MATCH trial with further study T-DM1 in the context of HER2 amplification.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>798, \"name\"=>\"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.\", \"citation\"=>\"Krop et al., 2014, Lancet Oncol.\", \"pubmed_id\"=>\"24793816\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24793816\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>6}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1133, \"name\"=>\"EID1133\", \"description\"=>\"In this Phase III trial, trastuzumab-based treatment was assessed in women with locally advanced or metastatic HER2 positive breast cancer who had progressed on trastuzumab.  Patients had 12 weeks or greater previous trastuzumab treatment with time since end of last cycle less than 6 weeks.  Primary endpoint was time to progression.  78 patients were assigned to each group, with median time to progression of 5.6 months in capecitabine group and 8.2 months in trastuzumab plus capecitabine group.  The results are in contrast to the principle of change of treatment on disease progression, and authors suggest that chemotherapy-sensitizing mechanisms of trastuzumab remain intact in HER2 breast cancer cells with trastuzumab progression.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>32, \"name\"=>\"Capecitabine\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>784, \"name\"=>\"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.\", \"citation\"=>\"von Minckwitz et al., 2009, J. Clin. Oncol.\", \"pubmed_id\"=>\"19289619\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19289619\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>4, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1012, \"name\"=>\"EID1012\", \"description\"=>\"LUX-Breast 1 is a phase 3 trial (NCT01125566) which enrolled 508 patients with metastatic HER2 positive BC who had progressed after adjuvant or first-line trastuzumab. It was thought that the wider range of ErbB family blocking and irreversible properties of afatinib could be beneficial in trastuzumab resistant cancer cells, since ErbB family members are thought to play a role in trastuzumab resistance. Primary endpoint was intention-to-treat group PFS. 339 patients were assigned to afatanib + vinorelbine and 169  to trastuzumab + vinorelbine.  Recruitment was stopped prematurely when it was deemed unlikely that the increased PFS would be seen in the afatinib group. Median PFS was 5.5 months in the afatinib group and 5.6 months in the trastuzumab group.  Afatanib plus vinorelbine was less well tolerated than trastuzumab plus vinorelbine, and the authors conclude that trastuzumab remains the best choice for treatment of trastuzumab-progressed HER2 positive metastatic BC.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>700, \"name\"=>\"Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.\", \"citation\"=>\"Harbeck et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"26822398\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26822398\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1113, \"name\"=>\"EID1113\", \"description\"=>\"In this two arm, Phase III study (NCT00878709) of the efficacy of a 12 month course of the TKI neratinib after trastuzumab-based adjuvant therapy of early stage HER2-positive breast cancer was assessed using invasive disease-free survival as primary endpoint.  HER2 positivity was assessed via FISH.  At 2 year follow-up, 70 vs. 109 disease-free survival events had occurred and disease-free survival rates were 93.9% vs. 91.6% (significant) in neratinib vs. placebo groups respectively.  Distant disease-free survival and time to distant recurrence were similar in both groups.  These results are an interesting contrast to results of long-term adjuvant therapy with trastuzumab (HERA) which did not show significant benefit.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>52, \"name\"=>\"Neratinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>768, \"name\"=>\"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.\", \"citation\"=>\"Chan et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"26874901\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26874901\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1160, \"name\"=>\"EID1160\", \"description\"=>\"The EMILIA study (NCT00829166) was a Phase II trial to assess the efficacy of trastuzumab emtansine (T-DM1, n=495) in comparison to lapatinib plus capecitabine (n=496), in treatment of advanced HER2 positive breast cancer.  Patients were required to have progressed on or after treatments involving trastuzumab and a taxane, and no prior exposure to lapatinib or T-DM1.   Primary endpoints included independently assessed progression free survival (PFS) and safety. PFS was 9.6 months in T-DM1 group vs. 6.4 months in lapatinib plus capecitabine.  Rates of adverse events of grade 3 or higher were greater with lapatinib plus capecitabine.  These results, together with other trials such as TH3RESA indicate promise for T-DM1 therapy in HER2 amplification, and this will be further studied in an arm of the NCI-MATCH trial.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>799, \"name\"=>\"Trastuzumab emtansine for HER2-positive advanced breast cancer.\", \"citation\"=>\"Verma et al., 2012, N. Engl. J. Med.\", \"pubmed_id\"=>\"23020162\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23020162\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>11, \"day\"=>8}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1007, \"name\"=>\"EID1007\", \"description\"=>\"In light of results showing increased PFS using mAB plus TKI in heavily pretreated patients, the efficacy of trastuzumab plus lapatinib in a neoadjuvant setting with untreated stage II or IIIA HER2 positive breast cancer was assessed.  In this randomized 3 arm phase II study (CHER-LOB), patients received (A) chemotherapy plus trastuzumab, (B) chemotherapy plus lapatinib, or (C) chemotherapy plus trastuzumab and lapatinib, with pathologic complete response (pCR) as endpoint.  From 121 patients, pCR rates were 25% in arm A, 26.3% in arm B, and 46.7% in arm C.  The authors conclude these results support the superiority of dual-HER2 inhibition in the neoadjuvant context of HER2 positive BC.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>696, \"name\"=>\"Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.\", \"citation\"=>\"Guarneri et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22493419\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22493419\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1008, \"name\"=>\"EID1008\", \"description\"=>\"This Phase III trial compared the activity of lapatinib vs. trastuzumab vs. sequential trastuzumab followed by lapatinib vs. lapatinib plus trastuzumab in an adjuvant treatment setting.  8381 women were randomized to one of four treatment arms. Patients had HER2 positive non-metastatic operable BC. The primary endpoint was disease free survival.  First results report that after median 4.5 year follow up, a non significant 16% improvement in DFS was seen in trastuzumab + lapatinib vs. trastuzumab alone.  The results are interpreted as showing no added benefit for labatinib addition to trastuzumab in the adjuvant treatment context.  This trial is ongoing but not recruiting patients (NCT00490139).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>697, \"name\"=>\"Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.\", \"citation\"=>\"Zardavas et al., 2015, Breast\", \"pubmed_id\"=>\"26255196\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26255196\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>11}, \"journal\"=>\"Breast\", \"full_journal_title\"=>\"Breast (Edinburgh, Scotland)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>529, \"name\"=>\"EID529\", \"description\"=>\"A randomized clinical trial of 186 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved overall survival, response rate, response duration, time to progression, and time to treatment failure for patients who received trastuzumab in addition to chemotherapy (docetaxel) compared to chemotherapy alone.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>329, \"name\"=>\"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.\", \"citation\"=>\"Marty et al., 2005, J. Clin. Oncol.\", \"pubmed_id\"=>\"15911866\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15911866\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>528, \"name\"=>\"EID528\", \"description\"=>\"A randomized clinical trial of 469 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved time to disease progression, objective response rate, and duration of response for patients who received trastuzumab in addition to chemotherapy compared to chemotherapy alone.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>328, \"name\"=>\"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.\", \"citation\"=>\"Slamon et al., 2001, N. Engl. J. Med.\", \"pubmed_id\"=>\"11248153\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11248153\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2001, \"month\"=>3, \"day\"=>15}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5985, \"name\"=>\"EID5985\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of nine patients (22%) with HER2 amplified/overexpressing pancreatic cancer had a PR with trastuzumab/pertuzumab combination. Another patient had SD > 120days.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5986, \"name\"=>\"EID5986\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. None of the 7 patients with HER2 amplified/overexpressing uterus cancer responded to pertuzumab/trastuzumab.\", \"disease\"=>{\"id\"=>825, \"name\"=>\"Uterine Cancer\", \"display_name\"=>\"Uterine Cancer\", \"doid\"=>\"363\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:363\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1993, \"name\"=>\"EID1993\", \"description\"=>\"We identified 142 patients with metastatic colorectal cancer whose tumors harbored both wild-type exons 2, 3, and 4 in KRAS and NRAS, and wild-type exon 15 in BRAF. All patients received cetuximab after oxaliplatin, irinotecan, and fluoropyrimidine failure. HER2 status was determined using immunohistochemistry and silver in situ hybridization and correlated with cetuximab efficacy. Of 142 RAS and BRAF wild-type tumors, we observed 7 cases (4.9%) of HER2 amplification by SISH. After a median follow-up of 13.2 months (range, 1.4-78.1 months), median progression-free survival (PFS) was significantly different according to HER2 status: 3.1 months in patients with HER2 amplification compared with 5.6 months in those with non-amplified HER2 (HR = 2.73; 95% CI = 1.18-6.31; P = 0.019). Overall survival (OS) was not significantly different between groups, although there was a tendency towards shorter OS in patients with HER2-amplified tumors (HR = 0.31; 95% CI = 0.61-2.82; 10.1 vs. 13.5 months; P = 0.488).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1399, \"name\"=>\"HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.\", \"citation\"=>\"Jeong et al., 2017, Clin Colorectal Cancer\", \"pubmed_id\"=>\"28223103\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28223103\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>1, \"day\"=>25}, \"journal\"=>\"Clin Colorectal Cancer\", \"full_journal_title\"=>\"Clinical colorectal cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5981, \"name\"=>\"EID5981\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. \\nThirty of 114 patients (26%; 95% CI, 19% to 35%) with HER2 amplification/overexpression had objective responses to treatment with trastuzumab plus pertuzumab (two CR, 28 PR). \\nPatients with HER2-amplified/overexpressing metastatic colorectal cancer composed the largest tumor-pathway cohort. In this group of 37 patients with refractory disease (median, four previous lines of therapy), treatment with trastuzumab plus pertuzumab produced PRs in 14 patients (38%; 95% CI, 23% to 55%; Fig 2A). An additional four patients had SD > 120 days. The median DOR was 11 months (range, < 1 to 16+ months; 95% CI, 2.8 months to not estimable).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5983, \"name\"=>\"EID5983\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of seven patients (29%; 95% CI, 4% to 71%) with biliary cancer and HER2 amplification/overexpression had PR, and three had SD > 120 days\", \"disease\"=>{\"id\"=>1065, \"name\"=>\"Biliary Tract Cancer\", \"display_name\"=>\"Biliary Tract Cancer\", \"doid\"=>\"4607\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4607\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5982, \"name\"=>\"EID5982\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Three of nine patients (33%; 95% CI, 8% to 70%) with advanced bladder cancer and HER2 amplification/overexpression had responses (one CR ongoing at 15 months; two PR lasting 1 and 6 months), and two patients had SD > 120 days.\", \"disease\"=>{\"id\"=>18, \"name\"=>\"Bladder Carcinoma\", \"display_name\"=>\"Bladder Carcinoma\", \"doid\"=>\"4007\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4007\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5984, \"name\"=>\"EID5984\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Four of five patients with HER2 amplified/overexpressing salivary gland carcinoma (80%; 95% CI, 28% to > 99%) had responses (all PR).\", \"disease\"=>{\"id\"=>66, \"name\"=>\"Salivary Gland Carcinoma\", \"display_name\"=>\"Salivary Gland Carcinoma\", \"doid\"=>\"0050904\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050904\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1437, \"name\"=>\"EID1437\", \"description\"=>\"In a randomized phase 3 trial, HER2 positive metastatic breast cancer patients given first-line treatment of pertuzumab plus trastuzumb plus docetaxel experienced improved progression free survival (18.5 vs 12.4 months,  P<0.001) and increased objective response rate (80.2% vs 69.3%, P=0.001) than the control group given placebo plus trastuzumab plus docetaxel.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>971, \"name\"=>\"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.\", \"citation\"=>\"Baselga et al., 2012, N. Engl. J. Med.\", \"pubmed_id\"=>\"22149875\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22149875\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>1, \"day\"=>12}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1132, \"name\"=>\"EID1132\", \"description\"=>\"This Phase III trial took patients with locally advanced or metastatic HER2 (ERBB2) positive breast cancer that had progressed on prior trastuzumab treatment.  Patients were given capecitabine (n=161) or lapatinib plus capecitabine (n=163). The primary endpoint of the study was time to progression. Median time to progression was 4.4 months in the capecitabine group and 8.4 months in capecitabine plus lapatinib group (hazard ratio was 0.49 ; 95% confidence interval, 0.34 to 0.71; P<0.001).  The results indicated that lapatinib may be useful in addressing the problem of trastuzumab progression in HER2 breast cancer.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>32, \"name\"=>\"Capecitabine\", \"pubchem_id\"=>nil}, {\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>783, \"name\"=>\"Lapatinib plus capecitabine for HER2-positive advanced breast cancer.\", \"citation\"=>\"Geyer et al., 2006, N. Engl. J. Med.\", \"pubmed_id\"=>\"17192538\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17192538\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>12, \"day\"=>28}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1381, \"name\"=>\"EID1381\", \"description\"=>\"Pharmacologic (A66; p110alpha specific inhibitor) or genetic (cre-mediated knockout) ablation of the p110alpha PI3K isoform reduced tumor growth and tumor formation, respectively, in athymic mice transplanted with cells transduced by MMTV-NeuT (mammary specific overexpression of HER2 that effectively induces tumors). A66 treatment of cells from MMTV-NeuT mouse tumors resulted in decreased lipid kinase activity and phospho Akt levels.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>337, \"name\"=>\"A66\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>937, \"name\"=>\"The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.\", \"citation\"=>\"Utermark et al., 2012, Genes Dev.\", \"pubmed_id\"=>\"22802530\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22802530\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3404385\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>7, \"day\"=>15}, \"journal\"=>\"Genes Dev.\", \"full_journal_title\"=>\"Genes & development\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>961, \"name\"=>\"EID961\", \"description\"=>\"A phase II study involving adult female patients, >=18 years, with stage IIIB or IV HER2-positive (by IHC and/or in situ fluorescence) metastatic breast cancer. All patients were previously treated with trastuzumab and a median of three chemotherapy lines. 41 patients received 50 mg afatinib once-daily until disease progression and the primary endpoint was objective response rate. 4 patients (10% of 41 treated; 11% of evaluable patients) had partial response and 15 patients (37% of 41) had stable disease as best response. Thus a total of 19 (46% of 41) achieved clinical benefit. Median progression-free survival was 15.1 weeks.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>663, \"name\"=>\"A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.\", \"citation\"=>\"Lin et al., 2012, Breast Cancer Res. Treat.\", \"pubmed_id\"=>\"22418700\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22418700\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3387495\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>6}, \"journal\"=>\"Breast Cancer Res. Treat.\", \"full_journal_title\"=>\"Breast cancer research and treatment\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>887, \"name\"=>\"EID887\", \"description\"=>\"In this phase 2 trial, treatment-naive, ERBB2-positive (by IHC) breast cancer patients with stage IIIA, B, C or inflammatory disease were randomized 1:1:1 to afatinib (n = 10), lapatinib (n = 8), or trastuzumab (n = 11). The primary end point was objective response rate. Objective response was seen in 8 afatinib-, 6 lapatinib-, and 4 trastuzumab-treated patients. Afatinib demonstrated clinical activity that compared favorably to trastuzumab and lapatinib for neoadjuvant treatment of HER2-positive breast cancer.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>597, \"name\"=>\"A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.\", \"citation\"=>\"Rimawi et al., 2015, Clin. Breast Cancer\", \"pubmed_id\"=>\"25537159\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25537159\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>4}, \"journal\"=>\"Clin. Breast Cancer\", \"full_journal_title\"=>\"Clinical breast cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1499, \"name\"=>\"EID1499\", \"description\"=>\"ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive (overexpression or amplification) advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer.\", \"disease\"=>{\"id\"=>147, \"name\"=>\"Gastric Adenocarcinoma\", \"display_name\"=>\"Gastric Adenocarcinoma\", \"doid\"=>\"3717\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3717\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>708, \"name\"=>\"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.\", \"citation\"=>\"Bang et al., 2010, Lancet\", \"pubmed_id\"=>\"20728210\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20728210\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>8, \"day\"=>28}, \"journal\"=>\"Lancet\", \"full_journal_title\"=>\"Lancet (London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1050, \"name\"=>\"EID1050\", \"description\"=>\"Efficacy of trastuzumab in HER2 overexpressing NSCLC remains unclear.  In this study using a panel of NSCLC HER2 overexpressing cell lines, antiproliferative effects of trastuzumab emtansine (T-DM1) were observed in a HER2-expression dependant manner, with strongest effects in Calu-3 (high expressing) and no effects in Calu-6 (low expressing).  Trastuzumab did not show notable effects on cell growth in any tested cells.  HER2 positivity in NSCLC is fairly common at 2-20%.  A clinical trial (NCT02289833) is currently underway to asses TDM-1 in HER2 overexpressing lung cancer.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>730, \"name\"=>\"Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.\", \"citation\"=>\"Cretella et al., 2014, Mol. Cancer\", \"pubmed_id\"=>\"24898067\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24898067\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4058446\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Mol. Cancer\", \"full_journal_title\"=>\"Molecular cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1097, \"name\"=>\"EID1097\", \"description\"=>\"HER2 expression in uterine serous papillary carcinoma (USPC) is thought to be associated with poor prognosis and may act as a targetable driver mutation in this cancer.  HER2 overexpression in USPC is more common in African American women.  This report covered 2 African American patients, the first of which presented high-grade endometrial adenocarcinoma with IHC3+ HER2-positivity as well as positivity by FISH.  Prior treatment involved surgery and chemotherapy.  Treatment with pacitaxel/carboplatin with trastuzumab showed clear clinical improvement assessed by CT scan and drop in CA-125 levels from 988 to 7.9 U/mL.  The second patient had USPC, and was treated with surgery and radiation.  Trastuzumab monotheraby was then administered.  After 7 months of treatment, the patient showed no sign of disease progression and CA-125 had dropped from 144 to 41 U/mL.  The investigators conclude there is promise in trastuzumab-based therapies in advanced endometrial cancers, including USPC.\", \"disease\"=>{\"id\"=>185, \"name\"=>\"Uterine Corpus Serous Adenocarcinoma\", \"display_name\"=>\"Uterine Corpus Serous Adenocarcinoma\", \"doid\"=>\"5750\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5750\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>756, \"name\"=>\"Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.\", \"citation\"=>\"Santin et al., 2008, Int J Gynaecol Obstet\", \"pubmed_id\"=>\"18555254\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18555254\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>8}, \"journal\"=>\"Int J Gynaecol Obstet\", \"full_journal_title\"=>\"International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1044, \"name\"=>\"EID1044\", \"description\"=>\"This report details 2 case studies in relapsed HER2 positive SCLC.  In the first case, a 50 pack-year patient showed intense non-mutant HER2 expression by IHC without DNA amplification, and had undergone multiple prior lines of treatment.  With induction of trastuzumab and irinotecan treatment, tumor regression was observed with progression free survival of 4.5 months.  Case 2 involved a 68 year old never-smoker with relapsed SCLC.  Tumor showed HER2 positive SCLC cells with no amplification or mutation.  Third line trastuzumab plus irinotecan brought about some symptom improvement and PFS of 3.5 months.  While the efficacy of trastuzumab against NSCLC with elevated levels of wild-type HER2 expression remains unclear, the authors conclude that trastuzumab based therapy is a promising strategy for chemo-resistant SCLC.\", \"disease\"=>{\"id\"=>174, \"name\"=>\"Lung Small Cell Carcinoma\", \"display_name\"=>\"Lung Small Cell Carcinoma\", \"doid\"=>\"5409\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5409\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>101, \"name\"=>\"Irinotecan\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>727, \"name\"=>\"Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.\", \"citation\"=>\"Kinehara et al., 2015, Lung Cancer\", \"pubmed_id\"=>\"25601188\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25601188\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>3}, \"journal\"=>\"Lung Cancer\", \"full_journal_title\"=>\"Lung cancer (Amsterdam, Netherlands)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1686, \"name\"=>\"EID1686\", \"description\"=>\"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.\\nAmong 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective patient cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1138, \"name\"=>\"A molecularly annotated platform of patient-derived xenografts (\\\"xenopatients\\\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.\", \"citation\"=>\"Bertotti et al., 2011, Cancer Discov\", \"pubmed_id\"=>\"22586653\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22586653\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1687, \"name\"=>\"EID1687\", \"description\"=>\"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed resistance whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1138, \"name\"=>\"A molecularly annotated platform of patient-derived xenografts (\\\"xenopatients\\\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.\", \"citation\"=>\"Bertotti et al., 2011, Cancer Discov\", \"pubmed_id\"=>\"22586653\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22586653\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1688, \"name\"=>\"EID1688\", \"description\"=>\"HER2 amplification (FISH) was assessed in 170 KRAS wt mCRC patients treated with cetuximab or panitumumab.\\nHER2 copy number status was significantly correlated with respoinse rate, PFS and OS. Patients with amplification in all neoplastic cells (4%) had worse outcome compared to patients without amplification (35%, intermediate outcome) or amplification in minor clones (61%, highest survival probability)\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1139, \"name\"=>\"HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.\", \"citation\"=>\"Martin et al., 2013, Br. J. Cancer\", \"pubmed_id\"=>\"23348520\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23348520\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3593567\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>2, \"day\"=>19}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1689, \"name\"=>\"EID1689\", \"description\"=>\"Phase 2 study in 27 patients with HER2 positive (IHC, FISH), KRAS wt metastatic colorectal cancer refractory to standard of care received trastuzumab and lapatinib.\\nAfter a median follow-up of 94 weeks, eight (30%, 95% CI 14-50) of 27 patients had achieved an objective response, with one patient (4%, 95% CI -3 to 11) achieving a complete response, and seven (26%, 95% CI 9-43) achieving partial responses; 12 (44%, 95% CI 25-63) patients had stable disease.\\nA total of 914 patients with KRAS wt were screened for this study, 48 patients (5%) were identified to have HER2-positive tumors.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1140, \"name\"=>\"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.\", \"citation\"=>\"Sartore-Bianchi et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"27108243\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27108243\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1764, \"name\"=>\"EID1764\", \"description\"=>\"In the single arm Phase II study (TDM4258g) breast cancer patients who had progressed on previous anti-HER2 therapy were given transtuzumab emtansine (T-DM1), a HER2 monoclonal antibody and antimicrotubule drug conjugate. 95 trial participants with archival primary tumor were reassessed for HER2 status (positivity defined by FISH or IHC 3+), and 74 patients were confirmed for HER2 positivity and 21 were normal. Overall response rate was 33.8% (95% CI, 23.2% to 44.9%) in patients with confirmed HER2-positive tumors and 4.8% (95% CI, 1.0% to 21.8%) in HER2 normal patients. Median PFS was 8.2 months (95% CI, 4.4 months to not estimable) in patients with confirmed HER2-positive tumors and 2.6 months (95% CI, 1.4 to 3.9 months) in HER2 normal patients.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1229, \"name\"=>\"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.\", \"citation\"=>\"Burris et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21172893\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21172893\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1448, \"name\"=>\"EID1448\", \"description\"=>\"In 5 trastuzumab resistant HER2 overexpressing breast cancer cell lines, combination of the pan-PI3K inhibitor XL147 and trastuzumab treatment induced cell death to similar or greater levels than XL147 alone. In three trastuzumab resistant cell lines tested, colony formation in matrigel was markedly inhibited by combination treatment. Apoptotic markers were apparent with combination treatment. In athymic mice, trastuzumab resistant cell line HR6 was used in tumor xenografts and tumors were allowed to form. Mice subsequently treated with trastuzumab or XL147 showed continued tumor growth without marked difference from control, while combination treatment essentially halted tumor growth rate.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>349, \"name\"=>\"XL147 (Pilaralisib)\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>977, \"name\"=>\"Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.\", \"citation\"=>\"Chakrabarty et al., 2013, Cancer Res.\", \"pubmed_id\"=>\"23204226\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23204226\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3563941\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1042, \"name\"=>\"EID1042\", \"description\"=>\"In this phase II trial a small group of patients with IHC2+ or IHC3+ HER2 NSCLC, in which primary platinum-based therapy had failed, were given either docetaxel or trastuzumab after which both groups were given docetaxel and trastuzumab together.  there was one partial response in the docetaxel group and none in the trastuzumab group.  The authors report that due to the limited clinical activity of trastuzumab-based therapy in this cohort, as well as similar results in other trastuzumab studies, that targets other than HER2 in NSCLC should be considered for future study.  This 2004 study remains cited in 2016 literature in discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC, but mutant HER2 in NSCLC has been further studied and a picture of different HER2 mutations being potentially responsive to specific targeted therapies is emerging.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>725, \"name\"=>\"Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.\", \"citation\"=>\"Lara et al., 2004, Clin Lung Cancer\", \"pubmed_id\"=>\"14967075\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/14967075\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>1}, \"journal\"=>\"Clin Lung Cancer\", \"full_journal_title\"=>\"Clinical lung cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1380, \"name\"=>\"EID1380\", \"description\"=>\"The HER2/Neu mammary tumor mouse model MMTV-NeuT was employed to demonstrate dependence of HER2 tumor formation on PIK3 p110alpha isoform. MMTV-NeuT mice were crossed with floxed p110alpha mice. Diassacociated tumors cells from these mice were treated with Cre adenovirus to delete p110alpha, or GFP adenovirus, and cells were transplanted into athymic mice. GFP treated cells formed new tumors, while p110alpha deletion blocked tumor formation indicating tumor dependence on PI3KA. Next, MMTV-NeuT tumors were dissociated and treated with pan-PI3K inhibitor GDC-0941. Reduced lipid kinase activity and reduced phospho-Akt levels were seen in these cells. Administration of 125 mg/kg GDC-0941 to athymic mice with transplantation of tumor cells caused marked reduction of tumor cell volume in comparison to control treatment.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>141, \"name\"=>\"Pictilisib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>937, \"name\"=>\"The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.\", \"citation\"=>\"Utermark et al., 2012, Genes Dev.\", \"pubmed_id\"=>\"22802530\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22802530\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3404385\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>7, \"day\"=>15}, \"journal\"=>\"Genes Dev.\", \"full_journal_title\"=>\"Genes & development\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1439, \"name\"=>\"EID1439\", \"description\"=>\"In a randomized open label phase 3 study (NCT00553358), women with HER2 positive primary breast cancer treated with lapatinib plus trasuzumab had higher rates of pathological complete responses than seen in control groups receiving either IV trastuzumab or oral lapatinib alone (combination treatment pCR rate of 51% vs 29.5% and 24.7% for trastuzumab and lapatinib alone, respectively).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>972, \"name\"=>\"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.\", \"citation\"=>\"Baselga et al., 2012, Lancet\", \"pubmed_id\"=>\"22257673\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22257673\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>2, \"day\"=>18}, \"journal\"=>\"Lancet\", \"full_journal_title\"=>\"Lancet (London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1382, \"name\"=>\"EID1382\", \"description\"=>\"Treatment of cells obtained from MMTV-NeuT mouse mammary tumors with the p110beta selective inhibitor TGX-221 showed significant but minimal reductions in lipid kinase activity and negligible reductions in phospho Akt levels. In simmilar cells subjected to p110alpha isoform knockout, TGX-221 treatment fully blocked Akt activation, indicating that TGX-221 was fully inhibiting the p110beta isoform. Athymic mice recieved MMTV-NeuT tumor cell transplants and were treated with TGX-221, which resulted in significant but minimal reduction in tumor growth compared to controls.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>338, \"name\"=>\"Tgx 221\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>937, \"name\"=>\"The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.\", \"citation\"=>\"Utermark et al., 2012, Genes Dev.\", \"pubmed_id\"=>\"22802530\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22802530\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3404385\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>7, \"day\"=>15}, \"journal\"=>\"Genes Dev.\", \"full_journal_title\"=>\"Genes & development\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1693, \"name\"=>\"EID1693\", \"description\"=>\"A 71-year old male with metastatic extramammary Pagetâs disease of the scrotum overexpressing Her2/neu was treated with trastuzumab, achieving a complete response. At 12 months, he maintains stable disease.\", \"disease\"=>{\"id\"=>779, \"name\"=>\"Scrotum Paget's Disease\", \"display_name\"=>\"Scrotum Paget's Disease\", \"doid\"=>\"3444\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3444\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1142, \"name\"=>\"Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.\", \"citation\"=>\"Barth et al., 2015, Case Rep Oncol Med\", \"pubmed_id\"=>\"25692060\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25692060\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4322830\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"Case Rep Oncol Med\", \"full_journal_title\"=>\"Case reports in oncological medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1393, \"name\"=>\"EID1393\", \"description\"=>\"155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 2 of 24 patients tested were found to have HER2 amplification (but no baseline samples available for analysis). One patient of which had a metastasis sample which was reported to have only HER2 amplification whereas another autopsy specimen from the same patient was HER2 negative but EGFR T790M positive.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}, {\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>943, \"name\"=>\"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.\", \"citation\"=>\"Yu et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23470965\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23470965\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3630270\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1891, \"name\"=>\"EID1891\", \"description\"=>\"Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. 4 patients with HER2 amplified NSCLC were enrolled in the trial, no one among them had a response.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>44, \"name\"=>\"Dacomitinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>729, \"name\"=>\"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.\", \"citation\"=>\"Kris et al., 2015, Ann. Oncol.\", \"pubmed_id\"=>\"25899785\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25899785\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>7}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1432, \"name\"=>\"EID1432\", \"description\"=>\"In a randomized phase II study, first line treatment of HER2-positive metastatic breast cancer with trastuzumab emtansine (T-DM1) resulted in improved progression free survival and fewer serious adverse effects when compared to treatment with combination trastuzumab plus docetaxel (HT) (median follow up 14 months, median PFS with T-DM1 14.2 vs 9.2 with HT).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>970, \"name\"=>\"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.\", \"citation\"=>\"Hurvitz et al., 2013, J. Clin. Oncol.\", \"pubmed_id\"=>\"23382472\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23382472\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>3, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1098, \"name\"=>\"EID1098\", \"description\"=>\"This phase II single arm study assessed trastuzumab monotherapy in HER2 positive endometrial cancers with tumor response as primary endpoint.  Participants had stage III, IV or recurrent HER2 positive endometrial cancer.  During the trial's initial phase, 23 of 132 patients screened met the criteria of IHC2+ or 3+ or FISH positivity for HER2 status.  In the absence of results, the trial entered phase B, where only patients with HER2 amplification by FISH were admitted.  The trial ended early due to poor accrual with 11 of 154 screened meeting the phase B criteria. No major objective tumor responses were observed in the study.  28% of the cancers were of the serous type that had shown trastuzumab response in case studies.  The investigators note that in other HER2 cancers, such as breast and gastrointestinal, trastuzumab in combination with chemotherapy has been found most effective, and could warrant more study.  Currently a clinical trial (NCT01367002) is evaluating carboplatin/paclitaxel with or without trastuzumab in uterine serous cancer.\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>757, \"name\"=>\"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.\", \"citation\"=>\"Fleming et al., 2010, Gynecol. Oncol.\", \"pubmed_id\"=>\"19840887\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19840887\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2804260\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>1}, \"journal\"=>\"Gynecol. Oncol.\", \"full_journal_title\"=>\"Gynecologic oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1077, \"name\"=>\"EID1077\", \"description\"=>\"CLEOPATRA (NCT00567190) was a Phase III, randomized and double-blind, placebo-controlled study of 808 patients with HER2-positive metastatic breast cancer.  Patients were HER2-positive by IHC3+ or FISH, and patients who had received prior hormonal treatment or adjuvant/neo-adjuvant therapy with or without trastuzumab for longer than 12 months before randomization were also eligible.  The two arms of the study were trastuzumab and docetaxel with either placebo or pertuzumab.  Median PFS in the placebo arm was 12.4 months while in the petuzumab arm 18.5 months was achieved.  Median OS in the control arm was 40.8 months and 56.5 months with pertuzumab.  These strong results make a case for dual antibody blockade in first line treatments of HER2-positive metastatic breast cancer.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>745, \"name\"=>\"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.\", \"citation\"=>\"Swain et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"25693012\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25693012\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>2, \"day\"=>19}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1096, \"name\"=>\"EID1096\", \"description\"=>\"In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient information.  Earlier deaths were seen with heavier HER2 expression.  Multivariate Cox regression indicated that shorter survival was associated with higher HER2 expression, and not with age or ethnicity, and that observed differences in survival rates between ethnicities can be ascribed to higher rates of HER2 overexpression in African American patients.  The authors conclude that high HER2 expression in USPC is associated with poor outcome and explains observed differences in outcome between ethnicities.\", \"disease\"=>{\"id\"=>185, \"name\"=>\"Uterine Corpus Serous Adenocarcinoma\", \"display_name\"=>\"Uterine Corpus Serous Adenocarcinoma\", \"doid\"=>\"5750\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5750\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>755, \"name\"=>\"Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.\", \"citation\"=>\"Santin et al., 2005, Am. J. Obstet. Gynecol.\", \"pubmed_id\"=>\"15746676\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15746676\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>3}, \"journal\"=>\"Am. J. Obstet. Gynecol.\", \"full_journal_title\"=>\"American journal of obstetrics and gynecology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1041, \"name\"=>\"EID1041\", \"description\"=>\"In this phase II trial with 2 arms, 103 patients with untreated stage IIIB/IV HER2 positive NSCLC were given gemcitabine-cisplatin with or without trastuzumab.  HER2 positivity was broadly defined as IHC2+/3+, positive by FISH, or increased circulating HER2 extracellular domain.  Significant differences between the treatment arms were not observed, but in a small subset of IHC3+/FISH positive patients, 5 of 6 responded to trastuzumab and had increased PFS of 8.5 months in comparison to 6.1 months in the IHC2+ group.  Although from 2004, this study remains cited in 2016 literature when discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC. The authors conclude that future studies of trastuzumab in HER2 positive NSCLC should focus on high expressing subjects.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>724, \"name\"=>\"Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.\", \"citation\"=>\"Gatzemeier et al., 2004, Ann. Oncol.\", \"pubmed_id\"=>\"14679114\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/14679114\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>1}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1122, \"name\"=>\"EID1122\", \"description\"=>\"HERA was a Phase III trial assessing application of trastuzumab in an extended adjuvant setting.  Patients were HER2 positive with completely excised invasive BC, node positive or negative, and having undergone prior adjuvant or neo-adjuvant chemotherapy.  In the 3 arm study patients were given trastuzumab courses of 1 year, 2 years, or untreated.  At the first planned interim analysis, trastuzumab treatment for one year was compared with observation alone.  A significant difference in disease-free survival was seen with 220 DFS events out of 1693 in the observation arm versus 127 DFS events out of 1694 in the 1 year trastuzumab arm.  1 year adjuvant trastuzumab is currently the standard of care.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>777, \"name\"=>\"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.\", \"citation\"=>\"Piccart-Gebhart et al., 2005, N. Engl. J. Med.\", \"pubmed_id\"=>\"16236737\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16236737\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>10, \"day\"=>20}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1561, \"name\"=>\"EID1561\", \"description\"=>\"In a panel of 47 breast cancer cell lines, HER2 overexpressing cells were among those more sensitive to CDK4/6 inhibitor Palbociclib (PD0332991). In the trastuzumab sensitive cell line Bt474, palbociclib synergized with trastuzumab in growth inhibition, while in 2 trastuzumab resistant cell lines, addition of trastuzumab to palbociclib treatment resulted in increased growth inhibition over palbociclib alone.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>48, \"name\"=>\"Palbociclib (PD0332991)\", \"pubchem_id\"=>\"\"}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1031, \"name\"=>\"PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.\", \"citation\"=>\"Finn et al., 2009, Breast Cancer Res.\", \"pubmed_id\"=>\"19874578\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19874578\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2790859\", \"publication_date\"=>{\"year\"=>2009}, \"journal\"=>\"Breast Cancer Res.\", \"full_journal_title\"=>\"Breast cancer research : BCR\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1613, \"name\"=>\"EID1613\", \"description\"=>\"In a panel of 31 breast cancer cell lines with varied mutation backgrounds, 10 cell lines harbored HER2 (ERBB2) amplification. Sensitivity to the mTORC1/2 inhibitor PP242 was assessed, and 8/10 HER2 positive cell lines were reported to be sensitive (IC50 < 1 micro molar PP242).  8/21 without HER2 amplification were reported as resistant (IC50 > 1 micro molar PP242). This pattern of HER2 positive cell sensitivity was not reported with the rapamycin analog  mTORC1 inhibitor everolimus.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>179, \"name\"=>\"PP242\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1066, \"name\"=>\"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.\", \"citation\"=>\"Weigelt et al., 2011, Oncogene\", \"pubmed_id\"=>\"21358673\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21358673\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>7, \"day\"=>21}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1022, \"name\"=>\"EID1022\", \"description\"=>\"ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer.\", \"disease\"=>{\"id\"=>147, \"name\"=>\"Gastric Adenocarcinoma\", \"display_name\"=>\"Gastric Adenocarcinoma\", \"doid\"=>\"3717\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3717\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>708, \"name\"=>\"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.\", \"citation\"=>\"Bang et al., 2010, Lancet\", \"pubmed_id\"=>\"20728210\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20728210\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>8, \"day\"=>28}, \"journal\"=>\"Lancet\", \"full_journal_title\"=>\"Lancet (London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1010, \"name\"=>\"EID1010\", \"description\"=>\"With multiple mechanisms of HER reprogramming thought to be behind trastuzumab resistance, including increased expression of ErbB members, afatinib, which broadly and irreversibly targets ErbB receptors was tested in a single arm phase II trial on advanced stage HER2 positive metastatic breast cancer. From 41 treated patients, 10% had partial response, 37% had stable disease as best response and 46% achieved clinical benefit.  Median progression free survival (PFS) was 15.1 weeks and median overall survival (OS) was 61.0 weeks. The authors conclude that Afatinib monotherapy shows promise in treatment of metastatic HER2 positive breast cancer that has progressed under trastuzumab.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>663, \"name\"=>\"A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.\", \"citation\"=>\"Lin et al., 2012, Breast Cancer Res. Treat.\", \"pubmed_id\"=>\"22418700\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22418700\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3387495\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>6}, \"journal\"=>\"Breast Cancer Res. Treat.\", \"full_journal_title\"=>\"Breast cancer research and treatment\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1009, \"name\"=>\"EID1009\", \"description\"=>\"This Phase III study (EGF104900) was motivated by preclinical and other data demonstrating synergistic activity between lapatinib and trastuzumab against HER2 positive breast cancer (BC) cells.  In this study of HER2 positive metastatic BC which had progressed on trastuzumab, two arms were compared: lapatinib vs. lapatinib + trastuzumab. Progression free survival (PFS) was the primary endpoint. For 296 patients, 148 in each arm, median PFS of 8.1 weeks for lapatinib and 12.0 for combination therapy was observed (P=0.008).  The authors conclude that in the context of metastatic trastuzumab-progressed HER2 positive BC, trastuzumab with lapatinib TKI addition is a favorable treatment.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>698, \"name\"=>\"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.\", \"citation\"=>\"Blackwell et al., 2010, J. Clin. Oncol.\", \"pubmed_id\"=>\"20124187\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20124187\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>962, \"name\"=>\"EID962\", \"description\"=>\"Afatinib was growth-inhibitory for three pancreatic cancer cell lines but cytotoxic only toward BxPC3 (KRAS wt) and Capan-2 (KRAS mut) cells, both of which express high levels of EGFR, ERBB2, and ERBB3 receptors. Afatinib increased the radiosensitivity of BxPC3 and Capan-2 cells. In comparison, Panc-1 cells (KRAS mut) expressing low levels of EGFR family receptors were resistant to afatinib-induced radiosensitization.\", \"disease\"=>{\"id\"=>158, \"name\"=>\"Pancreatic Adenocarcinoma\", \"display_name\"=>\"Pancreatic Adenocarcinoma\", \"doid\"=>\"4074\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4074\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>664, \"name\"=>\"Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.\", \"citation\"=>\"Huguet et al., 2016, Target Oncol\", \"pubmed_id\"=>\"26668065\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26668065\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Target Oncol\", \"full_journal_title\"=>\"Targeted oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>895, \"name\"=>\"EID895\", \"description\"=>\"141 patients were analyzed for ERBB2 (HER2) positivity by FISH and/or IHC. Only 6 (4.3%) were ERBB2 positive. These patients did not show a difference in outcome after capecitabine, oxaliplatin and chemoradiotherapy, with or without cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>32, \"name\"=>\"Capecitabine\", \"pubchem_id\"=>nil}, {\"id\"=>237, \"name\"=>\"Oxaliplatin\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>603, \"name\"=>\"HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.\", \"citation\"=>\"Sclafani et al., 2013, Ann. Oncol.\", \"pubmed_id\"=>\"24146218\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24146218\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>12}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>886, \"name\"=>\"EID886\", \"description\"=>\"Eight uterine cancer cell lines (four with ERBB2 amplification and four without) were treated with scalar concentrations of afatinib. Primary chemotherapy-resistant USC cell lines harbouring ERBB2 gene amplification were sensitive to afatinib exposure and significantly more sensitive than non-amplified cell lines.\", \"disease\"=>{\"id\"=>93, \"name\"=>\"Uterine Corpus Endometrial Carcinoma\", \"display_name\"=>\"Uterine Corpus Endometrial Carcinoma\", \"doid\"=>\"0050939\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050939\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>596, \"name\"=>\"Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.\", \"citation\"=>\"Schwab et al., 2014, Br. J. Cancer\", \"pubmed_id\"=>\"25268372\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25268372\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4453741\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>10, \"day\"=>28}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1023, \"name\"=>\"EID1023\", \"description\"=>\"TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer.  Primary endpoint was Overall Survival (OS).  Participants had progressed under previous treatment and only a small percentage had seen first line trastuzumab.  Patients were a mix of those having undergone gastrectomy and not.  OS was not significantly  different in the ITT population, but certain subpopulations showed significant differences.  In the subset of patients showing a stronger immunohistochemistry result for HER2 (IHC3+), progression free survival was significantly different at 5.6 months for lapatinib + pacitaxel vs. 4.2 months for pacitaxel alone.  The authors conclude that proof of concept for lapatanib addition to chemotherapy for certain subgroups is provided in this study.\", \"disease\"=>{\"id\"=>147, \"name\"=>\"Gastric Adenocarcinoma\", \"display_name\"=>\"Gastric Adenocarcinoma\", \"doid\"=>\"3717\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3717\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>709, \"name\"=>\"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.\", \"citation\"=>\"Satoh et al., 2014, J. Clin. Oncol.\", \"pubmed_id\"=>\"24868024\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24868024\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1006, \"name\"=>\"EID1006\", \"description\"=>\"In-vitro studies using ERBB2 over-expressing breast cancer cell lines BT474 and SKBR3 (with ERBB2 amplification) showed apoptosis under either labatinib or trastuzumab treatment.  A marked synergistic apoptotic effect under lapatinib and trastuzumab co-treatment was observed in BT474 cells, and a milder synergistic effect was observed in SKBR3 cells.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>695, \"name\"=>\"Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.\", \"citation\"=>\"Xia et al., 2005, Oncogene\", \"pubmed_id\"=>\"16091755\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16091755\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>9, \"day\"=>15}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>760, \"name\"=>\"EID760\", \"description\"=>\"Xenografts established from breast cancer cell lines with ERBB2 amplification and PIK3CA mutation (BT474) or PIK3CA mutation alone (MCF7) were effectively inhibited in-vivo with an AKT1/2-inhibitor (AKTi-1/2; naphthyridinone).\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>169, \"name\"=>\"AKTi-1/2\", \"pubchem_id\"=>\"\"}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>503, \"name\"=>\"Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.\", \"citation\"=>\"She et al., 2008, PLoS ONE\", \"pubmed_id\"=>\"18725974\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18725974\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2516933\", \"publication_date\"=>{\"year\"=>2008}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>761, \"name\"=>\"EID761\", \"description\"=>\"Oral neratinib showed objective response rates of 24 and 56% respectively in prior-trastuzumab and trastuzumab-naive cohorts in a Phase II trial with a primary endpoint of 16-week progression free survival.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>52, \"name\"=>\"Neratinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>504, \"name\"=>\"Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.\", \"citation\"=>\"Burstein et al., 2010, J. Clin. Oncol.\", \"pubmed_id\"=>\"20142587\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20142587\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>3, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}]}, {\"id\"=>131, \"entrez_name\"=>\"BRCA1\", \"entrez_id\"=>672, \"name\"=>\"LOSS-OF-FUNCTION\", \"description\"=>\"BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.\", \"gene_id\"=>6, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>97, \"name\"=>\"loss_of_heterozygosity\", \"display_name\"=>\"Loss Of Heterozygosity\", \"so_id\"=>\"SO:0001786\", \"description\"=>\"A functional variant whereby the sequence alteration causes a loss of function of one allele of a gene.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001786\"}, {\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>104.0, \"coordinates\"=>{\"chromosome\"=>\"17\", \"start\"=>41196312, \"stop\"=>41277387, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000357654.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/6/summary/variants/131/summary#variant\", \"evidence_items\"=>[{\"id\"=>4876, \"name\"=>\"EID4876\", \"description\"=>\"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>523, \"name\"=>\"Talazoparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2143, \"name\"=>\"Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.\", \"citation\"=>\"de Bono et al., 2017, Cancer Discov\", \"pubmed_id\"=>\"28242752\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28242752\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>6}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>131, \"phenotypes\"=>[]}, {\"id\"=>4838, \"name\"=>\"EID4838\", \"description\"=>\"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>523, \"name\"=>\"Talazoparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2143, \"name\"=>\"Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.\", \"citation\"=>\"de Bono et al., 2017, Cancer Discov\", \"pubmed_id\"=>\"28242752\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28242752\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>6}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>131, \"phenotypes\"=>[]}, {\"id\"=>5815, \"name\"=>\"EID5815\", \"description\"=>\"302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA1 patients specifically, the hazard ratio was 0.54, 95% CI 0.37-0.79).\", \"disease\"=>{\"id\"=>369, \"name\"=>\"Her2-receptor Negative Breast Cancer\", \"display_name\"=>\"Her2-receptor Negative Breast Cancer\", \"doid\"=>\"0060080\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060080\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2329, \"name\"=>\"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.\", \"citation\"=>\"Robson et al., 2017, N. Engl. J. Med.\", \"pubmed_id\"=>\"28578601\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28578601\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"day\"=>10}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02000622\", \"name\"=>\"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.\", \"description\"=>\"This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2 mutations.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02000622\"}]}, \"variant_id\"=>131, \"phenotypes\"=>[]}, {\"id\"=>1924, \"name\"=>\"EID1924\", \"description\"=>\"The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. Xenografts harbored both a germline BRCA and a somatic BRCA mutation leading to disruption of both. The BRCA and NHEJ pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>439, \"name\"=>\"CX-5461\", \"pubchem_id\"=>nil}, {\"id\"=>440, \"name\"=>\"CX-3543\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Unknown\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1346, \"name\"=>\"CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.\", \"citation\"=>\"Xu et al., 2017, Nat Commun\", \"pubmed_id\"=>\"28211448\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28211448\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>2, \"day\"=>17}, \"journal\"=>\"Nat Commun\", \"full_journal_title\"=>\"Nature communications\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>131, \"phenotypes\"=>[]}, {\"id\"=>1523, \"name\"=>\"EID1523\", \"description\"=>\"In a study of 2,019 patients with prostate cancer, 18 had germline BRCA1 mutations, 61 had germline BRCA2 mutations and 1,940 were non-carriers.  Patients with BRCA1/2 mutations had a 2-fold higher incidence of poorly differentiated cancer (Gleason score >8), a higher incidence of advanced stage (37% vs. 28%; P=0.003), a higher incidence of nodal involvement (15% vs. 5%; P=0.0005), and a higher incidence of metastatic spread (18% vs. 9%; P=0.005).\", \"disease\"=>{\"id\"=>46, \"name\"=>\"Prostate Cancer\", \"display_name\"=>\"Prostate Cancer\", \"doid\"=>\"10283\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10283\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1016, \"name\"=>\"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.\", \"citation\"=>\"Castro et al., 2013, J. Clin. Oncol.\", \"pubmed_id\"=>\"23569316\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23569316\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3641696\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>5, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>131, \"phenotypes\"=>[]}, {\"id\"=>211, \"name\"=>\"EID211\", \"description\"=>\"The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undifferentiated ovarian cancer.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>150, \"name\"=>\"Advanced ovarian cancer: what should be the standard of care?\", \"citation\"=>\"Goff, 2013, J Gynecol Oncol\", \"pubmed_id\"=>\"23346317\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23346317\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3549512\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>1}, \"journal\"=>\"J Gynecol Oncol\", \"full_journal_title\"=>\"Journal of gynecologic oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>131, \"phenotypes\"=>[]}, {\"id\"=>845, \"name\"=>\"EID845\", \"description\"=>\"1/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study.\", \"disease\"=>{\"id\"=>46, \"name\"=>\"Prostate Cancer\", \"display_name\"=>\"Prostate Cancer\", \"doid\"=>\"10283\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10283\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>409, \"name\"=>\"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.\", \"citation\"=>\"Mateo et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"26510020\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26510020\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>10, \"day\"=>29}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>131, \"phenotypes\"=>[]}]}, {\"id\"=>157, \"entrez_name\"=>\"TET2\", \"entrez_id\"=>54790, \"name\"=>\"MUTATION\", \"description\"=>\"TET2 mutations are commonly found in acute myeloid leukemia occurring in 9-23% of cases with many occurring in the elderly. Generally these mutations are loss-of-function which have been shown in mouse models to impair hematopoietic stem cell differentiation and cause aberrant hematopoiesis. These mutations have been found to be mutually exclusive with MLL and IDH1/2 mutations and have been associated with shortened event-free-survival and disease-free-survival when co-occurring with NPM1+/FLT3- genotypes. Overall Survival has been found to be shorter when occurring with NPM1+/FLT3+ genotypes. Studies involving \\\"CN AML\\\" and \\\"de novo AML\\\" however have been unable to elucidate a clinical impact.\", \"gene_id\"=>55, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>30, \"name\"=>\"gene_variant\", \"display_name\"=>\"Gene Variant\", \"so_id\"=>\"SO:0001564\", \"description\"=>\"A sequence variant where the structure of the gene is changed.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001564\"}, {\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>120.0, \"coordinates\"=>{\"chromosome\"=>\"4\", \"start\"=>106067450, \"stop\"=>106200973, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000513237.1\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/55/summary/variants/157/summary#variant\", \"evidence_items\"=>[{\"id\"=>427, \"name\"=>\"EID427\", \"description\"=>\"In patients with cytogenetically normal acute myeloid leukemia, those in the ELN favorable-risk group with TET2 mutations had shorter event-free survival, lower rates of complete remission, and shorter disease-free survival.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>250, \"name\"=>\"TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.\", \"citation\"=>\"Metzeler et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21343549\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21343549\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3084003\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>157, \"phenotypes\"=>[]}, {\"id\"=>426, \"name\"=>\"EID426\", \"description\"=>\"In patients classified as intermediate-risk via cytogenetics, TET2 mutations have been shown to be correlated with poor prognosis.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>253, \"name\"=>\"TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.\", \"citation\"=>\"Chou et al., 2011, Blood\", \"pubmed_id\"=>\"21828143\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21828143\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>10, \"day\"=>6}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>157, \"phenotypes\"=>[]}, {\"id\"=>421, \"name\"=>\"EID421\", \"description\"=>\"In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations did not have significantly different rates of event-free survival, complete remission, disease-free survival, or overall survival.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>250, \"name\"=>\"TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.\", \"citation\"=>\"Metzeler et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21343549\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21343549\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3084003\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>157, \"phenotypes\"=>[]}, {\"id\"=>419, \"name\"=>\"EID419\", \"description\"=>\"In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations had higher rates of complete remission.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>245, \"name\"=>\"TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.\", \"citation\"=>\"Gaidzik et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22430270\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22430270\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>157, \"phenotypes\"=>[]}, {\"id\"=>417, \"name\"=>\"EID417\", \"description\"=>\"In patients with myelodysplastic syndromes, those with TET2 mutations have been shown to have better overall survival than patients without TET2 mutations.\", \"disease\"=>{\"id\"=>34, \"name\"=>\"Myelodysplastic Syndrome\", \"display_name\"=>\"Myelodysplastic Syndrome\", \"doid\"=>\"0050908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050908\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>247, \"name\"=>\"TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).\", \"citation\"=>\"Kosmider et al., 2009, Blood\", \"pubmed_id\"=>\"19666869\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19666869\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>10, \"day\"=>8}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>157, \"phenotypes\"=>[]}, {\"id\"=>415, \"name\"=>\"EID415\", \"description\"=>\"In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>245, \"name\"=>\"TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.\", \"citation\"=>\"Gaidzik et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22430270\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22430270\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>157, \"phenotypes\"=>[]}]}, {\"id\"=>185, \"entrez_name\"=>\"BRCA1\", \"entrez_id\"=>672, \"name\"=>\"MUTATION\", \"description\"=>\"\", \"gene_id\"=>6, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>30, \"name\"=>\"gene_variant\", \"display_name\"=>\"Gene Variant\", \"so_id\"=>\"SO:0001564\", \"description\"=>\"A sequence variant where the structure of the gene is changed.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001564\"}, {\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>180.0, \"coordinates\"=>{\"chromosome\"=>\"17\", \"start\"=>41196312, \"stop\"=>41277387, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000357654.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/6/summary/variants/185/summary#variant\", \"evidence_items\"=>[{\"id\"=>5915, \"name\"=>\"EID5915\", \"description\"=>\"Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively.\\nIn patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2389, \"name\"=>\"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.\", \"citation\"=>\"Golan et al., 2014, Br. J. Cancer\", \"pubmed_id\"=>\"25072261\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25072261\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4453851\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>9, \"day\"=>9}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>5914, \"name\"=>\"EID5914\", \"description\"=>\"Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. All but one had received gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2388, \"name\"=>\"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.\", \"citation\"=>\"Kaufman et al., 2015, J. Clin. Oncol.\", \"pubmed_id\"=>\"25366685\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25366685\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>1, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>5934, \"name\"=>\"EID5934\", \"description\"=>\"Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy. No confirmed PR was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>556, \"name\"=>\"Veliparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2406, \"name\"=>\"Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.\", \"citation\"=>\"Lowery et al., 2018, Eur. J. Cancer\", \"pubmed_id\"=>\"29223478\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29223478\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1}, \"journal\"=>\"Eur. J. Cancer\", \"full_journal_title\"=>\"European journal of cancer (Oxford, England : 1990)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT01585805\", \"name\"=>\"Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer\", \"description\"=>\"This randomized phase II trial studies how well veliparib together with gemcitabine hydrochloride and cisplatin works compared to gemcitabine hydrochloride and cisplatin alone in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or spread from the primary site (place where it started) to other places in the body (metastatic). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving veliparib together with gemcitabine hydrochloride and cisplatin is an effective treatment for pancreatic cancer.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT01585805\"}, {\"nct_id\"=>\"NCT02184195\", \"name\"=>\"Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy\", \"description\"=>\"A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02184195\"}]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>5932, \"name\"=>\"EID5932\", \"description\"=>\"In Phase I study for pancreatic cancer patients\\nGEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>85, \"name\"=>\"Gemcitabine\", \"pubchem_id\"=>nil}, {\"id\"=>326, \"name\"=>\"Cisplatin\", \"pubchem_id\"=>nil}, {\"id\"=>556, \"name\"=>\"Veliparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2405, \"name\"=>\"Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.\", \"citation\"=>\"O'Reilly et al., 2018, Cancer\", \"pubmed_id\"=>\"29338080\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29338080\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>16}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT01585805\", \"name\"=>\"Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer\", \"description\"=>\"This randomized phase II trial studies how well veliparib together with gemcitabine hydrochloride and cisplatin works compared to gemcitabine hydrochloride and cisplatin alone in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or spread from the primary site (place where it started) to other places in the body (metastatic). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving veliparib together with gemcitabine hydrochloride and cisplatin is an effective treatment for pancreatic cancer.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT01585805\"}]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>5830, \"name\"=>\"EID5830\", \"description\"=>\"Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2ânegative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2357, \"name\"=>\"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.\", \"citation\"=>\"2017, N. Engl. J. Med.\", \"pubmed_id\"=>\"28792849\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28792849\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>8, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1897, \"name\"=>\"EID1897\", \"description\"=>\"A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor Rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA mutant patients, 10 had somatic BRCA1 mutation. Confirmed objective response was seen in 79% of the BRCA1 mutant subgroup, and 74% confirmed objective response was seen in the somatic BRCA mutant subgroup. In a BRCA wild-type subgroup, with low levels of Loss of Heterozygosity, confirmed objective response was observed in 10% of the patients.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>431, \"name\"=>\"Rucaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1328, \"name\"=>\"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.\", \"citation\"=>\"Swisher et al., 2017, Lancet Oncol.\", \"pubmed_id\"=>\"27908594\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27908594\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>1}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1684, \"name\"=>\"EID1684\", \"description\"=>\"In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.\", \"disease\"=>{\"id\"=>370, \"name\"=>\"Triple-receptor Negative Breast Cancer\", \"display_name\"=>\"Triple-receptor Negative Breast Cancer\", \"doid\"=>\"0060081\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060081\"}, \"drugs\"=>[{\"id\"=>93, \"name\"=>\"Carboplatin\", \"pubchem_id\"=>nil}, {\"id\"=>326, \"name\"=>\"Cisplatin\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1137, \"name\"=>\"TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.\", \"citation\"=>\"Isakoff et al., 2015, J. Clin. Oncol.\", \"pubmed_id\"=>\"25847936\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25847936\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4451173\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>6, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1675, \"name\"=>\"EID1675\", \"description\"=>\"664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo.  Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative.  Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1133, \"name\"=>\"BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.\", \"citation\"=>\"Harter et al., 2016, Gynecol. Oncol.\", \"pubmed_id\"=>\"26740259\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26740259\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Gynecol. Oncol.\", \"full_journal_title\"=>\"Gynecologic oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1677, \"name\"=>\"EID1677\", \"description\"=>\"46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}, {\"id\"=>400, \"name\"=>\"Cediranib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1134, \"name\"=>\"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.\", \"citation\"=>\"Liu et al., 2014, Lancet Oncol.\", \"pubmed_id\"=>\"25218906\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25218906\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4294183\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>10}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1529, \"name\"=>\"EID1529\", \"description\"=>\"In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.\", \"disease\"=>{\"id\"=>47, \"name\"=>\"Ovarian Carcinoma\", \"display_name\"=>\"Ovarian Carcinoma\", \"doid\"=>\"4001\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4001\"}, \"drugs\"=>[{\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1020, \"name\"=>\"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.\", \"citation\"=>\"Pennington et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24240112\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24240112\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3944197\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1531, \"name\"=>\"EID1531\", \"description\"=>\"In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum-based therapy.\", \"disease\"=>{\"id\"=>47, \"name\"=>\"Ovarian Carcinoma\", \"display_name\"=>\"Ovarian Carcinoma\", \"doid\"=>\"4001\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4001\"}, \"drugs\"=>[{\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1020, \"name\"=>\"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.\", \"citation\"=>\"Pennington et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24240112\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24240112\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3944197\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1772, \"name\"=>\"EID1772\", \"description\"=>\"In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1239, \"name\"=>\"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.\", \"citation\"=>\"Gelmon et al., 2011, Lancet Oncol.\", \"pubmed_id\"=>\"21862407\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21862407\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>9}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1775, \"name\"=>\"EID1775\", \"description\"=>\"In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.\", \"disease\"=>{\"id\"=>370, \"name\"=>\"Triple-receptor Negative Breast Cancer\", \"display_name\"=>\"Triple-receptor Negative Breast Cancer\", \"doid\"=>\"0060081\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060081\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1239, \"name\"=>\"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.\", \"citation\"=>\"Gelmon et al., 2011, Lancet Oncol.\", \"pubmed_id\"=>\"21862407\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21862407\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>9}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1370, \"name\"=>\"EID1370\", \"description\"=>\"In this phase 1 trial, 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers. 19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>359, \"name\"=>\"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.\", \"citation\"=>\"Fong et al., 2009, N. Engl. J. Med.\", \"pubmed_id\"=>\"19553641\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19553641\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>7, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>464, \"name\"=>\"EID464\", \"description\"=>\"In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival.\", \"disease\"=>{\"id\"=>225, \"name\"=>\"Epithelial Ovarian Cancer\", \"display_name\"=>\"Epithelial Ovarian Cancer\", \"doid\"=>\"2152\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2152\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>279, \"name\"=>\"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.\", \"citation\"=>\"Bolton et al., 2012, JAMA\", \"pubmed_id\"=>\"22274685\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22274685\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3727895\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>1, \"day\"=>25}, \"journal\"=>\"JAMA\", \"full_journal_title\"=>\"JAMA\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}]}, {\"id\"=>186, \"entrez_name\"=>\"BRCA2\", \"entrez_id\"=>675, \"name\"=>\"MUTATION\", \"description\"=>\"\", \"gene_id\"=>7, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>30, \"name\"=>\"gene_variant\", \"display_name\"=>\"Gene Variant\", \"so_id\"=>\"SO:0001564\", \"description\"=>\"A sequence variant where the structure of the gene is changed.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001564\"}, {\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>160.0, \"coordinates\"=>{\"chromosome\"=>\"13\", \"start\"=>32889611, \"stop\"=>32973347, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000380152.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/7/summary/variants/186/summary#variant\", \"evidence_items\"=>[{\"id\"=>5916, \"name\"=>\"EID5916\", \"description\"=>\"Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively.\\nIn patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2389, \"name\"=>\"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.\", \"citation\"=>\"Golan et al., 2014, Br. J. Cancer\", \"pubmed_id\"=>\"25072261\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25072261\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4453851\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>9, \"day\"=>9}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>5913, \"name\"=>\"EID5913\", \"description\"=>\"Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. All but one had received gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2388, \"name\"=>\"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.\", \"citation\"=>\"Kaufman et al., 2015, J. Clin. Oncol.\", \"pubmed_id\"=>\"25366685\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25366685\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>1, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>5936, \"name\"=>\"EID5936\", \"description\"=>\"Patient with germline BRCA2 mutation underwent resection of pancreatic cancer.\\nAround three years later, tumor recurrence was detected by MRI and PET-CT confirmed it. She was treated with gemcitabine plus iniparib in clinical trial. Excellent response to therapy was observed and surgery was performed but no residual tumor tissue was detected\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>557, \"name\"=>\"Iniparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2407, \"name\"=>\"Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.\", \"citation\"=>\"Fogelman et al., 2011, Anticancer Res.\", \"pubmed_id\"=>\"21508395\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21508395\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>4}, \"journal\"=>\"Anticancer Res.\", \"full_journal_title\"=>\"Anticancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>5935, \"name\"=>\"EID5935\", \"description\"=>\"Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy. No confirmed PR was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>556, \"name\"=>\"Veliparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2406, \"name\"=>\"Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.\", \"citation\"=>\"Lowery et al., 2018, Eur. J. Cancer\", \"pubmed_id\"=>\"29223478\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29223478\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1}, \"journal\"=>\"Eur. J. Cancer\", \"full_journal_title\"=>\"European journal of cancer (Oxford, England : 1990)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT01585805\", \"name\"=>\"Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer\", \"description\"=>\"This randomized phase II trial studies how well veliparib together with gemcitabine hydrochloride and cisplatin works compared to gemcitabine hydrochloride and cisplatin alone in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or spread from the primary site (place where it started) to other places in the body (metastatic). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving veliparib together with gemcitabine hydrochloride and cisplatin is an effective treatment for pancreatic cancer.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT01585805\"}, {\"nct_id\"=>\"NCT02184195\", \"name\"=>\"Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy\", \"description\"=>\"A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02184195\"}]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>5933, \"name\"=>\"EID5933\", \"description\"=>\"In Phase I study for pancreatic cancer patients\\nGEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>85, \"name\"=>\"Gemcitabine\", \"pubchem_id\"=>nil}, {\"id\"=>326, \"name\"=>\"Cisplatin\", \"pubchem_id\"=>nil}, {\"id\"=>556, \"name\"=>\"Veliparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2405, \"name\"=>\"Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.\", \"citation\"=>\"O'Reilly et al., 2018, Cancer\", \"pubmed_id\"=>\"29338080\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29338080\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>16}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT01585805\", \"name\"=>\"Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer\", \"description\"=>\"This randomized phase II trial studies how well veliparib together with gemcitabine hydrochloride and cisplatin works compared to gemcitabine hydrochloride and cisplatin alone in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or spread from the primary site (place where it started) to other places in the body (metastatic). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving veliparib together with gemcitabine hydrochloride and cisplatin is an effective treatment for pancreatic cancer.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT01585805\"}]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>5831, \"name\"=>\"EID5831\", \"description\"=>\"Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2ânegative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2357, \"name\"=>\"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.\", \"citation\"=>\"2017, N. Engl. J. Med.\", \"pubmed_id\"=>\"28792849\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28792849\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>8, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1685, \"name\"=>\"EID1685\", \"description\"=>\"In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.\", \"disease\"=>{\"id\"=>370, \"name\"=>\"Triple-receptor Negative Breast Cancer\", \"display_name\"=>\"Triple-receptor Negative Breast Cancer\", \"doid\"=>\"0060081\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060081\"}, \"drugs\"=>[{\"id\"=>93, \"name\"=>\"Carboplatin\", \"pubchem_id\"=>nil}, {\"id\"=>326, \"name\"=>\"Cisplatin\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1137, \"name\"=>\"TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.\", \"citation\"=>\"Isakoff et al., 2015, J. Clin. Oncol.\", \"pubmed_id\"=>\"25847936\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25847936\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4451173\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>6, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1678, \"name\"=>\"EID1678\", \"description\"=>\"46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}, {\"id\"=>400, \"name\"=>\"Cediranib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1134, \"name\"=>\"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.\", \"citation\"=>\"Liu et al., 2014, Lancet Oncol.\", \"pubmed_id\"=>\"25218906\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25218906\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4294183\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>10}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1676, \"name\"=>\"EID1676\", \"description\"=>\"664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo.  Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative.  Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1133, \"name\"=>\"BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.\", \"citation\"=>\"Harter et al., 2016, Gynecol. Oncol.\", \"pubmed_id\"=>\"26740259\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26740259\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Gynecol. Oncol.\", \"full_journal_title\"=>\"Gynecologic oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1532, \"name\"=>\"EID1532\", \"description\"=>\"In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum therapy.\", \"disease\"=>{\"id\"=>47, \"name\"=>\"Ovarian Carcinoma\", \"display_name\"=>\"Ovarian Carcinoma\", \"doid\"=>\"4001\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4001\"}, \"drugs\"=>[{\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1020, \"name\"=>\"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.\", \"citation\"=>\"Pennington et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24240112\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24240112\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3944197\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1530, \"name\"=>\"EID1530\", \"description\"=>\"In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.\", \"disease\"=>{\"id\"=>47, \"name\"=>\"Ovarian Carcinoma\", \"display_name\"=>\"Ovarian Carcinoma\", \"doid\"=>\"4001\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4001\"}, \"drugs\"=>[{\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1020, \"name\"=>\"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.\", \"citation\"=>\"Pennington et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24240112\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24240112\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3944197\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1371, \"name\"=>\"EID1371\", \"description\"=>\"In this phase 1 trial 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers.19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>359, \"name\"=>\"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.\", \"citation\"=>\"Fong et al., 2009, N. Engl. J. Med.\", \"pubmed_id\"=>\"19553641\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19553641\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>7, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1776, \"name\"=>\"EID1776\", \"description\"=>\"In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.\", \"disease\"=>{\"id\"=>370, \"name\"=>\"Triple-receptor Negative Breast Cancer\", \"display_name\"=>\"Triple-receptor Negative Breast Cancer\", \"doid\"=>\"0060081\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060081\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1239, \"name\"=>\"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.\", \"citation\"=>\"Gelmon et al., 2011, Lancet Oncol.\", \"pubmed_id\"=>\"21862407\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21862407\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>9}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1773, \"name\"=>\"EID1773\", \"description\"=>\"In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1239, \"name\"=>\"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.\", \"citation\"=>\"Gelmon et al., 2011, Lancet Oncol.\", \"pubmed_id\"=>\"21862407\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21862407\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>9}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>465, \"name\"=>\"EID465\", \"description\"=>\"In patients with invasive epithelial ovarian cancer, those with mutations in BRCA2 had better five-year overall survival.\", \"disease\"=>{\"id\"=>225, \"name\"=>\"Epithelial Ovarian Cancer\", \"display_name\"=>\"Epithelial Ovarian Cancer\", \"doid\"=>\"2152\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2152\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>279, \"name\"=>\"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.\", \"citation\"=>\"Bolton et al., 2012, JAMA\", \"pubmed_id\"=>\"22274685\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22274685\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3727895\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>1, \"day\"=>25}, \"journal\"=>\"JAMA\", \"full_journal_title\"=>\"JAMA\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}]}, {\"id\"=>214, \"entrez_name\"=>\"PTEN\", \"entrez_id\"=>5728, \"name\"=>\"LOSS\", \"description\"=>\"\", \"gene_id\"=>41, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>229.0, \"coordinates\"=>{\"chromosome\"=>\"10\", \"start\"=>89622870, \"stop\"=>89731687, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000371953.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/41/summary/variants/214/summary#variant\", \"evidence_items\"=>[{\"id\"=>5840, \"name\"=>\"EID5840\", \"description\"=>\"In a single-arm, open label phase 2 trial in PIK3CA amplified/mutated and/or PTEN loss encompassing 10 patients, no objective responses were observed but a stable disease response in 4 patients, resulting in a median PFS of 1.4 months. Everolimus failed to meet its enpoint.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2364, \"name\"=>\"Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.\", \"citation\"=>\"Kim et al., 2017, BMC Cancer\", \"pubmed_id\"=>\"28330462\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28330462\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5363054\", \"publication_date\"=>{\"year\"=>2017, \"month\"=>3, \"day\"=>23}, \"journal\"=>\"BMC Cancer\", \"full_journal_title\"=>\"BMC cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>5957, \"name\"=>\"EID5957\", \"description\"=>\"No objective responses were observed in the PTEN deficient cohort. Four out of 6 patients with stable disease (SD) had SD or better for â¥6 cycles, 2 of which had PTEN deficient tumors. Conclusion The addition of buparlisib to high dose carboplatin and paclitaxel was not tolerable. The combination did not reveal significant clinical activity amongst a small and heterogenous group of PTEN deficient tumors.\", \"disease\"=>{\"id\"=>2616, \"name\"=>\"Solid Tumor\", \"display_name\"=>\"Solid Tumor\", \"doid\"=>\"\", \"url\"=>\"http://www.disease-ontology.org/\"}, \"drugs\"=>[{\"id\"=>81, \"name\"=>\"Paclitaxel\", \"pubchem_id\"=>nil}, {\"id\"=>93, \"name\"=>\"Carboplatin\", \"pubchem_id\"=>nil}, {\"id\"=>116, \"name\"=>\"Buparlisib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2413, \"name\"=>\"A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.\", \"citation\"=>\"Smyth et al., 2017, Invest New Drugs\", \"pubmed_id\"=>\"28281183\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28281183\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5591764\", \"publication_date\"=>{\"year\"=>2017, \"month\"=>12}, \"journal\"=>\"Invest New Drugs\", \"full_journal_title\"=>\"Investigational new drugs\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT01297452\", \"name\"=>\"BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors\", \"description\"=>\"The purpose of this study is to find out the good and bad effects that occur when BKM120 is added to standard chemotherapy with carboplatin and paclitaxel.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT01297452\"}]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1502, \"name\"=>\"EID1502\", \"description\"=>\"In a panel of 182 cell lines (162 with PIK3CA mutation status known) from solid and hematological tumors, significant correlation was found between AZD5363 (pan-Akt inhibitor) sensitivity and PIK3CA mutation status (N=33, p=0.0059). In the subpopulation free of RAS mutation (N=19) the correlation was increased.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>112, \"name\"=>\"AZD5363\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1005, \"name\"=>\"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.\", \"citation\"=>\"Davies et al., 2012, Mol. Cancer Ther.\", \"pubmed_id\"=>\"22294718\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22294718\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1455, \"name\"=>\"EID1455\", \"description\"=>\"Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance. PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition, but co-treatment with trastuzumab and LY294002 induced growth inhibition comparable to trastuzumab alone in normal BT474 cells. BT474 mouse xenograft tumors were injected with PTEN antisense (AS) oligonucleotides and this resulted in trastuzumab resitance. Co-treatment of PTEN AS tumor mice with LY294002 and trastuzumab inhibited tumor growth in comparison to PTEN AS tumors treated with trastuzumab or LY294002 alone.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>115, \"name\"=>\"LY294002\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>983, \"name\"=>\"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.\", \"citation\"=>\"Nagata et al., 2004, Cancer Cell\", \"pubmed_id\"=>\"15324695\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15324695\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>8}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1493, \"name\"=>\"EID1493\", \"description\"=>\"Cancer and normal tissue samples were taken from 68 gastric cancer patients undergoing surgery without prior chemotherapy. Tissue samples were divided into high grade and low grade for phospho Akt (p-Akt) expression, and tested for PTEN LOH by sequencing. Patients with PTEN LOH were significantly more likely to have elevated p-Akt (p=0.0081), and high p-Akt samples were significantly less sensitive to chemotherapy agents 5-flourouracil, adriamycin, mitomycin and cis-platinum in MTT assay.\", \"disease\"=>{\"id\"=>1322, \"name\"=>\"Stomach Carcinoma\", \"display_name\"=>\"Stomach Carcinoma\", \"doid\"=>\"5517\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5517\"}, \"drugs\"=>[{\"id\"=>199, \"name\"=>\"Chemotherapy\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1000, \"name\"=>\"Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.\", \"citation\"=>\"Oki et al., 2005, Int. J. Cancer\", \"pubmed_id\"=>\"15900596\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15900596\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>11, \"day\"=>10}, \"journal\"=>\"Int. J. Cancer\", \"full_journal_title\"=>\"International journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1383, \"name\"=>\"EID1383\", \"description\"=>\"A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance. The most prominently enriched gene in trastuzumab resistant populations was PTEN. Subsequent knockdown of PTEN in BT-474 cells increased cell survival when treated with trastuzumab, and growth curves showed partial restoration of proliferation in PTEN knockdown BT-474 cells treated with trastuzumab.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>938, \"name\"=>\"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.\", \"citation\"=>\"Berns et al., 2007, Cancer Cell\", \"pubmed_id\"=>\"17936563\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17936563\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2007, \"month\"=>10}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1492, \"name\"=>\"EID1492\", \"description\"=>\"A cisplatin resistant derivative of ovarian cancer cell line OVCAR-3 was generated by long term passage with increasing cisplatin levels. Western blot showed decreased PTEN level in the resistant cell line, and siRNA against PTEN in parent OVCAR-3 cells induced cisplatin resistance.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>326, \"name\"=>\"Cisplatin\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>999, \"name\"=>\"Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.\", \"citation\"=>\"Lee et al., 2005, Gynecol. Oncol.\", \"pubmed_id\"=>\"15790433\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15790433\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>4}, \"journal\"=>\"Gynecol. Oncol.\", \"full_journal_title\"=>\"Gynecologic oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1385, \"name\"=>\"EID1385\", \"description\"=>\"A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and PTEN loss alone was found to be significantly associated with resistance to trastuzumab (p=0.028) and shorter overall survival (p=0.008).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>939, \"name\"=>\"PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.\", \"citation\"=>\"Esteva et al., 2010, Am. J. Pathol.\", \"pubmed_id\"=>\"20813970\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20813970\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2947262\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Am. J. Pathol.\", \"full_journal_title\"=>\"The American journal of pathology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1386, \"name\"=>\"EID1386\", \"description\"=>\"While some reports indicate PTEN loss is associated with resistance to trastuzumab, in a subgroup of HER2 breast cancer FFPE samples from patients receiving trastuzumab as later line therapy (second or greater line therapy), with 25 PTEN loss and and 25 normal samples, no association was seen between trastuzumab response and PTEN status (p=1.000) or overall survival and PTEN status (p=0.863).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>939, \"name\"=>\"PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.\", \"citation\"=>\"Esteva et al., 2010, Am. J. Pathol.\", \"pubmed_id\"=>\"20813970\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20813970\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2947262\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Am. J. Pathol.\", \"full_journal_title\"=>\"The American journal of pathology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1500, \"name\"=>\"EID1500\", \"description\"=>\"A patient derived mouse xenograft model was established with gastric cancer cells having PTEN loss. The xenograft was resistant to monotherapy with both the pan-Akt inhibitor AZD5363, and also to the commonly used gastric cancer chemotheraputic docetaxel. When used in combination, AZD5363 and docetaxel induced significant tumor growth inhibition in comparison to monotherapy and vehicle control.\", \"disease\"=>{\"id\"=>21, \"name\"=>\"Stomach Cancer\", \"display_name\"=>\"Stomach Cancer\", \"doid\"=>\"10534\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10534\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}, {\"id\"=>112, \"name\"=>\"AZD5363\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1004, \"name\"=>\"The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.\", \"citation\"=>\"Li et al., 2013, J Transl Med\", \"pubmed_id\"=>\"24088382\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24088382\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3850695\", \"publication_date\"=>{\"year\"=>2013}, \"journal\"=>\"J Transl Med\", \"full_journal_title\"=>\"Journal of translational medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1614, \"name\"=>\"EID1614\", \"description\"=>\"A panel of 24 endometroid endometrial cancer (EEC) cell lines was characterized for mutations and 18 cell lines were found to have mutations in PTEN or absence of expression. Cell lines were assessed for sensitivity to mTORC1 allosteric inhibitor temsirolimus, and it was reported that PTEN loss had significant association with temsirolimus sensitivity. .\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>83, \"name\"=>\"Temsirolimus\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1067, \"name\"=>\"PI3K pathway dependencies in endometrioid endometrial cancer cell lines.\", \"citation\"=>\"Weigelt et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23674493\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23674493\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3700760\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1297, \"name\"=>\"EID1297\", \"description\"=>\"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PTEN loss (as defined by IHC staining intensity and proportion of positive tumor cells) had a longer progression-free survival with everolimus compared to placebo (HR 0.54 (95%CI 0.31 to 0.96, P=0.04) whereas patients with PTEN normal status had a hazard ration of 1.00 (95%CI 0.8 to 1.26, P=0.97).\\nThe same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combined and analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>891, \"name\"=>\"Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.\", \"citation\"=>\"AndrÃ© et al., 2016, J. Clin. Oncol.\", \"pubmed_id\"=>\"27091708\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27091708\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1611, \"name\"=>\"EID1611\", \"description\"=>\"In a panel of 31 breast cancer cell lines, 11 had loss of PTEN function. Cells were tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/2 inhibitor PP242, and no significant correlation was found between PTEN status and sensitivity to mTORC inhibition.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}, {\"id\"=>179, \"name\"=>\"PP242\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1066, \"name\"=>\"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.\", \"citation\"=>\"Weigelt et al., 2011, Oncogene\", \"pubmed_id\"=>\"21358673\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21358673\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>7, \"day\"=>21}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>938, \"name\"=>\"EID938\", \"description\"=>\"Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.\", \"disease\"=>{\"id\"=>169, \"name\"=>\"Pancreatic Carcinoma\", \"display_name\"=>\"Pancreatic Carcinoma\", \"doid\"=>\"4905\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4905\"}, \"drugs\"=>[{\"id\"=>43, \"name\"=>\"MK-2206\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>641, \"name\"=>\"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.\", \"citation\"=>\"Yap et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"22025163\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22025163\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>12, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>864, \"name\"=>\"EID864\", \"description\"=>\"In 48 patients with advanced gastric cancer, retrospectively analyzed for PTEN expression using IHC, PTEN loss was associated with a shorter duration of response (median 4.2 vs. 6.1 months, p = 0.04) to HER2-targeted therapy (trastuzumab, N=39; lapatinib, N=9). Response rates did not differ between groups.\", \"disease\"=>{\"id\"=>147, \"name\"=>\"Gastric Adenocarcinoma\", \"display_name\"=>\"Gastric Adenocarcinoma\", \"doid\"=>\"3717\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3717\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>579, \"name\"=>\"PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.\", \"citation\"=>\"Zhang et al., 2015, Oncology\", \"pubmed_id\"=>\"25300346\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25300346\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"Oncology\", \"full_journal_title\"=>\"Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>893, \"name\"=>\"EID893\", \"description\"=>\"94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed.\\nNo predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss.\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>83, \"name\"=>\"Temsirolimus\", \"pubchem_id\"=>nil}, {\"id\"=>170, \"name\"=>\"Ridaforolimus\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>602, \"name\"=>\"Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.\", \"citation\"=>\"Mackay et al., 2014, Cancer\", \"pubmed_id\"=>\"24166148\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24166148\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>15}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>711, \"name\"=>\"EID711\", \"description\"=>\"Breast and prostate cancer cell lines responsive to AZD8186 were enriched for PTEN deficiency.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>114, \"name\"=>\"AZD8186\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>467, \"name\"=>\"Inhibition of PI3KÎ² signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.\", \"citation\"=>\"Hancox et al., 2015, Mol. Cancer Ther.\", \"pubmed_id\"=>\"25398829\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25398829\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>1}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>645, \"name\"=>\"EID645\", \"description\"=>\"PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free survival.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>406, \"name\"=>\"Therapeutic targeting of cancers with loss of PTEN function.\", \"citation\"=>\"Dillon et al., 2014, Curr Drug Targets\", \"pubmed_id\"=>\"24387334\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24387334\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4310752\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>1}, \"journal\"=>\"Curr Drug Targets\", \"full_journal_title\"=>\"Current drug targets\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>714, \"name\"=>\"EID714\", \"description\"=>\"All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>81, \"name\"=>\"Paclitaxel\", \"pubchem_id\"=>nil}, {\"id\"=>93, \"name\"=>\"Carboplatin\", \"pubchem_id\"=>nil}, {\"id\"=>116, \"name\"=>\"Buparlisib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>469, \"name\"=>\"Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.\", \"citation\"=>\"Hyman et al., 2015, Cancer Chemother. Pharmacol.\", \"pubmed_id\"=>\"25672916\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25672916\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>4}, \"journal\"=>\"Cancer Chemother. Pharmacol.\", \"full_journal_title\"=>\"Cancer chemotherapy and pharmacology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>716, \"name\"=>\"EID716\", \"description\"=>\"A case report described a responder to PI3K inhibitor BYL719 for a tumor with PIK3CA E542K mutation. After partial response for 9.5 months, resistance developed. Sequencing in this and other patients as well as preclinical models showed loss of PTEN as the probable mechanism of resistance.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>339, \"name\"=>\"BYL719 (Alpelisib)\", \"pubchem_id\"=>\"\"}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>471, \"name\"=>\"Convergent loss of PTEN leads to clinical resistance to a PI(3)KÎ± inhibitor.\", \"citation\"=>\"Juric et al., 2015, Nature\", \"pubmed_id\"=>\"25409150\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25409150\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4326538\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>2, \"day\"=>12}, \"journal\"=>\"Nature\", \"full_journal_title\"=>\"Nature\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>708, \"name\"=>\"EID708\", \"description\"=>\"Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor\\nGSK2141795B.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>111, \"name\"=>\"GSK2141795\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>465, \"name\"=>\"Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.\", \"citation\"=>\"Lassen et al., 2014, Mol. Cancer\", \"pubmed_id\"=>\"24735930\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24735930\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4021505\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Mol. Cancer\", \"full_journal_title\"=>\"Molecular cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>644, \"name\"=>\"EID644\", \"description\"=>\"PTEN loss is associated with reduced response to mTOR inhibitors in patients with bladder cancer.\", \"disease\"=>{\"id\"=>18, \"name\"=>\"Bladder Carcinoma\", \"display_name\"=>\"Bladder Carcinoma\", \"doid\"=>\"4007\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4007\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>407, \"name\"=>\"PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.\", \"citation\"=>\"Seront et al., 2013, Br. J. Cancer\", \"pubmed_id\"=>\"23989949\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23989949\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3777009\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>9, \"day\"=>17}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>643, \"name\"=>\"EID643\", \"description\"=>\"PTEN Loss (by FISH) is associated with poorer prognosis in patients with prostate cancer.\", \"disease\"=>{\"id\"=>46, \"name\"=>\"Prostate Cancer\", \"display_name\"=>\"Prostate Cancer\", \"doid\"=>\"10283\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10283\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>310, \"name\"=>\"FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.\", \"citation\"=>\"Yoshimoto et al., 2007, Br. J. Cancer\", \"pubmed_id\"=>\"17700571\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17700571\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2360375\", \"publication_date\"=>{\"year\"=>2007, \"month\"=>9, \"day\"=>3}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>507, \"name\"=>\"EID507\", \"description\"=>\"In prostate cancer xenographs, PTEN null tumors had a significant decrease in cell size and proliferation when treated with Temsirolimus (CCI-779).\", \"disease\"=>{\"id\"=>46, \"name\"=>\"Prostate Cancer\", \"display_name\"=>\"Prostate Cancer\", \"doid\"=>\"10283\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10283\"}, \"drugs\"=>[{\"id\"=>83, \"name\"=>\"Temsirolimus\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>312, \"name\"=>\"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.\", \"citation\"=>\"Neshat et al., 2001, Proc. Natl. Acad. Sci. U.S.A.\", \"pubmed_id\"=>\"11504908\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11504908\", \"open_access\"=>true, \"pmc_id\"=>\"PMC56958\", \"publication_date\"=>{\"year\"=>2001, \"month\"=>8, \"day\"=>28}, \"journal\"=>\"Proc. Natl. Acad. Sci. U.S.A.\", \"full_journal_title\"=>\"Proceedings of the National Academy of Sciences of the United States of America\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>506, \"name\"=>\"EID506\", \"description\"=>\"In 27 patients with chemotherapy-naive or chemotherapy-refractory metastatic colorectal cancer who were treated with cetuximab and chemotherapy, PTEN loss was associated with non-response.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>311, \"name\"=>\"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.\", \"citation\"=>\"De Roock et al., 2011, Lancet Oncol.\", \"pubmed_id\"=>\"21163703\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21163703\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>6}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}]}]"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#pull in CIViC API for RNA-based variants \n",
    "url_RNA = 'https://civicdb.org/api/panels/RNA-based/qualifying_variants?minimum_score=100'\n",
    "resp_RNA = Net::HTTP.get_response(URI.parse(url_RNA))\n",
    "variants_RNA = JSON.parse(resp_RNA.body)['records']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Evaluate RNA-based Variants"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 143,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "OVEREXPRESSION\n",
      "/overlap/id/ENST00000227507.2?feature=exonPROMOTER METHYLATION\n",
      "/overlap/id/ENST00000306010.7?feature=exonOVEREXPRESSION\n",
      "/overlap/id/ENST00000275493.2?feature=exonp16 EXPRESSION\n",
      "/overlap/id/ENST00000498124.1?feature=exonEXPRESSION\n",
      "/overlap/id/ENST00000381577.3?feature=exonMUTATION\n",
      "/overlap/id/ENST00000498907.2?feature=exonMUTATION\n",
      "/overlap/id/ENST00000300305.3?feature=exonMUTATION\n",
      "/overlap/id/ENST00000264709.3?feature=exonMUTATION\n",
      "/overlap/id/ENST00000369535.4?feature=exonMUTATION\n",
      "/overlap/id/ENST00000263967.3?feature=exonBCR-ABL\n",
      "/overlap/id/ENST00000305877.8?feature=exon/overlap/id/ENST00000318560.5?feature=exonPML-RARA\n",
      "/overlap/id/ENST00000268058.3?feature=exon/overlap/id/ENST00000254066.5?feature=exonALK FUSIONS\n",
      "/overlap/id/ENST00000389048.3?feature=exon/overlap/id/ENST00000254066.5?feature=exonAMPLIFICATION\n",
      "/overlap/id/ENST00000275493.2?feature=exon/overlap/id/ENST00000254066.5?feature=exonAMPLIFICATION\n",
      "/overlap/id/ENST00000425967.3?feature=exon/overlap/id/ENST00000254066.5?feature=exonAMPLIFICATION\n",
      "/overlap/id/ENST00000269571.5?feature=exon/overlap/id/ENST00000254066.5?feature=exonLOSS-OF-FUNCTION\n",
      "/overlap/id/ENST00000357654.3?feature=exon/overlap/id/ENST00000254066.5?feature=exonMUTATION\n",
      "/overlap/id/ENST00000513237.1?feature=exon/overlap/id/ENST00000254066.5?feature=exonMUTATION\n",
      "/overlap/id/ENST00000357654.3?feature=exon/overlap/id/ENST00000254066.5?feature=exonMUTATION\n",
      "/overlap/id/ENST00000380152.3?feature=exon/overlap/id/ENST00000254066.5?feature=exonLOSS\n",
      "/overlap/id/ENST00000371953.3?feature=exon/overlap/id/ENST00000254066.5?feature=exon"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[{\"id\"=>20, \"entrez_name\"=>\"CCND1\", \"entrez_id\"=>595, \"name\"=>\"OVEREXPRESSION\", \"description\"=>\"Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.\", \"gene_id\"=>8, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>183, \"name\"=>\"N/A\", \"display_name\"=>\"N/A\", \"so_id\"=>\"N/A\", \"description\"=>\"No suitable Sequence Ontology term exists.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/N/A\"}], \"civic_actionability_score\"=>106.0, \"coordinates\"=>{\"chromosome\"=>\"11\", \"start\"=>69455855, \"stop\"=>69469242, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000227507.2\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/8/summary/variants/20/summary#variant\", \"evidence_items\"=>[{\"id\"=>1536, \"name\"=>\"EID1536\", \"description\"=>\"A pharmacodynamic study (NCT00420056) of 17 mantle cell lymphoma MCL patients was performed using the CDK4/6 inhibitor palbociclib (PD0332991). Patients were verified by IHC, FISH or molecular testing for the t(11:14) rearrangement  causing Cyclin D overexpression in MCL. 1 patient demonstrated complete response, and 2 showed partial response for an 18% overall response rate. 7 patients showed stable disease. Patient population was heavily pretreated.\", \"disease\"=>{\"id\"=>38, \"name\"=>\"Mantle Cell Lymphoma\", \"display_name\"=>\"Mantle Cell Lymphoma\", \"doid\"=>\"0050746\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050746\"}, \"drugs\"=>[{\"id\"=>48, \"name\"=>\"Palbociclib (PD0332991)\", \"pubchem_id\"=>\"\"}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1023, \"name\"=>\"Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.\", \"citation\"=>\"Leonard et al., 2012, Blood\", \"pubmed_id\"=>\"22383795\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22383795\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>5, \"day\"=>17}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}, {\"id\"=>1563, \"name\"=>\"EID1563\", \"description\"=>\"In Mantle Cell Lymphoma (MCL), t(11:14)-induced overexpression of cyclin D1 was targeted by CDK4/6 inhibitor Palbociclib (PD0332991). Palbociclib caused Rb dephosphorylation in MCL cell lines and patient derived tumor cells. MCL cell lines overexpressing cyclin D1 showed growth inhibition with Palbociclib. The VAL DLBCL cell line was used as control to verify cyclin D1 overexpression but was not used as a control in Palbociclib inhibitor experiments. Instead, the investigators report that other publications report cell lines without cyclin D1 overexpression had higher IC50 values for palbociclib, suggesting overexpresssed cyclin D1 targetability in MCL.\", \"disease\"=>{\"id\"=>38, \"name\"=>\"Mantle Cell Lymphoma\", \"display_name\"=>\"Mantle Cell Lymphoma\", \"doid\"=>\"0050746\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050746\"}, \"drugs\"=>[{\"id\"=>48, \"name\"=>\"Palbociclib (PD0332991)\", \"pubchem_id\"=>\"\"}], \"rating\"=>1, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1032, \"name\"=>\"Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.\", \"citation\"=>\"Marzec et al., 2006, Blood\", \"pubmed_id\"=>\"16690963\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16690963\", \"open_access\"=>true, \"pmc_id\"=>\"PMC1895502\", \"publication_date\"=>{\"year\"=>2006, \"month\"=>9, \"day\"=>1}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}, {\"id\"=>856, \"name\"=>\"EID856\", \"description\"=>\"The authors performed a tissue microarray analysis of 167 postmenopausal breast cancers that had been randomized to treatment with or without tamoxifen.  ER +ve patients with high CCND1 tumor expression did not show any difference in survival between tamoxifen and no treatment.\", \"disease\"=>{\"id\"=>28, \"name\"=>\"Estrogen-receptor Positive Breast Cancer\", \"display_name\"=>\"Estrogen-receptor Positive Breast Cancer\", \"doid\"=>\"0060075\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060075\"}, \"drugs\"=>[{\"id\"=>53, \"name\"=>\"Tamoxifen\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>573, \"name\"=>\"Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.\", \"citation\"=>\"Stendahl et al., 2004, Br. J. Cancer\", \"pubmed_id\"=>\"15138475\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15138475\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2409465\", \"publication_date\"=>{\"year\"=>2004, \"month\"=>5, \"day\"=>17}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}, {\"id\"=>358, \"name\"=>\"EID358\", \"description\"=>\"Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma.\", \"disease\"=>{\"id\"=>38, \"name\"=>\"Mantle Cell Lymphoma\", \"display_name\"=>\"Mantle Cell Lymphoma\", \"doid\"=>\"0050746\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050746\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>219, \"name\"=>\"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.\", \"citation\"=>\"Jares et al., 2007, Nat. Rev. Cancer\", \"pubmed_id\"=>\"17891190\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17891190\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2007, \"month\"=>10}, \"journal\"=>\"Nat. Rev. Cancer\", \"full_journal_title\"=>\"Nature reviews. Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}, {\"id\"=>357, \"name\"=>\"EID357\", \"description\"=>\"Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>218, \"name\"=>\"Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.\", \"citation\"=>\"Thomas et al., 2005, Int J Exp Pathol\", \"pubmed_id\"=>\"16309541\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16309541\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2517451\", \"publication_date\"=>{\"year\"=>2005, \"month\"=>12}, \"journal\"=>\"Int J Exp Pathol\", \"full_journal_title\"=>\"International journal of experimental pathology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}, {\"id\"=>356, \"name\"=>\"EID356\", \"description\"=>\"In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>157, \"name\"=>\"Cyclin D1 in breast cancer pathogenesis.\", \"citation\"=>\"Arnold et al., 2005, J. Clin. Oncol.\", \"pubmed_id\"=>\"15961768\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15961768\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>6, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}, {\"id\"=>221, \"name\"=>\"EID221\", \"description\"=>\"Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>157, \"name\"=>\"Cyclin D1 in breast cancer pathogenesis.\", \"citation\"=>\"Arnold et al., 2005, J. Clin. Oncol.\", \"pubmed_id\"=>\"15961768\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15961768\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>6, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>20, \"phenotypes\"=>[]}]}, {\"id\"=>85, \"entrez_name\"=>\"MGMT\", \"entrez_id\"=>4255, \"name\"=>\"PROMOTER METHYLATION\", \"description\"=>\"MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.\", \"gene_id\"=>34, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>183, \"name\"=>\"N/A\", \"display_name\"=>\"N/A\", \"so_id\"=>\"N/A\", \"description\"=>\"No suitable Sequence Ontology term exists.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/N/A\"}], \"civic_actionability_score\"=>136.0, \"coordinates\"=>{\"chromosome\"=>\"10\", \"start\"=>131264495, \"stop\"=>131265656, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000306010.7\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/34/summary/variants/85/summary#variant\", \"evidence_items\"=>[{\"id\"=>490, \"name\"=>\"EID490\", \"description\"=>\"In a study of 152 anaplastic oligodendroglial tumors, 121 samples had MGMT promoter methylation. Those with promoter methylation had better progression-free and overall survival.\", \"disease\"=>{\"id\"=>241, \"name\"=>\"Anaplastic Oligodendroglioma\", \"display_name\"=>\"Anaplastic Oligodendroglioma\", \"doid\"=>\"3181\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3181\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>298, \"name\"=>\"MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.\", \"citation\"=>\"van den Bent et al., 2009, J. Clin. Oncol.\", \"pubmed_id\"=>\"19901104\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19901104\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2793037\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>12, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>85, \"phenotypes\"=>[]}, {\"id\"=>491, \"name\"=>\"EID491\", \"description\"=>\"In patients with glioblastoma, those with methylated MGMT promoters have better overall survival than those with unmethylated promoters.\", \"disease\"=>{\"id\"=>19, \"name\"=>\"Glioblastoma Multiforme\", \"display_name\"=>\"Glioblastoma Multiforme\", \"doid\"=>\"3068\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3068\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>299, \"name\"=>\"MGMT gene silencing and benefit from temozolomide in glioblastoma.\", \"citation\"=>\"Hegi et al., 2005, N. Engl. J. Med.\", \"pubmed_id\"=>\"15758010\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15758010\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>3, \"day\"=>10}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>85, \"phenotypes\"=>[]}, {\"id\"=>309, \"name\"=>\"EID309\", \"description\"=>\"In patients lacking MGMT promoter methylation, the use of an MGMT inhibitor, such as O(6)-benzylguanine, in combination with alkylating agents (Carmustine) may be useful in treating patients with initial resistance to alkylating agents.\", \"disease\"=>{\"id\"=>19, \"name\"=>\"Glioblastoma Multiforme\", \"display_name\"=>\"Glioblastoma Multiforme\", \"doid\"=>\"3068\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3068\"}, \"drugs\"=>[{\"id\"=>65, \"name\"=>\"O(6)-benzylguanine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"E\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>139, \"name\"=>\"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.\", \"citation\"=>\"Esteller et al., 2000, N. Engl. J. Med.\", \"pubmed_id\"=>\"11070098\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11070098\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2000, \"month\"=>11, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>85, \"phenotypes\"=>[]}, {\"id\"=>308, \"name\"=>\"EID308\", \"description\"=>\"MGMT promoter methylation has been shown to confer sensitivity to alkylating agents, such as carmustine, in glioblastoma cells.\", \"disease\"=>{\"id\"=>19, \"name\"=>\"Glioblastoma Multiforme\", \"display_name\"=>\"Glioblastoma Multiforme\", \"doid\"=>\"3068\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3068\"}, \"drugs\"=>[{\"id\"=>64, \"name\"=>\"Carmustine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>139, \"name\"=>\"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.\", \"citation\"=>\"Esteller et al., 2000, N. Engl. J. Med.\", \"pubmed_id\"=>\"11070098\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11070098\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2000, \"month\"=>11, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>85, \"phenotypes\"=>[]}, {\"id\"=>307, \"name\"=>\"EID307\", \"description\"=>\"In a randomized clinical trial, patients with MGMT promoter methyaltion benefitted from temozolomide. This benefit was also methylation status dependent, as those without methylation did not see increased survival.\", \"disease\"=>{\"id\"=>19, \"name\"=>\"Glioblastoma Multiforme\", \"display_name\"=>\"Glioblastoma Multiforme\", \"doid\"=>\"3068\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3068\"}, \"drugs\"=>[{\"id\"=>11, \"name\"=>\"Temozolomide\", \"pubchem_id\"=>\"\"}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>194, \"name\"=>\"MGMT gene silencing and benefit from temozolomide in glioblastoma.\", \"citation\"=>\"Hegi et al., 2005, N. Engl. J. Med.\", \"pubmed_id\"=>\"15758010\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15758010\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>3, \"day\"=>10}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>85, \"phenotypes\"=>[]}, {\"id\"=>172, \"name\"=>\"EID172\", \"description\"=>\"MGMT promoter methylation was associated with increased overall and disease-free survival as well as tumor regression in patients with gliomas.\", \"disease\"=>{\"id\"=>19, \"name\"=>\"Glioblastoma Multiforme\", \"display_name\"=>\"Glioblastoma Multiforme\", \"doid\"=>\"3068\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3068\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>139, \"name\"=>\"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.\", \"citation\"=>\"Esteller et al., 2000, N. Engl. J. Med.\", \"pubmed_id\"=>\"11070098\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11070098\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2000, \"month\"=>11, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>85, \"phenotypes\"=>[]}]}, {\"id\"=>193, \"entrez_name\"=>\"EGFR\", \"entrez_id\"=>1956, \"name\"=>\"OVEREXPRESSION\", \"description\"=>\"\", \"gene_id\"=>19, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>183, \"name\"=>\"N/A\", \"display_name\"=>\"N/A\", \"so_id\"=>\"N/A\", \"description\"=>\"No suitable Sequence Ontology term exists.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/N/A\"}], \"civic_actionability_score\"=>130.0, \"coordinates\"=>{\"chromosome\"=>\"7\", \"start\"=>55086794, \"stop\"=>55279321, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000275493.2\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/19/summary/variants/193/summary#variant\", \"evidence_items\"=>[{\"id\"=>3797, \"name\"=>\"EID3797\", \"description\"=>\"A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 deletion and L858R mutation; n= 493) who were treated with erlotinib had an improved progression free survival (44.6 weeks vs. 13 weeks, HR: 0.10, 95% CI 0.04-0.25, P<0.001) as compared to patients who received placebo.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>nil, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1938, \"name\"=>\"Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.\", \"citation\"=>\"Brugger et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21969500\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21969500\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>5827, \"name\"=>\"EID5827\", \"description\"=>\"A total of 57 patients with HER1/EGFR positive non-small cell lung cancer were treated with erlotinib therapy. Two patients achieved a complete response, five had a partial response, and 22/57 patients (39%) had stable disease. Median duration of response was 19.7 weeks, median progression-free survival was 9 weeks (95% CI, 8-15 weeks), median overall survival was 8.4 months (95% CI, 4.8-13.9 months), and 1-year survival rate was 40% (95% CI, 28%-54%).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2173, \"name\"=>\"Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.\", \"citation\"=>\"PÃ©rez-Soler et al., 2004, J. Clin. Oncol.\", \"pubmed_id\"=>\"15310767\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15310767\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>8, \"day\"=>15}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"submitted\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>784, \"name\"=>\"EID784\", \"description\"=>\"55 tumor samples were analyzed for EGFR expression using IHC.\\nPFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8 Â± 0.5 vs. 11.0 Â± 2.8 months, P = 0.007; OS: 9.7 Â± 0.5 vs. 21.5 Â± 1.5 months, P = 0.03.\", \"disease\"=>{\"id\"=>149, \"name\"=>\"Esophagus Squamous Cell Carcinoma\", \"display_name\"=>\"Esophagus Squamous Cell Carcinoma\", \"doid\"=>\"3748\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3748\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>522, \"name\"=>\"The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.\", \"citation\"=>\"Jia et al., 2016, Clin Transl Oncol\", \"pubmed_id\"=>\"26459251\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26459251\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Clin Transl Oncol\", \"full_journal_title\"=>\"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>834, \"name\"=>\"EID834\", \"description\"=>\"Overexpression of EGFR in 55 samples of esophageal squamous cell carcinoma as assesesed by IHC, was related to poor OS and PFS  (PFS: 5.8 Â± 0.5 vs. 11.0 Â± 2.8 months, P = 0.007; OS: 9.7 Â± 0.5 vs. 21.5 Â± 1.5 months, P = 0.03).\", \"disease\"=>{\"id\"=>149, \"name\"=>\"Esophagus Squamous Cell Carcinoma\", \"display_name\"=>\"Esophagus Squamous Cell Carcinoma\", \"doid\"=>\"3748\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3748\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"rejected\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>522, \"name\"=>\"The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.\", \"citation\"=>\"Jia et al., 2016, Clin Transl Oncol\", \"pubmed_id\"=>\"26459251\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26459251\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Clin Transl Oncol\", \"full_journal_title\"=>\"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>783, \"name\"=>\"EID783\", \"description\"=>\"55 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to moderate groups (37 pts).\", \"disease\"=>{\"id\"=>149, \"name\"=>\"Esophagus Squamous Cell Carcinoma\", \"display_name\"=>\"Esophagus Squamous Cell Carcinoma\", \"doid\"=>\"3748\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3748\"}, \"drugs\"=>[{\"id\"=>188, \"name\"=>\"Nimotuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>522, \"name\"=>\"The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.\", \"citation\"=>\"Jia et al., 2016, Clin Transl Oncol\", \"pubmed_id\"=>\"26459251\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26459251\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Clin Transl Oncol\", \"full_journal_title\"=>\"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>954, \"name\"=>\"EID954\", \"description\"=>\"82 patients treated with gefitinib were retrospectively analyzed for EGFR mRNA expression (rt-PCR in 64 patients). Patients with high EGFR mRNA expression (>5.01) had 43% response probability, whereas patients with low EGFR mRNA expression had 8% response probability (P = 0.006). PFS but not OS was also longer in patients with high EGFR mRNA expression.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>656, \"name\"=>\"Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.\", \"citation\"=>\"Dziadziuszko et al., 2006, Clin. Cancer Res.\", \"pubmed_id\"=>\"16707605\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16707605\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>5, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>833, \"name\"=>\"EID833\", \"description\"=>\"Expression of EGFR in 55 samples of esophageal squamous cell carcinoma with IHC was not predictive of response to EGFR inhibitor nimotuzumab. EGFR overexpression was related to poor OS and PFS.\", \"disease\"=>{\"id\"=>149, \"name\"=>\"Esophagus Squamous Cell Carcinoma\", \"display_name\"=>\"Esophagus Squamous Cell Carcinoma\", \"doid\"=>\"3748\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3748\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"rejected\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>522, \"name\"=>\"The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.\", \"citation\"=>\"Jia et al., 2016, Clin Transl Oncol\", \"pubmed_id\"=>\"26459251\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26459251\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Clin Transl Oncol\", \"full_journal_title\"=>\"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>782, \"name\"=>\"EID782\", \"description\"=>\"Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>521, \"name\"=>\"Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.\", \"citation\"=>\"Rubin Grandis et al., 1998, J. Natl. Cancer Inst.\", \"pubmed_id\"=>\"9625170\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/9625170\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>1998, \"month\"=>6, \"day\"=>3}, \"journal\"=>\"J. Natl. Cancer Inst.\", \"full_journal_title\"=>\"Journal of the National Cancer Institute\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>693, \"name\"=>\"EID693\", \"description\"=>\"EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>145, \"name\"=>\"EGFR Inhibitor\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>452, \"name\"=>\"EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.\", \"citation\"=>\"Pirker et al., 2012, Lancet Oncol.\", \"pubmed_id\"=>\"22056021\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22056021\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>1}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>737, \"name\"=>\"EID737\", \"description\"=>\"In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison to MET expression were correlated with longer PFS.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>145, \"name\"=>\"EGFR Inhibitor\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>485, \"name\"=>\"Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer.\", \"citation\"=>\"Park et al., 2015, Oncotarget\", \"pubmed_id\"=>\"26439803\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26439803\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4741578\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>10, \"day\"=>13}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>692, \"name\"=>\"EID692\", \"description\"=>\"EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcinoma.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>451, \"name\"=>\"Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.\", \"citation\"=>\"Licitra et al., 2013, Eur. J. Cancer\", \"pubmed_id\"=>\"23265711\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23265711\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>4}, \"journal\"=>\"Eur. J. Cancer\", \"full_journal_title\"=>\"European journal of cancer (Oxford, England : 1990)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}, {\"id\"=>474, \"name\"=>\"EID474\", \"description\"=>\"In patients with glioblastoma multiforme, those with overespression of wild-type EGFR had shorter overall survival.\", \"disease\"=>{\"id\"=>231, \"name\"=>\"Supratentorial Glioblastoma Multiforme\", \"display_name\"=>\"Supratentorial Glioblastoma Multiforme\", \"doid\"=>\"3073\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3073\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>288, \"name\"=>\"Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.\", \"citation\"=>\"Shinojima et al., 2003, Cancer Res.\", \"pubmed_id\"=>\"14583498\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/14583498\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2003, \"month\"=>10, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>193, \"phenotypes\"=>[]}]}, {\"id\"=>272, \"entrez_name\"=>\"CDKN2A\", \"entrez_id\"=>1029, \"name\"=>\"p16 EXPRESSION\", \"description\"=>\"CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.\", \"gene_id\"=>14, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>183, \"name\"=>\"N/A\", \"display_name\"=>\"N/A\", \"so_id\"=>\"N/A\", \"description\"=>\"No suitable Sequence Ontology term exists.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/N/A\"}], \"civic_actionability_score\"=>180.0, \"coordinates\"=>{\"chromosome\"=>\"9\", \"start\"=>21968055, \"stop\"=>21974865, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000498124.1\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/14/summary/variants/272/summary#variant\", \"evidence_items\"=>[{\"id\"=>4873, \"name\"=>\"EID4873\", \"description\"=>\"A preclinical study to explore the efficacy of CDK4/6 inhibition with palbociclib, in a panel of sarcoma cell lines and sarcoma tumor xenografts (PDXs). The responsiveness of these cell lines/PDX correlated with CDK4 mRNA levels but not in those showing high p16ink4a. High levels of CDKN2A predicted poorer efficacy.\", \"disease\"=>{\"id\"=>105, \"name\"=>\"Sarcoma\", \"display_name\"=>\"Sarcoma\", \"doid\"=>\"1115\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1115\"}, \"drugs\"=>[{\"id\"=>429, \"name\"=>\"Palbociclib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>nil, \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2168, \"name\"=>\"Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.\", \"citation\"=>\"Perez et al., 2015, Oncotarget\", \"pubmed_id\"=>\"26528855\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26528855\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4747352\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>12, \"day\"=>1}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>1155, \"name\"=>\"EID1155\", \"description\"=>\"Phase III trial to compare afatinib or metothrexate in recurrent or metastatic head and neck squamous cell carcinoma. 483 patients were randomized to either afatinib (n=322) or methotrexate (n=161). 285 patients were assessed for p16 Status (IHC). In the post-hoc analysis, benefit of afatinib compared with methotrexate was more pronounced in p16-negative disease (HR 0Â·69 [95% CI 0Â·50â0Â·96], p=0.022) than in p16-positive disease (HR 0Â·95 [CI 0Â·51â1Â·75], p=0.67, interaction test p=0Â·32).\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>795, \"name\"=>\"Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.\", \"citation\"=>\"Machiels et al., 2015, Lancet Oncol.\", \"pubmed_id\"=>\"25892145\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25892145\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>5}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>1314, \"name\"=>\"EID1314\", \"description\"=>\"In a cohort of 73 patients with stage I or stage II NSCLC it was discovered that the CDKN2A protein (p16-INK4A) retrospectively evaluated via IHC was associated with adverse outcomes (p=0.004).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>904, \"name\"=>\"Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer.\", \"citation\"=>\"Zhao et al., 2012, J Oncol\", \"pubmed_id\"=>\"22619677\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22619677\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3350860\", \"publication_date\"=>{\"year\"=>2012}, \"journal\"=>\"J Oncol\", \"full_journal_title\"=>\"Journal of oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>758, \"name\"=>\"EID758\", \"description\"=>\"720 patients with stage III/IV oropharyngeal cancer were retrospectively analyzed for p16 and HPV status. p16 and HPV-positivity correlated well and both showed improved overall-survival compared to patients with HPV-negative/p16 negative tumors. HPV/p16 status was shown to be a strong and independent risk factor in oropharyngeal carcinoma.\", \"disease\"=>{\"id\"=>204, \"name\"=>\"Oropharynx Cancer\", \"display_name\"=>\"Oropharynx Cancer\", \"doid\"=>\"8557\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8557\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>501, \"name\"=>\"Human papillomavirus and survival of patients with oropharyngeal cancer.\", \"citation\"=>\"Ang et al., 2010, N. Engl. J. Med.\", \"pubmed_id\"=>\"20530316\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20530316\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2943767\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>804, \"name\"=>\"EID804\", \"description\"=>\"Patients from three studies (RTOG 0129, 0234, and 0522; 85, 95 and 142 patients, respectively) were retrospectively analyzed for p16 (CDKN2A) expression (IHC) and HPV-high risk status (ISH). p16 expression in non-oropharyngeal HNSSC was also prognostic and associated with a better outcome. However, p16-positive oropharyngeal HNSSC still had better PFS and OS than p16-positive non-oropharyngeal HNSSC.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>538, \"name\"=>\"p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.\", \"citation\"=>\"Chung et al., 2014, J. Clin. Oncol.\", \"pubmed_id\"=>\"25267748\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25267748\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4251957\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>12, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>697, \"name\"=>\"EID697\", \"description\"=>\"In this study response to EGFR-inhibition by cetuximab was independent of HPV-status, represented by expression of p16 (CDKN2A, an established biomarker of HPV infection). Expression of p16 was assayed in 69 HNSCC patients by IHC.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>456, \"name\"=>\"Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.\", \"citation\"=>\"Pogorzelski et al., 2014, Cell Death Dis\", \"pubmed_id\"=>\"24577089\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24577089\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3944273\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Cell Death Dis\", \"full_journal_title\"=>\"Cell death & disease\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>695, \"name\"=>\"EID695\", \"description\"=>\"p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>454, \"name\"=>\"Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.\", \"citation\"=>\"Argiris et al., 2014, Ann. Oncol.\", \"pubmed_id\"=>\"24799460\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24799460\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4071756\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>7}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>696, \"name\"=>\"EID696\", \"description\"=>\"In this retrospective analysis of p16 status as surrogate marker for HPV in the SPECTRUM trial, p16 (CDKN2A) expression was not associated with improved response to EGFR-directed therapy (Panitumumab) in combination with chemotherapy compared to chemotherapy alone.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>455, \"name\"=>\"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.\", \"citation\"=>\"Vermorken et al., 2013, Lancet Oncol.\", \"pubmed_id\"=>\"23746666\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23746666\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>7}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>759, \"name\"=>\"EID759\", \"description\"=>\"This study shows that benefit of EGFR inhibition in addition to radiotherapy was independent of p16/HPV status. 182 patients were evaluated.\", \"disease\"=>{\"id\"=>204, \"name\"=>\"Oropharynx Cancer\", \"display_name\"=>\"Oropharynx Cancer\", \"doid\"=>\"8557\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8557\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>502, \"name\"=>\"Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.\", \"citation\"=>\"Rosenthal et al., 2016, J. Clin. Oncol.\", \"pubmed_id\"=>\"26712222\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26712222\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>694, \"name\"=>\"EID694\", \"description\"=>\"In this retrospective analysis of the SPECTRUM trial, p16 (CDKN2A) expression (and HPV-infection) was not predictive of response to EGFR-targeted therapy in combination with chemotherapy (n = 416 patient tumors).\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>145, \"name\"=>\"EGFR Inhibitor\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>453, \"name\"=>\"Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.\", \"citation\"=>\"Vermorken et al., 2014, Ann. Oncol.\", \"pubmed_id\"=>\"24577117\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24577117\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3969553\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>4}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}, {\"id\"=>753, \"name\"=>\"EID753\", \"description\"=>\"p16-negative patients (HPV negative) have a longer overall survival under panitumumab/chemotherapy in comparison to chemotherapy alone.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>455, \"name\"=>\"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.\", \"citation\"=>\"Vermorken et al., 2013, Lancet Oncol.\", \"pubmed_id\"=>\"23746666\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23746666\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>7}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>272, \"phenotypes\"=>[]}]}, {\"id\"=>276, \"entrez_name\"=>\"CD274\", \"entrez_id\"=>29126, \"name\"=>\"EXPRESSION\", \"description\"=>\"\", \"gene_id\"=>11335, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>183, \"name\"=>\"N/A\", \"display_name\"=>\"N/A\", \"so_id\"=>\"N/A\", \"description\"=>\"No suitable Sequence Ontology term exists.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/N/A\"}], \"civic_actionability_score\"=>315.0, \"coordinates\"=>{\"chromosome\"=>\"9\", \"start\"=>5450525, \"stop\"=>5470547, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000381577.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/11335/summary/variants/276/summary#variant\", \"evidence_items\"=>[{\"id\"=>5507, \"name\"=>\"EID5507\", \"description\"=>\"A meta analysis of 60 research studies involving 10,310 solid tumors indicated that CD274 over expression results in poor overall survival (HRâ=â1.58, Pâ<.001) and poor disease free/progression free survival (DFS/PFS) (HRâ=â1.72, Pâ=0â.001). When split into sub groups by cancer type overall survival  was poor for breast (HRâ=â1.98, Pâ=0â.014), urothelial (HRâ=â2.24, Pâ<0.001), renal (HRâ=â3.30,  Pâ<0.001), and gastric cancers (HRâ=â1.56, Pâ=0â.040). DFS/PFS was poor in patients with hepatocellular carcinoma (HRâ=â1.72,  Pâ=â0.003), melanoma (HRâ=â3.39,  Pâ<0.001), and renal carcinoma, (HRâ=â5.04,  Pâ<0.001).\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2256, \"name\"=>\"Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.\", \"citation\"=>\"Wang et al., 2017, Medicine (Baltimore)\", \"pubmed_id\"=>\"28471952\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28471952\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5419898\", \"publication_date\"=>{\"year\"=>2017, \"month\"=>5}, \"journal\"=>\"Medicine (Baltimore)\", \"full_journal_title\"=>\"Medicine\", \"status\"=>\"fully curated\", \"is_review\"=>true, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>4856, \"name\"=>\"EID4856\", \"description\"=>\"PD-L1 is not only expressed in tumor cells (TCs) but also upregulated in tumor-infiltrating immune cells (TIICs). This meta-analysis evaluated the prognostic value of PD-L1 expression in TIICs in different types of cancers. 18 studies involving 3674 patients were included. PD-L1 positivity in TIICs related to a lower risk of death (HR = 0.784, p=0.047), and TIICs indicated a better prognosis especially in breast cancer patients (HR = 0.359, p=0.002).\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2155, \"name\"=>\"Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.\", \"citation\"=>\"Zhao et al., 2017, PLoS ONE\", \"pubmed_id\"=>\"28453554\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28453554\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5409185\", \"publication_date\"=>{\"year\"=>2017}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>4844, \"name\"=>\"EID4844\", \"description\"=>\"A meta-analysis of the role of PD-L1 expression in breast cancer found nine relevant studies with a total 8583 patients. PD-L1 expression was found to be associated with several poor prognostic indicators, such as ductal cancer, high tumor grade, ER negativity, PR negativity, HER2 positivity and aggressive molecular subtypes. PD-L1 overexpression had no significant impact on metastasis-free survival (HR 0.924, 95% CI = 0.747-1.141, p = 0.462), disease-free survival (HR 1.122, 95% CI = 0.878-1.434, p = 0.357) and overall specific survival (HR 0.837, 95% CI = 0.640-1.093, p = 0.191), but significantly correlated with shortened overall survival (HR 1.573, 95% CI = 1.010-2.451, p = 0.045).\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2148, \"name\"=>\"Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.\", \"citation\"=>\"Wang et al., 2017, Breast J\", \"pubmed_id\"=>\"28079291\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28079291\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>1, \"day\"=>12}, \"journal\"=>\"Breast J\", \"full_journal_title\"=>\"The breast journal\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>4855, \"name\"=>\"EID4855\", \"description\"=>\"In this meta-analysis, 5 studies totalling 2,546 cases were combined to assess the prognostic association of PD-L1 expression in breast cancer. The combined hazard ratio (HR) for PD-L1 overexpression was 1.76 (OS). The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with positive lymph node metastasis, higher histological grades, estrogen receptor (ER)-negativity, and triple-negative breast cancer (TNBC).\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2154, \"name\"=>\"Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.\", \"citation\"=>\"Zhang et al., 2017, Oncotarget\", \"pubmed_id\"=>\"28430626\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28430626\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>5, \"day\"=>9}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>4857, \"name\"=>\"EID4857\", \"description\"=>\"In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}, {\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}, {\"id\"=>261, \"name\"=>\"Atezolizumab\", \"pubchem_id\"=>nil}, {\"id\"=>296, \"name\"=>\"Avelumab\", \"pubchem_id\"=>nil}, {\"id\"=>530, \"name\"=>\"Durvalumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2156, \"name\"=>\"PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.\", \"citation\"=>\"Aguiar et al., 2017, Immunotherapy\", \"pubmed_id\"=>\"28472902\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28472902\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>5}, \"journal\"=>\"Immunotherapy\", \"full_journal_title\"=>\"Immunotherapy\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>3000, \"name\"=>\"EID3000\", \"description\"=>\"Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamous cell carcinoma patient samples evaluated with different methods [reverse phase protein array (N=68), mRNA expression array (N=97) or immunohistochemistry (N=114), respectively], increased expression of PD-L1 was also correlated with local failure following radiotherapy as compared to the PD-L1âlow expression group (P = 0.01, 1.9 Ã 10â3, and 9 Ã 10â4, respectively).\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>360, \"name\"=>\"Radiation\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1728, \"name\"=>\"Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.\", \"citation\"=>\"Skinner et al., 2017, Clin. Cancer Res.\", \"pubmed_id\"=>\"28476872\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28476872\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>5, \"day\"=>5}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1733, \"name\"=>\"EID1733\", \"description\"=>\"This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of EGFR or translocation of ALK. Patients in the pembrolizumab group exhibited significantly better progression-free survival and overall survival compared to patients in the chemotherapy group.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1176, \"name\"=>\"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.\", \"citation\"=>\"Reck et al., 2016, N. Engl. J. Med.\", \"pubmed_id\"=>\"27718847\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27718847\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>11, \"day\"=>10}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1615, \"name\"=>\"EID1615\", \"description\"=>\"A clinical trial of 86 patients evaluated concurrent (n=53) or sequential (n=33) treatment of ipilimumab (anti-CTLA4) and nivolumab (anti-PD1). In the concurrent regimen cohort, 65% of patients showed clinical activity with no correlation between PD-L1 expression and response (6 of 13 patients were PD-L1 positive versus 9 of 22 patients were PD-L1 negative). In the sequential regimen cohort, 20% of patients had an objective response with a potential correlation between PD-L1 expression and response (4 of 8 patients were PD-L1 positive versus 1 of 13 patients were PD-L1 negative).\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}, {\"id\"=>365, \"name\"=>\"Ipilimumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1068, \"name\"=>\"Nivolumab plus ipilimumab in advanced melanoma.\", \"citation\"=>\"Wolchok et al., 2013, N. Engl. J. Med.\", \"pubmed_id\"=>\"23724867\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23724867\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>7, \"day\"=>11}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1578, \"name\"=>\"EID1578\", \"description\"=>\"Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab. Of these patients, 25 were evaluated for response rate to pembrolizumab and PD-L1 (CD274) expression.  The response rate to pembrolizumab was 56% (95%CI: 35-76%), however, there was no correlation between PD-L1 expression (cutoff >1%) on tumor cells or on infiltrating immune cells and clinical response to pembrolizumab (P=0.61).\", \"disease\"=>{\"id\"=>311, \"name\"=>\"Merkel Cell Carcinoma\", \"display_name\"=>\"Merkel Cell Carcinoma\", \"doid\"=>\"3965\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3965\"}, \"drugs\"=>[{\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1042, \"name\"=>\"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.\", \"citation\"=>\"Nghiem et al., 2016, N. Engl. J. Med.\", \"pubmed_id\"=>\"27093365\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27093365\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4927341\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>30}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1517, \"name\"=>\"EID1517\", \"description\"=>\"Trial NCT00730639 tested monoclonal antibody nivolumab against the PD-1 immune checkpoint receptor in pretreated patients with various cancer types. PD-L1 expression was tested in 42 patients by ICH from tumor FFPE biopsies. (18 melanoma, 10 NSCLC, 7 colorectal cancer, 5 renal cell cancer, 2 prostate cancer). 9 of 25 PD-L1 expressing patients showed objective response, and zero of 17 PD-L1 negative patients showed objective response (p=0.006). Biopsies were optional, and therefore not fully randomized.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1010, \"name\"=>\"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.\", \"citation\"=>\"Topalian et al., 2012, N. Engl. J. Med.\", \"pubmed_id\"=>\"22658127\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22658127\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3544539\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>28}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1274, \"name\"=>\"EID1274\", \"description\"=>\"Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE surgical tissues (66 benign thyroid nodules and 185 papillary thyroid carcinomas PTC, E1L3N antibody). Patients with increased PD-L1 protein had significantly shorter median DFS (36 months [membranous staining] and 49 months [cytoplasmic staining] vs. 186 months [negative], p < 0.001 and p < 0.01, respectively).\", \"disease\"=>{\"id\"=>156, \"name\"=>\"Papillary Thyroid Carcinoma\", \"display_name\"=>\"Papillary Thyroid Carcinoma\", \"doid\"=>\"3969\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3969\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>880, \"name\"=>\"Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.\", \"citation\"=>\"Chowdhury et al., 2016, Oncotarget\", \"pubmed_id\"=>\"27086918\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27086918\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>12}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1275, \"name\"=>\"EID1275\", \"description\"=>\"465 gastric cancer samples and 15 corresponding liver metastases underwent IHC for PD1/PD-L1 protein expression. PD-L1 positivity in tumor cells was defined by at least 2% tumor cells with membranous positivity, PD-L1 positivity in immune cells by at least 10% PD-L1 positive immune cells. Patients with PD-L1 positive tumor cells had a significant better overall (p=0.028) and tumor specific survival (p=0.018). The same applied for patients with PD-L1 positive immune cells (p<0.001 each).\", \"disease\"=>{\"id\"=>1322, \"name\"=>\"Stomach Carcinoma\", \"display_name\"=>\"Stomach Carcinoma\", \"doid\"=>\"5517\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5517\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>881, \"name\"=>\"PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.\", \"citation\"=>\"BÃ¶ger et al., 2016, Oncotarget\", \"pubmed_id\"=>\"27009855\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27009855\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>26}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1172, \"name\"=>\"EID1172\", \"description\"=>\"Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and docetaxel in previously treated, advanced or metastatic non-small cell lung cancer. Baseline PD-L1 expression (IHC) was assessed in tumour cells (as percentage of PD-L1-expressing tumour cells TC3â¥50%, TC2â¥5% and <50%, TC1â¥1% and <5%, and TC0<1%) and tumour-infiltrating immune cells (as percentage of tumour area: IC3â¥10%, IC2â¥5% and <10%, IC1â¥1% and <5%, and IC0<1%). Increasing PD-L1 Expression was associated with improved overall survival (TC3 or IC3 HR 0Â·49 [0Â·22-1Â·07; p=0Â·068], TC2/3 or IC2/3 HR 0Â·54 [0Â·33-0Â·89; p=0Â·014], TC1/2/3 or IC1/2/3 HR 0Â·59 [0Â·40-0Â·85; p=0Â·005], TC0 and IC0 HR 1Â·04 [0Â·62-1Â·75; p=0Â·871]) but not progression free survival or overall response rate.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>261, \"name\"=>\"Atezolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>809, \"name\"=>\"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.\", \"citation\"=>\"Fehrenbacher et al., 2016, Lancet\", \"pubmed_id\"=>\"26970723\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26970723\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>30}, \"journal\"=>\"Lancet\", \"full_journal_title\"=>\"Lancet (London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>1167, \"name\"=>\"EID1167\", \"description\"=>\"Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1/PD-L1 monoclonal antibodies. Patients with PD-L1 positive tumors (PD-L1 tumor cell staining â¥1%), had a significantly higher ORR, compared to patients with PD-L1 negative tumors (OR: 2.44; 95% CIs: 1.61-3.68).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}, {\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}, {\"id\"=>261, \"name\"=>\"Atezolizumab\", \"pubchem_id\"=>nil}, {\"id\"=>296, \"name\"=>\"Avelumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>804, \"name\"=>\"PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.\", \"citation\"=>\"Passiglia et al., 2016, Oncotarget\", \"pubmed_id\"=>\"26918451\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26918451\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>12}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>975, \"name\"=>\"EID975\", \"description\"=>\"74 patients with stage III NSCLC treated with concurrent chemoradiotherapy were retrospectively analyzed for PD-L1 expression and CD8+ tumour-infiltrating lymphocytes (TILs) density (IHC). CD8+ TIL density was an independent predictor of progression free survival (PFS) and overall survival (OS). Only when both TIL density and PD-L1 expression were both considered, was PD-L1 expression associated with survival. The subgroup, PD-L1+/CD8 low tumors had the shortest PFS (8.6 months, p = 0.02) and shortest, but not significantly different, OS (13.9 months, p = 0.11).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>674, \"name\"=>\"Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.\", \"citation\"=>\"Tokito et al., 2016, Eur. J. Cancer\", \"pubmed_id\"=>\"26771872\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26771872\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Eur. J. Cancer\", \"full_journal_title\"=>\"European journal of cancer (Oxford, England : 1990)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>743, \"name\"=>\"EID743\", \"description\"=>\"Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}, {\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>462, \"name\"=>\"Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.\", \"citation\"=>\"Carbognin et al., 2015, PLoS ONE\", \"pubmed_id\"=>\"26086854\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26086854\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4472786\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>702, \"name\"=>\"EID702\", \"description\"=>\"In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study).\", \"disease\"=>{\"id\"=>153, \"name\"=>\"Lung Squamous Cell Carcinoma\", \"display_name\"=>\"Lung Squamous Cell Carcinoma\", \"doid\"=>\"3907\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3907\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>460, \"name\"=>\"PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.\", \"citation\"=>\"Schmidt et al., 2015, PLoS ONE\", \"pubmed_id\"=>\"26313362\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26313362\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4552388\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>701, \"name\"=>\"EID701\", \"description\"=>\"This meta-analysis did not find a significant connection between expression of PD-L1 and overall survival in patients with NSCLC.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>459, \"name\"=>\"Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.\", \"citation\"=>\"Zhong et al., 2015, Onco Targets Ther\", \"pubmed_id\"=>\"26664143\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26664143\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4671817\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"Onco Targets Ther\", \"full_journal_title\"=>\"OncoTargets and therapy\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>704, \"name\"=>\"EID704\", \"description\"=>\"Based on a meta-analysis of 20 trials (1475 patients), of which 7 studies (636 patients) included melanoma, PD-L1 expression was associated with a higher ORR rate in patients with melanoma. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}, {\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>462, \"name\"=>\"Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.\", \"citation\"=>\"Carbognin et al., 2015, PLoS ONE\", \"pubmed_id\"=>\"26086854\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26086854\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4472786\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>703, \"name\"=>\"EID703\", \"description\"=>\"High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases).\", \"disease\"=>{\"id\"=>87, \"name\"=>\"Ovarian Serous Carcinoma\", \"display_name\"=>\"Ovarian Serous Carcinoma\", \"doid\"=>\"0050933\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050933\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>461, \"name\"=>\"Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.\", \"citation\"=>\"Darb-Esfahani et al., 2016, Oncotarget\", \"pubmed_id\"=>\"26625204\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26625204\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4811475\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>1, \"day\"=>12}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>276, \"phenotypes\"=>[]}, {\"id\"=>5811, \"name\"=>\"EID5811\", \"description\"=>\"PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2351, \"name\"=>\"Pembrolizumab for the treatment of non-small-cell lung cancer.\", \"citation\"=>\"Garon et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"25891174\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25891174\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>5, \"day\"=>21}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT01295827\", \"name\"=>\"Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)\", \"description\"=>\"This study will be done in 6 parts. In Part A the dose of intravenous (IV) pembrolizumab (MK-3475) will be escalated to find the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for participants with a histologically or cytologically confirmed diagnosis of any type of carcinoma or melanoma (MEL). Part B of the study will explore the safety, tolerability, and efficacy of the drug in participants with advanced or metastatic MEL and compare every 2 week to every 3 week dosing. Part C of the study will explore the safety, tolerability, and efficacy of the drug in participants with non-small cell lung carcinoma (NSCLC) that is locally advanced or metastatic. Part D of the study will explore the low and high doses of study drug identified in Parts A and B in participants with advanced or metastatic MEL. Part E (closed with Amendment 7) will explore low, medium, and high doses of study drug in combination with standard chemotherapy in participants with locally advanced or metastatic NSCLC. Part F will explore low and high doses of study drug in treatment-naive and previously-treated participants with NSCLC with programmed cell death 1 ligand (PD-L1) gene expression. In Parts D and F and some of Part B participants will be randomized to one dose level. The primary hypotheses are the following: that pembrolizumab has acceptable safety and tolerability; and that pembrolizumab shows a clinically meaningful response rate (RR) or disease-control rate (DCR) in participants with melanoma (ipilimumab-refractory or not), and a clinically meaningful RR in participants with NSCLC, especially a clinically meaningful RR in those participants with either cancer, whose tumors express PD-L1.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT01295827\"}]}, \"variant_id\"=>276, \"phenotypes\"=>[]}]}, {\"id\"=>29, \"entrez_name\"=>\"CEBPA\", \"entrez_id\"=>1050, \"name\"=>\"MUTATION\", \"description\"=>\"CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.\", \"gene_id\"=>15, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>42, \"name\"=>\"transcript_variant\", \"display_name\"=>\"Transcript Variant\", \"so_id\"=>\"SO:0001576\", \"description\"=>\"A sequence variant that changes the structure of the transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001576\"}, {\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>105.0, \"coordinates\"=>{\"chromosome\"=>\"19\", \"start\"=>33790840, \"stop\"=>33793470, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000498907.2\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/15/summary/variants/29/summary#variant\", \"evidence_items\"=>[{\"id\"=>167, \"name\"=>\"EID167\", \"description\"=>\"In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, CEBPA mutation was significantly associated with complete remission in multivariate analysis (odds ratio, 1.33; 95% confidence interval [CI], 1.01 to 1.74). Multivariate analysis was performed on all patients  that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study. Only 509 patients in the study were evaluated for CEBPA, 67 of which had a mutation.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>137, \"name\"=>\"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.\", \"citation\"=>\"Schlenk et al., 2008, N. Engl. J. Med.\", \"pubmed_id\"=>\"18450602\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18450602\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>5, \"day\"=>1}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>29, \"phenotypes\"=>[]}, {\"id\"=>122, \"name\"=>\"EID122\", \"description\"=>\"In a randomized trial of previously untreated younger (<60) patients with acute myeloid leukemia (excluding acute promyelocytic leukemia) and high-risk myelodysplastic syndrome CEBPA mutation status had no significant impact on patient response to ATRA (N=20) compared to randomized control (N=15).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>265, \"name\"=>\"All-trans Retinoic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>118, \"name\"=>\"The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.\", \"citation\"=>\"Burnett et al., 2010, Blood\", \"pubmed_id\"=>\"19965647\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19965647\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>2, \"day\"=>4}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>29, \"phenotypes\"=>[]}, {\"id\"=>467, \"name\"=>\"EID467\", \"description\"=>\"In children with acute myeloid leukemia, those with mutations in CEBPA had better overall and event-free survival and decreased cummulative incidence of relapse.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>281, \"name\"=>\"Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.\", \"citation\"=>\"Ho et al., 2009, Blood\", \"pubmed_id\"=>\"19304957\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19304957\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2943755\", \"publication_date\"=>{\"year\"=>2009, \"month\"=>6, \"day\"=>25}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>29, \"phenotypes\"=>[]}, {\"id\"=>468, \"name\"=>\"EID468\", \"description\"=>\"In a set of 315 pediatric patients with acute myeloid leukemia, 47 had mutations in CEBPA. Those with mutations had better overall survival than wild-type patients.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>282, \"name\"=>\"Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.\", \"citation\"=>\"Matsuo et al., 2014, Blood Cancer J\", \"pubmed_id\"=>\"25014773\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25014773\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4219441\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Blood Cancer J\", \"full_journal_title\"=>\"Blood cancer journal\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>29, \"phenotypes\"=>[]}, {\"id\"=>168, \"name\"=>\"EID168\", \"description\"=>\"Overall survival and remission duration were significantly longer (p=0.01 and p=0.05, respectively) in younger (16-60), cytogenetically normal acute myeloid leukemia patients with CEBPA mutations (21/236 patients).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>133, \"name\"=>\"CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.\", \"citation\"=>\"FrÃ¶hling et al., 2004, J. Clin. Oncol.\", \"pubmed_id\"=>\"14726504\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/14726504\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>2, \"day\"=>15}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>29, \"phenotypes\"=>[]}, {\"id\"=>166, \"name\"=>\"EID166\", \"description\"=>\"In a group of young (<60 years old) acute myeloid leukemia (exclude acute promyelocytic leukemia) and high-risk MDS patients, those with CEBPA mutations (35/423) showed marginally improved overall survival (36% vs 31%; P = .04) than those with wildtype CEBPA.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>118, \"name\"=>\"The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.\", \"citation\"=>\"Burnett et al., 2010, Blood\", \"pubmed_id\"=>\"19965647\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19965647\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>2, \"day\"=>4}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>29, \"phenotypes\"=>[]}]}, {\"id\"=>155, \"entrez_name\"=>\"RUNX1\", \"entrez_id\"=>861, \"name\"=>\"MUTATION\", \"description\"=>\"RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.\", \"gene_id\"=>43, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>42, \"name\"=>\"transcript_variant\", \"display_name\"=>\"Transcript Variant\", \"so_id\"=>\"SO:0001576\", \"description\"=>\"A sequence variant that changes the structure of the transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001576\"}, {\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>110.0, \"coordinates\"=>{\"chromosome\"=>\"21\", \"start\"=>36160098, \"stop\"=>36421641, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000300305.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/43/summary/variants/155/summary#variant\", \"evidence_items\"=>[{\"id\"=>429, \"name\"=>\"EID429\", \"description\"=>\"In 878 non-APL patients with AML, those who had mutations in RUNX1 (N=53) had higher rates of refractory disease than those without (30% versus 19%; P = 0.047).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>241, \"name\"=>\"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.\", \"citation\"=>\"Gaidzik et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21343560\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21343560\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>155, \"phenotypes\"=>[]}, {\"id\"=>509, \"name\"=>\"EID509\", \"description\"=>\"In a study of patients with cytogenically normal acute myeloid leukemia, RUNX1 mutations were more frequent in patients 60 years old or older. Patients with RUNX1 mutations had shorter disease-free (younger, P = 0.058; older, P < 0.001), event-free (both, P < 0.001), and overall survival (younger, P = 0.003; older, P < 0.001) as well as lower complete remission rates (younger, P = 0.005; older, P = 0.006).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>313, \"name\"=>\"RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.\", \"citation\"=>\"Mendler et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22753902\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22753902\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3732007\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>9, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>155, \"phenotypes\"=>[]}, {\"id\"=>430, \"name\"=>\"EID430\", \"description\"=>\"In 878 non-APL patients with AML (18-60 years), those who had mutations in RUNX1 (N=53) had shorter event-free survival (8% vs 30%, P<0.0001) and relapse-free survival (26% vs 44%, P=0.022) relative to wild-type. EFS was also shorter for the cytogenetically normal (CN) subgroup with RUNX1 mutations (N=34; 10% vs 34%; P<0.0001) compared to wild-type (N=499), but only trending for relapse-free survival (29% vs 43%; P=0.21). For multivariate analysis, RUNX1 was a significant marker of inferior EFS in the entire cohort (P=0.011) and the intermediate-risk (P=0.005) subgroup but not the CN subgroup.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>241, \"name\"=>\"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.\", \"citation\"=>\"Gaidzik et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21343560\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21343560\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>155, \"phenotypes\"=>[]}, {\"id\"=>1558, \"name\"=>\"EID1558\", \"description\"=>\"In patients with acute myeloid leukemia, those with RUNX1 mutations (n=245) had significantly worse outcomes when compared to those with RUNX1 wild-type alleles (n=2,194).  The complete remission rate for patients with RUNX1 mutations was significantly lower (48.4% vs. 68.1%; p <0.0001), the refractory disease rate was significantly higher (40.6% 23.4%; p=0.03), the 5-year event free survival rate was significantly lower (9%, 24%; p<0.0001), the 5-year relapse free survival rate was significantly lower (22%, 36%; p=0.0007), and the 5-year overall survival rate was significantly lower (22%, 37%; p=0.0001).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1029, \"name\"=>\"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.\", \"citation\"=>\"Gaidzik et al., 2016, Leukemia\", \"pubmed_id\"=>\"27137476\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27137476\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>10}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>155, \"phenotypes\"=>[]}, {\"id\"=>508, \"name\"=>\"EID508\", \"description\"=>\"In univariate analysis, mutations in RUNX1 were significantly associated with shorter overall survival compared to wildtype RUNX1 in adult (18-87 years old) T-cell acute lymphoblastic leukemia (N=9 mutated, 62 wild type patients; P=0.014) and the early subtype (N=7 mutated, 23 wild type patients; P=0.027). RUNX1 mutations were associated with other poor-risk parameters, early subtype and older age.\", \"disease\"=>{\"id\"=>43, \"name\"=>\"Acute Lymphocytic Leukemia\", \"display_name\"=>\"Acute Lymphocytic Leukemia\", \"doid\"=>\"9952\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9952\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>283, \"name\"=>\"The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.\", \"citation\"=>\"Grossmann et al., 2013, Genes Chromosomes Cancer\", \"pubmed_id\"=>\"23341344\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23341344\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>4}, \"journal\"=>\"Genes Chromosomes Cancer\", \"full_journal_title\"=>\"Genes, chromosomes & cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>155, \"phenotypes\"=>[]}, {\"id\"=>411, \"name\"=>\"EID411\", \"description\"=>\"In non-APL patients with AML (age 18-60), those who had mutations in RUNX1 had significantly shorter relapse-free survival following conventional post-remission treatment (repetitive cycles of high-dose cytarabine) than those treated with an allogeneic hematopoietic stem-cell transplantation (N=32) at first remission (4-year RFS; 0% vs 52%; P<0.0001).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>173, \"name\"=>\"Cytarabine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>241, \"name\"=>\"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.\", \"citation\"=>\"Gaidzik et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21343560\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21343560\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>155, \"phenotypes\"=>[]}]}, {\"id\"=>189, \"entrez_name\"=>\"DNMT3A\", \"entrez_id\"=>1788, \"name\"=>\"MUTATION\", \"description\"=>\"DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.\", \"gene_id\"=>18, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>42, \"name\"=>\"transcript_variant\", \"display_name\"=>\"Transcript Variant\", \"so_id\"=>\"SO:0001576\", \"description\"=>\"A sequence variant that changes the structure of the transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001576\"}], \"civic_actionability_score\"=>115.0, \"coordinates\"=>{\"chromosome\"=>\"2\", \"start\"=>25455845, \"stop\"=>25565459, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000264709.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/18/summary/variants/189/summary#variant\", \"evidence_items\"=>[{\"id\"=>2926, \"name\"=>\"EID2926\", \"description\"=>\"A subset of patients receiving PD1/PD-L1 inhibition appear to be \\\"hyper-progressors,\\\" with a greatly accelerated rate of tumor growth and clinical deterioration compared to pre-therapy. The current study investigated potential genomic markers associated with \\\"hyper-progression\\\". Consecutive stage IV cancer patients who received immunotherapies (CTLA-4, PD-1/PD-L1 inhibitors or other [investigational] agents) and had their tumor evaluated by next-generation sequencing Amongst 155 patients, TTF (time to treatment failure) <2 months was seen in 4/5 individuals harbouring DNMT3A alteration.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>137, \"name\"=>\"Nivolumab\", \"pubchem_id\"=>nil}, {\"id\"=>138, \"name\"=>\"Pembrolizumab\", \"pubchem_id\"=>nil}, {\"id\"=>261, \"name\"=>\"Atezolizumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1679, \"name\"=>\"Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.\", \"citation\"=>\"Kato et al., 2017, Clin. Cancer Res.\", \"pubmed_id\"=>\"28351930\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28351930\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>3, \"day\"=>28}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}, {\"id\"=>1587, \"name\"=>\"EID1587\", \"description\"=>\"Among 46 AML patients treated with decitabine, the response rate was 75% (6/8) among DNMT3A mutated and 34% (13/38) among DNMT3A wild-type patients (P=.008)\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>155, \"name\"=>\"Decitabine\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1049, \"name\"=>\"DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.\", \"citation\"=>\"Metzeler et al., 2012, Leukemia\", \"pubmed_id\"=>\"22124213\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22124213\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3696987\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>5}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}, {\"id\"=>1586, \"name\"=>\"EID1586\", \"description\"=>\"DNMT3A mutations associate with adverse overall survival in acute myeloid leukemia patients if they occur in the context of mutated NPM1 and  FLT3-ITD (NPM1-FLT3ITD-DNMT3A phenotype), and in the context of IDH2 codon R140 mutations.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1009, \"name\"=>\"Genomic Classification and Prognosis in Acute Myeloid Leukemia.\", \"citation\"=>\"Papaemmanuil et al., 2016, N. Engl. J. Med.\", \"pubmed_id\"=>\"27276561\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27276561\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4979995\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}, {\"id\"=>1585, \"name\"=>\"EID1585\", \"description\"=>\"In AML patients aged <60years, presence of a DNMT3A mutation associated with inferior CR rate (HR, 0.54; P=.05) and shorter OS (HR, 1.84; P<.001) in multivariate analyses. Mutated DNMT3A associated with shorter RFS (HR 1.38; P=.034) irrespective of patient age.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1048, \"name\"=>\"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.\", \"citation\"=>\"Metzeler et al., 2016, Blood\", \"pubmed_id\"=>\"27288520\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27288520\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>8, \"day\"=>4}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}, {\"id\"=>1238, \"name\"=>\"EID1238\", \"description\"=>\"12/150 patients with de novo myelodysplastic syndrome screened for DNMT3A mutations (bone marrow and paired normal skin) had heterozygous mutations with predicted translational consequences. 1 patient was identified with 2 nonsynonymous coding mutations. R882 mutations accounted for 4/13 reported mutations, P904L for 2/13 mutations and the remaining had not been previously reported at the time of this report. Overall and event-free survival were worse for DNMT3A mutant patients although transplantation status was not considered (log-rank p=0.005 and p=0.009). Transformation to AML was increased for mutant 7/12 (58%) versus wildtype 39/138 (28%) patients (p=0.007). The authors note larger cohorts will be required to confirm these results.\", \"disease\"=>{\"id\"=>34, \"name\"=>\"Myelodysplastic Syndrome\", \"display_name\"=>\"Myelodysplastic Syndrome\", \"doid\"=>\"0050908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050908\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>785, \"name\"=>\"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.\", \"citation\"=>\"Walter et al., 2011, Leukemia\", \"pubmed_id\"=>\"21415852\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21415852\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3202965\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>7}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}, {\"id\"=>469, \"name\"=>\"EID469\", \"description\"=>\"In adult patients with early (n = 30), cortical (n = 30), mature (n = 3) or unknown (n = 8) T-cell acute lymphoblastic leukemia, those with mutations in DNMT3A (n=12) had shorter overall survival than wild-type patients (n=59; p=0.011). This was also true for the subset of patients with early T-ALL DNMT3A-mutated (n = 8) compared to wild-type patients (n = 22; p=0.005).\", \"disease\"=>{\"id\"=>227, \"name\"=>\"T-cell Acute Lymphoblastic Leukemia\", \"display_name\"=>\"T-cell Acute Lymphoblastic Leukemia\", \"doid\"=>\"5603\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5603\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>283, \"name\"=>\"The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.\", \"citation\"=>\"Grossmann et al., 2013, Genes Chromosomes Cancer\", \"pubmed_id\"=>\"23341344\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23341344\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>4}, \"journal\"=>\"Genes Chromosomes Cancer\", \"full_journal_title\"=>\"Genes, chromosomes & cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}, {\"id\"=>188, \"name\"=>\"EID188\", \"description\"=>\"Young AML patients (415 patients; <60 years old) with any DNMT3A mutation (n=96) have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>54, \"name\"=>\"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.\", \"citation\"=>\"Ribeiro et al., 2012, Blood\", \"pubmed_id\"=>\"22490330\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22490330\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>14}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>189, \"phenotypes\"=>[]}]}, {\"id\"=>208, \"entrez_name\"=>\"NRAS\", \"entrez_id\"=>4893, \"name\"=>\"MUTATION\", \"description\"=>\"\", \"gene_id\"=>36, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>42, \"name\"=>\"transcript_variant\", \"display_name\"=>\"Transcript Variant\", \"so_id\"=>\"SO:0001576\", \"description\"=>\"A sequence variant that changes the structure of the transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001576\"}, {\"id\"=>160, \"name\"=>\"gain_of_function_variant\", \"display_name\"=>\"Gain Of Function Variant\", \"so_id\"=>\"SO:0002053\", \"description\"=>\"A sequence variant whereby new or enhanced function is conferred on the gene product.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002053\"}], \"civic_actionability_score\"=>198.0, \"coordinates\"=>{\"chromosome\"=>\"1\", \"start\"=>115247090, \"stop\"=>115259515, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000369535.4\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/36/summary/variants/208/summary#variant\", \"evidence_items\"=>[{\"id\"=>5344, \"name\"=>\"EID5344\", \"description\"=>\"NCCN guidelines indicate colorectal cancer patients with NRAS mutations should not be treated with EGFR inhibitors cetuximab or panitumumab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2236, \"name\"=>nil, \"citation\"=>\"Benson et al., 2017, J Natl Compr Canc Netw\", \"pubmed_id\"=>\"28275037\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28275037\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{}, \"journal\"=>nil, \"full_journal_title\"=>nil, \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1429, \"name\"=>\"EID1429\", \"description\"=>\"In six NRAS mutant melanoma cell lines, concomitant use of MEK inhibitor and PI3K/mTOR inhibitor resulted in greater decrease in cell viability than either alone, with the synergistic effect being marked in 4/6 cell lines. MEK inhibitor JTP-74057 and PI3K/mTOR inhibitor GSK2126458 together induced synergistic increase in apoptotic Annexin V+/PI+ cells in these cell lines. Tumor xenografts in nude mice were established with 5 of the 6 cell lines. Effects of single agent treatment with JTP-74057 or GSK2126458 ranged from minor inhibition to tumor stasis, while dual inhibitor treatment showed synergistic effects in each case, with marked tumor reductions in 2/5 cases and the authors report one compete response in a MaMel301 cell line xenograft mouse.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>346, \"name\"=>\"Omipalisib (GSK2126458)\", \"pubchem_id\"=>\"\"}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>968, \"name\"=>\"Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.\", \"citation\"=>\"Posch et al., 2013, Proc. Natl. Acad. Sci. U.S.A.\", \"pubmed_id\"=>\"23431193\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23431193\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3593920\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>3, \"day\"=>5}, \"journal\"=>\"Proc. Natl. Acad. Sci. U.S.A.\", \"full_journal_title\"=>\"Proceedings of the National Academy of Sciences of the United States of America\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>2937, \"name\"=>\"EID2937\", \"description\"=>\"NEMO is an ongoing, randomised, open-label phase 3 study of patients with advanced, unresectable, AJCC IIIC/IV NRAS-mutant melanoma. 402 patients that were previously untreated or progressed on or after previous immunotherapy were randomised to receive either binimetinib (269) or dacarbazine (133). The study's primary endpoint was progression free survival. Median follow-up was 1.7 months (IQR 1.4-4.1). Median progression-free survival was 2.8 months (95% CI 2.8-3.6) in the binimetinib group and 1.5 months (1.5-1.7) in the dacarbazine group, demonstrating improved progression-free survival of binimetinib compared with dacarbazine.\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>485, \"name\"=>\"Binimetinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1686, \"name\"=>\"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.\", \"citation\"=>\"Dummer et al., 2017, Lancet Oncol.\", \"pubmed_id\"=>\"28284557\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28284557\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>4}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>2931, \"name\"=>\"EID2931\", \"description\"=>\"Inhibition of CDK4 and 6, regulators of the G1/S cell cycle checkpoint, arrests the cell cycle in the G1 phase, suppresses DNA synthesis, and inhibits cancer cell growth. There is an ongoing phase 1/2 trial of binimetinib with the CDK4/6 inhibitor ribociclib (LEE011) in mutant NRAS melanoma patients (NCT01781572). Early results from the 21 evaluable patients were very promising, with 7 patients achieving a partial response (33%) and 11 patients with stable disease (52%)\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>381, \"name\"=>\"Ribociclib\", \"pubchem_id\"=>nil}, {\"id\"=>485, \"name\"=>\"Binimetinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1682, \"name\"=>\"Targeting mutant NRAS signaling pathways in melanoma.\", \"citation\"=>\"Vu et al., 2016, Pharmacol. Res.\", \"pubmed_id\"=>\"26987942\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26987942\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4867277\", \"publication_date\"=>{\"year\"=>2016}, \"journal\"=>\"Pharmacol. Res.\", \"full_journal_title\"=>\"Pharmacological research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1703, \"name\"=>\"EID1703\", \"description\"=>\"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1138, \"name\"=>\"A molecularly annotated platform of patient-derived xenografts (\\\"xenopatients\\\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.\", \"citation\"=>\"Bertotti et al., 2011, Cancer Discov\", \"pubmed_id\"=>\"22586653\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22586653\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1509, \"name\"=>\"EID1509\", \"description\"=>\"In a panel of 7 NRAS mutant melanoma cell lines, all 7 were found to be sensitive to the MEK inhibitor MEK162, whereas 3 of 5 melanoma cell lines that were wild type for BRAF and NRAS were not sensitive to MEK162. In further tests using two of the seven NRAS mutant cell lines (YUDOSO Q16K/wt and YUKIM Q16R), colony forming capacity was reduced with increased MEK162 treatment, and MEK162 induced apoptotic markers in these cells.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>355, \"name\"=>\"Binimetinib (MEK162)\", \"pubchem_id\"=>\"\"}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1008, \"name\"=>\"MEK targeting in N-RAS mutated metastatic melanoma.\", \"citation\"=>\"Thumar et al., 2014, Mol. Cancer\", \"pubmed_id\"=>\"24588908\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24588908\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3945937\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Mol. Cancer\", \"full_journal_title\"=>\"Molecular cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1227, \"name\"=>\"EID1227\", \"description\"=>\"Phase 1 trial in 97 patients with melanoma (81 cutaneous or unknown, 16 uveal). Seven patients were found to harbor an NRAS mutation and two of them experienced stable disease (one 48 weeks on treatment). Patients with concurrent BRAFV600wt/NRASwt (n=20) had a trend of higher response rates (20%) than BRAFV600wt/NRAS-mutant patients (n=11; RR=0%; p=0.27), as well as a trend of higher percentage of patients on study at Week 24 or at 1 year (40% vs. 18% [p=0.26] and 30% vs. 0% [p=0.07], respectively).\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>850, \"name\"=>\"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.\", \"citation\"=>\"Falchook et al., 2012, Lancet Oncol.\", \"pubmed_id\"=>\"22805292\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22805292\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4109286\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>8}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1225, \"name\"=>\"EID1225\", \"description\"=>\"Phase 1 trial of trametinib and docetaxel in patients with advanced melanoma lacking BRAF V600 mutations. 15 patients were enrolled (14 BRAF wt). Six patients had a partial response, including four out of eight patients with NRAS mutations.\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>848, \"name\"=>\"PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.\", \"citation\"=>\"Coupe et al., 2015, Eur. J. Cancer\", \"pubmed_id\"=>\"25542057\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25542057\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>2}, \"journal\"=>\"Eur. J. Cancer\", \"full_journal_title\"=>\"European journal of cancer (Oxford, England : 1990)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1476, \"name\"=>\"EID1476\", \"description\"=>\"Preclinical study in melanoma cell lines. Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growth inhibition, tyrosine phosphorylation inhibition, cell cycle and apoptotic (Annexin V) assays.\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>384, \"name\"=>\"Amuvatinib\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>989, \"name\"=>\"Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.\", \"citation\"=>\"Fedorenko et al., 2014, Melanoma Res.\", \"pubmed_id\"=>\"24950457\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24950457\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4384823\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>10}, \"journal\"=>\"Melanoma Res.\", \"full_journal_title\"=>\"Melanoma research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1472, \"name\"=>\"EID1472\", \"description\"=>\"Phase II study in 71 patients with NRAS or BRAF V600 mutant melanoma treated with MEK162. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed).\", \"disease\"=>{\"id\"=>206, \"name\"=>\"Skin Melanoma\", \"display_name\"=>\"Skin Melanoma\", \"doid\"=>\"8923\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8923\"}, \"drugs\"=>[{\"id\"=>355, \"name\"=>\"Binimetinib (MEK162)\", \"pubchem_id\"=>\"\"}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>849, \"name\"=>\"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.\", \"citation\"=>\"Ascierto et al., 2013, Lancet Oncol.\", \"pubmed_id\"=>\"23414587\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23414587\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>3}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>1230, \"name\"=>\"EID1230\", \"description\"=>\"Preclinical study in 16 NRAS mutant cell lines (melanoma, lung carcinoma, neuroblastoma with various Q61, G13, G12 mutations). The combination of metformin and trametinib shown synergistic effects in most tested cell lines (no antagonistic effects observed) and a melanoma xenograft model. Metformin-induced PI3K pathway suppression was identified as a potential mechanism.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>308, \"name\"=>\"Metformin\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>851, \"name\"=>\"Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.\", \"citation\"=>\"Vujic et al., 2015, Oncotarget\", \"pubmed_id\"=>\"25504439\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25504439\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4359268\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>1, \"day\"=>20}, \"journal\"=>\"Oncotarget\", \"full_journal_title\"=>\"Oncotarget\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>996, \"name\"=>\"EID996\", \"description\"=>\"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). Among 8 patients with NRAS mutated melanoma, 4 experienced SD or PR (1 Patient received study treatment for 323 days).\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>243, \"name\"=>\"RO4987655\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>688, \"name\"=>\"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.\", \"citation\"=>\"Zimmer et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24947927\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24947927\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>8, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>496, \"name\"=>\"EID496\", \"description\"=>\"In patients with multiple myeloma, the presence of a mutation in NRAS was not significantly associated with progression-free or overall survival.\", \"disease\"=>{\"id\"=>41, \"name\"=>\"Multiple Myeloma\", \"display_name\"=>\"Multiple Myeloma\", \"doid\"=>\"9538\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9538\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>297, \"name\"=>\"Clinical and biological significance of RAS mutations in multiple myeloma.\", \"citation\"=>\"Chng et al., 2008, Leukemia\", \"pubmed_id\"=>\"18528420\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18528420\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3864109\", \"publication_date\"=>{\"year\"=>2008, \"month\"=>12}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>71, \"name\"=>\"EID71\", \"description\"=>\"In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>87, \"name\"=>\"NRAS mutation status is an independent prognostic factor in metastatic melanoma.\", \"citation\"=>\"Jakob et al., 2012, Cancer\", \"pubmed_id\"=>\"22180178\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22180178\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3310961\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>8, \"day\"=>15}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>56, \"name\"=>\"EID56\", \"description\"=>\"The presence of NRAS mutation in AML patients does not impact diease prognosis (resistant disease, disease-free survival, complete remission rate, relapse rate, induction death).\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>83, \"name\"=>\"RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.\", \"citation\"=>\"Bowen et al., 2005, Blood\", \"pubmed_id\"=>\"15951308\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15951308\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>9, \"day\"=>15}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}, {\"id\"=>27, \"name\"=>\"EID27\", \"description\"=>\"Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>70, \"name\"=>\"The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.\", \"citation\"=>\"Therkildsen et al., 2014, Acta Oncol\", \"pubmed_id\"=>\"24666267\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24666267\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>7}, \"journal\"=>\"Acta Oncol\", \"full_journal_title\"=>\"Acta oncologica (Stockholm, Sweden)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>208, \"phenotypes\"=>[]}]}, {\"id\"=>311, \"entrez_name\"=>\"PIK3CA\", \"entrez_id\"=>5290, \"name\"=>\"MUTATION\", \"description\"=>\"PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer,  colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance ( trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.\", \"gene_id\"=>37, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>42, \"name\"=>\"transcript_variant\", \"display_name\"=>\"Transcript Variant\", \"so_id\"=>\"SO:0001576\", \"description\"=>\"A sequence variant that changes the structure of the transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001576\"}, {\"id\"=>160, \"name\"=>\"gain_of_function_variant\", \"display_name\"=>\"Gain Of Function Variant\", \"so_id\"=>\"SO:0002053\", \"description\"=>\"A sequence variant whereby new or enhanced function is conferred on the gene product.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002053\"}], \"civic_actionability_score\"=>124.0, \"coordinates\"=>{\"chromosome\"=>\"3\", \"start\"=>178866311, \"stop\"=>178957881, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000263967.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/37/summary/variants/311/summary#variant\", \"evidence_items\"=>[{\"id\"=>3040, \"name\"=>\"EID3040\", \"description\"=>\"In a study of 37 patients with AKT1 (E13K) mutations, 5 patients harbored a concurrent PI3K/mTOR pathway alteration. The PFS of patients with a concurrent PI3K/mTOR pathway alteration was significantly longer than those without when treated with AZD-5363 (median PFS, not reached v 4.3 months, respectively; HR, 0.21; P = 0.045).\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1745, \"name\"=>\"AKT Inhibition in Solid Tumors With AKT1 Mutations.\", \"citation\"=>\"Hyman et al., 2017, J. Clin. Oncol.\", \"pubmed_id\"=>\"28489509\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28489509\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>5, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1705, \"name\"=>\"EID1705\", \"description\"=>\"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab and only 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1138, \"name\"=>\"A molecularly annotated platform of patient-derived xenografts (\\\"xenopatients\\\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.\", \"citation\"=>\"Bertotti et al., 2011, Cancer Discov\", \"pubmed_id\"=>\"22586653\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22586653\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1384, \"name\"=>\"EID1384\", \"description\"=>\"The HER2 overexpressing breast cancer cell line BT-474 transduced with mutant PIK3CA H1047R demonstrated essentially normal proliferation under trastuzumab, while control cells showed negligible proliferation with trastuzumab. Sequencing of 55 HER2 breast cancer samples revealed 25% PIK3CA mutation rate and Kaplan Meier curves showed decreased time to progression for mutant PIK3CA at borderline statistical significance (p=0.052). This was potentially explained by presence of PTEN loss in wild-type PIK3CA sample and combining PTEN loss with PIK3CA mutation resulted in significant differences in time to progression (p=0.007).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>938, \"name\"=>\"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.\", \"citation\"=>\"Berns et al., 2007, Cancer Cell\", \"pubmed_id\"=>\"17936563\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17936563\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2007, \"month\"=>10}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1501, \"name\"=>\"EID1501\", \"description\"=>\"In a panel of 22 gastric cancer cell lines, 4 of 6 cell lines having the highest sensitivity to AZD5363 contained a PIK3CA mutation (E542K, E453K, E545K). A patient derived gastric cancer xenograft mouse model was established with PIK3CA H1047R mutant cells, and treatment with AZD5363 induced significant tumor growth inhibition in comparison to vehicle control.\", \"disease\"=>{\"id\"=>21, \"name\"=>\"Stomach Cancer\", \"display_name\"=>\"Stomach Cancer\", \"doid\"=>\"10534\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10534\"}, \"drugs\"=>[{\"id\"=>112, \"name\"=>\"AZD5363\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1004, \"name\"=>\"The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.\", \"citation\"=>\"Li et al., 2013, J Transl Med\", \"pubmed_id\"=>\"24088382\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24088382\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3850695\", \"publication_date\"=>{\"year\"=>2013}, \"journal\"=>\"J Transl Med\", \"full_journal_title\"=>\"Journal of translational medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1503, \"name\"=>\"EID1503\", \"description\"=>\"Sensitivity to pan-Akt inhibitor AZD5363 was assessed in a panel of 182 cell lines (160 with PTEN evaluated) derived from solid and hematological tumors. PTEN loss of function due to loss or mutation (N=32) was found to be significantly correlated with AZD5363 sensitivity (p=0.0099), and correlation improved in the subpopulation free of RAS mutation. Mouse xenografts with 786-0 (PTEN-null renal cancer) cells were established. 75 mg/kg twice daily AZD5363 caused tumor growth inhibition while 150 mg/kg twice daily induced moderate tumor regression.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>112, \"name\"=>\"AZD5363\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1005, \"name\"=>\"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.\", \"citation\"=>\"Davies et al., 2012, Mol. Cancer Ther.\", \"pubmed_id\"=>\"22294718\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22294718\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1600, \"name\"=>\"EID1600\", \"description\"=>\"Three PI3K mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941), and a panel of 42 inhibitor compounds was tested on the cells for ability to resensitize the cells to PI3K inhibition. The CDK4/6 inhibitor ribociclib (LEE011) acted synergistically with PI3K inhibitor to reduce viability in all three resistant cell lines. In a panel of 12 PIK3CA mutant and 10 wild type cell lines, synergistic effects between P110alpha inhibitor BYL719 and ribociclib were significantly stronger (weighted synergy score calculation, ANOVA, p=0.012) in PIK3CA mutant cells, indicating variant specific sensitization. Mouse xenografts of 4 different PIK3CA mutant breast cancer cells resistant to PI3K inhibitor showed stronger regression under dual PI3K inhibitor and ribociclib treatment than with either treatment alone.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>381, \"name\"=>\"Ribociclib\", \"pubchem_id\"=>nil}, {\"id\"=>382, \"name\"=>\"PI3K Inhibitor\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>178, \"name\"=>\"CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.\", \"citation\"=>\"Vora et al., 2014, Cancer Cell\", \"pubmed_id\"=>\"25002028\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25002028\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4155598\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>7, \"day\"=>14}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1402, \"name\"=>\"EID1402\", \"description\"=>\"A set of 474 cell lines from the Cancer Cell Line Encyclopedia was tested for responsiveness to the PI3Kalpha specific inhibitor BYL719 (Alpelisib). In the PIK3CA wild type subroup of cell lines, 22% were assessed as responsive, while in the subgroup of cell lines with PIK3CA mutations, 64% were labeled as responders. 7 patient derived xenografts with PIK3CA mutations (H1047R, E545K, M1043I, C420R, Q546K) were transplanted into mice and treated with BYL719. 6/7 mice responded with strong tumor growth inhibition or regression, while one (H1047R) responded with weak growth inhibition.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>339, \"name\"=>\"BYL719 (Alpelisib)\", \"pubchem_id\"=>\"\"}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>950, \"name\"=>\"Characterization of the novel and specific PI3KÎ± inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.\", \"citation\"=>\"Fritsch et al., 2014, Mol. Cancer Ther.\", \"pubmed_id\"=>\"24608574\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24608574\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>5}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1360, \"name\"=>\"EID1360\", \"description\"=>\"Preclinical analysis of the predicitive value of PIK3CA mutations for mTOR/PI3K Inhibition with BEZ-235. Two cell lines with PIK3CA Mutation (H1047R) were more sensitive to BEZ-235 than two cell lines with wild-type PIK3CA (in-vitro, results from one cell line also confirmed in-vivo). Two patient-derived xenografts with PIK3CA mutations (E110K, E542K) showed sensitivity to BEZ-235.\", \"disease\"=>{\"id\"=>453, \"name\"=>\"Head And Neck Cancer\", \"display_name\"=>\"Head And Neck Cancer\", \"doid\"=>\"11934\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:11934\"}, \"drugs\"=>[{\"id\"=>343, \"name\"=>\"BEZ235 (NVP-BEZ235, Dactolisib)\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>927, \"name\"=>\"Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.\", \"citation\"=>\"Lui et al., 2013, Cancer Discov\", \"pubmed_id\"=>\"23619167\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23619167\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3710532\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>7}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1358, \"name\"=>\"EID1358\", \"description\"=>\"Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to class I PI3K inhibitor GDC-0941 (p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines).\\nIC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the sanger cell line screening but these results could not be reproduced in the cancer cell line encyclopedia screening.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>10, \"name\"=>\"17-AAG\", \"pubchem_id\"=>nil}, {\"id\"=>141, \"name\"=>\"Pictilisib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>926, \"name\"=>\"Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.\", \"citation\"=>\"Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg\", \"pubmed_id\"=>\"25855885\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25855885\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4474763\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>6}, \"journal\"=>\"JAMA Otolaryngol Head Neck Surg\", \"full_journal_title\"=>\"JAMA otolaryngology-- head & neck surgery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1296, \"name\"=>\"EID1296\", \"description\"=>\"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PI3K mutations had longer progression-free survival with everolimus compared to placebo (HR 0.67 95%CI 0.45 to 1.00, P=0.05) whereas patients with PI3K wild type status did not benefit significantly (HR 1.1, 95%CI 0.83 to 1.46, P=0.5). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combinedly analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>891, \"name\"=>\"Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.\", \"citation\"=>\"AndrÃ© et al., 2016, J. Clin. Oncol.\", \"pubmed_id\"=>\"27091708\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27091708\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1364, \"name\"=>\"EID1364\", \"description\"=>\"6 head and neck cancer cell lines were tested for Response to 17-AAG, GDC-0941. Two of the cell lines did not carry PIK3CA mutations. No clear difference was shown between PIK3CA-mutant and wild-type cell lines and there was a trend towards increased resistance. SCC25 cell line was lentivirally transduced with PIK3CA E545K or H1047R mutation. Engineered cells, compared to the parental cell line, showed decreased sensitivity to 17-AAG, GDC-0941 or trametinib.\", \"disease\"=>{\"id\"=>453, \"name\"=>\"Head And Neck Cancer\", \"display_name\"=>\"Head And Neck Cancer\", \"doid\"=>\"11934\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:11934\"}, \"drugs\"=>[{\"id\"=>10, \"name\"=>\"17-AAG\", \"pubchem_id\"=>nil}, {\"id\"=>19, \"name\"=>\"Trametinib\", \"pubchem_id\"=>nil}, {\"id\"=>141, \"name\"=>\"Pictilisib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>926, \"name\"=>\"Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.\", \"citation\"=>\"Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg\", \"pubmed_id\"=>\"25855885\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25855885\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4474763\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>6}, \"journal\"=>\"JAMA Otolaryngol Head Neck Surg\", \"full_journal_title\"=>\"JAMA otolaryngology-- head & neck surgery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1607, \"name\"=>\"EID1607\", \"description\"=>\"Three PIK3CA mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941) by chronic exposure. Co-treatment of all three cell lines with PI3K inhibitor and CDK4/6 inhibitor palbociclib resulted in synergistic reductions in cell viability which were not seen with treatment of either compound alone, and resulted in similar suppression to viability as seen in the respective PI3K inhibitor sensitive parental cell lines.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>48, \"name\"=>\"Palbociclib (PD0332991)\", \"pubchem_id\"=>\"\"}, {\"id\"=>382, \"name\"=>\"PI3K Inhibitor\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>178, \"name\"=>\"CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.\", \"citation\"=>\"Vora et al., 2014, Cancer Cell\", \"pubmed_id\"=>\"25002028\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25002028\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4155598\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>7, \"day\"=>14}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>771, \"name\"=>\"EID771\", \"description\"=>\"20 patient-derived colorectal cancer xenografts were treated with cabozantinib, a c-MET and VEGFR2 inhibitor. 16 xenografts showed sensitivity (as defined by TGII: tumor growth of treated compared to controlââ¤â20%). Among the genes tested for mutations (KRAS, TP53, PIK3CA, MET, VEGFR2, RET and AXL), PIK3CA mutations (4 PDTX) showed a significant enrichment in sensitive xenografts. PIK3CA mutations were observed in 4/5 of the most responsive tumors. Treating xenografts derived from isogenic PIK3CA wildtype or mutant cell lines corroborated this finding with PIK3CA mutant xenografts showing greater sensitivity to cabozantinib.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>144, \"name\"=>\"Cabozantinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>510, \"name\"=>\"Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.\", \"citation\"=>\"Song et al., 2015, Int. J. Cancer\", \"pubmed_id\"=>\"25242168\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25242168\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4323738\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Int. J. Cancer\", \"full_journal_title\"=>\"International journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1616, \"name\"=>\"EID1616\", \"description\"=>\"A panel of 24 endometrioid endometrial cancer (EEC) cell lines was characterized for a set of mutations and sensitivity to pan PI3K class I inhibitor GDC-0941 (pictilisib) was assessed. EEC cell lines with PIK3CA mutations were significantly more sensitive to GDC-0941 (Fisherâs exact test, two-tailed, P=0.038). Some of the PIK3CA mutant cells contained PTEN and KRAS mutations, but in these cells, these mutations did not effect sensitivity.\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>141, \"name\"=>\"Pictilisib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1067, \"name\"=>\"PI3K pathway dependencies in endometrioid endometrial cancer cell lines.\", \"citation\"=>\"Weigelt et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23674493\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23674493\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3700760\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1610, \"name\"=>\"EID1610\", \"description\"=>\"A panel of 31 breast cancer cell lines was tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/mTORC2 inhibitor PP242. Inhibitor concentrations for 50% survival fraction (SF50) were measured and SF50 less than one micro molar was considered sensitive. PIK3CA mutant cell lines were significantly more sensitive to both everolimus and PP242 than PIK3CA wild type cell lines. Apoptotic indicators and cell cycle analysis indicated that the mTOR inhibitors induced G1 arrest instead of apoptosis in the cell lines.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}, {\"id\"=>179, \"name\"=>\"PP242\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1066, \"name\"=>\"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.\", \"citation\"=>\"Weigelt et al., 2011, Oncogene\", \"pubmed_id\"=>\"21358673\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21358673\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>7, \"day\"=>21}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>915, \"name\"=>\"EID915\", \"description\"=>\"A meta-analysis of 8 metastatic colorectal cancer studies (839 patients) was performed. PIK3CA mutations were significantly associated with shorter PFS and OS following therapy with anti-EGFR monoclonal antibodies (PFS: 8 studies, 839 patients; HR = 1.53; 95 % confidence interval (CI) 1.28-1.84; P < 0.001; OS: 5 studies; 587 patients; HR = 1.28; 95 % CI 1.05-1.56; P = 0.015).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>252, \"name\"=>\"Anti-EGFR Monoclonal Antibody\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>622, \"name\"=>\"PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.\", \"citation\"=>\"Wu et al., 2013, J. Cancer Res. Clin. Oncol.\", \"pubmed_id\"=>\"23435830\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23435830\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>5}, \"journal\"=>\"J. Cancer Res. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of cancer research and clinical oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>892, \"name\"=>\"EID892\", \"description\"=>\"94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed.\\nNo predictive biomarkers were identified, including PIK3CA mutations (N=21/73), KRAS mutations (10/73) or PTEN loss.\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>83, \"name\"=>\"Temsirolimus\", \"pubchem_id\"=>nil}, {\"id\"=>170, \"name\"=>\"Ridaforolimus\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>602, \"name\"=>\"Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.\", \"citation\"=>\"Mackay et al., 2014, Cancer\", \"pubmed_id\"=>\"24166148\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24166148\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>15}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1490, \"name\"=>\"EID1490\", \"description\"=>\"A panel of 26 HNSCC cell lines was tested for efficacy of the p110 alpha, delta and gamma isoform inhibitor taselisib (GDC-0032). Cell lines with PIK3CA mutation or amplification were the most sensitive. Four HNSCC cell lines with activating PIK3CA alterations showed synergistic cell death response to the combination of drug with radiation treatment. This synergism was not apparent in 4 tested HNSCC cell lines with wild-type PIK3CA or PTEN mutation. Nude mouse xenografts were established with Cal-33 PIK3CA H1047R cells. Radiation and taselisib treatments alone showed some growth inhibition in comparison to control, but only the combined treatment led durable tumor regressions.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>351, \"name\"=>\"Taselisib (GDC-0032)\", \"pubchem_id\"=>nil}, {\"id\"=>360, \"name\"=>\"Radiation\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>984, \"name\"=>\"Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.\", \"citation\"=>\"Zumsteg et al., 2016, Clin. Cancer Res.\", \"pubmed_id\"=>\"26589432\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26589432\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4870591\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}, {\"id\"=>1504, \"name\"=>\"EID1504\", \"description\"=>\"HER2 overexpressing breast cancer cell lines with PIK3CA mutation BT474c (K111N) and HCC-1954 (H1047R) were used to establish mouse tumor xenografts. In BT474c xenografts, three dosing schedules of AZD5363 caused significant tumor inhibition (200 mg/kg twice daily > 200 mg/kg once daily > 100 mg/kg once daily). In HCC-1954 xenografts two doses of AZD5363 induced significant tumor inhibition (150 mg/kg twice daily > 75 mg/kg twice daily) while 30 mg/kg twice weekly trastuzumab was inactive.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>112, \"name\"=>\"AZD5363\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1005, \"name\"=>\"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.\", \"citation\"=>\"Davies et al., 2012, Mol. Cancer Ther.\", \"pubmed_id\"=>\"22294718\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22294718\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>311, \"phenotypes\"=>[]}]}, {\"id\"=>1, \"entrez_name\"=>\"ABL1\", \"entrez_id\"=>25, \"name\"=>\"BCR-ABL\", \"description\"=>\"The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.\", \"gene_id\"=>4, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>120, \"name\"=>\"transcript_fusion\", \"display_name\"=>\"Transcript Fusion\", \"so_id\"=>\"SO:0001886\", \"description\"=>\"A feature fusion where the deletion brings together transcript regions.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001886\"}], \"civic_actionability_score\"=>238.0, \"coordinates\"=>{\"chromosome\"=>\"22\", \"start\"=>23522397, \"stop\"=>23632600, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000305877.8\", \"chromosome2\"=>\"9\", \"start2\"=>133729451, \"stop2\"=>133763063, \"representative_transcript2\"=>\"ENST00000318560.5\", \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/4/summary/variants/1/summary#variant\", \"evidence_items\"=>[{\"id\"=>344, \"name\"=>\"EID344\", \"description\"=>\"BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens.\", \"disease\"=>{\"id\"=>4, \"name\"=>\"Chronic Myeloid Leukemia\", \"display_name\"=>\"Chronic Myeloid Leukemia\", \"doid\"=>\"8552\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8552\"}, \"drugs\"=>[{\"id\"=>5, \"name\"=>\"Imatinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>156, \"name\"=>\"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.\", \"citation\"=>\"An et al., 2010, Leuk. Res.\", \"pubmed_id\"=>\"20537386\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20537386\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Leuk. Res.\", \"full_journal_title\"=>\"Leukemia research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}, {\"id\"=>259, \"name\"=>\"EID259\", \"description\"=>\"Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>5, \"name\"=>\"Imatinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>164, \"name\"=>\"Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.\", \"citation\"=>\"Nimmanapalli et al., 2002, Oncogene\", \"pubmed_id\"=>\"12476305\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/12476305\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2002, \"month\"=>12, \"day\"=>9}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}, {\"id\"=>260, \"name\"=>\"EID260\", \"description\"=>\"The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML.\", \"disease\"=>{\"id\"=>4, \"name\"=>\"Chronic Myeloid Leukemia\", \"display_name\"=>\"Chronic Myeloid Leukemia\", \"doid\"=>\"8552\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8552\"}, \"drugs\"=>[{\"id\"=>5, \"name\"=>\"Imatinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>156, \"name\"=>\"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.\", \"citation\"=>\"An et al., 2010, Leuk. Res.\", \"pubmed_id\"=>\"20537386\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20537386\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Leuk. Res.\", \"full_journal_title\"=>\"Leukemia research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}, {\"id\"=>213, \"name\"=>\"EID213\", \"description\"=>\"Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML.\", \"disease\"=>{\"id\"=>4, \"name\"=>\"Chronic Myeloid Leukemia\", \"display_name\"=>\"Chronic Myeloid Leukemia\", \"doid\"=>\"8552\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8552\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>151, \"name\"=>\"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.\", \"citation\"=>\"Schmidt et al., 2014, Leukemia\", \"pubmed_id\"=>\"25212276\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25212276\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>12}, \"journal\"=>\"Leukemia\", \"full_journal_title\"=>\"Leukemia\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}, {\"id\"=>232, \"name\"=>\"EID232\", \"description\"=>\"BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[{\"id\"=>5, \"name\"=>\"Imatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>164, \"name\"=>\"Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.\", \"citation\"=>\"Nimmanapalli et al., 2002, Oncogene\", \"pubmed_id\"=>\"12476305\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/12476305\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2002, \"month\"=>12, \"day\"=>9}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}, {\"id\"=>220, \"name\"=>\"EID220\", \"description\"=>\"The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease.\", \"disease\"=>{\"id\"=>4, \"name\"=>\"Chronic Myeloid Leukemia\", \"display_name\"=>\"Chronic Myeloid Leukemia\", \"doid\"=>\"8552\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8552\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>156, \"name\"=>\"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.\", \"citation\"=>\"An et al., 2010, Leuk. Res.\", \"pubmed_id\"=>\"20537386\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20537386\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Leuk. Res.\", \"full_journal_title\"=>\"Leukemia research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}, {\"id\"=>261, \"name\"=>\"EID261\", \"description\"=>\"The use of nilotinib and dasatinib, second-generation BCR-ABL targeted therapies, has been effective in patients resistant to imatinib, leading to their FDA-approval.\", \"disease\"=>{\"id\"=>4, \"name\"=>\"Chronic Myeloid Leukemia\", \"display_name\"=>\"Chronic Myeloid Leukemia\", \"doid\"=>\"8552\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:8552\"}, \"drugs\"=>[{\"id\"=>13, \"name\"=>\"Nilotinib\", \"pubchem_id\"=>nil}, {\"id\"=>20, \"name\"=>\"Dasatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>156, \"name\"=>\"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.\", \"citation\"=>\"An et al., 2010, Leuk. Res.\", \"pubmed_id\"=>\"20537386\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20537386\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Leuk. Res.\", \"full_journal_title\"=>\"Leukemia research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>1, \"phenotypes\"=>[]}]}, {\"id\"=>108, \"entrez_name\"=>\"PML\", \"entrez_id\"=>5371, \"name\"=>\"PML-RARA\", \"description\"=>\"The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.\", \"gene_id\"=>39, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>120, \"name\"=>\"transcript_fusion\", \"display_name\"=>\"Transcript Fusion\", \"so_id\"=>\"SO:0001886\", \"description\"=>\"A feature fusion where the deletion brings together transcript regions.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001886\"}], \"civic_actionability_score\"=>132.5, \"coordinates\"=>{\"chromosome\"=>\"15\", \"start\"=>74287058, \"stop\"=>74325755, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000268058.3\", \"chromosome2\"=>\"17\", \"start2\"=>38504568, \"stop2\"=>38513048, \"representative_transcript2\"=>\"ENST00000254066.5\", \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/39/summary/variants/108/summary#variant\", \"evidence_items\"=>[{\"id\"=>1519, \"name\"=>\"EID1519\", \"description\"=>\"A 39-year old woman who presented with acute myeloid leukemia revealed a complicated genetic profile using conventional metaphase cytogenetics and FISH analysis.  Whole genome sequencing elucidated a PML-RARA fusion, which can be successfully treated with ATRA. Uncovering this mutation prevented an unnecessary allogeneic transplant and the patient remained in remission 15 months post-treatment (date of publication).\", \"disease\"=>{\"id\"=>379, \"name\"=>\"Acute Promyelocytic Leukemia\", \"display_name\"=>\"Acute Promyelocytic Leukemia\", \"doid\"=>\"0060318\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060318\"}, \"drugs\"=>[{\"id\"=>265, \"name\"=>\"All-trans Retinoic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1012, \"name\"=>\"Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.\", \"citation\"=>\"Welch et al., 2011, JAMA\", \"pubmed_id\"=>\"21505136\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21505136\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3156695\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>20}, \"journal\"=>\"JAMA\", \"full_journal_title\"=>\"JAMA\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>108, \"phenotypes\"=>[]}, {\"id\"=>1091, \"name\"=>\"EID1091\", \"description\"=>\"ATRA/Arsenic combined with standard chemotherapy has been shown to induce a complete remission rate of greater than 75% of patients with acute promyelocytic leukemia harboring the PML-RARa fusion.\", \"disease\"=>{\"id\"=>379, \"name\"=>\"Acute Promyelocytic Leukemia\", \"display_name\"=>\"Acute Promyelocytic Leukemia\", \"doid\"=>\"0060318\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060318\"}, \"drugs\"=>[{\"id\"=>47, \"name\"=>\"Arsenic Trioxide\", \"pubchem_id\"=>nil}, {\"id\"=>265, \"name\"=>\"All-trans Retinoic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>750, \"name\"=>\"All trans retinoic acid in acute promyelocytic leukemia.\", \"citation\"=>\"Degos et al., 2001, Oncogene\", \"pubmed_id\"=>\"11704842\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11704842\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2001, \"month\"=>10, \"day\"=>29}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>108, \"phenotypes\"=>[]}, {\"id\"=>1090, \"name\"=>\"EID1090\", \"description\"=>\"The presence of the PML-RARa fusion protein is a diagnostic marker of Acute Promyelocytic Leukemia, or M3 AML.\", \"disease\"=>{\"id\"=>379, \"name\"=>\"Acute Promyelocytic Leukemia\", \"display_name\"=>\"Acute Promyelocytic Leukemia\", \"doid\"=>\"0060318\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060318\"}, \"drugs\"=>[], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>749, \"name\"=>\"The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia.\", \"citation\"=>\"Diverio et al., Haematologica\", \"pubmed_id\"=>\"7628753\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/7628753\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{}, \"journal\"=>\"Haematologica\", \"full_journal_title\"=>\"Haematologica\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>108, \"phenotypes\"=>[]}, {\"id\"=>316, \"name\"=>\"EID316\", \"description\"=>\"Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations.\", \"disease\"=>{\"id\"=>379, \"name\"=>\"Acute Promyelocytic Leukemia\", \"display_name\"=>\"Acute Promyelocytic Leukemia\", \"doid\"=>\"0060318\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060318\"}, \"drugs\"=>[{\"id\"=>265, \"name\"=>\"All-trans Retinoic Acid\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>197, \"name\"=>\"Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.\", \"citation\"=>\"Yoshida et al., 1996, Cancer Res.\", \"pubmed_id\"=>\"8674046\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/8674046\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>1996, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>108, \"phenotypes\"=>[]}]}, {\"id\"=>499, \"entrez_name\"=>\"ALK\", \"entrez_id\"=>238, \"name\"=>\"ALK FUSIONS\", \"description\"=>\"Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer. \\n\\nIn a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response. \\n\\nDue to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets.  ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib â a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC.   \\n\\nALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC.  Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.\", \"gene_id\"=>1, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>120, \"name\"=>\"transcript_fusion\", \"display_name\"=>\"Transcript Fusion\", \"so_id\"=>\"SO:0001886\", \"description\"=>\"A feature fusion where the deletion brings together transcript regions.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001886\"}], \"civic_actionability_score\"=>440.5, \"coordinates\"=>{\"chromosome\"=>\"2\", \"start\"=>29415640, \"stop\"=>29446394, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000389048.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/1/summary/variants/499/summary#variant\", \"evidence_items\"=>[{\"id\"=>4858, \"name\"=>\"EID4858\", \"description\"=>\"In a randomized, open-label phase 3 trial 303 patients with ALK-positive, previously untreated NSCLC (including asympt. CNS disease) were randomized to reiceive either Alectinib or Crizotinib. During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression/death occurred in 41% (62/152  pt) in the alectinib group and 68% (102/151 patients) in the crizotinib group. 12-month event-free survival rate 68.4% with alectinib vs. 48.7% with crizotinib. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, compared to 68 patients (45%) in the crizotinib group. Response rates were 82.9% (Alectinib) and 75.5% (crizotinib).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}, {\"id\"=>526, \"name\"=>\"Alectinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2157, \"name\"=>\"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.\", \"citation\"=>\"Peters et al., 2017, N. Engl. J. Med.\", \"pubmed_id\"=>\"28586279\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28586279\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>6, \"day\"=>6}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>4835, \"name\"=>\"EID4835\", \"description\"=>\"In a phase II randomized trial we evaluated two regimens of Brigatinib in Crizotinib-refractory ALK-pos. NSCLC. They were randomly assigned (1:1) to oral Brigatinib 90 mg once daily (arm A) or 180 mg once daily with a 7-day lead-in at 90 mg. Of 222 patients enrolled (arm A: n = 112, arm B: n = 110), 154 (69%) had baseline brain metastases and 164 of 222 (74%) had received prior chemotherapy. investigator-assessed confirmed ORR was 45 (arm A) and 54% (B). Investigator-assessed median PFS was 9.2 months (A) and 12.9 months (B). Independent review committee-assessed intracranial ORR in patients with measurable brain metastases at baseline was 42% (11/26, A) and 67% (12/18, B). Brigatinib yielded substantial whole-body and intracranial responses as well as robust PFS; 180 mg (with lead-in) showed consistently better efficacy than 90 mg, with acceptable safety.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>318, \"name\"=>\"Brigatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2141, \"name\"=>\"Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.\", \"citation\"=>\"Kim et al., 2017, J. Clin. Oncol.\", \"pubmed_id\"=>\"28475456\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28475456\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>5, \"day\"=>5}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>2952, \"name\"=>\"EID2952\", \"description\"=>\"Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>426, \"name\"=>\"Entrectinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1689, \"name\"=>\"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).\", \"citation\"=>\"Drilon et al., 2017, Cancer Discov\", \"pubmed_id\"=>\"28183697\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28183697\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5380583\", \"publication_date\"=>{\"year\"=>2017, \"month\"=>4}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1264, \"name\"=>\"EID1264\", \"description\"=>\"A 27 year old female patient with advanced-stage IV, CD20 negative diffuse large B cell lymphoma (DLBCL). ALK rearrangement was determined by FISH, but the ALK fusion partner was not determined due to limited tissue. The patient underwent treatment with CHOP chemotherapy regimen and radiation but did not respond. The patient progressed following salvage chemotherapy and autologous stem cell transplant. Crizotinib was then administered at 250 mg twice daily, and LDH levels rapidly dropped along with disappearance of palpable lymphadenopathy, but progression ensued after 21 days and the patient died soon after. The authors attribute the short response to crizotinib to the possibility of this tumor having an ALK fusion variant less responsive to ALK inhibition and to a high Ki-67 index in the patient, and deem that despite the brief response, crizotinib shows promise in ALK rearranged DLBCL.\", \"disease\"=>{\"id\"=>45, \"name\"=>\"Diffuse Large B-cell Lymphoma\", \"display_name\"=>\"Diffuse Large B-cell Lymphoma\", \"doid\"=>\"0050745\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050745\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>874, \"name\"=>\"Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.\", \"citation\"=>\"Wass et al., 2014, Eur. J. Haematol.\", \"pubmed_id\"=>\"24330038\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24330038\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>3}, \"journal\"=>\"Eur. J. Haematol.\", \"full_journal_title\"=>\"European journal of haematology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1202, \"name\"=>\"EID1202\", \"description\"=>\"In this study, heavily pretreated advanced NSCLC patients with various molecular tumor makeup were treated with Hsp90 inhibitor IPI-504 to assess overall response rate. The study did not reach the targeted endpoint of 20% ORR. However, of 3/12 patients found to be ALK-rearranged via break apart FISH assay, 2 showed a partial response and the third stable disease, which was durable for 7.2 months. The authors note that the break apart FISH assay used to determine ALK-rearrangement status does not determine the identity of the ALK fusion partner and the promising results shown here may be dependent on the nature of the ALK fusion partner.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>303, \"name\"=>\"IPI-504\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>831, \"name\"=>\"Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.\", \"citation\"=>\"Sequist et al., 2010, J. Clin. Oncol.\", \"pubmed_id\"=>\"20940188\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20940188\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4676802\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>11, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1273, \"name\"=>\"EID1273\", \"description\"=>\"In this case study of a critically ill 29 year old male nonsmoker with advanced metastatic ALK-positive NSCLC, alectinib (CH5424802), was administered as first line treatment. Where most clinical trials only admit patients with Eastern Cooperative Oncology Performance status (PS) of 0 or 1, this patient had PS 4 due to respiratory failure, multiple bone metastases and complications from disseminated intravascular coagulation (DIC). Administration of alectinib at 300 mg twice daily was followed by marked improvement seen in tests associated with DIC, pulmonary metastasis and change in PS from 4 to 0. Further improvements after a couple of months suggested a rapid complete response. Alectinib was well tolerated in this first line treatment of a critically ill ALK-positive NSCLC patient.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>17, \"name\"=>\"CH5424802\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>879, \"name\"=>\"Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.\", \"citation\"=>\"Yoshida et al., 2016, Anticancer Drugs\", \"pubmed_id\"=>\"26938871\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26938871\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>7}, \"journal\"=>\"Anticancer Drugs\", \"full_journal_title\"=>\"Anti-cancer drugs\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1691, \"name\"=>\"EID1691\", \"description\"=>\"In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an EML4-ALK-E13;A20 rearrangement was identified using CGP.  The patient attained a reduction in the target lesions by 14.2%, however, the patient relapsed 17 months later.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1141, \"name\"=>\"Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.\", \"citation\"=>\"Le et al., 2015, Clin Lung Cancer\", \"pubmed_id\"=>\"25922291\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25922291\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4418215\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>9}, \"journal\"=>\"Clin Lung Cancer\", \"full_journal_title\"=>\"Clinical lung cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1577, \"name\"=>\"EID1577\", \"description\"=>\"A phase-3 clinical trial evaluated 347 patients with ALK-positive lung cancer.  The study compared crizotinib treatment (n=173) with chemotherapy treatment of either pemetrexed or docetaxel (n=174).  In the crizotinib arm, the response rate was significantly higher (65% vs 20%; P<0.001), the progression-free survival was increased (7.7 months vs. 3.0 months; HR=0.49, 95%CI:14 months-26 months; p<0.001), however, there was no significant improvement in overall survival (HR=1.02; 95%CI:0.68-1.54; P=0.54).  Of the patients on crizotinib treatment, global quality of life was improved relative to baseline when compared to chemotherapy patients (+5 mean change, -5 mean change; P<0.001).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1041, \"name\"=>\"Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.\", \"citation\"=>\"2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"26466010\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26466010\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>10, \"day\"=>15}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1200, \"name\"=>\"EID1200\", \"description\"=>\"This retrospective study of patients from the PROFILE 1001 and 1005 studies of crizotinib in advanced ALK-rearranged NSCLC assessed the potential benefit of crizotinib beyond progressive disease (CBPD), defined as continuation of crizotinib for 3 or more weeks after disease progression on crizotinib. 194 patients who had developed PD by data cutoff were studied, where 120 received crizotinib for a median duration of 19.4 weeks and 74 discontinued crizotinib after PD. No gross imbalances in clinicopathologic features of the two groups were evident.  Significantly longer overall survival was observed in the crizotinib continuing group from time of PD (16.4 vs. 3.9 months; hazard ratio 0.27, 95% CI: 0.17â0.42; P < 0.0001), and from the time of initial crizotinib (29.6 vs. 10.8 months; HR 0.30, 95% CI: 0.19â0.46; P < 0.0001).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>829, \"name\"=>\"Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.\", \"citation\"=>\"Ou et al., 2014, Ann. Oncol.\", \"pubmed_id\"=>\"24478318\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24478318\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>2}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1783, \"name\"=>\"EID1783\", \"description\"=>\"Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 and immunohistochemistry revealed ALK expression, suggesting ALK fusions in three cases of IMT.\", \"disease\"=>{\"id\"=>12, \"name\"=>\"Inflammatory Myofibroblastic Tumor\", \"display_name\"=>\"Inflammatory Myofibroblastic Tumor\", \"doid\"=>\"0050905\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050905\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Diagnostic\", \"clinical_significance\"=>\"Positive\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1245, \"name\"=>\"Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.\", \"citation\"=>\"Griffin et al., 1999, Cancer Res.\", \"pubmed_id\"=>\"10383129\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/10383129\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>1999, \"month\"=>6, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1282, \"name\"=>\"EID1282\", \"description\"=>\"In this Phase II trial of 87 patients (NCT01871805), alectinib was assayed for safety and efficacy in ALK positive NSCLC that had progressed on crizotinib. Of 69 patients with measurable disease, 35 achieved objective response, with median duration of response 13.5 months. Of 16 patients with measurable CNS disease, four achieved CNS complete response and 8 showed CNS partial response. median duration of CNS response was 11.1 months. 2 deaths were observed, and 1 was judged related to study treatment. In early 2016, alectinib was approved by the FDA partly based on this study for treatment of crizotinib-progressed ALK positive NSCLC\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>321, \"name\"=>\"Alectinib (CH5424802)\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>886, \"name\"=>\"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.\", \"citation\"=>\"Shaw et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"26708155\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26708155\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4752892\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>2}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1279, \"name\"=>\"EID1279\", \"description\"=>\"In this Phase I trial (NCT01588028) in 47 patients, alectinib was assessed for its effectiveness in treating locally advanced or metastatic ALK-positive NSCLC that had progressed or been resistant to crizotinib treatment. ALK rearrangement was assessed via approved break apart FISH kit, and patients with asymptomatic CNS metastases were also included. Patients were divided into different cohorts receiving different doses of alectinib. In the 600 mg cohort (N=13), there were 4 confirmed partial responses, 3 unconfirmed partial responses and 3 instances of stable disease. Also, five of nine patients throughout the cohorts with measurable baseline CNS lesions showed partial response to alectinib. Cerebrospinal fluid levels of alectinib increased linearly with blood alectinib levels, indicating it effectively crossed the blood-brain barrier.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>321, \"name\"=>\"Alectinib (CH5424802)\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>884, \"name\"=>\"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.\", \"citation\"=>\"Gadgeel et al., 2014, Lancet Oncol.\", \"pubmed_id\"=>\"25153538\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25153538\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>9}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1334, \"name\"=>\"EID1334\", \"description\"=>\"26 colorectal adenocarcinoma samples were run on Affymetrix human Exon 1.0 arrays and a computational method that assessed differential 5' and 3' gene expression for each gene was used to find potential rearrangements.  One sample showed potential rearrangement and RT-PCR demonstrated an EML4-ALK fusion where EML4 exon 21 was fused to ALK exon 13. This EML4-ALK variant is different from those commonly found in NSCLC. Genomic PCR verified the existence of the fusion breakpoint in intronic space, indicating that some colorectal adenocarcinoma may have targetable ALK-fusion driver mutations.\", \"disease\"=>{\"id\"=>57, \"name\"=>\"Colorectal Adenocarcinoma\", \"display_name\"=>\"Colorectal Adenocarcinoma\", \"doid\"=>\"0050861\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050861\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"E\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>920, \"name\"=>\"Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.\", \"citation\"=>\"Lin et al., 2009, Mol. Cancer Res.\", \"pubmed_id\"=>\"19737969\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19737969\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>9}, \"journal\"=>\"Mol. Cancer Res.\", \"full_journal_title\"=>\"Molecular cancer research : MCR\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1335, \"name\"=>\"EID1335\", \"description\"=>\"84 breast cancer samples acquired from commercial sources were assayed on Affymetrix human exon 1.0 arrays. A computational method was used to find potential gene fusions which assessed differential exon expression between the 3' and 5' ends of each gene. Two potential fusions were found and assessed using RNA ligase mediated rapid amplifiation of cDNA ends and RT-PCR. The fusions were EML4-ALK variants 1 and 2. Genomic PCR identified fusion breakpoints, and these differed from breakpoints for these EML4-ALK variants reported in NSCLC.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"E\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>920, \"name\"=>\"Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.\", \"citation\"=>\"Lin et al., 2009, Mol. Cancer Res.\", \"pubmed_id\"=>\"19737969\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19737969\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>9}, \"journal\"=>\"Mol. Cancer Res.\", \"full_journal_title\"=>\"Molecular cancer research : MCR\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1419, \"name\"=>\"EID1419\", \"description\"=>\"In a retrospective study comparing survival outcomes in a subgroup of 82 ALK-positive crizotinib-treated patients enrolled in a phase 1 clinical trial (NCT00585195), crizotinib therapy was associated with improved survival. For the crizotinib-treated, ALK-positive patient group, 1 year survival was 74% and 2 year overall survival was 54%, compared with 72% and 36% for the control group (ALK-positive crizotinib naive patients).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>961, \"name\"=>\"Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.\", \"citation\"=>\"Shaw et al., 2011, Lancet Oncol.\", \"pubmed_id\"=>\"21933749\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21933749\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3328296\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>10}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1240, \"name\"=>\"EID1240\", \"description\"=>\"Crizotinib at 250mg daily was given to two patients with relapsed ALK-rearranged anaplastic large cell lymphoma (ALCL). Patient one, 26 yrs old, had been treated with the CHOP-15 chemotherapy regimen, then salvage chemotherapy to prepare for autologous bone marrow transplant but ultimately relapsed. After initiation of crizotinib, PET, CT and bone marrow aspirates showed complete remission of previous lesions at 28 days. At time of publication the patient continued to show persistent response at 6 months. A 20 year old patient relapsed after one month of CHOP, and was treated with further chemotherapy and autologous bone marrow transplantation resulting in partial response of 1 month. Crizotinib was initialized, and after 12 days PET scan showed complete regression of all lesions. On day 60 bone marrow aspirates were ALK-negative (pretreatment evaluation showed 8% ALK-positive). The authors conclude these two cases indicate sensitivity to crizotinib of relapsed ALK-rearranged ALCL.\", \"disease\"=>{\"id\"=>348, \"name\"=>\"Anaplastic Large Cell Lymphoma\", \"display_name\"=>\"Anaplastic Large Cell Lymphoma\", \"doid\"=>\"0050744\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050744\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>858, \"name\"=>\"Crizotinib in anaplastic large-cell lymphoma.\", \"citation\"=>\"Gambacorti-Passerini et al., 2011, N. Engl. J. Med.\", \"pubmed_id\"=>\"21345110\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21345110\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>2, \"day\"=>24}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1272, \"name\"=>\"EID1272\", \"description\"=>\"In this initial report of a single-arm Phase I and II study (JapicCTI-101264) of alectinib (CH5424802), 46 patients with advanced or metastatic ALK-rearranged non small cell lung cancer (NSCLC) were assessed for objective response during phase II. ALK positivity was assessed via IHC and verified with FISH or RT-PCR. Patients had received one or more rounds of previous chemotherapy, but no prior targeted therapy towards ALK. From the 46 patients, 41 showed partial response, and 2 showed complete response. CNS metastases in three patients which had not received prior brain irradiation showed response to alectinib. Alectinib was generally well tolerated, and the authors conclude that alectinib compared favorably to crizotinib and could be an effective and safe option in ALK-rearranged NSCLC.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>321, \"name\"=>\"Alectinib (CH5424802)\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>878, \"name\"=>\"CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.\", \"citation\"=>\"Seto et al., 2013, Lancet Oncol.\", \"pubmed_id\"=>\"23639470\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23639470\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>6}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1323, \"name\"=>\"EID1323\", \"description\"=>\"Development of second generation ALK inhibitors has been underway in order to address resistance to first line treatments such as crizotinib in ALK-rearranged NSCLC.  Brigatinib is a potent dual inhibitor against ALK and EGFR.  In an update from the Phase I/II trial NCT01449461 of brigatinib in ALK+ NSCLC, patients were given 90 mg/day, 180 mg/day, or 90 followed by 180 mg/day. In crizotinib-naive patients, overall response rate (ORR) was 7/7 patients with progression free survival (PFS) of 56 weeks. In patients who failed on crizotinib treatment ORR was 69% (45/65 patients) with PFS of 47 weeks, and activity against CNS metastases was seen with ORR 37% in 38 patients with PFS 97 weeks indicating substantial brigatinib activity in crizotinib-progressed patients, as well as promise in CNS metastases.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>318, \"name\"=>\"Brigatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"rejected\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>912, \"name\"=>\"Second- and third-generation ALK inhibitors for non-small cell lung cancer.\", \"citation\"=>\"Wu et al., 2016, J Hematol Oncol\", \"pubmed_id\"=>\"26951079\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26951079\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4782349\", \"publication_date\"=>{\"year\"=>2016}, \"journal\"=>\"J Hematol Oncol\", \"full_journal_title\"=>\"Journal of hematology & oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1242, \"name\"=>\"EID1242\", \"description\"=>\"Four adult ALK-rearranged anaplastic large cell lymphoma (ALCL) patients were resistant to chemotherapy after 3 or more lines of treatment.  The patients were administered 250 mg crizotinib twice daily. Normalization of symptoms was observed at a median time of 5 days, with an overall response rate of 100% (3 complete responses and one partial response)\", \"disease\"=>{\"id\"=>348, \"name\"=>\"Anaplastic Large Cell Lymphoma\", \"display_name\"=>\"Anaplastic Large Cell Lymphoma\", \"doid\"=>\"0050744\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050744\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"rejected\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>860, \"name\"=>\"Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.\", \"citation\"=>\"Foyil et al., Cancer J\", \"pubmed_id\"=>\"23006951\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23006951\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{}, \"journal\"=>\"Cancer J\", \"full_journal_title\"=>\"Cancer journal (Sudbury, Mass.)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1243, \"name\"=>\"EID1243\", \"description\"=>\"As part of a phase 1 dose-escalation trial (NCT00939770), seven patients between ages 12 months and 22 years with relapsed or refractory inflammatory myofibroblastic tumors with ALK-rearrangement were given crizotinib. In six patients with measurable disease, responses included 3 with partial response and 3 with stable disease. One patient with evaluable disease had stable disease with treatment ongoing at the time of publication. Crizotinib was well tolerated in this group of pediatric patients.\", \"disease\"=>{\"id\"=>12, \"name\"=>\"Inflammatory Myofibroblastic Tumor\", \"display_name\"=>\"Inflammatory Myofibroblastic Tumor\", \"doid\"=>\"0050905\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050905\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>859, \"name\"=>\"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.\", \"citation\"=>\"MossÃ© et al., 2013, Lancet Oncol.\", \"pubmed_id\"=>\"23598171\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23598171\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3730818\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>5}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1201, \"name\"=>\"EID1201\", \"description\"=>\"This prospective Phase III study named Profile 1014 on NSCLC ALK-rearranged patients assessed intracranial disease control rate (IC-DCR) in the subset of patients entering the study with preexisting treated brain metastasis (tBM). IC-DCR was significantly improved in the tBM group given crizotinib (N=39) over chemotherapy (pemetrexed + cisplatin or carboplatin; N=40) at 12 weeks (85% vs. 45%, P<0.001), and at 24 weeks (56% vs. 25%, P=0.006). Progression free survival was also significantly improved with crizotinib over chemotherapy in the tBM subgroup (9.0 vs. 4.0 months; HR 0.40; P<0.001), where in the intent to treat population it was 10.9 vs. 7.0 months (HR 0.45; P<0.001), indicating that the difficult to treat BM population obtained benefit from crizotinib at both the brain and systemic level.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>830, \"name\"=>\"Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.\", \"citation\"=>\"Solomon et al., 2016, J. Clin. Oncol.\", \"pubmed_id\"=>\"27022118\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27022118\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>8, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1199, \"name\"=>\"EID1199\", \"description\"=>\"This phase 3 trial named PROFILE 1014 (NCT01154140) compared crizotinib to established chemotherapy in first-line treatment for this disease. The study consisted of 343 patients with advanced or metastatic NSCLC that tested positive for ALK rearrangement via break-apart FISH assay, and had no prior systemic treatment. Patients were assigned in a 1:1 ratio to crizotinib (N=172) or pemetrexed with cisplatin or carboplatin (N=171). Progression free survival was significantly longer with crizotinib treatment than chemotherapy (10.9 vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% CI, 0.35 to 0.60;P<0.001), and objective response rate was higher with crizotinib treatment than chemotherapy (75% vs. 45%, P<0.001). Improvement in quality of life was also reported.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>828, \"name\"=>\"First-line crizotinib versus chemotherapy in ALK-positive lung cancer.\", \"citation\"=>\"Solomon et al., 2014, N. Engl. J. Med.\", \"pubmed_id\"=>\"25470694\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25470694\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>12, \"day\"=>4}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1175, \"name\"=>\"EID1175\", \"description\"=>\"Updated results from ASCEND-1 trial assessing safety and activity of ceritinib in ALK rearranged locally advanced or metastatic NSCLC. 255 patients were enrolled and received at least one dose of ceritinib 750 mg/day, of whom 246 had ALK-rearranged NSCLC (Median follow-up: 11.1 months). Overall response rate was 72% [95% CI 61-82] of 83 ALK inhibitor-naive patients and 56% [49-64] of 163 ALK inhibitor-pretreated patients. Median duration of response was 17Â·0 months (95% CI 11.3-non-estimable [NE]) in ALK inhibitor-naive patients and 8.3 months (6.8-9.7) in ALK inhibitor-pretreated patients. Median progression-free survival was 18.4 months (95% CI 11.1-NE) in ALK inhibitor-naive patients and 6.9 months (5.6-8.7) in ALK inhibitor-pretreated patients. Brain metastases control was reported in 79% [95% CI 54-94] of 19 ALK inhibitor-naive patients and in 65% [54-76] of 75 ALK inhibitor-pretreated patients.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>159, \"name\"=>\"Ceritinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>812, \"name\"=>\"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.\", \"citation\"=>\"Kim et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"26973324\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26973324\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>4}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1187, \"name\"=>\"EID1187\", \"description\"=>\"In the Phase I study PROFILE 1001 (NCT00585195), a recommended crizotinib dose of 250 mg twice daily for 28 day cycles was established. Among 1,500 advanced NSCLC patients who were screened for ALK-rearrangement using a break-apart FISH assay, 82 patients were eligible for crizotinib treatment.  Overall response rate was 57%, with 46 partial responses and one complete response.  Since crizotinib inhibits MET, 33 patients with available tissue were screened for MET amplification and were found negative, further indicating that patient response was due to ALK inhibition.  31 patients were tested via RT-PCR for known EML4-ALK fusions, and 13 were shown to have EML4-ALK variant 1, four cases had variant 3, and one instance of variants 2, 3b and 5 were seen.  9 were unidentified, suggesting other fusion partners in these instances.  On the basis of this and a Phase II study, accelerated approval for crizotinib in ALK-positive advanced NSCLC was granted.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>819, \"name\"=>\"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.\", \"citation\"=>\"Kwak et al., 2010, N. Engl. J. Med.\", \"pubmed_id\"=>\"20979469\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20979469\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3014291\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>10, \"day\"=>28}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>1198, \"name\"=>\"EID1198\", \"description\"=>\"This two arm Phase III study named PROFILE 1007 (NCT00932893) was performed to assess crizotinib vs. established chemotherapy in non-small cell lung cancer patients positive for ALK rearrangement (assessed by break-apart FISH) with locally advanced or metastatic disease. 347 patients with disease progression after one round of platinum-based chemotherapy were randomized to receive crizotinib (N=173) or chemotherapy (N=174) consisting of pemetrexed in pemetrexed-naive patients and docetaxel for patients previously treated with pemetrexed. The primary endpoint - progression free survival (PFS) - was found to be significantly better for patients treated with crizotinib (median 7.7 months) than with chemotherapy (median 3.0 months) (hazard ratio for disease progression or death with crizotinib, 0.49; 95% CI, 0.37 to 0.64; P<0.001). Response rates were 65% for crizotinib treatment and 20% for chemotherapy (P<0.001). Improvements in quality of life were also reported.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>12, \"name\"=>\"Crizotinib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>827, \"name\"=>\"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.\", \"citation\"=>\"Shaw et al., 2013, N. Engl. J. Med.\", \"pubmed_id\"=>\"23724913\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23724913\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>6, \"day\"=>20}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}, {\"id\"=>945, \"name\"=>\"EID945\", \"description\"=>\"Among 95 patients with NSCLC in this study, 15 had an ALK translocation. ORR of these patients compared to EGFR mutated or wild-type tumors was superior (46.7 versus 4.7 versus 16.2%, p = 0.001). TYMS expression was lower in ALK-positive cells.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>156, \"name\"=>\"Pemetrexed\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>647, \"name\"=>\"Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.\", \"citation\"=>\"Lee et al., 2011, J Thorac Oncol\", \"pubmed_id\"=>\"21642865\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21642865\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>9}, \"journal\"=>\"J Thorac Oncol\", \"full_journal_title\"=>\"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>499, \"phenotypes\"=>[]}]}, {\"id\"=>190, \"entrez_name\"=>\"EGFR\", \"entrez_id\"=>1956, \"name\"=>\"AMPLIFICATION\", \"description\"=>\"\", \"gene_id\"=>19, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>123, \"name\"=>\"transcript_amplification\", \"display_name\"=>\"Transcript Amplification\", \"so_id\"=>\"SO:0001889\", \"description\"=>\"A feature amplification of a region containing a transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001889\"}], \"civic_actionability_score\"=>133.0, \"coordinates\"=>{\"chromosome\"=>\"7\", \"start\"=>55086794, \"stop\"=>55279321, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000275493.2\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/19/summary/variants/190/summary#variant\", \"evidence_items\"=>[{\"id\"=>3015, \"name\"=>\"EID3015\", \"description\"=>\"Evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment. This study reports that the Src-AKT pathway contributes to acquired resistance to third generation EGFR TKIs. In addition, amplification of EGFR wild-type alleles but not mutant alleles was sufficient to confer acquired resistance.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>91, \"name\"=>\"Rociletinib\", \"pubchem_id\"=>nil}, {\"id\"=>187, \"name\"=>\"Osimertinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1733, \"name\"=>\"Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.\", \"citation\"=>\"Nukaga et al., 2017, Cancer Res.\", \"pubmed_id\"=>\"28202511\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28202511\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>691, \"name\"=>\"EID691\", \"description\"=>\"EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}, {\"id\"=>395, \"name\"=>\"5-fluorouracil\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>450, \"name\"=>\"Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.\", \"citation\"=>\"Licitra et al., 2011, Ann. Oncol.\", \"pubmed_id\"=>\"21048039\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21048039\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3082162\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>5}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>977, \"name\"=>\"EID977\", \"description\"=>\"In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib). EGFR amplification (Multiplex ligation-dependent probe amplification; MLPA) and Mutation (PCR) were analzed. EGFR amplification was associated with EGFR mutation but not independently with patient benefit from EGFR TKI (overall and progression-free survival).\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}, {\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>676, \"name\"=>\"Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.\", \"citation\"=>\"Fiala et al., 2016, Anticancer Res.\", \"pubmed_id\"=>\"26722081\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26722081\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>1}, \"journal\"=>\"Anticancer Res.\", \"full_journal_title\"=>\"Anticancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>948, \"name\"=>\"EID948\", \"description\"=>\"A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy number), 10 (822 patients, 290 with increased gene copy number) and 5 studies (294 patients, 129 with increased gene copy number) were analyzed for overall survival (OS), progression-free survival (PFS) and time-to-progression (TTP) meta-analyses respectively. EGFR amplification was associated with increased OS (HR = 0.77; 95% CI 0.66-0.89; P = 0.001), PFS (HR = 0.60; 95% CI 0.46-0.79; P<0.001) and TTP (HR = 0.50; 95% CI 0.28-0.91; P = 0.02). This effect was shown to influence survival in predominantly white patient populations but not patients of Asian descent.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>145, \"name\"=>\"EGFR Inhibitor\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>650, \"name\"=>\"EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.\", \"citation\"=>\"Dahabreh et al., 2011, Ann. Oncol.\", \"pubmed_id\"=>\"20826716\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20826716\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>3}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>911, \"name\"=>\"EID911\", \"description\"=>\"87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and overall survival independent of KRAS status.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>618, \"name\"=>\"Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.\", \"citation\"=>\"Personeni et al., 2008, Clin. Cancer Res.\", \"pubmed_id\"=>\"18794099\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18794099\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>9, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>473, \"name\"=>\"EID473\", \"description\"=>\"The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tumors.\", \"disease\"=>{\"id\"=>37, \"name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"display_name\"=>\"Head And Neck Squamous Cell Carcinoma\", \"doid\"=>\"5520\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5520\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>287, \"name\"=>\"Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.\", \"citation\"=>\"Chung et al., 2006, J. Clin. Oncol.\", \"pubmed_id\"=>\"16943533\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16943533\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>9, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>854, \"name\"=>\"EID854\", \"description\"=>\"In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regardless of KRAS status. For the pooled analysis, the objective response rate (ORR) was 65.2% (167/256) in patients with high EFGR GCN, while in patients with low EFGR GCN, the pooled ORR was 12.2% (44/361). The odds ratio (OR) was 6.905 (95% CI: 4.489-10.620; Z=8.79, P=0.000). In wild type KRAS patients, the pooled OR was 8.133 (95% CI: 4.316-15.326; Z=6.48, P=0.000).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>571, \"name\"=>\"EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.\", \"citation\"=>\"Shen et al., 2014, Chin. J. Cancer Res.\", \"pubmed_id\"=>\"24653627\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24653627\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3937753\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>2}, \"journal\"=>\"Chin. J. Cancer Res.\", \"full_journal_title\"=>\"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>471, \"name\"=>\"EID471\", \"description\"=>\"In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival.\", \"disease\"=>{\"id\"=>148, \"name\"=>\"Cervical Squamous Cell Carcinoma\", \"display_name\"=>\"Cervical Squamous Cell Carcinoma\", \"doid\"=>\"3744\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3744\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>285, \"name\"=>\"EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.\", \"citation\"=>\"Iida et al., 2011, Br. J. Cancer\", \"pubmed_id\"=>\"21730982\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21730982\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3172895\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>7, \"day\"=>26}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}, {\"id\"=>470, \"name\"=>\"EID470\", \"description\"=>\"In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial.\", \"disease\"=>{\"id\"=>228, \"name\"=>\"Barrett's Adenocarcinoma\", \"display_name\"=>\"Barrett's Adenocarcinoma\", \"doid\"=>\"7941\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:7941\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>284, \"name\"=>\"Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.\", \"citation\"=>\"Marx et al., 2010, Histopathology\", \"pubmed_id\"=>\"20840671\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20840671\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>9}, \"journal\"=>\"Histopathology\", \"full_journal_title\"=>\"Histopathology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>190, \"phenotypes\"=>[]}]}, {\"id\"=>267, \"entrez_name\"=>\"FGFR1\", \"entrez_id\"=>2260, \"name\"=>\"AMPLIFICATION\", \"description\"=>\"FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).\", \"gene_id\"=>1885, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>123, \"name\"=>\"transcript_amplification\", \"display_name\"=>\"Transcript Amplification\", \"so_id\"=>\"SO:0001889\", \"description\"=>\"A feature amplification of a region containing a transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001889\"}], \"civic_actionability_score\"=>158.0, \"coordinates\"=>{\"chromosome\"=>\"8\", \"start\"=>38268656, \"stop\"=>38325363, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000425967.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/1885/summary/variants/267/summary#variant\", \"evidence_items\"=>[{\"id\"=>1908, \"name\"=>\"EID1908\", \"description\"=>\"Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. In the subgroup of FGFR1-amplified NSCLC, 36 patients were treated at doses >100mg and disease control was achieved in 50% of patients (4 PR and 14 SD) with 6 patients receiving treatment after 16 weeks.\", \"disease\"=>{\"id\"=>153, \"name\"=>\"Lung Squamous Cell Carcinoma\", \"display_name\"=>\"Lung Squamous Cell Carcinoma\", \"doid\"=>\"3907\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3907\"}, \"drugs\"=>[{\"id\"=>151, \"name\"=>\"BGJ398\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1337, \"name\"=>\"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.\", \"citation\"=>\"Nogova et al., 2017, J. Clin. Oncol.\", \"pubmed_id\"=>\"27870574\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27870574\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>3027, \"name\"=>\"EID3027\", \"description\"=>\"Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications. Objective response for the cohort was 11.5%, disease control rate was 50%. 11.5% of patients exhibited partial response, 38.5% exhibited stable disease. Median PFS was 2.9 months, median OS was 5 months, this trend was worse with increases in FGFR1 amplification above average.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>228, \"name\"=>\"Dovitinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1342, \"name\"=>\"Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.\", \"citation\"=>\"Lim et al., 2016, Cancer\", \"pubmed_id\"=>\"27315356\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27315356\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>10}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1909, \"name\"=>\"EID1909\", \"description\"=>\"Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Among the 26 patients with breast cancer and FGFR1/2 amplification (n=25,  n= 21 with FGFR1 amplification only) or FGFR3 mutation (n=1) four (15.4%) had a reduced tumor burden. In total, 10 of 32 patients with breast cancer treated at doses >100mg had a best response of SD.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>433, \"name\"=>\"BGJ-398\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>nil, \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1337, \"name\"=>\"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.\", \"citation\"=>\"Nogova et al., 2017, J. Clin. Oncol.\", \"pubmed_id\"=>\"27870574\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27870574\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1911, \"name\"=>\"EID1911\", \"description\"=>\"Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. One patient with FGFR1 amplified bladder/urothelial carcinoma was treated with 125 mg and progressed rapidly in cycle 1 after 11 days of treatment.\", \"disease\"=>{\"id\"=>18, \"name\"=>\"Bladder Carcinoma\", \"display_name\"=>\"Bladder Carcinoma\", \"doid\"=>\"4007\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4007\"}, \"drugs\"=>[{\"id\"=>433, \"name\"=>\"BGJ-398\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1337, \"name\"=>\"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.\", \"citation\"=>\"Nogova et al., 2017, J. Clin. Oncol.\", \"pubmed_id\"=>\"27870574\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27870574\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1991, \"name\"=>\"EID1991\", \"description\"=>\"Activity of the FGFR-selective inhibitor AZD4547 in FGFR1-amplified breast cancer and FGFR2-amplified gastroesophageal cancer was analyzed in this study. 341 patients with advanced cancer were screened by FISH, identifying FGFR1 amplification in 18% of advanced HER2-negative breast cancers and FGFR2 amplification in 9% of advanced gastroesophageal cancer. 1 patient had a confirmed response among 8 patients treated with FGFR1-amplified breast cancer. In a preclinical model, FGFR1 amplification in breast cancer cell lines was less pronounced than FGFR2-amplifications in gastroesophageal cancers, which also had a higher response rate in the trial, indicating that high level amplification is associated with response and less common in FGFR1-amplified breast cancer.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>452, \"name\"=>\"AZD4547\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1397, \"name\"=>\"High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.\", \"citation\"=>\"Pearson et al., 2016, Cancer Discov\", \"pubmed_id\"=>\"27179038\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27179038\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5338732\", \"publication_date\"=>{\"year\"=>2016, \"month\"=>8}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1604, \"name\"=>\"EID1604\", \"description\"=>\"Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study.\\nDovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines. Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model.\\n81 patients were enrolled in the trial and treated with dovitinib. Unconfirmed response or stable disease >6 months was observed in 25% of FGFR1-amplified/HR-positive vs. 3% FGFR1-nonamplified/HR-positive breast cancer patientes. When FGF3 and FGFR2 amplifications were also assessed, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>228, \"name\"=>\"Dovitinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1064, \"name\"=>\"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.\", \"citation\"=>\"AndrÃ© et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23658459\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23658459\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1767, \"name\"=>\"EID1767\", \"description\"=>\"In MDA-MB-134 cells (ER-positive breast cancer cells with amplified FGFR1) ponatinib potently inhibited cell growth with a GI50 value of 23 nmol/L and inhibited FGFR1 phosphorylation with an IC50 value of 7 nmol/L.\", \"disease\"=>{\"id\"=>28, \"name\"=>\"Estrogen-receptor Positive Breast Cancer\", \"display_name\"=>\"Estrogen-receptor Positive Breast Cancer\", \"doid\"=>\"0060075\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060075\"}, \"drugs\"=>[{\"id\"=>55, \"name\"=>\"Ponatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1233, \"name\"=>\"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.\", \"citation\"=>\"Gozgit et al., 2012, Mol. Cancer Ther.\", \"pubmed_id\"=>\"22238366\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22238366\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>3}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1247, \"name\"=>\"EID1247\", \"description\"=>\"116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines.\", \"disease\"=>{\"id\"=>135, \"name\"=>\"Bone Ewing's Sarcoma\", \"display_name\"=>\"Bone Ewing's Sarcoma\", \"doid\"=>\"3368\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3368\"}, \"drugs\"=>[{\"id\"=>55, \"name\"=>\"Ponatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>446, \"name\"=>\"Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.\", \"citation\"=>\"Agelopoulos et al., 2015, Clin. Cancer Res.\", \"pubmed_id\"=>\"26179511\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26179511\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>11, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>682, \"name\"=>\"EID682\", \"description\"=>\"In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates with cigarette smoking.\", \"disease\"=>{\"id\"=>153, \"name\"=>\"Lung Squamous Cell Carcinoma\", \"display_name\"=>\"Lung Squamous Cell Carcinoma\", \"doid\"=>\"3907\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3907\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>436, \"name\"=>\"Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.\", \"citation\"=>\"Kim et al., 2013, J. Clin. Oncol.\", \"pubmed_id\"=>\"23182986\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23182986\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>2, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>684, \"name\"=>\"EID684\", \"description\"=>\"This study shows a reduction in the risk of death for patients with FGFR1 copy-number between 4 and 6. No difference in survival is seen between amplified and non-amplified patients in general.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>438, \"name\"=>\"Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.\", \"citation\"=>\"Tran et al., 2013, Lung Cancer\", \"pubmed_id\"=>\"23806793\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23806793\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>9}, \"journal\"=>\"Lung Cancer\", \"full_journal_title\"=>\"Lung cancer (Amsterdam, Netherlands)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>685, \"name\"=>\"EID685\", \"description\"=>\"Meta-Analysis on prognostic value of FGFR1 amplification in different types of cancer shows significantly worse overall survival for patients with FGFR1 and FGFR2 amplification.\\nHowever, larger studies are warranted for confirmation.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>439, \"name\"=>\"Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis.\", \"citation\"=>\"Chang et al., 2014, PLoS ONE\", \"pubmed_id\"=>\"25171497\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25171497\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4149366\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>687, \"name\"=>\"EID687\", \"description\"=>\"Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metastasis.\", \"disease\"=>{\"id\"=>153, \"name\"=>\"Lung Squamous Cell Carcinoma\", \"display_name\"=>\"Lung Squamous Cell Carcinoma\", \"doid\"=>\"3907\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3907\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>441, \"name\"=>\"FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis.\", \"citation\"=>\"Jiang et al., 2015, Lung Cancer\", \"pubmed_id\"=>\"25433983\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25433983\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>1}, \"journal\"=>\"Lung Cancer\", \"full_journal_title\"=>\"Lung cancer (Amsterdam, Netherlands)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>683, \"name\"=>\"EID683\", \"description\"=>\"This study shows an association of FGFR1 amplification with shorter overall and disease-free survival. However, no statistically significant association is seen on multivariate analysis.\", \"disease\"=>{\"id\"=>153, \"name\"=>\"Lung Squamous Cell Carcinoma\", \"display_name\"=>\"Lung Squamous Cell Carcinoma\", \"doid\"=>\"3907\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3907\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>437, \"name\"=>\"FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer.\", \"citation\"=>\"Seo et al., 2014, Virchows Arch.\", \"pubmed_id\"=>\"25086725\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25086725\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>11}, \"journal\"=>\"Virchows Arch.\", \"full_journal_title\"=>\"Virchows Archiv : an international journal of pathology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>680, \"name\"=>\"EID680\", \"description\"=>\"Preclinical (in-vitro, in-vivo) evidence suggests predictive value of FGFR1 amplification for treatment with FGFR1-inhibitors. 4 of 83 cell lines exhibited FGFR1 amplification, and 3 of these were highly sensitive to PD173074. This sensitivity was confirmed in a mouse xenograft. Clinical trials are currently ongoing.\", \"disease\"=>{\"id\"=>153, \"name\"=>\"Lung Squamous Cell Carcinoma\", \"display_name\"=>\"Lung Squamous Cell Carcinoma\", \"doid\"=>\"3907\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3907\"}, \"drugs\"=>[{\"id\"=>36, \"name\"=>\"PD173074\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>434, \"name\"=>\"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.\", \"citation\"=>\"Weiss et al., 2010, Sci Transl Med\", \"pubmed_id\"=>\"21160078\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21160078\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3990281\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>12, \"day\"=>15}, \"journal\"=>\"Sci Transl Med\", \"full_journal_title\"=>\"Science translational medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>1105, \"name\"=>\"EID1105\", \"description\"=>\"FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>277, \"name\"=>\"4-hydroxytamoxifen\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>763, \"name\"=>\"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.\", \"citation\"=>\"Turner et al., 2010, Cancer Res.\", \"pubmed_id\"=>\"20179196\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20179196\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2832818\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}, {\"id\"=>686, \"name\"=>\"EID686\", \"description\"=>\"Preclinical study showing FGFR1 amplification in NSCLC and efficacy of FGFR-1 inhibition in one amplified cell line.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>36, \"name\"=>\"PD173074\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>440, \"name\"=>\"Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.\", \"citation\"=>\"Dutt et al., 2011, PLoS ONE\", \"pubmed_id\"=>\"21666749\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21666749\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3110189\", \"publication_date\"=>{\"year\"=>2011}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>267, \"phenotypes\"=>[]}]}, {\"id\"=>306, \"entrez_name\"=>\"ERBB2\", \"entrez_id\"=>2064, \"name\"=>\"AMPLIFICATION\", \"description\"=>\"Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy.  These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors.  Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC.  Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC.  The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases.  In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely.  Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy.  Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.\", \"gene_id\"=>20, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>123, \"name\"=>\"transcript_amplification\", \"display_name\"=>\"Transcript Amplification\", \"so_id\"=>\"SO:0001889\", \"description\"=>\"A feature amplification of a region containing a transcript.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001889\"}], \"civic_actionability_score\"=>822.5, \"coordinates\"=>{\"chromosome\"=>\"17\", \"start\"=>37856333, \"stop\"=>37884915, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000269571.5\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/20/summary/variants/306/summary#variant\", \"evidence_items\"=>[{\"id\"=>1011, \"name\"=>\"EID1011\", \"description\"=>\"This Phase II trial (LUX-Breast 3 - NCT01441596) compared afatinib, afatinib plus vinorelbine, or investigator's choice of treatment.  121 patients with HER2 overexpressing breast cancer with CNS recurrence or regression who had previously progressed on trastuzumab or lapatinib were assigned to 3 arms, with endpoint in the intention-to-treat population being patient benefit at 12 weeks defined as absence of CNS or extra CNS progression, no tumor related worsening of neurological symptoms and no increase in corticosteroid dose. Benefit was seen in 30% of 40 patients assigned to afatinib alone, 34.2% of 38 assigned to afatinib plus vinorelbine, and 41.9% of 43 assigned to investigator's treatment choice.  Differences were not statistically significant, and afatanib patients experienced more adverse effects.  While Afatanib did show response in HER2 breast cancer patients, it was not better than investigator's treatment choice and the investigators state that no further development of afatinib for HER2 breast cancer will be planned.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>699, \"name\"=>\"Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.\", \"citation\"=>\"CortÃ©s et al., 2015, Lancet Oncol.\", \"pubmed_id\"=>\"26596672\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26596672\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>12}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1013, \"name\"=>\"EID1013\", \"description\"=>\"Trastuzumab resistance is thought to consist of multiple compensatory mechanisms involving ErbB family members such as increased signaling through ErbB family heterodimers.  The irreversible TKI afatinib blocks EGFR, HER2, ErbB3 and ErbB4.  Thus afatinib was studied in this Phase I trial of trastuzumab-progressed HER2 positive metastatic BC (MBC) in combination with continued trastuzumab treatment, where trastuzumab is still the perferred treatment for trastuzumab-progressed MBC.  Objective response and disease control rates were 11% and 39%.  The authors conclude that the clinical activity observed in this trial warrants further work with afatinib and trastuzumab combination therapy.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>701, \"name\"=>\"Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.\", \"citation\"=>\"Ring et al., 2015, Clin. Cancer Res.\", \"pubmed_id\"=>\"25370464\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25370464\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>6, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1159, \"name\"=>\"EID1159\", \"description\"=>\"The Phase III trial, TH3RESA (NCT01419197), was performed in patients with advanced HER2 breast cancer that was heavily pretreated.  Patients were required to have prior exposure to trastuzumab and lapatinib as well as a taxane.  This patient population has not seen many studies, responds poorly to late-line treatment with trastuzumab, and in this study was treated with trastuzumab emtansine (T-DM1, n=404) vs. physician's choice (usually trastuzumab plus chemotherapy, n=198).  Results showed progression free survival was 6.2 months in T-DM1 treatment vs. 3.3 months under physician's choice, along with lower incidence of grade 3 or worse events with T-DM1.  The authors conclude that their findings in this heavily pretreated population, along with findings in the EMILIA trial, indicate promise for antibody-drug conjugates.  The NCI-MATCH trial with further study T-DM1 in the context of HER2 amplification.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>798, \"name\"=>\"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.\", \"citation\"=>\"Krop et al., 2014, Lancet Oncol.\", \"pubmed_id\"=>\"24793816\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24793816\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>6}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1133, \"name\"=>\"EID1133\", \"description\"=>\"In this Phase III trial, trastuzumab-based treatment was assessed in women with locally advanced or metastatic HER2 positive breast cancer who had progressed on trastuzumab.  Patients had 12 weeks or greater previous trastuzumab treatment with time since end of last cycle less than 6 weeks.  Primary endpoint was time to progression.  78 patients were assigned to each group, with median time to progression of 5.6 months in capecitabine group and 8.2 months in trastuzumab plus capecitabine group.  The results are in contrast to the principle of change of treatment on disease progression, and authors suggest that chemotherapy-sensitizing mechanisms of trastuzumab remain intact in HER2 breast cancer cells with trastuzumab progression.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>32, \"name\"=>\"Capecitabine\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>784, \"name\"=>\"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.\", \"citation\"=>\"von Minckwitz et al., 2009, J. Clin. Oncol.\", \"pubmed_id\"=>\"19289619\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19289619\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>4, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1012, \"name\"=>\"EID1012\", \"description\"=>\"LUX-Breast 1 is a phase 3 trial (NCT01125566) which enrolled 508 patients with metastatic HER2 positive BC who had progressed after adjuvant or first-line trastuzumab. It was thought that the wider range of ErbB family blocking and irreversible properties of afatinib could be beneficial in trastuzumab resistant cancer cells, since ErbB family members are thought to play a role in trastuzumab resistance. Primary endpoint was intention-to-treat group PFS. 339 patients were assigned to afatanib + vinorelbine and 169  to trastuzumab + vinorelbine.  Recruitment was stopped prematurely when it was deemed unlikely that the increased PFS would be seen in the afatinib group. Median PFS was 5.5 months in the afatinib group and 5.6 months in the trastuzumab group.  Afatanib plus vinorelbine was less well tolerated than trastuzumab plus vinorelbine, and the authors conclude that trastuzumab remains the best choice for treatment of trastuzumab-progressed HER2 positive metastatic BC.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>700, \"name\"=>\"Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.\", \"citation\"=>\"Harbeck et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"26822398\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26822398\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1113, \"name\"=>\"EID1113\", \"description\"=>\"In this two arm, Phase III study (NCT00878709) of the efficacy of a 12 month course of the TKI neratinib after trastuzumab-based adjuvant therapy of early stage HER2-positive breast cancer was assessed using invasive disease-free survival as primary endpoint.  HER2 positivity was assessed via FISH.  At 2 year follow-up, 70 vs. 109 disease-free survival events had occurred and disease-free survival rates were 93.9% vs. 91.6% (significant) in neratinib vs. placebo groups respectively.  Distant disease-free survival and time to distant recurrence were similar in both groups.  These results are an interesting contrast to results of long-term adjuvant therapy with trastuzumab (HERA) which did not show significant benefit.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>52, \"name\"=>\"Neratinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>768, \"name\"=>\"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.\", \"citation\"=>\"Chan et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"26874901\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26874901\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1160, \"name\"=>\"EID1160\", \"description\"=>\"The EMILIA study (NCT00829166) was a Phase II trial to assess the efficacy of trastuzumab emtansine (T-DM1, n=495) in comparison to lapatinib plus capecitabine (n=496), in treatment of advanced HER2 positive breast cancer.  Patients were required to have progressed on or after treatments involving trastuzumab and a taxane, and no prior exposure to lapatinib or T-DM1.   Primary endpoints included independently assessed progression free survival (PFS) and safety. PFS was 9.6 months in T-DM1 group vs. 6.4 months in lapatinib plus capecitabine.  Rates of adverse events of grade 3 or higher were greater with lapatinib plus capecitabine.  These results, together with other trials such as TH3RESA indicate promise for T-DM1 therapy in HER2 amplification, and this will be further studied in an arm of the NCI-MATCH trial.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>799, \"name\"=>\"Trastuzumab emtansine for HER2-positive advanced breast cancer.\", \"citation\"=>\"Verma et al., 2012, N. Engl. J. Med.\", \"pubmed_id\"=>\"23020162\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23020162\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>11, \"day\"=>8}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1007, \"name\"=>\"EID1007\", \"description\"=>\"In light of results showing increased PFS using mAB plus TKI in heavily pretreated patients, the efficacy of trastuzumab plus lapatinib in a neoadjuvant setting with untreated stage II or IIIA HER2 positive breast cancer was assessed.  In this randomized 3 arm phase II study (CHER-LOB), patients received (A) chemotherapy plus trastuzumab, (B) chemotherapy plus lapatinib, or (C) chemotherapy plus trastuzumab and lapatinib, with pathologic complete response (pCR) as endpoint.  From 121 patients, pCR rates were 25% in arm A, 26.3% in arm B, and 46.7% in arm C.  The authors conclude these results support the superiority of dual-HER2 inhibition in the neoadjuvant context of HER2 positive BC.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>696, \"name\"=>\"Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.\", \"citation\"=>\"Guarneri et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22493419\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22493419\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>6, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1008, \"name\"=>\"EID1008\", \"description\"=>\"This Phase III trial compared the activity of lapatinib vs. trastuzumab vs. sequential trastuzumab followed by lapatinib vs. lapatinib plus trastuzumab in an adjuvant treatment setting.  8381 women were randomized to one of four treatment arms. Patients had HER2 positive non-metastatic operable BC. The primary endpoint was disease free survival.  First results report that after median 4.5 year follow up, a non significant 16% improvement in DFS was seen in trastuzumab + lapatinib vs. trastuzumab alone.  The results are interpreted as showing no added benefit for labatinib addition to trastuzumab in the adjuvant treatment context.  This trial is ongoing but not recruiting patients (NCT00490139).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>697, \"name\"=>\"Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.\", \"citation\"=>\"Zardavas et al., 2015, Breast\", \"pubmed_id\"=>\"26255196\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26255196\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>11}, \"journal\"=>\"Breast\", \"full_journal_title\"=>\"Breast (Edinburgh, Scotland)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>529, \"name\"=>\"EID529\", \"description\"=>\"A randomized clinical trial of 186 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved overall survival, response rate, response duration, time to progression, and time to treatment failure for patients who received trastuzumab in addition to chemotherapy (docetaxel) compared to chemotherapy alone.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>329, \"name\"=>\"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.\", \"citation\"=>\"Marty et al., 2005, J. Clin. Oncol.\", \"pubmed_id\"=>\"15911866\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15911866\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>528, \"name\"=>\"EID528\", \"description\"=>\"A randomized clinical trial of 469 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved time to disease progression, objective response rate, and duration of response for patients who received trastuzumab in addition to chemotherapy compared to chemotherapy alone.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>328, \"name\"=>\"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.\", \"citation\"=>\"Slamon et al., 2001, N. Engl. J. Med.\", \"pubmed_id\"=>\"11248153\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11248153\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2001, \"month\"=>3, \"day\"=>15}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5985, \"name\"=>\"EID5985\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of nine patients (22%) with HER2 amplified/overexpressing pancreatic cancer had a PR with trastuzumab/pertuzumab combination. Another patient had SD > 120days.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5986, \"name\"=>\"EID5986\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. None of the 7 patients with HER2 amplified/overexpressing uterus cancer responded to pertuzumab/trastuzumab.\", \"disease\"=>{\"id\"=>825, \"name\"=>\"Uterine Cancer\", \"display_name\"=>\"Uterine Cancer\", \"doid\"=>\"363\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:363\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1993, \"name\"=>\"EID1993\", \"description\"=>\"We identified 142 patients with metastatic colorectal cancer whose tumors harbored both wild-type exons 2, 3, and 4 in KRAS and NRAS, and wild-type exon 15 in BRAF. All patients received cetuximab after oxaliplatin, irinotecan, and fluoropyrimidine failure. HER2 status was determined using immunohistochemistry and silver in situ hybridization and correlated with cetuximab efficacy. Of 142 RAS and BRAF wild-type tumors, we observed 7 cases (4.9%) of HER2 amplification by SISH. After a median follow-up of 13.2 months (range, 1.4-78.1 months), median progression-free survival (PFS) was significantly different according to HER2 status: 3.1 months in patients with HER2 amplification compared with 5.6 months in those with non-amplified HER2 (HR = 2.73; 95% CI = 1.18-6.31; P = 0.019). Overall survival (OS) was not significantly different between groups, although there was a tendency towards shorter OS in patients with HER2-amplified tumors (HR = 0.31; 95% CI = 0.61-2.82; 10.1 vs. 13.5 months; P = 0.488).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1399, \"name\"=>\"HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.\", \"citation\"=>\"Jeong et al., 2017, Clin Colorectal Cancer\", \"pubmed_id\"=>\"28223103\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28223103\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>1, \"day\"=>25}, \"journal\"=>\"Clin Colorectal Cancer\", \"full_journal_title\"=>\"Clinical colorectal cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5981, \"name\"=>\"EID5981\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. \\nThirty of 114 patients (26%; 95% CI, 19% to 35%) with HER2 amplification/overexpression had objective responses to treatment with trastuzumab plus pertuzumab (two CR, 28 PR). \\nPatients with HER2-amplified/overexpressing metastatic colorectal cancer composed the largest tumor-pathway cohort. In this group of 37 patients with refractory disease (median, four previous lines of therapy), treatment with trastuzumab plus pertuzumab produced PRs in 14 patients (38%; 95% CI, 23% to 55%; Fig 2A). An additional four patients had SD > 120 days. The median DOR was 11 months (range, < 1 to 16+ months; 95% CI, 2.8 months to not estimable).\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5983, \"name\"=>\"EID5983\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of seven patients (29%; 95% CI, 4% to 71%) with biliary cancer and HER2 amplification/overexpression had PR, and three had SD > 120 days\", \"disease\"=>{\"id\"=>1065, \"name\"=>\"Biliary Tract Cancer\", \"display_name\"=>\"Biliary Tract Cancer\", \"doid\"=>\"4607\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4607\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5982, \"name\"=>\"EID5982\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Three of nine patients (33%; 95% CI, 8% to 70%) with advanced bladder cancer and HER2 amplification/overexpression had responses (one CR ongoing at 15 months; two PR lasting 1 and 6 months), and two patients had SD > 120 days.\", \"disease\"=>{\"id\"=>18, \"name\"=>\"Bladder Carcinoma\", \"display_name\"=>\"Bladder Carcinoma\", \"doid\"=>\"4007\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4007\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>5984, \"name\"=>\"EID5984\", \"description\"=>\"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Four of five patients with HER2 amplified/overexpressing salivary gland carcinoma (80%; 95% CI, 28% to > 99%) had responses (all PR).\", \"disease\"=>{\"id\"=>66, \"name\"=>\"Salivary Gland Carcinoma\", \"display_name\"=>\"Salivary Gland Carcinoma\", \"doid\"=>\"0050904\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050904\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2414, \"name\"=>\"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.\", \"citation\"=>\"Hainsworth et al., 2018, J. Clin. Oncol.\", \"pubmed_id\"=>\"29320312\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29320312\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02091141\", \"name\"=>\"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors\", \"description\"=>\"This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02091141\"}]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1437, \"name\"=>\"EID1437\", \"description\"=>\"In a randomized phase 3 trial, HER2 positive metastatic breast cancer patients given first-line treatment of pertuzumab plus trastuzumb plus docetaxel experienced improved progression free survival (18.5 vs 12.4 months,  P<0.001) and increased objective response rate (80.2% vs 69.3%, P=0.001) than the control group given placebo plus trastuzumab plus docetaxel.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>971, \"name\"=>\"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.\", \"citation\"=>\"Baselga et al., 2012, N. Engl. J. Med.\", \"pubmed_id\"=>\"22149875\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22149875\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>1, \"day\"=>12}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1132, \"name\"=>\"EID1132\", \"description\"=>\"This Phase III trial took patients with locally advanced or metastatic HER2 (ERBB2) positive breast cancer that had progressed on prior trastuzumab treatment.  Patients were given capecitabine (n=161) or lapatinib plus capecitabine (n=163). The primary endpoint of the study was time to progression. Median time to progression was 4.4 months in the capecitabine group and 8.4 months in capecitabine plus lapatinib group (hazard ratio was 0.49 ; 95% confidence interval, 0.34 to 0.71; P<0.001).  The results indicated that lapatinib may be useful in addressing the problem of trastuzumab progression in HER2 breast cancer.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>32, \"name\"=>\"Capecitabine\", \"pubchem_id\"=>nil}, {\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>783, \"name\"=>\"Lapatinib plus capecitabine for HER2-positive advanced breast cancer.\", \"citation\"=>\"Geyer et al., 2006, N. Engl. J. Med.\", \"pubmed_id\"=>\"17192538\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17192538\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2006, \"month\"=>12, \"day\"=>28}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1381, \"name\"=>\"EID1381\", \"description\"=>\"Pharmacologic (A66; p110alpha specific inhibitor) or genetic (cre-mediated knockout) ablation of the p110alpha PI3K isoform reduced tumor growth and tumor formation, respectively, in athymic mice transplanted with cells transduced by MMTV-NeuT (mammary specific overexpression of HER2 that effectively induces tumors). A66 treatment of cells from MMTV-NeuT mouse tumors resulted in decreased lipid kinase activity and phospho Akt levels.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>337, \"name\"=>\"A66\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>937, \"name\"=>\"The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.\", \"citation\"=>\"Utermark et al., 2012, Genes Dev.\", \"pubmed_id\"=>\"22802530\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22802530\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3404385\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>7, \"day\"=>15}, \"journal\"=>\"Genes Dev.\", \"full_journal_title\"=>\"Genes & development\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>961, \"name\"=>\"EID961\", \"description\"=>\"A phase II study involving adult female patients, >=18 years, with stage IIIB or IV HER2-positive (by IHC and/or in situ fluorescence) metastatic breast cancer. All patients were previously treated with trastuzumab and a median of three chemotherapy lines. 41 patients received 50 mg afatinib once-daily until disease progression and the primary endpoint was objective response rate. 4 patients (10% of 41 treated; 11% of evaluable patients) had partial response and 15 patients (37% of 41) had stable disease as best response. Thus a total of 19 (46% of 41) achieved clinical benefit. Median progression-free survival was 15.1 weeks.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>663, \"name\"=>\"A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.\", \"citation\"=>\"Lin et al., 2012, Breast Cancer Res. Treat.\", \"pubmed_id\"=>\"22418700\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22418700\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3387495\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>6}, \"journal\"=>\"Breast Cancer Res. Treat.\", \"full_journal_title\"=>\"Breast cancer research and treatment\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>887, \"name\"=>\"EID887\", \"description\"=>\"In this phase 2 trial, treatment-naive, ERBB2-positive (by IHC) breast cancer patients with stage IIIA, B, C or inflammatory disease were randomized 1:1:1 to afatinib (n = 10), lapatinib (n = 8), or trastuzumab (n = 11). The primary end point was objective response rate. Objective response was seen in 8 afatinib-, 6 lapatinib-, and 4 trastuzumab-treated patients. Afatinib demonstrated clinical activity that compared favorably to trastuzumab and lapatinib for neoadjuvant treatment of HER2-positive breast cancer.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>597, \"name\"=>\"A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.\", \"citation\"=>\"Rimawi et al., 2015, Clin. Breast Cancer\", \"pubmed_id\"=>\"25537159\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25537159\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>4}, \"journal\"=>\"Clin. Breast Cancer\", \"full_journal_title\"=>\"Clinical breast cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1499, \"name\"=>\"EID1499\", \"description\"=>\"ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive (overexpression or amplification) advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer.\", \"disease\"=>{\"id\"=>147, \"name\"=>\"Gastric Adenocarcinoma\", \"display_name\"=>\"Gastric Adenocarcinoma\", \"doid\"=>\"3717\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3717\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>708, \"name\"=>\"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.\", \"citation\"=>\"Bang et al., 2010, Lancet\", \"pubmed_id\"=>\"20728210\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20728210\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>8, \"day\"=>28}, \"journal\"=>\"Lancet\", \"full_journal_title\"=>\"Lancet (London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1050, \"name\"=>\"EID1050\", \"description\"=>\"Efficacy of trastuzumab in HER2 overexpressing NSCLC remains unclear.  In this study using a panel of NSCLC HER2 overexpressing cell lines, antiproliferative effects of trastuzumab emtansine (T-DM1) were observed in a HER2-expression dependant manner, with strongest effects in Calu-3 (high expressing) and no effects in Calu-6 (low expressing).  Trastuzumab did not show notable effects on cell growth in any tested cells.  HER2 positivity in NSCLC is fairly common at 2-20%.  A clinical trial (NCT02289833) is currently underway to asses TDM-1 in HER2 overexpressing lung cancer.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>730, \"name\"=>\"Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.\", \"citation\"=>\"Cretella et al., 2014, Mol. Cancer\", \"pubmed_id\"=>\"24898067\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24898067\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4058446\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Mol. Cancer\", \"full_journal_title\"=>\"Molecular cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1097, \"name\"=>\"EID1097\", \"description\"=>\"HER2 expression in uterine serous papillary carcinoma (USPC) is thought to be associated with poor prognosis and may act as a targetable driver mutation in this cancer.  HER2 overexpression in USPC is more common in African American women.  This report covered 2 African American patients, the first of which presented high-grade endometrial adenocarcinoma with IHC3+ HER2-positivity as well as positivity by FISH.  Prior treatment involved surgery and chemotherapy.  Treatment with pacitaxel/carboplatin with trastuzumab showed clear clinical improvement assessed by CT scan and drop in CA-125 levels from 988 to 7.9 U/mL.  The second patient had USPC, and was treated with surgery and radiation.  Trastuzumab monotheraby was then administered.  After 7 months of treatment, the patient showed no sign of disease progression and CA-125 had dropped from 144 to 41 U/mL.  The investigators conclude there is promise in trastuzumab-based therapies in advanced endometrial cancers, including USPC.\", \"disease\"=>{\"id\"=>185, \"name\"=>\"Uterine Corpus Serous Adenocarcinoma\", \"display_name\"=>\"Uterine Corpus Serous Adenocarcinoma\", \"doid\"=>\"5750\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5750\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>756, \"name\"=>\"Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.\", \"citation\"=>\"Santin et al., 2008, Int J Gynaecol Obstet\", \"pubmed_id\"=>\"18555254\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18555254\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2008, \"month\"=>8}, \"journal\"=>\"Int J Gynaecol Obstet\", \"full_journal_title\"=>\"International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1044, \"name\"=>\"EID1044\", \"description\"=>\"This report details 2 case studies in relapsed HER2 positive SCLC.  In the first case, a 50 pack-year patient showed intense non-mutant HER2 expression by IHC without DNA amplification, and had undergone multiple prior lines of treatment.  With induction of trastuzumab and irinotecan treatment, tumor regression was observed with progression free survival of 4.5 months.  Case 2 involved a 68 year old never-smoker with relapsed SCLC.  Tumor showed HER2 positive SCLC cells with no amplification or mutation.  Third line trastuzumab plus irinotecan brought about some symptom improvement and PFS of 3.5 months.  While the efficacy of trastuzumab against NSCLC with elevated levels of wild-type HER2 expression remains unclear, the authors conclude that trastuzumab based therapy is a promising strategy for chemo-resistant SCLC.\", \"disease\"=>{\"id\"=>174, \"name\"=>\"Lung Small Cell Carcinoma\", \"display_name\"=>\"Lung Small Cell Carcinoma\", \"doid\"=>\"5409\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5409\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>101, \"name\"=>\"Irinotecan\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>727, \"name\"=>\"Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.\", \"citation\"=>\"Kinehara et al., 2015, Lung Cancer\", \"pubmed_id\"=>\"25601188\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25601188\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>3}, \"journal\"=>\"Lung Cancer\", \"full_journal_title\"=>\"Lung cancer (Amsterdam, Netherlands)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1686, \"name\"=>\"EID1686\", \"description\"=>\"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.\\nAmong 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective patient cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1138, \"name\"=>\"A molecularly annotated platform of patient-derived xenografts (\\\"xenopatients\\\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.\", \"citation\"=>\"Bertotti et al., 2011, Cancer Discov\", \"pubmed_id\"=>\"22586653\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22586653\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1687, \"name\"=>\"EID1687\", \"description\"=>\"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed resistance whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1138, \"name\"=>\"A molecularly annotated platform of patient-derived xenografts (\\\"xenopatients\\\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.\", \"citation\"=>\"Bertotti et al., 2011, Cancer Discov\", \"pubmed_id\"=>\"22586653\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22586653\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>11}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1688, \"name\"=>\"EID1688\", \"description\"=>\"HER2 amplification (FISH) was assessed in 170 KRAS wt mCRC patients treated with cetuximab or panitumumab.\\nHER2 copy number status was significantly correlated with respoinse rate, PFS and OS. Patients with amplification in all neoplastic cells (4%) had worse outcome compared to patients without amplification (35%, intermediate outcome) or amplification in minor clones (61%, highest survival probability)\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>28, \"name\"=>\"Panitumumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1139, \"name\"=>\"HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.\", \"citation\"=>\"Martin et al., 2013, Br. J. Cancer\", \"pubmed_id\"=>\"23348520\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23348520\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3593567\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>2, \"day\"=>19}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1689, \"name\"=>\"EID1689\", \"description\"=>\"Phase 2 study in 27 patients with HER2 positive (IHC, FISH), KRAS wt metastatic colorectal cancer refractory to standard of care received trastuzumab and lapatinib.\\nAfter a median follow-up of 94 weeks, eight (30%, 95% CI 14-50) of 27 patients had achieved an objective response, with one patient (4%, 95% CI -3 to 11) achieving a complete response, and seven (26%, 95% CI 9-43) achieving partial responses; 12 (44%, 95% CI 25-63) patients had stable disease.\\nA total of 914 patients with KRAS wt were screened for this study, 48 patients (5%) were identified to have HER2-positive tumors.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1140, \"name\"=>\"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.\", \"citation\"=>\"Sartore-Bianchi et al., 2016, Lancet Oncol.\", \"pubmed_id\"=>\"27108243\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27108243\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1764, \"name\"=>\"EID1764\", \"description\"=>\"In the single arm Phase II study (TDM4258g) breast cancer patients who had progressed on previous anti-HER2 therapy were given transtuzumab emtansine (T-DM1), a HER2 monoclonal antibody and antimicrotubule drug conjugate. 95 trial participants with archival primary tumor were reassessed for HER2 status (positivity defined by FISH or IHC 3+), and 74 patients were confirmed for HER2 positivity and 21 were normal. Overall response rate was 33.8% (95% CI, 23.2% to 44.9%) in patients with confirmed HER2-positive tumors and 4.8% (95% CI, 1.0% to 21.8%) in HER2 normal patients. Median PFS was 8.2 months (95% CI, 4.4 months to not estimable) in patients with confirmed HER2-positive tumors and 2.6 months (95% CI, 1.4 to 3.9 months) in HER2 normal patients.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1229, \"name\"=>\"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.\", \"citation\"=>\"Burris et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21172893\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21172893\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1448, \"name\"=>\"EID1448\", \"description\"=>\"In 5 trastuzumab resistant HER2 overexpressing breast cancer cell lines, combination of the pan-PI3K inhibitor XL147 and trastuzumab treatment induced cell death to similar or greater levels than XL147 alone. In three trastuzumab resistant cell lines tested, colony formation in matrigel was markedly inhibited by combination treatment. Apoptotic markers were apparent with combination treatment. In athymic mice, trastuzumab resistant cell line HR6 was used in tumor xenografts and tumors were allowed to form. Mice subsequently treated with trastuzumab or XL147 showed continued tumor growth without marked difference from control, while combination treatment essentially halted tumor growth rate.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>349, \"name\"=>\"XL147 (Pilaralisib)\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>977, \"name\"=>\"Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.\", \"citation\"=>\"Chakrabarty et al., 2013, Cancer Res.\", \"pubmed_id\"=>\"23204226\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23204226\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3563941\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"Cancer Res.\", \"full_journal_title\"=>\"Cancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1042, \"name\"=>\"EID1042\", \"description\"=>\"In this phase II trial a small group of patients with IHC2+ or IHC3+ HER2 NSCLC, in which primary platinum-based therapy had failed, were given either docetaxel or trastuzumab after which both groups were given docetaxel and trastuzumab together.  there was one partial response in the docetaxel group and none in the trastuzumab group.  The authors report that due to the limited clinical activity of trastuzumab-based therapy in this cohort, as well as similar results in other trastuzumab studies, that targets other than HER2 in NSCLC should be considered for future study.  This 2004 study remains cited in 2016 literature in discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC, but mutant HER2 in NSCLC has been further studied and a picture of different HER2 mutations being potentially responsive to specific targeted therapies is emerging.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>725, \"name\"=>\"Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.\", \"citation\"=>\"Lara et al., 2004, Clin Lung Cancer\", \"pubmed_id\"=>\"14967075\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/14967075\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>1}, \"journal\"=>\"Clin Lung Cancer\", \"full_journal_title\"=>\"Clinical lung cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1380, \"name\"=>\"EID1380\", \"description\"=>\"The HER2/Neu mammary tumor mouse model MMTV-NeuT was employed to demonstrate dependence of HER2 tumor formation on PIK3 p110alpha isoform. MMTV-NeuT mice were crossed with floxed p110alpha mice. Diassacociated tumors cells from these mice were treated with Cre adenovirus to delete p110alpha, or GFP adenovirus, and cells were transplanted into athymic mice. GFP treated cells formed new tumors, while p110alpha deletion blocked tumor formation indicating tumor dependence on PI3KA. Next, MMTV-NeuT tumors were dissociated and treated with pan-PI3K inhibitor GDC-0941. Reduced lipid kinase activity and reduced phospho-Akt levels were seen in these cells. Administration of 125 mg/kg GDC-0941 to athymic mice with transplantation of tumor cells caused marked reduction of tumor cell volume in comparison to control treatment.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>141, \"name\"=>\"Pictilisib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>937, \"name\"=>\"The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.\", \"citation\"=>\"Utermark et al., 2012, Genes Dev.\", \"pubmed_id\"=>\"22802530\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22802530\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3404385\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>7, \"day\"=>15}, \"journal\"=>\"Genes Dev.\", \"full_journal_title\"=>\"Genes & development\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1439, \"name\"=>\"EID1439\", \"description\"=>\"In a randomized open label phase 3 study (NCT00553358), women with HER2 positive primary breast cancer treated with lapatinib plus trasuzumab had higher rates of pathological complete responses than seen in control groups receiving either IV trastuzumab or oral lapatinib alone (combination treatment pCR rate of 51% vs 29.5% and 24.7% for trastuzumab and lapatinib alone, respectively).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>972, \"name\"=>\"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.\", \"citation\"=>\"Baselga et al., 2012, Lancet\", \"pubmed_id\"=>\"22257673\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22257673\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>2, \"day\"=>18}, \"journal\"=>\"Lancet\", \"full_journal_title\"=>\"Lancet (London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1382, \"name\"=>\"EID1382\", \"description\"=>\"Treatment of cells obtained from MMTV-NeuT mouse mammary tumors with the p110beta selective inhibitor TGX-221 showed significant but minimal reductions in lipid kinase activity and negligible reductions in phospho Akt levels. In simmilar cells subjected to p110alpha isoform knockout, TGX-221 treatment fully blocked Akt activation, indicating that TGX-221 was fully inhibiting the p110beta isoform. Athymic mice recieved MMTV-NeuT tumor cell transplants and were treated with TGX-221, which resulted in significant but minimal reduction in tumor growth compared to controls.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>338, \"name\"=>\"Tgx 221\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>937, \"name\"=>\"The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.\", \"citation\"=>\"Utermark et al., 2012, Genes Dev.\", \"pubmed_id\"=>\"22802530\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22802530\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3404385\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>7, \"day\"=>15}, \"journal\"=>\"Genes Dev.\", \"full_journal_title\"=>\"Genes & development\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1693, \"name\"=>\"EID1693\", \"description\"=>\"A 71-year old male with metastatic extramammary Pagetâs disease of the scrotum overexpressing Her2/neu was treated with trastuzumab, achieving a complete response. At 12 months, he maintains stable disease.\", \"disease\"=>{\"id\"=>779, \"name\"=>\"Scrotum Paget's Disease\", \"display_name\"=>\"Scrotum Paget's Disease\", \"doid\"=>\"3444\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3444\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1142, \"name\"=>\"Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.\", \"citation\"=>\"Barth et al., 2015, Case Rep Oncol Med\", \"pubmed_id\"=>\"25692060\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25692060\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4322830\", \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"Case Rep Oncol Med\", \"full_journal_title\"=>\"Case reports in oncological medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1393, \"name\"=>\"EID1393\", \"description\"=>\"155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 2 of 24 patients tested were found to have HER2 amplification (but no baseline samples available for analysis). One patient of which had a metastasis sample which was reported to have only HER2 amplification whereas another autopsy specimen from the same patient was HER2 negative but EGFR T790M positive.\", \"disease\"=>{\"id\"=>26, \"name\"=>\"Lung Adenocarcinoma\", \"display_name\"=>\"Lung Adenocarcinoma\", \"doid\"=>\"3910\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3910\"}, \"drugs\"=>[{\"id\"=>14, \"name\"=>\"Gefitinib\", \"pubchem_id\"=>nil}, {\"id\"=>15, \"name\"=>\"Erlotinib\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>943, \"name\"=>\"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.\", \"citation\"=>\"Yu et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23470965\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23470965\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3630270\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>4, \"day\"=>15}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1891, \"name\"=>\"EID1891\", \"description\"=>\"Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. 4 patients with HER2 amplified NSCLC were enrolled in the trial, no one among them had a response.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>44, \"name\"=>\"Dacomitinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>729, \"name\"=>\"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.\", \"citation\"=>\"Kris et al., 2015, Ann. Oncol.\", \"pubmed_id\"=>\"25899785\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25899785\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>7}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1432, \"name\"=>\"EID1432\", \"description\"=>\"In a randomized phase II study, first line treatment of HER2-positive metastatic breast cancer with trastuzumab emtansine (T-DM1) resulted in improved progression free survival and fewer serious adverse effects when compared to treatment with combination trastuzumab plus docetaxel (HT) (median follow up 14 months, median PFS with T-DM1 14.2 vs 9.2 with HT).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>293, \"name\"=>\"Trastuzumab Emtansine\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>970, \"name\"=>\"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.\", \"citation\"=>\"Hurvitz et al., 2013, J. Clin. Oncol.\", \"pubmed_id\"=>\"23382472\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23382472\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>3, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1098, \"name\"=>\"EID1098\", \"description\"=>\"This phase II single arm study assessed trastuzumab monotherapy in HER2 positive endometrial cancers with tumor response as primary endpoint.  Participants had stage III, IV or recurrent HER2 positive endometrial cancer.  During the trial's initial phase, 23 of 132 patients screened met the criteria of IHC2+ or 3+ or FISH positivity for HER2 status.  In the absence of results, the trial entered phase B, where only patients with HER2 amplification by FISH were admitted.  The trial ended early due to poor accrual with 11 of 154 screened meeting the phase B criteria. No major objective tumor responses were observed in the study.  28% of the cancers were of the serous type that had shown trastuzumab response in case studies.  The investigators note that in other HER2 cancers, such as breast and gastrointestinal, trastuzumab in combination with chemotherapy has been found most effective, and could warrant more study.  Currently a clinical trial (NCT01367002) is evaluating carboplatin/paclitaxel with or without trastuzumab in uterine serous cancer.\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>757, \"name\"=>\"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.\", \"citation\"=>\"Fleming et al., 2010, Gynecol. Oncol.\", \"pubmed_id\"=>\"19840887\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19840887\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2804260\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>1}, \"journal\"=>\"Gynecol. Oncol.\", \"full_journal_title\"=>\"Gynecologic oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1077, \"name\"=>\"EID1077\", \"description\"=>\"CLEOPATRA (NCT00567190) was a Phase III, randomized and double-blind, placebo-controlled study of 808 patients with HER2-positive metastatic breast cancer.  Patients were HER2-positive by IHC3+ or FISH, and patients who had received prior hormonal treatment or adjuvant/neo-adjuvant therapy with or without trastuzumab for longer than 12 months before randomization were also eligible.  The two arms of the study were trastuzumab and docetaxel with either placebo or pertuzumab.  Median PFS in the placebo arm was 12.4 months while in the petuzumab arm 18.5 months was achieved.  Median OS in the control arm was 40.8 months and 56.5 months with pertuzumab.  These strong results make a case for dual antibody blockade in first line treatments of HER2-positive metastatic breast cancer.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>247, \"name\"=>\"Pertuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>745, \"name\"=>\"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.\", \"citation\"=>\"Swain et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"25693012\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25693012\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>2, \"day\"=>19}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1096, \"name\"=>\"EID1096\", \"description\"=>\"In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient information.  Earlier deaths were seen with heavier HER2 expression.  Multivariate Cox regression indicated that shorter survival was associated with higher HER2 expression, and not with age or ethnicity, and that observed differences in survival rates between ethnicities can be ascribed to higher rates of HER2 overexpression in African American patients.  The authors conclude that high HER2 expression in USPC is associated with poor outcome and explains observed differences in outcome between ethnicities.\", \"disease\"=>{\"id\"=>185, \"name\"=>\"Uterine Corpus Serous Adenocarcinoma\", \"display_name\"=>\"Uterine Corpus Serous Adenocarcinoma\", \"doid\"=>\"5750\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5750\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>755, \"name\"=>\"Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.\", \"citation\"=>\"Santin et al., 2005, Am. J. Obstet. Gynecol.\", \"pubmed_id\"=>\"15746676\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15746676\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>3}, \"journal\"=>\"Am. J. Obstet. Gynecol.\", \"full_journal_title\"=>\"American journal of obstetrics and gynecology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1041, \"name\"=>\"EID1041\", \"description\"=>\"In this phase II trial with 2 arms, 103 patients with untreated stage IIIB/IV HER2 positive NSCLC were given gemcitabine-cisplatin with or without trastuzumab.  HER2 positivity was broadly defined as IHC2+/3+, positive by FISH, or increased circulating HER2 extracellular domain.  Significant differences between the treatment arms were not observed, but in a small subset of IHC3+/FISH positive patients, 5 of 6 responded to trastuzumab and had increased PFS of 8.5 months in comparison to 6.1 months in the IHC2+ group.  Although from 2004, this study remains cited in 2016 literature when discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC. The authors conclude that future studies of trastuzumab in HER2 positive NSCLC should focus on high expressing subjects.\", \"disease\"=>{\"id\"=>8, \"name\"=>\"Non-small Cell Lung Carcinoma\", \"display_name\"=>\"Non-small Cell Lung Carcinoma\", \"doid\"=>\"3908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3908\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>724, \"name\"=>\"Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.\", \"citation\"=>\"Gatzemeier et al., 2004, Ann. Oncol.\", \"pubmed_id\"=>\"14679114\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/14679114\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>1}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1122, \"name\"=>\"EID1122\", \"description\"=>\"HERA was a Phase III trial assessing application of trastuzumab in an extended adjuvant setting.  Patients were HER2 positive with completely excised invasive BC, node positive or negative, and having undergone prior adjuvant or neo-adjuvant chemotherapy.  In the 3 arm study patients were given trastuzumab courses of 1 year, 2 years, or untreated.  At the first planned interim analysis, trastuzumab treatment for one year was compared with observation alone.  A significant difference in disease-free survival was seen with 220 DFS events out of 1693 in the observation arm versus 127 DFS events out of 1694 in the 1 year trastuzumab arm.  1 year adjuvant trastuzumab is currently the standard of care.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>777, \"name\"=>\"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.\", \"citation\"=>\"Piccart-Gebhart et al., 2005, N. Engl. J. Med.\", \"pubmed_id\"=>\"16236737\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16236737\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>10, \"day\"=>20}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1561, \"name\"=>\"EID1561\", \"description\"=>\"In a panel of 47 breast cancer cell lines, HER2 overexpressing cells were among those more sensitive to CDK4/6 inhibitor Palbociclib (PD0332991). In the trastuzumab sensitive cell line Bt474, palbociclib synergized with trastuzumab in growth inhibition, while in 2 trastuzumab resistant cell lines, addition of trastuzumab to palbociclib treatment resulted in increased growth inhibition over palbociclib alone.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>48, \"name\"=>\"Palbociclib (PD0332991)\", \"pubchem_id\"=>\"\"}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1031, \"name\"=>\"PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.\", \"citation\"=>\"Finn et al., 2009, Breast Cancer Res.\", \"pubmed_id\"=>\"19874578\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19874578\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2790859\", \"publication_date\"=>{\"year\"=>2009}, \"journal\"=>\"Breast Cancer Res.\", \"full_journal_title\"=>\"Breast cancer research : BCR\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1613, \"name\"=>\"EID1613\", \"description\"=>\"In a panel of 31 breast cancer cell lines with varied mutation backgrounds, 10 cell lines harbored HER2 (ERBB2) amplification. Sensitivity to the mTORC1/2 inhibitor PP242 was assessed, and 8/10 HER2 positive cell lines were reported to be sensitive (IC50 < 1 micro molar PP242).  8/21 without HER2 amplification were reported as resistant (IC50 > 1 micro molar PP242). This pattern of HER2 positive cell sensitivity was not reported with the rapamycin analog  mTORC1 inhibitor everolimus.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>179, \"name\"=>\"PP242\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1066, \"name\"=>\"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.\", \"citation\"=>\"Weigelt et al., 2011, Oncogene\", \"pubmed_id\"=>\"21358673\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21358673\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>7, \"day\"=>21}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1022, \"name\"=>\"EID1022\", \"description\"=>\"ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer.\", \"disease\"=>{\"id\"=>147, \"name\"=>\"Gastric Adenocarcinoma\", \"display_name\"=>\"Gastric Adenocarcinoma\", \"doid\"=>\"3717\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3717\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>708, \"name\"=>\"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.\", \"citation\"=>\"Bang et al., 2010, Lancet\", \"pubmed_id\"=>\"20728210\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20728210\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>8, \"day\"=>28}, \"journal\"=>\"Lancet\", \"full_journal_title\"=>\"Lancet (London, England)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1010, \"name\"=>\"EID1010\", \"description\"=>\"With multiple mechanisms of HER reprogramming thought to be behind trastuzumab resistance, including increased expression of ErbB members, afatinib, which broadly and irreversibly targets ErbB receptors was tested in a single arm phase II trial on advanced stage HER2 positive metastatic breast cancer. From 41 treated patients, 10% had partial response, 37% had stable disease as best response and 46% achieved clinical benefit.  Median progression free survival (PFS) was 15.1 weeks and median overall survival (OS) was 61.0 weeks. The authors conclude that Afatinib monotherapy shows promise in treatment of metastatic HER2 positive breast cancer that has progressed under trastuzumab.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>663, \"name\"=>\"A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.\", \"citation\"=>\"Lin et al., 2012, Breast Cancer Res. Treat.\", \"pubmed_id\"=>\"22418700\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22418700\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3387495\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>6}, \"journal\"=>\"Breast Cancer Res. Treat.\", \"full_journal_title\"=>\"Breast cancer research and treatment\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1009, \"name\"=>\"EID1009\", \"description\"=>\"This Phase III study (EGF104900) was motivated by preclinical and other data demonstrating synergistic activity between lapatinib and trastuzumab against HER2 positive breast cancer (BC) cells.  In this study of HER2 positive metastatic BC which had progressed on trastuzumab, two arms were compared: lapatinib vs. lapatinib + trastuzumab. Progression free survival (PFS) was the primary endpoint. For 296 patients, 148 in each arm, median PFS of 8.1 weeks for lapatinib and 12.0 for combination therapy was observed (P=0.008).  The authors conclude that in the context of metastatic trastuzumab-progressed HER2 positive BC, trastuzumab with lapatinib TKI addition is a favorable treatment.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>698, \"name\"=>\"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.\", \"citation\"=>\"Blackwell et al., 2010, J. Clin. Oncol.\", \"pubmed_id\"=>\"20124187\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20124187\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>3, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>962, \"name\"=>\"EID962\", \"description\"=>\"Afatinib was growth-inhibitory for three pancreatic cancer cell lines but cytotoxic only toward BxPC3 (KRAS wt) and Capan-2 (KRAS mut) cells, both of which express high levels of EGFR, ERBB2, and ERBB3 receptors. Afatinib increased the radiosensitivity of BxPC3 and Capan-2 cells. In comparison, Panc-1 cells (KRAS mut) expressing low levels of EGFR family receptors were resistant to afatinib-induced radiosensitization.\", \"disease\"=>{\"id\"=>158, \"name\"=>\"Pancreatic Adenocarcinoma\", \"display_name\"=>\"Pancreatic Adenocarcinoma\", \"doid\"=>\"4074\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4074\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>664, \"name\"=>\"Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.\", \"citation\"=>\"Huguet et al., 2016, Target Oncol\", \"pubmed_id\"=>\"26668065\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26668065\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6}, \"journal\"=>\"Target Oncol\", \"full_journal_title\"=>\"Targeted oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>895, \"name\"=>\"EID895\", \"description\"=>\"141 patients were analyzed for ERBB2 (HER2) positivity by FISH and/or IHC. Only 6 (4.3%) were ERBB2 positive. These patients did not show a difference in outcome after capecitabine, oxaliplatin and chemoradiotherapy, with or without cetuximab.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}, {\"id\"=>32, \"name\"=>\"Capecitabine\", \"pubchem_id\"=>nil}, {\"id\"=>237, \"name\"=>\"Oxaliplatin\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>603, \"name\"=>\"HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.\", \"citation\"=>\"Sclafani et al., 2013, Ann. Oncol.\", \"pubmed_id\"=>\"24146218\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24146218\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2013, \"month\"=>12}, \"journal\"=>\"Ann. Oncol.\", \"full_journal_title\"=>\"Annals of oncology : official journal of the European Society for Medical Oncology / ESMO\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>886, \"name\"=>\"EID886\", \"description\"=>\"Eight uterine cancer cell lines (four with ERBB2 amplification and four without) were treated with scalar concentrations of afatinib. Primary chemotherapy-resistant USC cell lines harbouring ERBB2 gene amplification were sensitive to afatinib exposure and significantly more sensitive than non-amplified cell lines.\", \"disease\"=>{\"id\"=>93, \"name\"=>\"Uterine Corpus Endometrial Carcinoma\", \"display_name\"=>\"Uterine Corpus Endometrial Carcinoma\", \"doid\"=>\"0050939\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050939\"}, \"drugs\"=>[{\"id\"=>146, \"name\"=>\"Afatinib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>596, \"name\"=>\"Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.\", \"citation\"=>\"Schwab et al., 2014, Br. J. Cancer\", \"pubmed_id\"=>\"25268372\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25268372\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4453741\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>10, \"day\"=>28}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1023, \"name\"=>\"EID1023\", \"description\"=>\"TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer.  Primary endpoint was Overall Survival (OS).  Participants had progressed under previous treatment and only a small percentage had seen first line trastuzumab.  Patients were a mix of those having undergone gastrectomy and not.  OS was not significantly  different in the ITT population, but certain subpopulations showed significant differences.  In the subset of patients showing a stronger immunohistochemistry result for HER2 (IHC3+), progression free survival was significantly different at 5.6 months for lapatinib + pacitaxel vs. 4.2 months for pacitaxel alone.  The authors conclude that proof of concept for lapatanib addition to chemotherapy for certain subgroups is provided in this study.\", \"disease\"=>{\"id\"=>147, \"name\"=>\"Gastric Adenocarcinoma\", \"display_name\"=>\"Gastric Adenocarcinoma\", \"doid\"=>\"3717\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3717\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>709, \"name\"=>\"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.\", \"citation\"=>\"Satoh et al., 2014, J. Clin. Oncol.\", \"pubmed_id\"=>\"24868024\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24868024\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>1006, \"name\"=>\"EID1006\", \"description\"=>\"In-vitro studies using ERBB2 over-expressing breast cancer cell lines BT474 and SKBR3 (with ERBB2 amplification) showed apoptosis under either labatinib or trastuzumab treatment.  A marked synergistic apoptotic effect under lapatinib and trastuzumab co-treatment was observed in BT474 cells, and a milder synergistic effect was observed in SKBR3 cells.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>695, \"name\"=>\"Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.\", \"citation\"=>\"Xia et al., 2005, Oncogene\", \"pubmed_id\"=>\"16091755\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/16091755\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>9, \"day\"=>15}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>760, \"name\"=>\"EID760\", \"description\"=>\"Xenografts established from breast cancer cell lines with ERBB2 amplification and PIK3CA mutation (BT474) or PIK3CA mutation alone (MCF7) were effectively inhibited in-vivo with an AKT1/2-inhibitor (AKTi-1/2; naphthyridinone).\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>169, \"name\"=>\"AKTi-1/2\", \"pubchem_id\"=>\"\"}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>503, \"name\"=>\"Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.\", \"citation\"=>\"She et al., 2008, PLoS ONE\", \"pubmed_id\"=>\"18725974\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/18725974\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2516933\", \"publication_date\"=>{\"year\"=>2008}, \"journal\"=>\"PLoS ONE\", \"full_journal_title\"=>\"PloS one\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}, {\"id\"=>761, \"name\"=>\"EID761\", \"description\"=>\"Oral neratinib showed objective response rates of 24 and 56% respectively in prior-trastuzumab and trastuzumab-naive cohorts in a Phase II trial with a primary endpoint of 16-week progression free survival.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>52, \"name\"=>\"Neratinib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>504, \"name\"=>\"Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.\", \"citation\"=>\"Burstein et al., 2010, J. Clin. Oncol.\", \"pubmed_id\"=>\"20142587\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20142587\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2010, \"month\"=>3, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>306, \"phenotypes\"=>[]}]}, {\"id\"=>131, \"entrez_name\"=>\"BRCA1\", \"entrez_id\"=>672, \"name\"=>\"LOSS-OF-FUNCTION\", \"description\"=>\"BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.\", \"gene_id\"=>6, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>97, \"name\"=>\"loss_of_heterozygosity\", \"display_name\"=>\"Loss Of Heterozygosity\", \"so_id\"=>\"SO:0001786\", \"description\"=>\"A functional variant whereby the sequence alteration causes a loss of function of one allele of a gene.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001786\"}, {\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>104.0, \"coordinates\"=>{\"chromosome\"=>\"17\", \"start\"=>41196312, \"stop\"=>41277387, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000357654.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/6/summary/variants/131/summary#variant\", \"evidence_items\"=>[{\"id\"=>4876, \"name\"=>\"EID4876\", \"description\"=>\"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>523, \"name\"=>\"Talazoparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2143, \"name\"=>\"Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.\", \"citation\"=>\"de Bono et al., 2017, Cancer Discov\", \"pubmed_id\"=>\"28242752\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28242752\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>6}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>131, \"phenotypes\"=>[]}, {\"id\"=>4838, \"name\"=>\"EID4838\", \"description\"=>\"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>523, \"name\"=>\"Talazoparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2143, \"name\"=>\"Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.\", \"citation\"=>\"de Bono et al., 2017, Cancer Discov\", \"pubmed_id\"=>\"28242752\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28242752\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>6}, \"journal\"=>\"Cancer Discov\", \"full_journal_title\"=>\"Cancer discovery\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>131, \"phenotypes\"=>[]}, {\"id\"=>5815, \"name\"=>\"EID5815\", \"description\"=>\"302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA1 patients specifically, the hazard ratio was 0.54, 95% CI 0.37-0.79).\", \"disease\"=>{\"id\"=>369, \"name\"=>\"Her2-receptor Negative Breast Cancer\", \"display_name\"=>\"Her2-receptor Negative Breast Cancer\", \"doid\"=>\"0060080\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060080\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>5, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2329, \"name\"=>\"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.\", \"citation\"=>\"Robson et al., 2017, N. Engl. J. Med.\", \"pubmed_id\"=>\"28578601\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28578601\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"day\"=>10}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT02000622\", \"name\"=>\"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.\", \"description\"=>\"This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2 mutations.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02000622\"}]}, \"variant_id\"=>131, \"phenotypes\"=>[]}, {\"id\"=>1924, \"name\"=>\"EID1924\", \"description\"=>\"The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. Xenografts harbored both a germline BRCA and a somatic BRCA mutation leading to disruption of both. The BRCA and NHEJ pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>439, \"name\"=>\"CX-5461\", \"pubchem_id\"=>nil}, {\"id\"=>440, \"name\"=>\"CX-3543\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Unknown\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1346, \"name\"=>\"CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.\", \"citation\"=>\"Xu et al., 2017, Nat Commun\", \"pubmed_id\"=>\"28211448\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28211448\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>2, \"day\"=>17}, \"journal\"=>\"Nat Commun\", \"full_journal_title\"=>\"Nature communications\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>131, \"phenotypes\"=>[]}, {\"id\"=>1523, \"name\"=>\"EID1523\", \"description\"=>\"In a study of 2,019 patients with prostate cancer, 18 had germline BRCA1 mutations, 61 had germline BRCA2 mutations and 1,940 were non-carriers.  Patients with BRCA1/2 mutations had a 2-fold higher incidence of poorly differentiated cancer (Gleason score >8), a higher incidence of advanced stage (37% vs. 28%; P=0.003), a higher incidence of nodal involvement (15% vs. 5%; P=0.0005), and a higher incidence of metastatic spread (18% vs. 9%; P=0.005).\", \"disease\"=>{\"id\"=>46, \"name\"=>\"Prostate Cancer\", \"display_name\"=>\"Prostate Cancer\", \"doid\"=>\"10283\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10283\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1016, \"name\"=>\"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.\", \"citation\"=>\"Castro et al., 2013, J. Clin. Oncol.\", \"pubmed_id\"=>\"23569316\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23569316\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3641696\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>5, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>131, \"phenotypes\"=>[]}, {\"id\"=>211, \"name\"=>\"EID211\", \"description\"=>\"The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undifferentiated ovarian cancer.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>150, \"name\"=>\"Advanced ovarian cancer: what should be the standard of care?\", \"citation\"=>\"Goff, 2013, J Gynecol Oncol\", \"pubmed_id\"=>\"23346317\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23346317\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3549512\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>1}, \"journal\"=>\"J Gynecol Oncol\", \"full_journal_title\"=>\"Journal of gynecologic oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>131, \"phenotypes\"=>[]}, {\"id\"=>845, \"name\"=>\"EID845\", \"description\"=>\"1/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study.\", \"disease\"=>{\"id\"=>46, \"name\"=>\"Prostate Cancer\", \"display_name\"=>\"Prostate Cancer\", \"doid\"=>\"10283\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10283\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>409, \"name\"=>\"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.\", \"citation\"=>\"Mateo et al., 2015, N. Engl. J. Med.\", \"pubmed_id\"=>\"26510020\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26510020\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>10, \"day\"=>29}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>131, \"phenotypes\"=>[]}]}, {\"id\"=>157, \"entrez_name\"=>\"TET2\", \"entrez_id\"=>54790, \"name\"=>\"MUTATION\", \"description\"=>\"TET2 mutations are commonly found in acute myeloid leukemia occurring in 9-23% of cases with many occurring in the elderly. Generally these mutations are loss-of-function which have been shown in mouse models to impair hematopoietic stem cell differentiation and cause aberrant hematopoiesis. These mutations have been found to be mutually exclusive with MLL and IDH1/2 mutations and have been associated with shortened event-free-survival and disease-free-survival when co-occurring with NPM1+/FLT3- genotypes. Overall Survival has been found to be shorter when occurring with NPM1+/FLT3+ genotypes. Studies involving \\\"CN AML\\\" and \\\"de novo AML\\\" however have been unable to elucidate a clinical impact.\", \"gene_id\"=>55, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>30, \"name\"=>\"gene_variant\", \"display_name\"=>\"Gene Variant\", \"so_id\"=>\"SO:0001564\", \"description\"=>\"A sequence variant where the structure of the gene is changed.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001564\"}, {\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>120.0, \"coordinates\"=>{\"chromosome\"=>\"4\", \"start\"=>106067450, \"stop\"=>106200973, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000513237.1\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/55/summary/variants/157/summary#variant\", \"evidence_items\"=>[{\"id\"=>427, \"name\"=>\"EID427\", \"description\"=>\"In patients with cytogenetically normal acute myeloid leukemia, those in the ELN favorable-risk group with TET2 mutations had shorter event-free survival, lower rates of complete remission, and shorter disease-free survival.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>250, \"name\"=>\"TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.\", \"citation\"=>\"Metzeler et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21343549\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21343549\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3084003\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>157, \"phenotypes\"=>[]}, {\"id\"=>426, \"name\"=>\"EID426\", \"description\"=>\"In patients classified as intermediate-risk via cytogenetics, TET2 mutations have been shown to be correlated with poor prognosis.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>253, \"name\"=>\"TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.\", \"citation\"=>\"Chou et al., 2011, Blood\", \"pubmed_id\"=>\"21828143\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21828143\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>10, \"day\"=>6}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>157, \"phenotypes\"=>[]}, {\"id\"=>421, \"name\"=>\"EID421\", \"description\"=>\"In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations did not have significantly different rates of event-free survival, complete remission, disease-free survival, or overall survival.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>250, \"name\"=>\"TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.\", \"citation\"=>\"Metzeler et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"21343549\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21343549\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3084003\", \"publication_date\"=>{\"year\"=>2011, \"month\"=>4, \"day\"=>1}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>157, \"phenotypes\"=>[]}, {\"id\"=>419, \"name\"=>\"EID419\", \"description\"=>\"In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations had higher rates of complete remission.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>245, \"name\"=>\"TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.\", \"citation\"=>\"Gaidzik et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22430270\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22430270\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>157, \"phenotypes\"=>[]}, {\"id\"=>417, \"name\"=>\"EID417\", \"description\"=>\"In patients with myelodysplastic syndromes, those with TET2 mutations have been shown to have better overall survival than patients without TET2 mutations.\", \"disease\"=>{\"id\"=>34, \"name\"=>\"Myelodysplastic Syndrome\", \"display_name\"=>\"Myelodysplastic Syndrome\", \"doid\"=>\"0050908\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0050908\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>247, \"name\"=>\"TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).\", \"citation\"=>\"Kosmider et al., 2009, Blood\", \"pubmed_id\"=>\"19666869\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19666869\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>10, \"day\"=>8}, \"journal\"=>\"Blood\", \"full_journal_title\"=>\"Blood\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>157, \"phenotypes\"=>[]}, {\"id\"=>415, \"name\"=>\"EID415\", \"description\"=>\"In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death.\", \"disease\"=>{\"id\"=>3, \"name\"=>\"Acute Myeloid Leukemia\", \"display_name\"=>\"Acute Myeloid Leukemia\", \"doid\"=>\"9119\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9119\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"N/A\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>245, \"name\"=>\"TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.\", \"citation\"=>\"Gaidzik et al., 2012, J. Clin. Oncol.\", \"pubmed_id\"=>\"22430270\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22430270\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>157, \"phenotypes\"=>[]}]}, {\"id\"=>185, \"entrez_name\"=>\"BRCA1\", \"entrez_id\"=>672, \"name\"=>\"MUTATION\", \"description\"=>\"\", \"gene_id\"=>6, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>30, \"name\"=>\"gene_variant\", \"display_name\"=>\"Gene Variant\", \"so_id\"=>\"SO:0001564\", \"description\"=>\"A sequence variant where the structure of the gene is changed.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001564\"}, {\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>180.0, \"coordinates\"=>{\"chromosome\"=>\"17\", \"start\"=>41196312, \"stop\"=>41277387, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000357654.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/6/summary/variants/185/summary#variant\", \"evidence_items\"=>[{\"id\"=>5915, \"name\"=>\"EID5915\", \"description\"=>\"Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively.\\nIn patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2389, \"name\"=>\"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.\", \"citation\"=>\"Golan et al., 2014, Br. J. Cancer\", \"pubmed_id\"=>\"25072261\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25072261\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4453851\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>9, \"day\"=>9}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>5914, \"name\"=>\"EID5914\", \"description\"=>\"Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. All but one had received gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2388, \"name\"=>\"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.\", \"citation\"=>\"Kaufman et al., 2015, J. Clin. Oncol.\", \"pubmed_id\"=>\"25366685\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25366685\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>1, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>5934, \"name\"=>\"EID5934\", \"description\"=>\"Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy. No confirmed PR was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>556, \"name\"=>\"Veliparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2406, \"name\"=>\"Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.\", \"citation\"=>\"Lowery et al., 2018, Eur. J. Cancer\", \"pubmed_id\"=>\"29223478\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29223478\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1}, \"journal\"=>\"Eur. J. Cancer\", \"full_journal_title\"=>\"European journal of cancer (Oxford, England : 1990)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT01585805\", \"name\"=>\"Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer\", \"description\"=>\"This randomized phase II trial studies how well veliparib together with gemcitabine hydrochloride and cisplatin works compared to gemcitabine hydrochloride and cisplatin alone in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or spread from the primary site (place where it started) to other places in the body (metastatic). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving veliparib together with gemcitabine hydrochloride and cisplatin is an effective treatment for pancreatic cancer.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT01585805\"}, {\"nct_id\"=>\"NCT02184195\", \"name\"=>\"Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy\", \"description\"=>\"A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02184195\"}]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>5932, \"name\"=>\"EID5932\", \"description\"=>\"In Phase I study for pancreatic cancer patients\\nGEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>85, \"name\"=>\"Gemcitabine\", \"pubchem_id\"=>nil}, {\"id\"=>326, \"name\"=>\"Cisplatin\", \"pubchem_id\"=>nil}, {\"id\"=>556, \"name\"=>\"Veliparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2405, \"name\"=>\"Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.\", \"citation\"=>\"O'Reilly et al., 2018, Cancer\", \"pubmed_id\"=>\"29338080\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29338080\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>16}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT01585805\", \"name\"=>\"Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer\", \"description\"=>\"This randomized phase II trial studies how well veliparib together with gemcitabine hydrochloride and cisplatin works compared to gemcitabine hydrochloride and cisplatin alone in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or spread from the primary site (place where it started) to other places in the body (metastatic). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving veliparib together with gemcitabine hydrochloride and cisplatin is an effective treatment for pancreatic cancer.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT01585805\"}]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>5830, \"name\"=>\"EID5830\", \"description\"=>\"Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2ânegative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2357, \"name\"=>\"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.\", \"citation\"=>\"2017, N. Engl. J. Med.\", \"pubmed_id\"=>\"28792849\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28792849\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>8, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1897, \"name\"=>\"EID1897\", \"description\"=>\"A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor Rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA mutant patients, 10 had somatic BRCA1 mutation. Confirmed objective response was seen in 79% of the BRCA1 mutant subgroup, and 74% confirmed objective response was seen in the somatic BRCA mutant subgroup. In a BRCA wild-type subgroup, with low levels of Loss of Heterozygosity, confirmed objective response was observed in 10% of the patients.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>431, \"name\"=>\"Rucaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1328, \"name\"=>\"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.\", \"citation\"=>\"Swisher et al., 2017, Lancet Oncol.\", \"pubmed_id\"=>\"27908594\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27908594\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>1}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"partially curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1684, \"name\"=>\"EID1684\", \"description\"=>\"In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.\", \"disease\"=>{\"id\"=>370, \"name\"=>\"Triple-receptor Negative Breast Cancer\", \"display_name\"=>\"Triple-receptor Negative Breast Cancer\", \"doid\"=>\"0060081\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060081\"}, \"drugs\"=>[{\"id\"=>93, \"name\"=>\"Carboplatin\", \"pubchem_id\"=>nil}, {\"id\"=>326, \"name\"=>\"Cisplatin\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1137, \"name\"=>\"TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.\", \"citation\"=>\"Isakoff et al., 2015, J. Clin. Oncol.\", \"pubmed_id\"=>\"25847936\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25847936\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4451173\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>6, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1675, \"name\"=>\"EID1675\", \"description\"=>\"664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo.  Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative.  Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1133, \"name\"=>\"BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.\", \"citation\"=>\"Harter et al., 2016, Gynecol. Oncol.\", \"pubmed_id\"=>\"26740259\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26740259\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Gynecol. Oncol.\", \"full_journal_title\"=>\"Gynecologic oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1677, \"name\"=>\"EID1677\", \"description\"=>\"46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}, {\"id\"=>400, \"name\"=>\"Cediranib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1134, \"name\"=>\"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.\", \"citation\"=>\"Liu et al., 2014, Lancet Oncol.\", \"pubmed_id\"=>\"25218906\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25218906\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4294183\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>10}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1529, \"name\"=>\"EID1529\", \"description\"=>\"In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.\", \"disease\"=>{\"id\"=>47, \"name\"=>\"Ovarian Carcinoma\", \"display_name\"=>\"Ovarian Carcinoma\", \"doid\"=>\"4001\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4001\"}, \"drugs\"=>[{\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1020, \"name\"=>\"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.\", \"citation\"=>\"Pennington et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24240112\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24240112\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3944197\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1531, \"name\"=>\"EID1531\", \"description\"=>\"In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum-based therapy.\", \"disease\"=>{\"id\"=>47, \"name\"=>\"Ovarian Carcinoma\", \"display_name\"=>\"Ovarian Carcinoma\", \"doid\"=>\"4001\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4001\"}, \"drugs\"=>[{\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1020, \"name\"=>\"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.\", \"citation\"=>\"Pennington et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24240112\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24240112\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3944197\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1772, \"name\"=>\"EID1772\", \"description\"=>\"In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1239, \"name\"=>\"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.\", \"citation\"=>\"Gelmon et al., 2011, Lancet Oncol.\", \"pubmed_id\"=>\"21862407\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21862407\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>9}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1775, \"name\"=>\"EID1775\", \"description\"=>\"In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.\", \"disease\"=>{\"id\"=>370, \"name\"=>\"Triple-receptor Negative Breast Cancer\", \"display_name\"=>\"Triple-receptor Negative Breast Cancer\", \"doid\"=>\"0060081\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060081\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1239, \"name\"=>\"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.\", \"citation\"=>\"Gelmon et al., 2011, Lancet Oncol.\", \"pubmed_id\"=>\"21862407\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21862407\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>9}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>1370, \"name\"=>\"EID1370\", \"description\"=>\"In this phase 1 trial, 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers. 19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>359, \"name\"=>\"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.\", \"citation\"=>\"Fong et al., 2009, N. Engl. J. Med.\", \"pubmed_id\"=>\"19553641\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19553641\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>7, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}, {\"id\"=>464, \"name\"=>\"EID464\", \"description\"=>\"In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival.\", \"disease\"=>{\"id\"=>225, \"name\"=>\"Epithelial Ovarian Cancer\", \"display_name\"=>\"Epithelial Ovarian Cancer\", \"doid\"=>\"2152\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2152\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>279, \"name\"=>\"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.\", \"citation\"=>\"Bolton et al., 2012, JAMA\", \"pubmed_id\"=>\"22274685\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22274685\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3727895\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>1, \"day\"=>25}, \"journal\"=>\"JAMA\", \"full_journal_title\"=>\"JAMA\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>185, \"phenotypes\"=>[]}]}, {\"id\"=>186, \"entrez_name\"=>\"BRCA2\", \"entrez_id\"=>675, \"name\"=>\"MUTATION\", \"description\"=>\"\", \"gene_id\"=>7, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>30, \"name\"=>\"gene_variant\", \"display_name\"=>\"Gene Variant\", \"so_id\"=>\"SO:0001564\", \"description\"=>\"A sequence variant where the structure of the gene is changed.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0001564\"}, {\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>160.0, \"coordinates\"=>{\"chromosome\"=>\"13\", \"start\"=>32889611, \"stop\"=>32973347, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000380152.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/7/summary/variants/186/summary#variant\", \"evidence_items\"=>[{\"id\"=>5916, \"name\"=>\"EID5916\", \"description\"=>\"Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively.\\nIn patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2389, \"name\"=>\"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.\", \"citation\"=>\"Golan et al., 2014, Br. J. Cancer\", \"pubmed_id\"=>\"25072261\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25072261\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4453851\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>9, \"day\"=>9}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>5913, \"name\"=>\"EID5913\", \"description\"=>\"Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. All but one had received gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2388, \"name\"=>\"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.\", \"citation\"=>\"Kaufman et al., 2015, J. Clin. Oncol.\", \"pubmed_id\"=>\"25366685\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25366685\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>1, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>5936, \"name\"=>\"EID5936\", \"description\"=>\"Patient with germline BRCA2 mutation underwent resection of pancreatic cancer.\\nAround three years later, tumor recurrence was detected by MRI and PET-CT confirmed it. She was treated with gemcitabine plus iniparib in clinical trial. Excellent response to therapy was observed and surgery was performed but no residual tumor tissue was detected\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>557, \"name\"=>\"Iniparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2407, \"name\"=>\"Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.\", \"citation\"=>\"Fogelman et al., 2011, Anticancer Res.\", \"pubmed_id\"=>\"21508395\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21508395\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>4}, \"journal\"=>\"Anticancer Res.\", \"full_journal_title\"=>\"Anticancer research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>5935, \"name\"=>\"EID5935\", \"description\"=>\"Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy. No confirmed PR was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>556, \"name\"=>\"Veliparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2406, \"name\"=>\"Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.\", \"citation\"=>\"Lowery et al., 2018, Eur. J. Cancer\", \"pubmed_id\"=>\"29223478\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29223478\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1}, \"journal\"=>\"Eur. J. Cancer\", \"full_journal_title\"=>\"European journal of cancer (Oxford, England : 1990)\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT01585805\", \"name\"=>\"Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer\", \"description\"=>\"This randomized phase II trial studies how well veliparib together with gemcitabine hydrochloride and cisplatin works compared to gemcitabine hydrochloride and cisplatin alone in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or spread from the primary site (place where it started) to other places in the body (metastatic). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving veliparib together with gemcitabine hydrochloride and cisplatin is an effective treatment for pancreatic cancer.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT01585805\"}, {\"nct_id\"=>\"NCT02184195\", \"name\"=>\"Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy\", \"description\"=>\"A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT02184195\"}]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>5933, \"name\"=>\"EID5933\", \"description\"=>\"In Phase I study for pancreatic cancer patients\\nGEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.\", \"disease\"=>{\"id\"=>556, \"name\"=>\"Pancreatic Cancer\", \"display_name\"=>\"Pancreatic Cancer\", \"doid\"=>\"1793\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1793\"}, \"drugs\"=>[{\"id\"=>85, \"name\"=>\"Gemcitabine\", \"pubchem_id\"=>nil}, {\"id\"=>326, \"name\"=>\"Cisplatin\", \"pubchem_id\"=>nil}, {\"id\"=>556, \"name\"=>\"Veliparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2405, \"name\"=>\"Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.\", \"citation\"=>\"O'Reilly et al., 2018, Cancer\", \"pubmed_id\"=>\"29338080\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/29338080\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2018, \"month\"=>1, \"day\"=>16}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT01585805\", \"name\"=>\"Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer\", \"description\"=>\"This randomized phase II trial studies how well veliparib together with gemcitabine hydrochloride and cisplatin works compared to gemcitabine hydrochloride and cisplatin alone in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or spread from the primary site (place where it started) to other places in the body (metastatic). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving veliparib together with gemcitabine hydrochloride and cisplatin is an effective treatment for pancreatic cancer.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT01585805\"}]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>5831, \"name\"=>\"EID5831\", \"description\"=>\"Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2ânegative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"submitted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2357, \"name\"=>\"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.\", \"citation\"=>\"2017, N. Engl. J. Med.\", \"pubmed_id\"=>\"28792849\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28792849\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2017, \"month\"=>8, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1685, \"name\"=>\"EID1685\", \"description\"=>\"In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.\", \"disease\"=>{\"id\"=>370, \"name\"=>\"Triple-receptor Negative Breast Cancer\", \"display_name\"=>\"Triple-receptor Negative Breast Cancer\", \"doid\"=>\"0060081\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060081\"}, \"drugs\"=>[{\"id\"=>93, \"name\"=>\"Carboplatin\", \"pubchem_id\"=>nil}, {\"id\"=>326, \"name\"=>\"Cisplatin\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1137, \"name\"=>\"TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.\", \"citation\"=>\"Isakoff et al., 2015, J. Clin. Oncol.\", \"pubmed_id\"=>\"25847936\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25847936\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4451173\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>6, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1678, \"name\"=>\"EID1678\", \"description\"=>\"46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients).\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}, {\"id\"=>400, \"name\"=>\"Cediranib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1134, \"name\"=>\"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.\", \"citation\"=>\"Liu et al., 2014, Lancet Oncol.\", \"pubmed_id\"=>\"25218906\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25218906\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4294183\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>10}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1676, \"name\"=>\"EID1676\", \"description\"=>\"664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo.  Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative.  Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1133, \"name\"=>\"BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.\", \"citation\"=>\"Harter et al., 2016, Gynecol. Oncol.\", \"pubmed_id\"=>\"26740259\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/26740259\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>3}, \"journal\"=>\"Gynecol. Oncol.\", \"full_journal_title\"=>\"Gynecologic oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1532, \"name\"=>\"EID1532\", \"description\"=>\"In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum therapy.\", \"disease\"=>{\"id\"=>47, \"name\"=>\"Ovarian Carcinoma\", \"display_name\"=>\"Ovarian Carcinoma\", \"doid\"=>\"4001\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4001\"}, \"drugs\"=>[{\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1020, \"name\"=>\"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.\", \"citation\"=>\"Pennington et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24240112\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24240112\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3944197\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1530, \"name\"=>\"EID1530\", \"description\"=>\"In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy.\", \"disease\"=>{\"id\"=>47, \"name\"=>\"Ovarian Carcinoma\", \"display_name\"=>\"Ovarian Carcinoma\", \"doid\"=>\"4001\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4001\"}, \"drugs\"=>[{\"id\"=>103, \"name\"=>\"PLATINUM\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1020, \"name\"=>\"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.\", \"citation\"=>\"Pennington et al., 2014, Clin. Cancer Res.\", \"pubmed_id\"=>\"24240112\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24240112\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3944197\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1371, \"name\"=>\"EID1371\", \"description\"=>\"In this phase 1 trial 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers.19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"A\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>359, \"name\"=>\"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.\", \"citation\"=>\"Fong et al., 2009, N. Engl. J. Med.\", \"pubmed_id\"=>\"19553641\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/19553641\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2009, \"month\"=>7, \"day\"=>9}, \"journal\"=>\"N. Engl. J. Med.\", \"full_journal_title\"=>\"The New England journal of medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1776, \"name\"=>\"EID1776\", \"description\"=>\"In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.\", \"disease\"=>{\"id\"=>370, \"name\"=>\"Triple-receptor Negative Breast Cancer\", \"display_name\"=>\"Triple-receptor Negative Breast Cancer\", \"doid\"=>\"0060081\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060081\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1239, \"name\"=>\"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.\", \"citation\"=>\"Gelmon et al., 2011, Lancet Oncol.\", \"pubmed_id\"=>\"21862407\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21862407\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>9}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>1773, \"name\"=>\"EID1773\", \"description\"=>\"In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>42, \"name\"=>\"Olaparib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1239, \"name\"=>\"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.\", \"citation\"=>\"Gelmon et al., 2011, Lancet Oncol.\", \"pubmed_id\"=>\"21862407\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21862407\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>9}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}, {\"id\"=>465, \"name\"=>\"EID465\", \"description\"=>\"In patients with invasive epithelial ovarian cancer, those with mutations in BRCA2 had better five-year overall survival.\", \"disease\"=>{\"id\"=>225, \"name\"=>\"Epithelial Ovarian Cancer\", \"display_name\"=>\"Epithelial Ovarian Cancer\", \"doid\"=>\"2152\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2152\"}, \"drugs\"=>[], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Better Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Germline Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>279, \"name\"=>\"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.\", \"citation\"=>\"Bolton et al., 2012, JAMA\", \"pubmed_id\"=>\"22274685\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22274685\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3727895\", \"publication_date\"=>{\"year\"=>2012, \"month\"=>1, \"day\"=>25}, \"journal\"=>\"JAMA\", \"full_journal_title\"=>\"JAMA\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>186, \"phenotypes\"=>[]}]}, {\"id\"=>214, \"entrez_name\"=>\"PTEN\", \"entrez_id\"=>5728, \"name\"=>\"LOSS\", \"description\"=>\"\", \"gene_id\"=>41, \"type\"=>\"variant\", \"variant_types\"=>[{\"id\"=>161, \"name\"=>\"loss_of_function_variant\", \"display_name\"=>\"Loss Of Function Variant\", \"so_id\"=>\"SO:0002054\", \"description\"=>\"A sequence variant whereby the gene product has diminished or abolished function.\", \"url\"=>\"http://www.sequenceontology.org/browser/current_svn/term/SO:0002054\"}], \"civic_actionability_score\"=>229.0, \"coordinates\"=>{\"chromosome\"=>\"10\", \"start\"=>89622870, \"stop\"=>89731687, \"reference_bases\"=>nil, \"variant_bases\"=>nil, \"representative_transcript\"=>\"ENST00000371953.3\", \"chromosome2\"=>nil, \"start2\"=>nil, \"stop2\"=>nil, \"representative_transcript2\"=>nil, \"ensembl_version\"=>75, \"reference_build\"=>\"GRCh37\"}, \"variant_url\"=>\"/events/genes/41/summary/variants/214/summary#variant\", \"evidence_items\"=>[{\"id\"=>5840, \"name\"=>\"EID5840\", \"description\"=>\"In a single-arm, open label phase 2 trial in PIK3CA amplified/mutated and/or PTEN loss encompassing 10 patients, no objective responses were observed but a stable disease response in 4 patients, resulting in a median PFS of 1.4 months. Everolimus failed to meet its enpoint.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2364, \"name\"=>\"Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.\", \"citation\"=>\"Kim et al., 2017, BMC Cancer\", \"pubmed_id\"=>\"28330462\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28330462\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5363054\", \"publication_date\"=>{\"year\"=>2017, \"month\"=>3, \"day\"=>23}, \"journal\"=>\"BMC Cancer\", \"full_journal_title\"=>\"BMC cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>5957, \"name\"=>\"EID5957\", \"description\"=>\"No objective responses were observed in the PTEN deficient cohort. Four out of 6 patients with stable disease (SD) had SD or better for â¥6 cycles, 2 of which had PTEN deficient tumors. Conclusion The addition of buparlisib to high dose carboplatin and paclitaxel was not tolerable. The combination did not reveal significant clinical activity amongst a small and heterogenous group of PTEN deficient tumors.\", \"disease\"=>{\"id\"=>2616, \"name\"=>\"Solid Tumor\", \"display_name\"=>\"Solid Tumor\", \"doid\"=>\"\", \"url\"=>\"http://www.disease-ontology.org/\"}, \"drugs\"=>[{\"id\"=>81, \"name\"=>\"Paclitaxel\", \"pubchem_id\"=>nil}, {\"id\"=>93, \"name\"=>\"Carboplatin\", \"pubchem_id\"=>nil}, {\"id\"=>116, \"name\"=>\"Buparlisib\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>1, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>2413, \"name\"=>\"A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.\", \"citation\"=>\"Smyth et al., 2017, Invest New Drugs\", \"pubmed_id\"=>\"28281183\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/28281183\", \"open_access\"=>true, \"pmc_id\"=>\"PMC5591764\", \"publication_date\"=>{\"year\"=>2017, \"month\"=>12}, \"journal\"=>\"Invest New Drugs\", \"full_journal_title\"=>\"Investigational new drugs\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[{\"nct_id\"=>\"NCT01297452\", \"name\"=>\"BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors\", \"description\"=>\"The purpose of this study is to find out the good and bad effects that occur when BKM120 is added to standard chemotherapy with carboplatin and paclitaxel.\", \"clinical_trial_url\"=>\"https://clinicaltrials.gov/show/NCT01297452\"}]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1502, \"name\"=>\"EID1502\", \"description\"=>\"In a panel of 182 cell lines (162 with PIK3CA mutation status known) from solid and hematological tumors, significant correlation was found between AZD5363 (pan-Akt inhibitor) sensitivity and PIK3CA mutation status (N=33, p=0.0059). In the subpopulation free of RAS mutation (N=19) the correlation was increased.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>112, \"name\"=>\"AZD5363\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1005, \"name\"=>\"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.\", \"citation\"=>\"Davies et al., 2012, Mol. Cancer Ther.\", \"pubmed_id\"=>\"22294718\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22294718\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2012, \"month\"=>4}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1455, \"name\"=>\"EID1455\", \"description\"=>\"Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance. PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition, but co-treatment with trastuzumab and LY294002 induced growth inhibition comparable to trastuzumab alone in normal BT474 cells. BT474 mouse xenograft tumors were injected with PTEN antisense (AS) oligonucleotides and this resulted in trastuzumab resitance. Co-treatment of PTEN AS tumor mice with LY294002 and trastuzumab inhibited tumor growth in comparison to PTEN AS tumors treated with trastuzumab or LY294002 alone.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}, {\"id\"=>115, \"name\"=>\"LY294002\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>983, \"name\"=>\"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.\", \"citation\"=>\"Nagata et al., 2004, Cancer Cell\", \"pubmed_id\"=>\"15324695\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15324695\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2004, \"month\"=>8}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1493, \"name\"=>\"EID1493\", \"description\"=>\"Cancer and normal tissue samples were taken from 68 gastric cancer patients undergoing surgery without prior chemotherapy. Tissue samples were divided into high grade and low grade for phospho Akt (p-Akt) expression, and tested for PTEN LOH by sequencing. Patients with PTEN LOH were significantly more likely to have elevated p-Akt (p=0.0081), and high p-Akt samples were significantly less sensitive to chemotherapy agents 5-flourouracil, adriamycin, mitomycin and cis-platinum in MTT assay.\", \"disease\"=>{\"id\"=>1322, \"name\"=>\"Stomach Carcinoma\", \"display_name\"=>\"Stomach Carcinoma\", \"doid\"=>\"5517\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:5517\"}, \"drugs\"=>[{\"id\"=>199, \"name\"=>\"Chemotherapy\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1000, \"name\"=>\"Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.\", \"citation\"=>\"Oki et al., 2005, Int. J. Cancer\", \"pubmed_id\"=>\"15900596\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15900596\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>11, \"day\"=>10}, \"journal\"=>\"Int. J. Cancer\", \"full_journal_title\"=>\"International journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1383, \"name\"=>\"EID1383\", \"description\"=>\"A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance. The most prominently enriched gene in trastuzumab resistant populations was PTEN. Subsequent knockdown of PTEN in BT-474 cells increased cell survival when treated with trastuzumab, and growth curves showed partial restoration of proliferation in PTEN knockdown BT-474 cells treated with trastuzumab.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>938, \"name\"=>\"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.\", \"citation\"=>\"Berns et al., 2007, Cancer Cell\", \"pubmed_id\"=>\"17936563\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17936563\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2007, \"month\"=>10}, \"journal\"=>\"Cancer Cell\", \"full_journal_title\"=>\"Cancer cell\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1492, \"name\"=>\"EID1492\", \"description\"=>\"A cisplatin resistant derivative of ovarian cancer cell line OVCAR-3 was generated by long term passage with increasing cisplatin levels. Western blot showed decreased PTEN level in the resistant cell line, and siRNA against PTEN in parent OVCAR-3 cells induced cisplatin resistance.\", \"disease\"=>{\"id\"=>20, \"name\"=>\"Ovarian Cancer\", \"display_name\"=>\"Ovarian Cancer\", \"doid\"=>\"2394\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:2394\"}, \"drugs\"=>[{\"id\"=>326, \"name\"=>\"Cisplatin\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>999, \"name\"=>\"Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.\", \"citation\"=>\"Lee et al., 2005, Gynecol. Oncol.\", \"pubmed_id\"=>\"15790433\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/15790433\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2005, \"month\"=>4}, \"journal\"=>\"Gynecol. Oncol.\", \"full_journal_title\"=>\"Gynecologic oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1385, \"name\"=>\"EID1385\", \"description\"=>\"A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and PTEN loss alone was found to be significantly associated with resistance to trastuzumab (p=0.028) and shorter overall survival (p=0.008).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>939, \"name\"=>\"PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.\", \"citation\"=>\"Esteva et al., 2010, Am. J. Pathol.\", \"pubmed_id\"=>\"20813970\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20813970\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2947262\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Am. J. Pathol.\", \"full_journal_title\"=>\"The American journal of pathology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1386, \"name\"=>\"EID1386\", \"description\"=>\"While some reports indicate PTEN loss is associated with resistance to trastuzumab, in a subgroup of HER2 breast cancer FFPE samples from patients receiving trastuzumab as later line therapy (second or greater line therapy), with 25 PTEN loss and and 25 normal samples, no association was seen between trastuzumab response and PTEN status (p=1.000) or overall survival and PTEN status (p=0.863).\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>939, \"name\"=>\"PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.\", \"citation\"=>\"Esteva et al., 2010, Am. J. Pathol.\", \"pubmed_id\"=>\"20813970\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/20813970\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2947262\", \"publication_date\"=>{\"year\"=>2010, \"month\"=>10}, \"journal\"=>\"Am. J. Pathol.\", \"full_journal_title\"=>\"The American journal of pathology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1500, \"name\"=>\"EID1500\", \"description\"=>\"A patient derived mouse xenograft model was established with gastric cancer cells having PTEN loss. The xenograft was resistant to monotherapy with both the pan-Akt inhibitor AZD5363, and also to the commonly used gastric cancer chemotheraputic docetaxel. When used in combination, AZD5363 and docetaxel induced significant tumor growth inhibition in comparison to monotherapy and vehicle control.\", \"disease\"=>{\"id\"=>21, \"name\"=>\"Stomach Cancer\", \"display_name\"=>\"Stomach Cancer\", \"doid\"=>\"10534\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10534\"}, \"drugs\"=>[{\"id\"=>73, \"name\"=>\"Docetaxel\", \"pubchem_id\"=>nil}, {\"id\"=>112, \"name\"=>\"AZD5363\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1004, \"name\"=>\"The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.\", \"citation\"=>\"Li et al., 2013, J Transl Med\", \"pubmed_id\"=>\"24088382\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24088382\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3850695\", \"publication_date\"=>{\"year\"=>2013}, \"journal\"=>\"J Transl Med\", \"full_journal_title\"=>\"Journal of translational medicine\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1614, \"name\"=>\"EID1614\", \"description\"=>\"A panel of 24 endometroid endometrial cancer (EEC) cell lines was characterized for mutations and 18 cell lines were found to have mutations in PTEN or absence of expression. Cell lines were assessed for sensitivity to mTORC1 allosteric inhibitor temsirolimus, and it was reported that PTEN loss had significant association with temsirolimus sensitivity. .\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>83, \"name\"=>\"Temsirolimus\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1067, \"name\"=>\"PI3K pathway dependencies in endometrioid endometrial cancer cell lines.\", \"citation\"=>\"Weigelt et al., 2013, Clin. Cancer Res.\", \"pubmed_id\"=>\"23674493\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23674493\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3700760\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>7, \"day\"=>1}, \"journal\"=>\"Clin. Cancer Res.\", \"full_journal_title\"=>\"Clinical cancer research : an official journal of the American Association for Cancer Research\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1297, \"name\"=>\"EID1297\", \"description\"=>\"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PTEN loss (as defined by IHC staining intensity and proportion of positive tumor cells) had a longer progression-free survival with everolimus compared to placebo (HR 0.54 (95%CI 0.31 to 0.96, P=0.04) whereas patients with PTEN normal status had a hazard ration of 1.00 (95%CI 0.8 to 1.26, P=0.97).\\nThe same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combined and analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.\", \"disease\"=>{\"id\"=>368, \"name\"=>\"Her2-receptor Positive Breast Cancer\", \"display_name\"=>\"Her2-receptor Positive Breast Cancer\", \"doid\"=>\"0060079\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:0060079\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>891, \"name\"=>\"Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.\", \"citation\"=>\"AndrÃ© et al., 2016, J. Clin. Oncol.\", \"pubmed_id\"=>\"27091708\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/27091708\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2016, \"month\"=>6, \"day\"=>20}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>1611, \"name\"=>\"EID1611\", \"description\"=>\"In a panel of 31 breast cancer cell lines, 11 had loss of PTEN function. Cells were tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/2 inhibitor PP242, and no significant correlation was found between PTEN status and sensitivity to mTORC inhibition.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}, {\"id\"=>179, \"name\"=>\"PP242\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>1066, \"name\"=>\"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.\", \"citation\"=>\"Weigelt et al., 2011, Oncogene\", \"pubmed_id\"=>\"21358673\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21358673\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>7, \"day\"=>21}, \"journal\"=>\"Oncogene\", \"full_journal_title\"=>\"Oncogene\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>938, \"name\"=>\"EID938\", \"description\"=>\"Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.\", \"disease\"=>{\"id\"=>169, \"name\"=>\"Pancreatic Carcinoma\", \"display_name\"=>\"Pancreatic Carcinoma\", \"doid\"=>\"4905\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4905\"}, \"drugs\"=>[{\"id\"=>43, \"name\"=>\"MK-2206\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"C\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>641, \"name\"=>\"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.\", \"citation\"=>\"Yap et al., 2011, J. Clin. Oncol.\", \"pubmed_id\"=>\"22025163\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/22025163\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>12, \"day\"=>10}, \"journal\"=>\"J. Clin. Oncol.\", \"full_journal_title\"=>\"Journal of clinical oncology : official journal of the American Society of Clinical Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>864, \"name\"=>\"EID864\", \"description\"=>\"In 48 patients with advanced gastric cancer, retrospectively analyzed for PTEN expression using IHC, PTEN loss was associated with a shorter duration of response (median 4.2 vs. 6.1 months, p = 0.04) to HER2-targeted therapy (trastuzumab, N=39; lapatinib, N=9). Response rates did not differ between groups.\", \"disease\"=>{\"id\"=>147, \"name\"=>\"Gastric Adenocarcinoma\", \"display_name\"=>\"Gastric Adenocarcinoma\", \"doid\"=>\"3717\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:3717\"}, \"drugs\"=>[{\"id\"=>45, \"name\"=>\"Lapatinib\", \"pubchem_id\"=>nil}, {\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"N/A\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>579, \"name\"=>\"PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.\", \"citation\"=>\"Zhang et al., 2015, Oncology\", \"pubmed_id\"=>\"25300346\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25300346\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015}, \"journal\"=>\"Oncology\", \"full_journal_title\"=>\"Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>893, \"name\"=>\"EID893\", \"description\"=>\"94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed.\\nNo predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss.\", \"disease\"=>{\"id\"=>108, \"name\"=>\"Endometrial Cancer\", \"display_name\"=>\"Endometrial Cancer\", \"doid\"=>\"1380\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1380\"}, \"drugs\"=>[{\"id\"=>83, \"name\"=>\"Temsirolimus\", \"pubchem_id\"=>nil}, {\"id\"=>170, \"name\"=>\"Ridaforolimus\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Does Not Support\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Substitutes\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>602, \"name\"=>\"Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.\", \"citation\"=>\"Mackay et al., 2014, Cancer\", \"pubmed_id\"=>\"24166148\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24166148\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2014, \"month\"=>2, \"day\"=>15}, \"journal\"=>\"Cancer\", \"full_journal_title\"=>\"Cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>711, \"name\"=>\"EID711\", \"description\"=>\"Breast and prostate cancer cell lines responsive to AZD8186 were enriched for PTEN deficiency.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>114, \"name\"=>\"AZD8186\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>467, \"name\"=>\"Inhibition of PI3KÎ² signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.\", \"citation\"=>\"Hancox et al., 2015, Mol. Cancer Ther.\", \"pubmed_id\"=>\"25398829\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25398829\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>1}, \"journal\"=>\"Mol. Cancer Ther.\", \"full_journal_title\"=>\"Molecular cancer therapeutics\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>645, \"name\"=>\"EID645\", \"description\"=>\"PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free survival.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>84, \"name\"=>\"Trastuzumab\", \"pubchem_id\"=>nil}], \"rating\"=>1, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>406, \"name\"=>\"Therapeutic targeting of cancers with loss of PTEN function.\", \"citation\"=>\"Dillon et al., 2014, Curr Drug Targets\", \"pubmed_id\"=>\"24387334\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24387334\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4310752\", \"publication_date\"=>{\"year\"=>2014, \"month\"=>1}, \"journal\"=>\"Curr Drug Targets\", \"full_journal_title\"=>\"Current drug targets\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>714, \"name\"=>\"EID714\", \"description\"=>\"All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers.\", \"disease\"=>{\"id\"=>216, \"name\"=>\"Cancer\", \"display_name\"=>\"Cancer\", \"doid\"=>\"162\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:162\"}, \"drugs\"=>[{\"id\"=>81, \"name\"=>\"Paclitaxel\", \"pubchem_id\"=>nil}, {\"id\"=>93, \"name\"=>\"Carboplatin\", \"pubchem_id\"=>nil}, {\"id\"=>116, \"name\"=>\"Buparlisib\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>\"Combination\", \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>469, \"name\"=>\"Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.\", \"citation\"=>\"Hyman et al., 2015, Cancer Chemother. Pharmacol.\", \"pubmed_id\"=>\"25672916\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25672916\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2015, \"month\"=>4}, \"journal\"=>\"Cancer Chemother. Pharmacol.\", \"full_journal_title\"=>\"Cancer chemotherapy and pharmacology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>716, \"name\"=>\"EID716\", \"description\"=>\"A case report described a responder to PI3K inhibitor BYL719 for a tumor with PIK3CA E542K mutation. After partial response for 9.5 months, resistance developed. Sequencing in this and other patients as well as preclinical models showed loss of PTEN as the probable mechanism of resistance.\", \"disease\"=>{\"id\"=>22, \"name\"=>\"Breast Cancer\", \"display_name\"=>\"Breast Cancer\", \"doid\"=>\"1612\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1612\"}, \"drugs\"=>[{\"id\"=>339, \"name\"=>\"BYL719 (Alpelisib)\", \"pubchem_id\"=>\"\"}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>471, \"name\"=>\"Convergent loss of PTEN leads to clinical resistance to a PI(3)KÎ± inhibitor.\", \"citation\"=>\"Juric et al., 2015, Nature\", \"pubmed_id\"=>\"25409150\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/25409150\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4326538\", \"publication_date\"=>{\"year\"=>2015, \"month\"=>2, \"day\"=>12}, \"journal\"=>\"Nature\", \"full_journal_title\"=>\"Nature\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>708, \"name\"=>\"EID708\", \"description\"=>\"Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor\\nGSK2141795B.\", \"disease\"=>{\"id\"=>7, \"name\"=>\"Melanoma\", \"display_name\"=>\"Melanoma\", \"doid\"=>\"1909\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:1909\"}, \"drugs\"=>[{\"id\"=>111, \"name\"=>\"GSK2141795\", \"pubchem_id\"=>nil}], \"rating\"=>2, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>465, \"name\"=>\"Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.\", \"citation\"=>\"Lassen et al., 2014, Mol. Cancer\", \"pubmed_id\"=>\"24735930\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/24735930\", \"open_access\"=>true, \"pmc_id\"=>\"PMC4021505\", \"publication_date\"=>{\"year\"=>2014}, \"journal\"=>\"Mol. Cancer\", \"full_journal_title\"=>\"Molecular cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>644, \"name\"=>\"EID644\", \"description\"=>\"PTEN loss is associated with reduced response to mTOR inhibitors in patients with bladder cancer.\", \"disease\"=>{\"id\"=>18, \"name\"=>\"Bladder Carcinoma\", \"display_name\"=>\"Bladder Carcinoma\", \"doid\"=>\"4007\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:4007\"}, \"drugs\"=>[{\"id\"=>41, \"name\"=>\"Everolimus\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>407, \"name\"=>\"PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.\", \"citation\"=>\"Seront et al., 2013, Br. J. Cancer\", \"pubmed_id\"=>\"23989949\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/23989949\", \"open_access\"=>true, \"pmc_id\"=>\"PMC3777009\", \"publication_date\"=>{\"year\"=>2013, \"month\"=>9, \"day\"=>17}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>643, \"name\"=>\"EID643\", \"description\"=>\"PTEN Loss (by FISH) is associated with poorer prognosis in patients with prostate cancer.\", \"disease\"=>{\"id\"=>46, \"name\"=>\"Prostate Cancer\", \"display_name\"=>\"Prostate Cancer\", \"doid\"=>\"10283\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10283\"}, \"drugs\"=>[], \"rating\"=>4, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Prognostic\", \"clinical_significance\"=>\"Poor Outcome\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>310, \"name\"=>\"FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.\", \"citation\"=>\"Yoshimoto et al., 2007, Br. J. Cancer\", \"pubmed_id\"=>\"17700571\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/17700571\", \"open_access\"=>true, \"pmc_id\"=>\"PMC2360375\", \"publication_date\"=>{\"year\"=>2007, \"month\"=>9, \"day\"=>3}, \"journal\"=>\"Br. J. Cancer\", \"full_journal_title\"=>\"British journal of cancer\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>507, \"name\"=>\"EID507\", \"description\"=>\"In prostate cancer xenographs, PTEN null tumors had a significant decrease in cell size and proliferation when treated with Temsirolimus (CCI-779).\", \"disease\"=>{\"id\"=>46, \"name\"=>\"Prostate Cancer\", \"display_name\"=>\"Prostate Cancer\", \"doid\"=>\"10283\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:10283\"}, \"drugs\"=>[{\"id\"=>83, \"name\"=>\"Temsirolimus\", \"pubchem_id\"=>nil}], \"rating\"=>4, \"evidence_level\"=>\"D\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Sensitivity\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>312, \"name\"=>\"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.\", \"citation\"=>\"Neshat et al., 2001, Proc. Natl. Acad. Sci. U.S.A.\", \"pubmed_id\"=>\"11504908\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/11504908\", \"open_access\"=>true, \"pmc_id\"=>\"PMC56958\", \"publication_date\"=>{\"year\"=>2001, \"month\"=>8, \"day\"=>28}, \"journal\"=>\"Proc. Natl. Acad. Sci. U.S.A.\", \"full_journal_title\"=>\"Proceedings of the National Academy of Sciences of the United States of America\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}, {\"id\"=>506, \"name\"=>\"EID506\", \"description\"=>\"In 27 patients with chemotherapy-naive or chemotherapy-refractory metastatic colorectal cancer who were treated with cetuximab and chemotherapy, PTEN loss was associated with non-response.\", \"disease\"=>{\"id\"=>11, \"name\"=>\"Colorectal Cancer\", \"display_name\"=>\"Colorectal Cancer\", \"doid\"=>\"9256\", \"url\"=>\"http://www.disease-ontology.org/?id=DOID:9256\"}, \"drugs\"=>[{\"id\"=>16, \"name\"=>\"Cetuximab\", \"pubchem_id\"=>nil}], \"rating\"=>3, \"evidence_level\"=>\"B\", \"evidence_type\"=>\"Predictive\", \"clinical_significance\"=>\"Resistance or Non-Response\", \"evidence_direction\"=>\"Supports\", \"variant_origin\"=>\"Somatic Mutation\", \"drug_interaction_type\"=>nil, \"status\"=>\"accepted\", \"open_change_count\"=>0, \"type\"=>\"evidence\", \"source\"=>{\"id\"=>311, \"name\"=>\"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.\", \"citation\"=>\"De Roock et al., 2011, Lancet Oncol.\", \"pubmed_id\"=>\"21163703\", \"source_url\"=>\"http://www.ncbi.nlm.nih.gov/pubmed/21163703\", \"open_access\"=>nil, \"pmc_id\"=>nil, \"publication_date\"=>{\"year\"=>2011, \"month\"=>6}, \"journal\"=>\"Lancet Oncol.\", \"full_journal_title\"=>\"The Lancet. Oncology\", \"status\"=>\"fully curated\", \"is_review\"=>false, \"clinical_trials\"=>[]}, \"variant_id\"=>214, \"phenotypes\"=>[]}]}]"
      ]
     },
     "execution_count": 143,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#set list for RNA-based capture\n",
    "capture_RNA = []\n",
    "\n",
    "## For variants listed in the DNA-based API, create bed-like files for capture design\n",
    "pipeline = 'RNA-based' #set pipeline\n",
    "blank = ' ' #set blanks\n",
    "\n",
    "#iterate through evidence items\n",
    "for item in variants_RNA\n",
    "  exons1 = []\n",
    "  exons2 = []\n",
    "  \n",
    "  #Get Gene Information from JSON\n",
    "  gene = item['entrez_name']  #Call Gene name\n",
    "  variant = item['name'] #call variant\n",
    "  puts variant\n",
    "  chrom = item['coordinates']['chromosome'].to_i #call chrom\n",
    "  start = item['coordinates']['start'].to_i #call start\n",
    "  stop = item['coordinates']['stop'].to_i\n",
    "  gene_ENST = item['coordinates'][\"representative_transcript\"]\n",
    "  \n",
    "  #If there are 2 sets of coordiantes pull them\n",
    "  if item['coordinates']['chromosome2'] and item['coordinates']['start2'] and item['coordinates']['stop2'] #determine if there is a second set of coordinates\n",
    "    gene_ENST2 = item['coordinates'][\"representative_transcript2\"]\n",
    "    chrom2 = item['coordinates']['chromosome2'].to_i  # call chrom2\n",
    "    start2 = item['coordinates']['start2'].to_i  # call start2\n",
    "    stop2 = item['coordinates']['stop2'].to_i  # call stop2\n",
    "    flag = true #set flag for coordinates; true = second set of coordinates available\n",
    "  end\n",
    "\n",
    "  #If there is a coordinates flag pull both genes and get the exons\n",
    "  if flag\n",
    "    flag2 = true\n",
    "    exons1 = get_exons(gene_ENST, chrom)\n",
    "    exons2 = get_exons(gene_ENST2, chrom2)\n",
    "    probe_type = 'exon_coding'\n",
    "\n",
    "  #Evaluate for SNVs/Indels\n",
    "  elsif (start - stop).abs < 25\n",
    "    probe_type = 'SNV/indel'\n",
    "    region_length = (start - stop).abs \n",
    "\n",
    "  #Evaluate for small variants\n",
    "  elsif (start - stop).abs  < 1000\n",
    "    flag2 = true\n",
    "    probe_type = 'small_variant'\n",
    "    region_length = (start - stop).abs\n",
    "\n",
    "  #Evaluate for Exon Coding\n",
    "  elsif (start - stop).abs  > 1000\n",
    "    exons1 = get_exons(gene_ENST, chrom)\n",
    "    probe_type = 'exon_coding'\n",
    "  end\n",
    "\n",
    "  #Print to lists\n",
    "  if exons1.any? #if there is two sets of coordinates\n",
    "    for item in exons1\n",
    "      start = item[1].to_i\n",
    "      stop = item[2].to_i\n",
    "      region_length = (start - stop).abs\n",
    "      chrom = item[0]\n",
    "      capture_RNA << [gene, variant, probe_type, pipeline, region_length, chrom, start, stop] #append to list\n",
    "    end\n",
    "  if exons2.any?\n",
    "      start = item[1].to_i\n",
    "      stop = item[2].to_i\n",
    "      region_length = (start - stop).abs\n",
    "      chrom = item[0]\n",
    "      capture_RNA << [gene, variant, probe_type, pipeline, region_length, chrom, start, stop] #append to list\n",
    "    end\n",
    "  end\n",
    "\n",
    "  if exons1.empty? and exons2.empty? #if there is only one set of coordinates\n",
    "    capture_RNA << [gene, variant, probe_type, pipeline, region_length, chrom, start, stop] #append to list\n",
    "  end\n",
    "end \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 230,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "/overlap/id/ENST00000269305?feature=exon;expand=1;utr=10\n",
      "0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 230,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "def get_exons(gene_id, chromosome)\n",
    "  server='http://grch37.rest.ensembl.org'\n",
    "  path = \"/overlap/id/#{gene_id}?feature=exon;expand=1;utr=1\"\n",
    "  print path\n",
    "  url = URI.parse(server)\n",
    "  http = Net::HTTP.new(url.host, url.port)\n",
    "  request = Net::HTTP::Get.new(path, {'Content-Type' => 'application/json'})\n",
    "\n",
    "  response = http.request(request)\n",
    "  result = JSON.parse(response.body)\n",
    "  intervals = []\n",
    "  for item in result\n",
    "    stop = item[\"end\"].to_i\n",
    "    start = item[\"start\"].to_i\n",
    "    intervals << [start, stop]\n",
    "  end\n",
    "  \n",
    "  #Merge overlapping intervals\n",
    "  intervals.sort! { |x, y|\n",
    "      x[0] <=> y[0]\n",
    "    }\n",
    "  merged_intervals = []\n",
    "  temp_interval = []\n",
    "  \n",
    "  intervals.each_with_index do |interval, i|\n",
    "    if i == 0\n",
    "      temp_interval = interval\n",
    "      puts i\n",
    "    elsif interval[0] <= temp_interval[1] && interval[1] >= temp_interval[1]\n",
    "      temp_interval[1] = interval[1]\n",
    "    elsif interval[0] > temp_interval[1]\n",
    "      merged_intervals << temp_interval\n",
    "      temp_interval = interval\n",
    "    end\n",
    "  return merged_intervals\n",
    "  end\n",
    "end\n",
    "#   merged_intervals = []\n",
    "\n",
    "    \n",
    "#     if i == 0\n",
    "#       temp_interval = interval\n",
    "#     elsif interval[0] <= temp_interval[1] && interval[1] > temp_interval[1]\n",
    "#       temp_interval[1] = interval[1]\n",
    "#     elsif interval[0] > temp_interval[1]\n",
    "#       merged_intervals << temp_interval\n",
    "#       temp_interval = interval\n",
    "#     end\n",
    "#   merged_intervals << temp_interval\n",
    "#   return merged_intervals\n",
    "# end\n",
    "\n",
    "tp53 = get_exons(\"ENST00000269305\", 17)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 226,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[]\n"
     ]
    }
   ],
   "source": [
    "puts tp53"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Ruby 2.4.1",
   "language": "ruby",
   "name": "ruby"
  },
  "language_info": {
   "file_extension": ".rb",
   "mimetype": "application/x-ruby",
   "name": "ruby",
   "version": "2.4.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
